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Abstract 
 
Introduction 
 
Approximately one in five women experience abdominal pain and/or vaginal 
bleeding in early pregnancy.  This usually prompts referral to an Early 
Pregnancy Assessment Unit where an ultrasound scan will be performed.  
Following the ultrasound, either a certain or uncertain diagnosis will be made.  
Certain diagnoses may be positive, i.e. a viable intrauterine pregnancy, or 
negative, i.e. a non-viable or ectopic pregnancy.  Uncertain diagnoses occur 
when there is ambiguity regarding either the location or the viability of the 
pregnancy. Up to 25% of women attending an Early Pregnancy Assessment 
Unit are given such a diagnosis at their initial visit.     
 
All women with a diagnosis of either a pregnancy of unknown location or 
uncertain viability need to be followed-up until a definitive diagnosis can be 
made.  At present this is haphazard and protracted, commonly taking up to 
two weeks to resolve and requiring multiple visits for various different 
investigations.  This takes a considerable amount of time and costs a not 
insignificant amount of money.  Furthermore, in the time taken to make a 
definitive diagnosis, a stable woman with an unknown miscarriage or ectopic 
pregnancy may become unstable and require immediate resuscitation, life-
saving blood transfusion and/or emergency surgery.   
 
Aims  
 
The aim of this PhD was to develop methods to minimise the number of 
women given uncertain diagnoses in early pregnancy, or to at least minimise 
the duration of uncertainty if the diagnosis is unavoidable.  Several different 
studies were undertaken in an attempt to accomplish this. 
 
Studies 
 
We initially undertook a prospective cohort study to determine the levels of 
anxiety generated by uncertain diagnoses in early pregnancy was 
undertaken.  Women with uncertain diagnoses were found to be significantly 
more anxious (as measured using the standardized short form of Spielberger’s 
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state-trait anxiety inventory) than their counterparts given certain diagnoses 
(23±0.79 versus 14±6.6), even if these certain diagnoses were not associated 
with an ongoing pregnancy.  This study served to further justify the main 
objective.   
 
We then performed a systematic review and meta-analysis to identify and 
determine the diagnostic accuracy of various different ultrasonographic 
features to predict (a) an intrauterine pregnancy prior to visualization of 
embryonic contents and (b) a tubal ectopic pregnancy in the absence of an 
obvious extra-uterine embryo.  This study identified the double decidual sac 
sign as a potential marker to be able to accurately differentiate a true 
gestation sac from a pseudosac with a sensitivity of 82% (95% CI, 68-90%), 
specificity of 97% (95% Ci, 76-100%), positive likelihood ratio of 30 (95% CI, 2.8-
331) and negative likelihood ratio of 0.19 (95% CI, 0.10-0.35).  The quality of the 
studies included in the meta-analysis however precluded the use of the 
double decidual sac sign in clinical practice without further validation 
 
As a consequence, we carried out a prospective study following STARD 
guidelines to determine the diagnostic accuracy of the double decidual sac 
sign to predict an intrauterine pregnancy prior to visualization of embryonic 
contents using modern, high-resolution transvaginal ultrasound. This study 
found that the double decidual sac sign predicted an intrauterine pregnancy 
with a sensitivity of 94% (95% Ci, 85-98%), specificity of 100% (95% CI, 16-100%) 
and overall diagnostic accuracy of 94% (95% CI, 88-100%).  The positive and 
negative predictive values are 100% (95% CI, 94-100%) and 33% (95% CI, 4.3-
78%) respectively whilst the positive likelihood ratio was infinite and the 
negative likelihood ratio was 0.06 (95% CI, 0.02-0.16).  These results suggest that 
the meta-analysis under-estimated the ability of the double decidual sac sign 
to differentiate between a true gestation sac and a pseudosac.   
 
Subsequently, we conducted a study incorporating off-line analysis of 
ultrasonographic images to determine the inter- and intra-observer reliability of 
the double decidual sac sign to predict an intrauterine pregnancy prior to 
ultrasonographic visualization of embryonic contents.  This involved fifteen 
observers from around the United Kingdom remotely assessing a selection of 
two-dimensional images from 25 of the diagnostic accuracy study 
participants.  There was significant (p<0.01) agreement amongst the observers 
but the level of agreement was only ‘fair’, reflected by kappa statistics of 0.25, 
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0.33 and 0.21. Following a period of focused training, the inter-observer 
reliability significantly increased demonstrated by kappa statistics of 0.70, 0.63 
and 0.53.  The intra-observer reliability ranged from ‘substantial’ (K=0.65) to 
‘almost perfect’ (K=0.92). These results demonstrate that the double decidual 
sac sign has the potential, after training, to be both reliable and precise, 
making it a very useful ultrasonographic sign in clinical practice.   
 
Finally, we undertook a prognostic research study, following REMARK 
recommendations, investigating the ability of five serum biomarkers to predict 
pregnancy outcome in women with pregnancies of uncertain viability.  
Candidate biomarkers included Angiopoietin-1 (Ang-1), Angiopoietin-2 (Ang-
2), soluble FMS-like Tyrosine Kinase-1 (Flt-1), serum TNF-Related Apoptosis 
Inducing Ligand and Interleukin-15.  Serum concentrations of Ang-2 and Flt-1 
were significantly lower in pregnancies of uncertain viability that were 
subsequently proven to be viable than those that were subsequently proven 
to be non-viable (Ang-2 1510pg/ml versus 2365pg/ml and Flt-1 103pg/ml versus 
202pg/ml). Furthermore, there were statistically significant (p<0.01), linear (p-
value for trend <0.01) associations between Ang-2 and Flt-1 concentrations 
and subsequent pregnancy viability such that women with a pregnancy of 
uncertain viability and Ang-2 concentrations greater than or equal to 
2666pg/ml were 64% less likely to have a viable pregnancy than those with 
Ang-2 concentrations less than or equal to 1382pg/ml and women with a 
pregnancy of uncertain viability and Flt-1 concentrations greater than or 
equal to 142pg/ml were 50% less likely to have a viable pregnancy than those 
with Flt-1 concentrations less than or equal to 87pg/ml. These findings suggest 
that Ang-2 and Flt-1 may be useful in the prediction of pregnancy viability in 
cases of uncertainty. 
 
Discussion  
 
One of the biggest challenges in early pregnancy ultrasonography is accurate 
differentiation between a true gestation sac and a pseudosac.  Pseudosacs, 
although rare, are strongly suggestive of an ectopic pregnancy, hence it is an 
important distinction to make, ideally as soon as possible.  Both appear initially 
as intrauterine fluid collections or ‘empty sacs’.  Whilst experts may claim that it 
is not difficult to differentiate between the two structures, in clinical practice, 
many of the individuals undertaking the scans in early pregnancy do not claim 
to be experts.  Traditional teaching has always been to wait until either a yolk 
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sac or fetal pole are visualized within the sac before confirming a definite 
intrauterine pregnancy.  Although safe, inherent with this approach is that an 
intrauterine fluid collection is visible using transvaginal ultrasound from around 
day 28 but a yolk sac is not visible until at least day 35.  If an ultrasound is 
undertaken during this time, an ‘empty sac’ will be seen and uncertainty will 
ensue.   
 
Application of the results from the studies described above could potentially 
revolutionize the care of women with diagnostic uncertainties in early 
pregnancy.  Firstly, the confirmation that uncertain diagnoses in early 
pregnancy are highly anxiogenic, means that Early Pregnancy Assessment 
Units can now justify the allocation of resources to help alleviate this distress.  
This is crucial if we are to improve the holistic nature of the care provided to 
women with complications of early pregnancy.   
 
Furthermore, the discovery that the double decidual sac sign can accurately 
predict an intrauterine pregnancy prior to visualization of embryonic contents 
(and therefore effectively exclude an ectopic pregnancy) means that we can 
rationalise follow-up, improve consistency and minimise error in the 
management of women with ultrasonographic evidence of an empty sac in 
early pregnancy.  
 
Although it could be argued that utilization of the double decidual sac sign 
does not minimise the number of women given uncertain diagnoses in early 
pregnancy, merely swap concerns regarding location to ones regarding 
viability, in clinical practice it is the potential consequences of pregnancies of 
unknown location that are most hazardous, both because of the immediate 
threat to health and the future threats to fertility.  Furthermore, if the findings 
from our prognosis study are confirmed, and appropriate threshold levels for 
our biomarkers determined, it may be possible to minimise the duration of 
uncertainty for women with pregnancies of uncertain viability to hours rather 
than weeks.   
 
Using a combination of approaches therefore, we have achieved the overall 
aim of this thesis in minimising diagnostic uncertainties in early pregnancy, the 
clinical benefits of which are multifold.  Not only does it reduce anxiety for 
women, but also prevents unnecessary investigations from being performed in 
those with an intrauterine pregnancy and minimise morbidity and mortality, 
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permit earlier, potentially less invasive intervention and possibly preserve future 
fertility for women with an ectopic pregnancy. 
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1. Normal Early Pregnancy 
Development 
 
1.1 Introduction 
 
It is important to have an understanding of both normal and abnormal early 
pregnancy development before attempting to understand diagnostic 
uncertainties in early pregnancy, which is the focus of this thesis.  This chapter 
will first discuss the normal development of an embryo from fertilization to 
implantation and then subsequent development of the amniotic cavity, yolk 
sac and chorionic cavity and formation of the trilaminar embryonic disc.  It will 
then go on to describe the normal ultrasonographic development of an early 
pregnancy including the sequence of events in which structures such as the 
gestation sac, yolk sac, fetal pole and fetal heart become visible.  Finally, the 
two principal hormones involved in normal early pregnancy development and 
their role in clinical practice will be discussed. 
 
NB; In section 1.2 the term ‘days’ refers to the number of days following 
fertilization. In all other sections of this thesis, the term days refers to the 
menstrual age i.e. the number of days since the first day of the last menstrual 
period.  Fertilization is conventionally said to occur at a menstrual age of 
fourteen days.  
 
1.2 Embryology 
 
Embryogenesis is a complex and carefully coordinated process that begins 
following the fusion of definitive male and female gametes.   
 
Fertilization 
 
Fertilization occurs in the ampulla of the fallopian tube when a viable 
spermatozoon, having penetrated its way through the cumulus, is able to bind 
to the zona pellucida surrounding an oocyte.  Upon binding, the acrosome in 
the head of the sperm releases digestive enzymes that enable the sperm to 
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penetrate the zona pellucida.  Following penetration, the cell membranes of 
the spermatozoon and oocyte fuse, which not only initiates a sequence of 
events that ultimately results in the zona becoming impenetrable by additional 
spermatozoa but also enables the oocyte to complete meiosis and develop 
into a definitive oocyte.  Within the fertilized oocyte, the nuclei of the sperm 
and oocyte swell to form male and female pronuclei.  Their nuclear 
membranes subsequently disappear as both maternal and paternal 
chromosomes are replicated in preparation for mitosis.   
 
Cleavage 
 
Following fertilization, a rapid series of mitotic cell divisions called cleavage is 
initiated within the fertilized oocyte (zygote).  During cleavage, the embryo 
remains enclosed within the zona pellucida and does not increase in size at all 
as cell growth does not accompany the cell division at this stage.  The first 
cleavage division therefore splits the zygote into two smaller daughter cells 
called blastomeres.  The second division, which is complete within 40 hours of 
fertilization, produces four blastomeres, which are smaller still.  By day three, 
the embryo consists of six to twelve cells and by day four, the morula as it is 
now known, consists of sixteen to 32 cells.  
 
Compaction 
 
During the process of compaction, which occurs simultaneously with 
cleavage, some blastomeres segregate to the centre of the morula and 
others to the outside.  The centrally placed blastomeres constitute the inner 
cell mass, which ultimately gives rise to the embryo, whereas the blastomeres 
at the periphery form the trophoblast, which develops into the fetal 
component of the placenta.  
 
Blastocyst Formation 
 
From day four onwards, the morula begins to absorb fluid.  This is possible 
because the developing trophoblast cells express a membrane ion channel 
which transports sodium into and potassium out of the morula.  Water 
subsequently follows the sodium by osmosis.  As the hydrostatic pressure 
increases, a large fluid cavity develops within the morula, which is now 
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referred to as a blastocyst.  The inner cell mass or embryoblast then forms a 
compact mass at one side of this cavity and the trophoblast organizes into a 
thin, single-layered epithelium.   
 
Hatching 
 
Within three or four days of fertilization, the morula, still surrounded by the zona 
pellucida, enters the uterus.  By day five, the blastocyst hatches from the zona 
pellucida by enzymatically boring a hole in it and squeezing out.  The 
blastocyst is now relieved of all its original investments and is able to directly 
interact with the endometrium.   
 
Implantation 
 
Upon entering the uterus, the blastocyst adheres to the lining of the womb.  
The endometrial stromal cells respond to both the presence of the blastocyst 
and the progesterone secreted by the corpus luteum by differentiating into 
secretory decidual cells.  This response is called the decidual reaction.  In 
addition to this, nearby endometrial glands enlarge and the local uterine wall 
becomes more highly vascularized and oedematous.  The decidual cells and 
endometrial glands secrete growth factors and metabolites that support the 
development of the implanting embryo.    Once the embryo has implanted, 
the trophoblast cells produce the hormone human chorionic gonadotropin 
(hCG), which supports the corpus luteum and thus maintains the supply of 
progesterone.  The corpus luteum continues to secrete progesterone for up to 
twelve weeks, after which time the placenta itself takes over progesterone 
production and the corpus luteum slowly involutes, becoming a corpus 
albicans.   
 
Contact with the endometrium induces the trophoblast at the embryonic pole 
(the side of the blastocyst containing the inner cell mass) to proliferate.  Some 
of these proliferating cells lose their cell membranes and coalesce to form a 
mass of cytoplasm containing numerous dispersed nuclei and this is called the 
syncytiotrophoblast. 
 
In contrast, the cells of the trophoblast that line the wall of the blastocyst, 
retain their cell membranes and constitute the cytotrophoblast.  The 
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syncytiotrophoblast increases in volume throughout the second week as cells 
detach from the proliferating cytotrophoblast at the embryonic pole and fuse 
with the syncytium (Figure 1.1a). 
 
Figure 1.1: Appearances (a) seven, (b) nine, (c) eleven, (d) thirteen and (e) 
fourteen days after fertilization (Images on the left taken from Larsen’s Human 
Embryology [1] and images on the right courtesy of The Virtual Human Embryo 
project (www.prenatalorigins.org/virtual-human-embryo/) 
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Nine days after fertilization, the embryo is fully implanted within the 
endometrium (Figure 1.1b).  Active finger like projections extend from the 
syncytiotrophoblast and penetrate between the endometrial cells further 
pulling the embryo into the endometrium.  As implantation progresses further, 
the expanding syncytiotrophoblast envelops the entire blastocyst excluding a 
small region at the abembryonic pole (the side of the blastocyst opposite the 
inner cell mass).  A coagulation plug, seals this small hole where the blastocyst 
implanted, temporarily marking this point in the endometrial epithelium. 
 
This stepwise process of implantation described above, involving apposition 
and adherence of a blastocyst to the endometrium followed by breaching of 
the luminal epithelium and finally invasion of maternal tissues, has been 
conceptualized largely on the basis of animal models [2]. This process is 
analogous to an invading cancer, with the embryo driving the destruction of 
endometrial epithelial cells, the enzymatic digestion of the stromal matrix, and 
finally, the invasion of the maternal decidua and inner myometrium (Figure 
1.2a) [3].  
 
Figure 1.2: The (a) traditional and (b) emerging view of implantation (adapted 
from [3]) 
 
 
 
Notwithstanding the complexity at a cellular level, implantation in the 
conventional paradigm outlined above seems to require little more than a 
receptive endometrium and an invasive embryo capable of evading 
maternal immune detection.  This may be true for certain species, for example 
the mouse [2], but recent studies [4-10] indicate that implantation of a human 
embryo is much more dynamically controlled by the endometrium than 
previously appreciated: it is not simply a case of having an invasive embryo, 
capable of evading maternal immune detection, and a receptive 
endometrium. Emerging concepts suggest that human embryos do not 
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embed in the endometrium randomly but rather at receptive sites where 
stromal cells are poised to encapsulate the conceptus and create a micro-
environment tailored to the individual embryo (Figure 1.2b) [3], a concept that 
fits well with the appearance of early human implantation sites on high-
resolution ultrasound (Figure 1.3a) or histological analysis (Figure 1.3b). 
 
Figure 1.3: Embryo invasion or decidual encapsulation? (a) High-resolution 
ultrasound image of an early implantation site. The abnormal amount of free 
fluid in the uterine cavity (dotted line) allowed clear visualization of the 
gestational sac bulging into the lumen cavity (b) Drawing of an early human 
implantation site [11].   
 
 
Formation of a Bilaminar Embryonic Disc 
 
During the process of implantation, the inner cell mass, or embryoblast, begins 
to differentiate into two epithelial layers: an external upper (dorsal) layer of 
columnar cells called the epiblast, and an internal lower (ventral) layer of 
cuboidal cells called the hypoblast (or primitive endoderm).  
 
Development of the Amniotic Cavity 
 
The amniotic cavity appears on day eight as fluid begins to collect between 
the cells of the epiblast and the overlying trophoblast.  A layer of epiblast cells 
migrates towards the embryonic pole forming a thin membrane that 
separates the newly developed amniotic cavity from the overlying 
cytotrophoblast cells.  This membrane is the lining of the amnion.  Although the 
amniotic cavity is initially much smaller than the blastocyst cavity, it expands 
steadily.  By the eighth week, the amnion encloses the entire embryo.   
 
Chapter 1 
 
7 
Development of the Yolk Sac and Chorionic Cavity 
 
The hypoblast cells also begin to proliferate and migrate from day eight 
onwards extending into the blastocyst cavity forming the primary yolk sac 
(Figure 1.1c).  At the same time, the extraembryonic mesoderm develops, 
filling the remainder of the blastocyst cavity with loosely arranged cells. A new 
space develops within the extraembryonic mesoderm and this is the 
beginning of the chorionic cavity (Figure 1.1d), which separates the embryo 
with its dorsal amnion and ventral yolk sac from the outer wall of the 
blastocyst, now called the chorion. 
 
By day twelve, the primary yolk sac is displaced as a subsequent wave of 
migrating hypoblast cells form the secondary or definitive yolk sac. By day 
thirteen, the bilaminar embryonic disc is suspended in the chorionic cavity by 
a thick connecting stalk of extraembryonic mesoderm (Figure 1.1e).  The yolk 
sac remains a major structure associated with the developing embryo through 
the fourth week and performs important early functions.  After the fourth week, 
the yolk sac is rapidly overgrown by the developing embryonic disc. 
 
Gastrulation and Formation of a Trilaminar Embryonic 
Disc 
 
On day fifteen, a thickening, containing a midline groove develops along the 
mid-sagittal plane of the now oval bilaminar embryonic disc.  Over the next 24 
hours, this primitive streak elongates to occupy half the length of the 
embryonic disc, and the primitive groove becomes deeper and more 
defined.  The cranial end of the primitive streak expands to form the primitive 
node, which contains a depression called the primitive pit.  This continues 
caudally with the primitive groove.  Formation of the primitive streak therefore 
defines the cranial-caudal, medial-lateral, left-right and dorsal-ventral axes of 
the developing embryo.   
 
From day sixteen onwards, epiblast cells lateral to the primitive streak begin to 
move into the primitive streak and migrate into the space between the 
epiblast and hypoblast.  This process is known as gastrulation.  Initially the 
migrating epiblast cells invade and displace the hypoblast forming a new 
layer of cells known as definitive endoderm which gives rise to the lining of the 
future gut and gut derivatives.  Subsequently, the epiblast cells migrate in the 
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space between the epiblast and definitive endoderm to form a third germ 
layer known as the intraembryonic mesoderm.  These cells migrate bilaterally 
from the primitive streak and organize themselves into four main subdivisions: 
cardiogenic mesoderm, paraxial mesoderm, intermediate mesoderm and 
lateral plate mesoderm.  Additionally, a fifth population of mesodermal cells 
migrates cranially from the primitive node in the midline to form a thick walled 
midline tube called the notochordal process.   
 
During the third week of development, two faint depressions form in the 
ectoderm and the ectoderm in these areas fuse directly with the endoderm 
below (excluding any interspersed mesoderm) and two bilaminar membranes, 
which later become the blind ends of the gut tube, are formed.  One of these 
is the oropharyngeal membrane located at the cranial end of the embryo 
overlying the prechordal plate and the other is the cloacal membrane, 
located caudally, behind the primitive streak.  The oropharyngeal membrane 
disintegrates in week four to become the opening into the oral cavity and the 
cloacal membrane breaks down in week seven to form the openings of the 
anus and urogenital tract.   
 
Once formation of the definitive endoderm and intraembryonic mesoderm is 
complete, epiblast cells no longer migrate towards the primitive streak and the 
remaining epiblast cells now constitute ectoderm, which quickly differentiates 
into the central neural plate and peripheral surface ectoderm.  The process of 
gastrulation is then complete and the previously bilaminar embryonic disc is 
now trilaminar, with all three germ layers being derived from the epiblast.   
 
Forming the Embryo 
 
At the end of the third week, the embryo is a flat, ovoid, trilaminar disc.  During 
the fourth week it grows rapidly, particularly in length, and undergoes a 
process of folding (Figure 1.4).  Although some active remodeling of tissue 
layers takes place, the main force responsible for embryonic folding is 
differential growth of various embryonic structures.  During the fourth week, the 
embryonic disc and amnion grow vigorously, whereas the yolk sac hardly 
grows at all.  As the outer rim of the embryonic endoderm is attached to the 
yolk sac, the expanding disc bulges into a convex shape.  Folding 
commences in the cranial and lateral regions of the embryo on day 22 and in 
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the caudal region on day 23.  As a result of folding, the cranial, lateral and 
caudal edges of the embryonic disc are brought together along the ventral 
midline.  The endodermal, mesodermal and ectodermal layers of the 
embryonic disc each fuse to the corresponding layer on the opposite side, 
thus creating a tubular, three dimensional body form. 
 
Figure 1.4: Development of the three-dimensional ‘tube-within-a-tube’ body 
plan. Top image taken from Larsen’s Human Embryology [1] and image below 
courtesy of The Virtual Human Embryo project 
(www.prenatalorigins.org/virtual-human-embryo/)    
 
 
Forming the Heart 
 
The heart is the first functioning organ in humans.  It begins beating 
rhythmically as early as day 22 and pumps blood by day 25.  Much of the 
development of the heart therefore occurs whilst the heart is pumping blood.  
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This is essential to provide nutrients and oxygen and dispose of waste during 
embryonic and fetal development.  Morphologically, the embryonic heart is 
first identifiable as a single heart tube composed of contractile myocardium 
surrounding an inner endocardial tube. Between weeks four and eight, this 
primitive heart tube undergoes a process of looping, remodeling, realignment 
and septation that transforms its single lumen into the four chambers of the 
definitive heart. 
 
1.3 Ultrasonography 
 
Ultrasound is one of the most useful diagnostic tools in the field of obstetrics 
and gynaecology. Its main advantage over other imaging modalities being 
that it does not involve the use of the ionizing radiation.  In addition to this, 
there are other more subjective benefits such as that it is relatively non-
invasive, inexpensive, portable, quick, accurate and widely acceptable.  Over 
the last few decades, ultrasound has been used extensively in the evaluation 
of early pregnancy enabling the development and growth of the fetus to be 
monitored, an ability which has been significantly enhanced over the years by 
dramatic improvements in ultrasound technology.   
 
Transabdominal ultrasonography utilizes lower frequencies with poorer axial 
resolution than its transvaginal counterpart and nowadays it is therefore used 
predominantly in the second and third trimesters of pregnancy.  Its use in the 
first trimester is relatively limited and mostly diagnostic in nature but this has not 
always been the case.  Much of the information obtained from the original 
early pregnancy studies was collected using transabdominal ultrasound.  The 
relatively recent introduction of higher frequency transvaginal ultrasound 
probes that can be placed closer to the pelvic organs providing images with 
better resolution has revolutionized the ultrasonographic study of very early 
pregnancy.  For example, a gestation sac can be visualized from day 28 [12] 
using transvaginal ultrasound but often not until day 42 [13] using 
transabdominal ultrasound.  A recent study comparing transabdominal and 
transvaginal ultrasonography in the same group of 50 women has concluded 
that transvaginal ultrasound reliably identifies normal and abnormal 
pregnancies at an earlier stage than transabdominal ultrasound [14].   
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Furthermore, the ability to visualize structures in early pregnancy is critically 
dependent not only the imaging route (transabdominal versus transvaginal) 
but also on the transducer frequency.  In a study of 39 pregnancies, women 
were initially imaged with a 5-MHz transvaginal transducer and immediately 
afterwards were re-imaged with a 9MHz transvaginal transducer.  Threshold 
values and discriminatory sizes used to distinguish normal and abnormal 
pregnancies were found to be smaller on higher frequency than on lower 
frequency imaging [15, 16].  It is therefore of paramount importance that 
thresholds be determined for both the specific imaging route and transducer 
frequency.   
 
With that caveat in mind, we shall now go on to discuss the ultrasonographic 
development of a normal very early pregnancy.   
 
Endometrial Thickness 
 
The first visible ultrasonographic finding suggestive of a potential pregnancy is 
a thickened hyperechogenic homogenous endometrium (known as the 
decidual reaction).   
 
Gestation Sac 
 
The first ultrasonographic sign of an intrauterine pregnancy is the appearance 
of a gestation sac (Figure 1.5a).  It appears as a uniformly round, hypoechoic 
structure with an echogenic rim and is situated asymmetrically within the 
decidua, at or near the uterine fundus.  A gestation sac is first visible with 
transvaginal ultrasound from day 28-31 onwards [12] when it measures 
approximately 2-3mm in diameter.  Thereafter it grows at a rate of 
approximately 1mm/day (rendering it a good predictor of gestational age) 
and eventually it acquires a more elliptical outline.  The gestation sac should 
always be present by 37 days when it measures approximately 5mm [17].  
Initially the gestation sac does not contain any internal echoes and at this 
stage can be mistaken for a ‘pseudosac’, that is, an endometrial fluid 
collection that occurs in up to 15% of ectopic pregnancies [18].  Although this 
finding is relatively uncommon with an ectopic pregnancy, it is clinically 
important not to mistake the two structures.   
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Figure 1.5: Ultrasonogram showing a (a) gestation sac (b) yolk sac and (c) 
fetal pole  
Images taken from: www.fetalultrasound.com 
Yolk Sac 
 
The identification of the (secondary) yolk sac therefore is especially important 
because it is, at present, the first incontrovertible sign of an intrauterine 
pregnancy.  The yolk sac is the first structure to become visible within the 
gestation sac and, if detected, is a reliable indicator of a true gestation sac 
and therefore an intrauterine pregnancy with a positive predictive value of 
100% [19].  Identification of a yolk sac therefore excludes the possibility of an 
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ectopic pregnancy (unless in the very rare circumstance of a heterotopic 
pregnancy).  It is usually visible with transvaginal ultrasound from about day 35 
(four to seven days after the appearance of the gestation sac).  It may be 
seen in gestation sacs as small as 5-6mm and should always be seen 
transvaginally when the gestation sac measures more than 10mm.  The yolk 
sac appears as a spherical, hyperechoic ring and is situated eccentrically 
within the gestation sac (Figure 1.5b).  It normally grows slowly during the first 
trimester, ranging from 2mm at five weeks gestation, to 6mm at ten weeks 
gestation. Thereafter it starts to regress and has usually disappeared 
completely by approximately twelve weeks gestation [20].   
 
Fetal Pole 
 
The next structure to appear within the gestation sac is the fetal pole.  The 
earliest reported sighting of this structure is day 35 but it may not be seen 
within the gestation sac until six weeks gestation even in normal pregnancies.  
It initially appears as a small linear echogenic structure adjacent to the yolk 
sac, on the side closest to the gestational sac (Figure 1.5c), giving the 
appearance of a ‘signet ring’.  The fetus is approximately 1-2mm when first 
detected ultrasonographically and increases in size by approximately 
1mm/day.  As it grows, it develops into a ‘kidney bean’ shape and, in doing 
so, gradually becomes positioned further away from the yolk sac. 
 
Fetal Heart 
 
A fetal heart pulsation is typically appreciated as soon as, if not before, a fetal 
pole is detected.  It has been documented as early as 37 days gestation in 
normal pregnancies [21] which is when the fetal heart tube starts to beat [22].  
Cardiac activity should be evident when the fetal pole measures 2mm or 
more [23] but it is however not abnormal for it to be absent until the fetal pole 
is larger: 5-10% of viable embryos measuring between 2 and 4mm do not have 
visible cardiac activity [24, 25]. Once detected, the initial fetal heart rates are 
relatively slow, increasing from 100-110bpm at six weeks gestation to 150-
170bpm at eight weeks gestation.  
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1.4 Serology 
 
The two principal hormones in early pregnancy development are human 
chorionic gonadotropin (hCG) and progesterone.  These may be used alone 
or in combination to give information regarding pregnancy gestation (hCG), 
viability (serial hCG and progesterone) and to a lesser extent, location (serial 
hCG). 
 
Human Chorionic Gonadotropin 
 
Human chorionic gonadotropin is secreted by the syncytiotrophoblast in 
response to gonadotropin-releasing hormone (GnRH) production by the 
adjacent cytotrophoblast cells.  hCG is a glycoprotein composed of 237 
amino acids and like many other pituitary hormones, it consists of two subunits: 
an α-subunit which is identical to that of luteinizing hormone, follicle-stimulating 
hormone and thyroid stimulating hormone and a β-subunit that is unique to 
hCG. 
 
hCG acts to maintain the function of the corpus luteum that would otherwise 
degenerate in the absence of a pregnancy.  During a menstrual cycle without 
conception, progesterone concentrations in the serum increase for the first 6-7 
days of the luteal phase, followed by a 3-4 day plateau and then a decrease 
resulting in shedding of the endometrial lining.  After conception and 
implantation, the corpus luteum continues to secrete progesterone and 17-
hydroxyprogesterone for another 4-6 weeks.  The maternal serum 
concentrations of progesterone and 17-hydroxyprogesterone then decrease, 
indicating a marked diminution in corpus luteum function.  The fall in 17-
hydroxyprogesterone continues but the drop in progesterone levels is only 
transient.  This marks the transition from dependence on ovarian progesterone 
production to placental progesterone secretion and the corpus luteum 
subsequently regresses.  This occurs towards the end of the first trimester of 
pregnancy.   
 
In male fetuses, hCG also stimulates the early secretion of testosterone by the 
Leydig cells, an action that is critical to masculine genital tract differentiation.  
The very high hCG levels have enough structural overlap with thyroid 
stimulating hormone to stimulate increased maternal thyroid activity in early 
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pregnancy and may also contribute to the development of hyperemesis 
gravidarum.   
 
If fertilization has occurred, hCG is detectable in the maternal circulation 
approximately ten days after ovulation.  As the pregnancy develops, so too 
does the syncytiotrophoblast and hence the concentration of hCG in the 
maternal blood increases with advancing gestation.   Serum hCG levels 
increase at an exponential rate, reaching a peak at between ten and twelve 
weeks gestation. The concentration then declines to a stable plateau for the 
remainder of the pregnancy (Figure 1.6)[26]. 
 
Figure 1.6: Mean (± standard error) maternal serum hCG levels throughout 
normal pregnancy [26] 
 
Urinary and serum pregnancy tests work by detecting the presence of hCG in 
either the urine or blood respectively.  Urinary pregnancy tests detect hCG 
levels as low as 20iu/l depending on the brand of the test.  Older tests tend to 
only detect the presence or absence of the hormone in the urine but newer 
tests are increasingly analyzing the level of hormone present in the urine and 
translating this into an estimated gestation, which appears as a number in a 
digital display screen. 
 
Serum hCG analysis can detect levels as low as 5iu/l and have the advantage 
of being a quantitative measure.  A single serum hCG analysis therefore has 
the ability to confirm the diagnosis of pregnancy and may also give some 
indication as to gestation with higher hCG levels generally implying a more 
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advanced gestation.  However, this is not a precise indicator of gestation as 
the range of normal hCG levels seen at any gestation is wide with 
considerable overlap [27, 28] (see Table 1.1). Furthermore, higher hCG levels 
are seen with multiple and molar pregnancies.  
 
Table 1.1: Correlation between gestation mean sac diameter (MSD), serum 
hCG [27, 28] and menstrual age [28]  
 
Gestation Sac MSD 
(mm) 
Menstrual Age 
(weeks+days) 
Predicted hCG (95% CI) 
(iu/l) 
3 4+4 1710 (1050-2800) 
4 4+5 2320 (1440-3760) 
5 4+6 3100 (1940-4980) 
6 5+1 4090 (2580-6530) 
7 5+2 5340 (3400-8450) 
8 5+3 6880 (4420-10810) 
9 5+4 8770 (5680-13660) 
10 5+5 11040 (7220-17050) 
11 5+6 13730 (9050-210408) 
12 6+0 16870 (11230-25640) 
13 6+1 20480 (13750-30880) 
14 6+2 24560 (16650-36750) 
15 6+3 29110 (19910-43220) 
16 6+4 34100 (23530-50210) 
17 6+5 39460 (27470-57640) 
18 6+6 45120 (31700-65380) 
19 7+0 50970 (40700-81150) 
20 7+1 56900 (40700-81150) 
21 7+2 62760 (45300-88790) 
22 7+3 68390 (49810-95990) 
23 7+4 73640 (54120-102540) 
24 7+5 78350 (58100-108230) 
25 7+6 82370 (61640-112870) 
26 8+0 85560 (64600-116310) 
27 8+1 87820 (66900-118420) 
28 8+2 89050 (68460-119130) 
29 8+3 89230 (69220-118420) 
30 8+4 88340 (69150-116310) 
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Serum hCG analysis can detect levels as low as 5iu/l and have the advantage 
of being a quantitative measure.  A single serum hCG analysis therefore has 
the ability to confirm the diagnosis of pregnancy and may also give some 
indication as to gestation with higher hCG levels generally implying a more 
advanced gestation.  However, this is not a precise indicator of gestation as 
the range of normal hCG levels seen at any gestation is wide with 
considerable overlap [27, 28] (see Table 1.1). Furthermore, higher hCG levels 
are seen with multiple and molar pregnancies.  
 
The main clinical benefit of a single serum hCG is that it can be used to 
rationalise the use of ultrasound in women presenting with symptoms of 
abdominal pain and/or vaginal bleeding in early pregnancy and help 
interpret sonograms when there is uncertainty.  If the serum hCG is  below a 
certain level or ‘discriminatory zone’ ,  it  is unlikely that ultrasound will detect a 
gestation sac.  If however the serum hCG is above this discriminatory zone, a 
gestation sac should be visible on ultrasound with a sensitivity approaching 
100% [29].  With the use of high resolution transvaginal ultrasound, the 
discriminatory level has been reported to be approximately 1000iu/l [30] 
although the American Fertility Society recommends a more conservative 
level of 2400iu/l.  In reality, the discriminatory zone may vary in different units 
depending on the specific hCG assay utilized, the quality of the ultrasound 
equipment available and the experience of the individual sonographer.    In 
women with a hCG result above the discriminatory level but with no gestation 
sac visible on ultrasound, there is a high possibility of an ectopic pregnancy 
(PPV 18.2%) [31].  
 
As described therefore, a single serum hCG can be used to confirm 
pregnancy, give an approximate estimate of gestation and help rationalise 
and interpret ultrasonography but unfortunately, a single serum hCG on its 
own, provides little or no information regarding pregnancy location or viability.  
Ectopic pregnancies secrete hCG as do failing pregnancies and serum hCG 
levels can remain elevated for several weeks following a complete 
miscarriage [32].  Serial serum hCG levels may therefore be of more benefit 
than solitary measures in providing information on pregnancy viability. A 
doubling of hCG is often expected every 48 hours, although this tends to vary 
with gestation: as pregnancy progresses, the doubling time lengthens [33]. In 
1981, the concept of a minimal rise in serum hCG of 66% in 48 hours to predict 
a viable intrauterine pregnancy was first described in 20 women using an 85% 
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confidence interval [34].  It predicts an intrauterine pregnancy with a positive 
predictive value of 96.5%.  Intervention for an hCG rise of less than 66% over 
two days, a practice supported by previous data, might however potentially 
result in the interruption of a viable pregnancy [35, 36], which is unacceptable.  
Recent studies have therefore attempted to redefine the hCG values in an 
effort to reduce the unintentional termination of a viable pregnancy.   In a 
cohort of 287 women who presented with vaginal bleeding and/or pain, the 
minimum rise for a potentially viable pregnancy was 53% at two days [37].  
However, in clinical practice, based on observations from 1249 women, a 
more conservative minimal rise in serum hCG of 35% over 48 hours has been 
suggested to minimise the potential risk of interrupting an on-going viable 
pregnancy [38].  It is important to remember however that up to 15% of normal 
pregnancies will have an abnormal doubling time [34]. 
 
Progesterone 
 
Progesterone is initially secreted solely by the corpus luteum.  From 
approximately seven weeks’ gestation, the placenta begins to synthesize 
progesterone and by twelve weeks it produces enough to replace the corpus 
luteum source.  Cholesterol extracted from maternal plasma serves as the 
major precursor for placental progesterone.  The synthetic pathway is identical 
to that of the adrenal gland and the ovary.  By the end of pregnancy, 
placental progesterone production reaches a level that is ten times greater 
than peak production by the corpus luteum. 
 
Progesterone has many functions during early pregnancy.  It not only 
stimulates endometrial glands to secrete nutrients on which the developing 
embryo depends but also maintains the decidual lining of the uterus, where it 
induces prolactin synthesis.  Prolactin helps inhibit the maternal immune 
responses to fetal antigens of paternal origin, thus helping to prevent rejection 
of the fetus.  Progesterone also promotes uterine quiescence by inhibiting 
prostaglandin production and desensitizing the uterus to oxytocin thereby 
encouraging prolongation of the pregnancy.  
 
Serum progesterone levels are therefore elevated during pregnancy.  Levels 
change little during the first 8-10 weeks of gestation unless the pregnancy fails.  
Several studies [39-41], including a meta-analysis [42], have shown levels 
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>25nmol/l are ‘likely to indicate’, and levels >60nmol/l are ‘strongly associated 
with’, pregnancies subsequently shown to be viable.  However, a small 
proportion (0.3%) of viable pregnancies have been reported with initial levels 
<15.9nmol/l [33].  Unfortunately however, whilst progesterone levels seem to 
be good at predicting pregnancy viability, they are poor at predicting 
pregnancy location [43].  
 
1.5 Summary 
 
This chapter has focused on normal early pregnancy development including 
the development of an embryo from fertilization to implantation, including the 
development of the amniotic cavity, yolk sac, chorionic cavity, formation of 
the trilaminar embryonic disc, and fetal heart.  It has also described the 
ultrasonographic findings of a normal early pregnancy including the sequence 
of events in which structures such as the gestation sac, yolk sac, fetal pole and 
fetal heart become visible.  Finally, the two principal hormones involved in 
normal early pregnancy development and their role in clinical practice, 
including their limitations, has been discussed. 
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2. Abnormal Early Pregnancy 
Development 
 
2.1 Introduction 
 
Having considered normal early pregnancy development, we shall now move 
on to discuss abnormal early pregnancy development, for example 
miscarriage and ectopic pregnancy, in more detail.   
 
Complications arise more frequently during the first trimester of pregnancy 
than at any other stage of pregnancy.  Most present with abdominal pain 
and/or vaginal bleeding, both of which cause considerable anxiety for the 
couple.  Unfortunately, in the vast majority of cases, no intervention alters the 
outcome.  The main aim of clinical management is a prompt and accurate 
diagnosis (Table 2.1) with reassurance if the pregnancy is progressing 
appropriately, or suitable intervention if it is not.   
 
Table 2.1: Differential diagnosis of abdominal pain and/or vaginal bleeding in 
the first trimester of pregnancy [44]   
Related to Pregnancy Unrelated to Pregnancy 
Gynaecological Non-gynaecological 
Miscarriage Ovarian cyst accident Urinary tract infection 
Ectopic pregnancy Torsion/degeneration of a 
pedunculated fibroid 
Renal colic 
Hydatidiform mole Bleeding from cervical 
malignancy 
Bowel obstruction 
Cervical ectropion Dysfunctional uterine 
bleeding 
Cholecystitis 
Pelvic inflammatory 
disease 
Appendicitis 
Endometriosis 
 
This chapter first introduces the clinical problems of miscarriage and ectopic 
pregnancy and then goes on to describe the ultrasonographic appearance 
of abnormal early pregnancies including miscarriages and various different 
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types of ectopic pregnancies.  The final section discusses the role of hCG and 
progesterone in diagnosing abnormal early pregnancy development. 
 
Miscarriage 
 
Spontaneous miscarriage refers to the natural loss of a pregnancy before 
independent viability of the fetus.  Viability implies the ability of the fetus to 
survive extra-uterine life but the gestational age at which the fetus is capable 
of independent existence is controversial.  The definition of miscarriage 
according to the World Health Organization is ‘the expulsion from its mother of 
an embryo or fetus weighing 500g or less’ (500g is approximately the 50th 
centile for 20 weeks’ gestation).  In the UK, any pregnancy loss before 24 
weeks is regarded as a miscarriage.  
 
Figure 2.1: The pregnancy loss iceberg [45] 
 
Miscarriage occurs in approximately 25% of recognized pregnancies.  It is 
known however that a far greater unrecognized pregnancy loss is present in 
the background, with more pregnancies being lost before the pregnancy has 
been suspected, recognized or confirmed, giving rise to the term ‘pregnancy 
loss iceberg’ (Figure 2.1).  Preliminary investigations using hCG to study early 
pregnancy demonstrated great variations in the rate of unrecognized 
pregnancy loss ranging from 3-34% [45].  This variation reflects the limitations of 
the hCG assays used, the different patient populations involved and 
methodological problems relating to the timing of ovulation.  The detection of 
‘background hCG’ in non-pregnant women may have further confused the 
issue.  Many of these problems were addressed by a landmark study in which 
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daily urine samples from 221 women, collected during six months of attempted 
conception, were analyzed for hCG [46].  The degree of sensitivity of the hCG 
assay employed meant that background hCG produced by the endometrium 
of non-pregnant women could be detected.  Therefore a control group of 
women who had undergone sterilization by tubal ligation were also studied, 
and cut off values for identifying pregnancy were determined.  Of the 198 
pregnancies that were detected, 31% were subsequently lost.  22% of all 
pregnancy losses were occult, occurring before the woman could have been 
aware of the pregnancy.  In a similar study in which 200 women collected 
daily urine specimens for hCG analysis over three menstrual cycles, an overall 
pregnancy loss rate of 31% was observed but only 13% of these were occult 
[47].  The discrepancy may be due to the lower sensitivity of the assay used or 
the lack of a control group.  However, when taken together, data from the 
published studies point to a rate of pregnancy loss prior to implantation of 30%, 
a further 30% following implantation but prior to the missed period and 10% as 
clinical miscarriages.   
 
Table 2.2: Different types of miscarriage [48] 
Type of Miscarriage Description 
Threatened Vaginal bleeding and an ongoing pregnancy 
Inevitable The cervix begins to dilate 
Incomplete Passage of some, but not all, products of conception 
Complete All products of conception have been passed from 
the uterus 
Missed/silent Where the fetus has died in utero but has not been 
expelled 
Anembryonic A type of missed miscarriage in which embryonic 
development fails at a very early stage in the 
pregnancy; the sac continues to develop but there 
are no fetal parts evident on ultrasound scan 
Septic A complication of an incomplete miscarriage when 
intrauterine infection occurs 
Recurrent The somewhat arbitrary definition of three or more 
consecutive miscarriages 
 
NB; Whilst accepting that a significant proportion of pregnancy losses occur 
prior to implantation, for the purposes of this research, a miscarriage was 
defined as that which occurs after a positive urinary pregnancy test has been 
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obtained.  The delineation was made at this point because whilst perhaps not 
clinically recognizable (based on a history of a missed menstrual period or 
ultrasonographically identifiable), the pregnancy had been recognized by the 
woman.   
 
Table 2.3: Terminology for classifying pregnancy failure prior to viability [49] 
Term Description of pregnancy loss and clinical or 
ultrasound findings 
Pregnancy loss Spontaneous pregnancy demise 
Early pregnancy loss Spontaneous pregnancy demise before 10 weeks of 
gestational age (before 8th developmental week) 
Non-visualized 
pregnancy loss 
Spontaneous pregnancy demise based on 
decreasing serum or urinary hCG levels and non-
localization on ultrasound , if performed 
Biochemical 
pregnancy loss 
Spontaneous pregnancy demise based on 
decreasing serum or urinary hCG levels without an 
ultrasound evaluation 
Resolved pregnancy 
loss of unknown 
location 
Pregnancy demise not visualized on transvaginal 
ultrasound with resolution of serum hCG after 
expectant management or after uterine evacuation 
without chorionic villi on histology 
Treated pregnancy 
loss of unknown 
location 
Pregnancy demise not visualized on transvaginal 
ultrasound with resolution of serum hCG after medical 
management 
Miscarriage Intrauterine pregnancy demise confirmed by 
histology or ultrasound 
Early miscarriage Intrauterine pregnancy loss <10 weeks’ size on 
ultrasound 
Anembyonic (empty 
sac) miscarriage 
Intrauterine pregnancy loss with a gestational sac but 
without a yolk sac or an embryo on ultrasound 
Yolk sac miscarriage Intrauterine pregnancy loss with a gestational sac 
and yolk sac, without an embryo on ultrasound 
Embryonic 
miscarriage 
Intrauterine pregnancy loss with an embryo without 
cardiac activity on ultrasound 
Fetal miscarriage Pregnancy loss ≥ 10 weeks’ size with a fetus (≥33mm) 
on ultrasound 
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Not all pregnancy losses are symptomatic occurring following presentation 
with abdominal pain and/or vaginal bleeding. Pregnancy losses may also be 
asymptomatic, identified only at the time of a routine scan.  Equally, not all 
women that present with abdominal pain and/or vaginal bleeding go on to 
miscarry.  In one study, only 12% of pregnancies in which bleeding occurred 
went on to miscarry.  Miscarriages have traditionally been classified in a 
clinical way (Table 2.2). More recently, recommendations for pregnancy 
terminology and definitions for adverse pregnancy outcomes before viability 
have been proposed primarily to provide clear, consistent and widely 
applicable terminology for early pregnancy research (Table 2.3) [49].   
 
The maternal risks of any type of miscarriage include haemorrhage (which 
may be significant), infection and the psychological effects of the loss of the 
pregnancy (which may be severe and prolonged) [50].  In the latest 
confidential enquiry into maternal deaths in the UK [51], nine women died as a 
consequence of complications of spontaneous miscarriage, an increase 
compared with each of the five previous triennia.  Four of these deaths 
occurred secondary to infection and the remaining five women died as a 
result of haemorrhage.   
 
Management may be conservative, medical or surgical, the choice of which 
depends on the clinical situation and patient preference.  Medical 
management involves the use of misoprostol with or without prior treatment 
with mifepristone.  Mifepristone is an anti-progestogenic steroid, which 
sensitizes the myometrium to prostaglandin-induced contractions and ripens 
the cervix.  Misoprostol is a synthetic prostaglandin analogue that can be 
administered orally or vaginally to induce medical miscarriage or to ripen the 
cervix prior to surgical evacuation.   A dose of 600-800µg is recommended.  
Surgical management may involve manual vacuum aspiration under local 
anaesthetic in an outpatient or clinic setting or evacuation of retained 
products of conception in theatre under general anaesthetic.  Several studies 
exist that demonstrate that in selected women, both conservative and 
medical management compare favourably with surgical evacuation of the 
uterus with no increase in the risk of infection or severe haemorrhage [52].   
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Ectopic Pregnancy 
 
An ectopic pregnancy is one that occurs in a site outside of the uterine cavity, 
but usually in an adjacent site.  The most common site for an ectopic 
pregnancy is within the fallopian tube but a pregnancy can implant anywhere 
(Figure 2.2), for example, on the ovary or within the abdominal cavity [53].  
Ectopic pregnancies within the appendix [54], liver [55], spleen [56] and 
omentum [57] have all been reported in the literature.  Pregnancies that 
implant in the uterine cornua or cervix, or within a previous caesarean section 
scar, are also referred to as ectopic pregnancies.   
 
Figure 2.2: Common sites of ectopic pregnancies 
 
 
Image taken from: www.ectopic.org.uk 
 
Approximately 1 in 100 spontaneous pregnancies are ectopic in nature and 
the incidence of is rising.  This is largely due to the increased prevalence of 
sexually transmitted diseases and availability of assisted reproduction 
techniques, both of which are major risk factors for the development of the 
condition.  Although the recognition of high risk individuals has improved, and 
prompt diagnosis using high resolution transvaginal ultrasound and serum hCG 
levels is possible, the number of deaths from ectopic pregnancy has remained 
relatively constant over the years although the latest confidential enquiry into 
maternal deaths in the UK [51] shows the case fatality rate of ectopic 
pregnancies to be the lowest since these figures were first estimated in 1988 
(Figure 2.3).   
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Maternal risks include haemorrhage and its consequences, implications for 
future reproductive performance and the psychological effects of the loss of 
the pregnancy.  The choice of management depends largely on the clinical 
situation and to a lesser extent patient preference.  It may be conservative, 
medical using methotrexate, or surgical involving either a salpingectomy or 
salpingotomy performed via laparoscopy or rarely laparotomy.  Whilst 
laparoscopy is associated with shorter operating times, smaller intraoperative 
blood losses, shorter hospital stays, lower costs, decreased analgesia 
requirements and less adhesion formation than laparotomy [58-60], evidence 
suggests that there is no difference in the rates of subsequent successful 
pregnancy between the two approaches.  Similarly, there does not appear to 
be a significant difference in subsequent ongoing pregnancies (56.2% versus 
60.7%) or repeat ectopic pregnancies (5% versus 8%) in tubal ectopic 
pregnancies managed via salpingectomy or salpingotomy in women without 
a history of fertility-reducing factors [61].   
 
Figure 2.3: Numbers of deaths from ectopic pregnancies and rates per 100, 000 
estimated ectopic pregnancies [51]  
 
 
2.2 Ultrasonography 
 
Not only is ultrasound a sensitive method for dating early pregnancies, but it 
can also be used to localize and assess viability in women who present with 
abdominal pain and vaginal bleeding in early pregnancy.   
 
An understanding of the ultrasonographic development of a normal viable 
early intrauterine pregnancy is a pre-requisite for being able to diagnose 
abnormal early pregnancy development, for example non-viable 
(miscarriage) and extra-uterine (ectopic) pregnancies.   
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The Use of Ultrasound to Diagnose Miscarriage 
 
Whilst defining fetal viability is relatively easy (the presence of a fetal pole with 
a fetal heart beat), the definition of non-viability is often less straightforward.   
 
The diagnosis of miscarriage by ultrasound was first described in the 1960s [62].  
It can be diagnosed with confidence relatively easily when an ultrasound 
scan detects an intrauterine pregnancy without a visible fetal heartbeat when 
previously it had been visible and/or when there is failure of the embryo or 
fetus to increase in size over a period of at least one week.     
 
Unfortunately however not all miscarriage diagnoses are as clear-cut as this.  
As described in chapter one, there are landmarks in normally developing 
pregnancies for when structures such as the gestation sac, yolk sac, fetal pole 
and fetal heart should be visible with ultrasound.  However, it cannot be 
assumed that the absence of certain landmarks by a certain time implies a 
failed or failing pregnancy because, except in cases of assisted conception, 
the timing of ovulation and fertilization cannot be known with certainty.  
Furthermore, not all pregnancies exhibit uniform growth in the first trimester 
[63].  The key question is, when can the absence of a feature be used to 
diagnose miscarriage with absolute certainty? 
 
To complicate matters further there is considerable geographic variation in 
the criteria used to confirm non-viability and therefore diagnose miscarriage.  
Until relatively recently, guidelines (based on expert committee reports or 
opinions and/or clinical experience of respected authorities) produced by the 
Royal College of Obstetricians and Gynaecologists and the Royal College of 
Radiologists stated that pregnancies with a fetal pole (or crown rump length) 
measuring 6mm or more with no visible fetal heart activity or a mean 
gestational sac diameter measuring 20mm or more without an identifiable yolk 
sac or fetal were non-viable [64].  However, the American College of 
Obstetricians and Gynaecologists and the Hong Kong College of Obstetricians 
and Gynaecologists use a crown rump length threshold of 5mm and a mean 
sac diameter of 16mm for the diagnosis of a miscarriage [65, 66] whilst the 
Society of Gynaecology of Canada suggest a mean sac diameter exceeding 
8mm without a yolk sac is sufficient for the diagnosis of a miscarriage [67].  This 
disparity reflects the limited evidence available to define viability.  Furthermore 
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the guidelines are based on a small number of poor quality studies performed 
in the 1980s and 1990s that used ultrasound technology unquestionably inferior 
to that available today.  Many of these studies were underpowered with 
sample sizes ranging between 55 and 211 and did not take into consideration 
the reliability of the measurements made.   A recent systematic review [68] 
showed that an empty gestation sac with mean sac diameter of 25mm or 
more or an absent yolk sac with a mean gestation sac diameter of 20mm or 
more were associated with the highest and most precise estimates of 
specificity for diagnosing early embryonic demise.  Whilst these thresholds 
were associated with an estimated specificity of 1.00 their confidence intervals 
(95% CI 0.96-1.00) showed even these values could lead to a false positive 
diagnosis in 4% of cases.   
 
The false negative rate of diagnosing a miscarriage must however be zero, 
otherwise termination of a potentially viable pregnancy may ensue.  Abdallah 
et al [69] defined the false negative rate for the diagnosis of miscarriage using 
different thresholds for both crown rump length with absent cardiac activity 
and mean sac diameter with an empty gestation sac in a cross-sectional 
observational study of 1060 women with intrauterine pregnancies of uncertain 
viability.  Using the American and Hong Kong guidelines, an empty gestation 
sac with a mean sac diameter of 16mm and a crown rump length threshold of 
5mm were associated with false negative rates of 4.4% and 8.3% respectively.  
An empty gestation sac with a mean sac diameter of 20mm was associated 
with a false negative rate of 0.5%.  The false negative rate was zero only at a 
mean sac diameter of greater than 21mm.  A crown rump length threshold of 
6mm was also associated with a false negative rate of zero.  This would imply 
that a diagnosis of a miscarriage can only be made if there is a gestation sac 
with a mean sac diameter measuring at least 21mm with no identifiable yolk 
sac or fetal pole or there is a crown rump length of at least 6mm with no visible 
fetal heart activity. 
 
However, one must take into consideration the inter- and intra-observer 
reliability of the mean gestation sac diameter and crown rump length 
measurements and these have been shown to be poor in pregnancies 
between six and nine weeks of gestation [70].  The limits of agreement 
between observers for mean sac diameter and crown rump length 
measurements are ±19% and ±14% respectively.  This means that in order to 
take into account the variation that can occur when measuring early 
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pregnancies, the threshold for the safe and accurate diagnosis of miscarriage 
should be increased to a gestation sac with a mean sac diameter measuring 
25mm or more or a crown rump length of at least 7mm with no visible fetal 
heart activity.  This fact was incorporated into an addendum on the 2006 
RCOG Guideline on the ‘Management of Early Pregnancy Loss’ in October 
2011 [64]. 
 
The Use of Ultrasound to Diagnose Ectopic Pregnancy 
 
Tubal Ectopic Pregnancy 
 
The majority of tubal ectopic pregnancies should be visualized on transvaginal 
ultrasound, which has reported sensitivities and specificities of 87.0-99.0% and 
94.0-99.9% respectively [71-75].  The presence of a yolk sac and/or fetal pole 
with or without cardiac activity in a sac outside the uterus is the only 
pathognomonic sign of a tubal ectopic pregnancy (Figure 2.4a) but 
unfortunately this is reported in as few as 8-26% of ectopic pregnancies 
detected on transvaginal ultrasound [72, 76-78].  Other non-specific 
ultrasonographic findings suggestive but not diagnostic of tubal ectopic 
pregnancy are discussed in chapter six.   
 
Cornual Ectopic Pregnancy 
 
Cornual pregnancies are the rarest form of ectopic pregnancy with a 
reported incidence of 1 in 76000 pregnancies [79].  A cornual ectopic 
pregnancy can be diagnosed using ultrasound following visualization of (1) a 
single interstitial portion of fallopian tube in the main uterine body, (2) a mobile 
gestation sac/products of conception separate from the uterus and 
completely surrounded by myometrium and (3) a vascular pedicle adjoining 
the gestation sac to the unicornuate uterus [80] (Figure 2.4b).  However it may 
not be directly recognizable because there is often no unique discernable 
abnormal feature and/or clotted blood in the cul-de-sac [81].   
 
Cervical Ectopic Pregnancy 
 
Cervical pregnancies are rare, accounting for less than 1% of all ectopic 
pregnancies [82].  The ultrasonographic diagnosis of a cervical pregnancy 
(Figure 2.4c) is facilitated by the proximity of the probe to the area of interest 
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[81].  The following criteria is used to diagnose a cervical ectopic pregnancy 
(1) an empty uterus (2) a barrel shaped cervix (3) a gestational sac present 
below the level of the internal cervical os (4) the absence of the ‘sliding sign’ 
(when pressure is applied to the cervix using the probe, in a miscarriage the 
gestation sac slides against the endocervical canal but in an implanted 
cervical pregnancy it does not) and (5) blood flow around the gestation sac 
using colour Doppler [83, 84].  
 
Figure 2.4: Ultrasonogram showing a (a) tubal (b) cornual, (c) cervical, (d) 
ovarian, (e) Caesarean scar and (f) interstitial ectopic pregnancy 
Images taken from: www.fetalultrasound.com 
 
Ovarian Ectopic Pregnancy 
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Ovarian Ectopic Pregnancy 
 
There are no specific agreed criteria for the ultrasonographic diagnosis of an 
ovarian ectopic pregnancy, despite there being strict surgical criteria.  
Ultrasound findings have been described in individual case reports.  A study on 
six cases of ovarian pregnancies reported that the pregnancies commonly 
appear as a cyst, on or within the ovary, with a wide echogenic outside ring 
(Figure 2.4d).  A yolk sac or fetal pole is not commonly seen [85, 86].  It is not 
possible to separate the cystic structure or gestation sac from the ovary on 
gentle palpation (negative sliding organ sign).  The corpus luteum should be 
identified separate from the suspected ovarian pregnancy.  Colour Doppler 
may aid detection of a fetal heart pulsation within the ovary.  Diagnosis of an 
ovarian ectopic pregnancy is usually confirmed surgically and histologically as 
it is difficult to differentiate them from corpus luteal cysts, adherent tubal 
ectopic pregnancies, ovarian germ cell tumours and other ovarian 
pathologies.   
 
Caesarean Scar Ectopic Pregnancy 
 
Caesarean scar pregnancy is defined as implantation into the myometrial 
defect occurring at the site of previous uterine incision.  The prevalence of 
Caesarean scar pregnancy is estimated to be approximately 1 in 2000 
pregnancies [87] although the true prevalence is likely to be somewhat higher 
than estimated in the literature as some cases will end in the first trimester 
either by spontaneous miscarriage or termination, and go unreported and 
undiagnosed.  Ultrasound is the primary modality for diagnosing a Caesarean 
scar ectopic pregnancy.  A transvaginal approach may be supplemented by 
transabdominal imaging if required.  The diagnosis of a Caesarean scar 
ectopic pregnancy (Figure 2.4e) can be made using the following criteria: (1) 
an empty uterus, (2) a gestation sac located anteriorly at the level of the 
internal os covering the site (visible or presumed) of the previous lower 
segment Caesarean section incision, (3) thin or absent layer of myometrium 
between the gestation sac and the bladder, (4) evidence of functional 
trophoblastic/placental circulation on Doppler examination and (5) an empty 
endocervical canal/absent ‘sliding sign’ [88-94].  Magnetic resonance 
imaging (MRI) can be used as a second-line investigation if the diagnosis is 
equivocal and there is local expertise available.   It is important to note that 
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the diagnostic criteria described above have not been subject to validation 
and are derived from descriptive case series.   
 
Abdominal Ectopic Pregnancy 
 
The following ultrasound criteria have been suggested as being diagnostic of 
an early abdominal pregnancy: (1) absence of an intrauterine gestation sac, 
(2) absence of both an evident dilated tube and a complex adnexal mass, (3) 
a gestational cavity surrounded by loops of bowel and separated from them 
by peritoneum and (4) a wide mobility similar to fluctuation of the sac, 
particularly evident with pressure of the transvaginal probe toward the 
posterior cul-de-sac [95].  MRI can be a useful diagnostic adjunct in advanced 
abdominal pregnancy [96].   
 
Interstitial Ectopic Pregnancy 
 
Interstitial pregnancy occurs when the ectopic pregnancy implants in the 
interstitial part of the fallopian tube.  The reported incidence varies between 
1.0% and 6.3% of ectopic pregnancies [97-99].  The interstitial part of the 
fallopian tube is about 1-2cm in length and traverses the muscular 
myometrium of the uterine wall, opening via the tubal ostium into the uterine 
cavity [100]. 
 
The following ultrasound criteria may be used for the diagnosis of interstitial 
pregnancy: (1) an empty uterus, (2) products of conception/gestation sac 
located laterally in the interstitial (intramural) part of the tube and surrounded 
by less than 5mm of myometrium in all imaging planes, and (3) presence of 
the ‘interstitial line sign’ i.e. a thin echogenic line extending from the central 
uterine cavity echo to the periphery of the interstitial sac (see the arrow in 
Figure 2.4f).  The interstitial line sign has been shown to have a sensitivity of 80% 
and specificity of 98% for the diagnosis of interstitial ectopic pregnancy [101].  
Three-dimensional ultrasound, if available, can be used to confirm two-
dimensional ultrasound findings as can MRI.  In the three-dimensional coronal 
view of the uterus, a connection between the endometrial cavity and the 
interstitial part of the tube can be visualized [102, 103] and on MRI, a 
gestational sac-like structure is seen lateral to the cornua surrounded by the 
myometrium.  The presence of the intact junctional zone (endomyometrial 
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junction) between the uterine cavity and the gestational-sac like structure also 
supports the diagnosis [104, 105].   
 
2.3 Serology 
 
The role of serum hCG and progesterone and their limitations in normal early 
pregnancy development has been discussed in the previous chapter.  These 
hormones can also aid in the diagnosis of abnormal early pregnancy 
development for example in miscarriage and ectopic pregnancy.  
Unfortunately however, as will become apparent in this section, these two 
hormones are unable to diagnose abnormal early pregnancy development 
with absolute certainty and hence numerous other biomarkers have been 
investigated in an attempt to definitively discriminate viable intrauterine 
pregnancies from non-viable and/or extra-uterine pregnancies and the more 
promising candidates will be discussed in more detail in chapters three and 
nine. 
 
Human Chorionic Gonadotropin (hCG) and 
Progesterone 
 
hCG is secreted by the syncytiotrophoblast in response to GnRH production by 
the adjacent cytotrophoblast cells.  As a pregnancy develops it increases in 
size and hence the syncytiotrophoblast produces more hCG.  An increase in 
hCG of at least 66% in forty eight hours is associated with an intrauterine 
pregnancy with a positive predictive value of 96.5% [34].  A decrease in hCG 
of at least 15% in a forty eight hour period is most usually associated with a 
failing pregnancy [33] although a similar decline is seen in approximately 8% of 
ectopic pregnancies [38, 106]. 
 
If the serum hCG increases by less than 66% or decreases by less than 15% in a 
forty eight hour period, the most likely outcome is an ectopic pregnancy [32, 
38, 106].  Approximately 71% of ectopic pregnancies have a suboptimal 
increase or decrease in serum hCG over a forty eight hour period but this is not 
diagnostic of an ectopic pregnancy as 13-21% of ectopic pregnancies have a 
hCG pattern which mimics that of a viable intrauterine pregnancy [34, 106].  A 
suboptimal rise in serum hCG over a forty eight hour period predicts an 
ectopic pregnancy with a positive predictive value of 43.5% [31]. 
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As mentioned in the previous chapter, the hCG can be used in combination 
with ultrasonographic findings to guide the management of women when 
uncertainties in early pregnancy exist.  For example, if a woman has an empty 
uterus on ultrasound and a serum hCG below the discriminatory zone, the 
pregnancy is most likely too small to be visible on scan and a very early 
intrauterine pregnancy is still a possibility (although ectopic cannot be 
excluded).  In this instance, as long as the woman is in a stable condition, 
management can be more conservative.  If a woman has an empty uterus on 
ultrasound and the serum hCG is above the discriminatory zone, there is a 
much higher possibility that the pregnancy is ectopic and management may 
be more aggressive.   
 
Serum progesterone levels are elevated during pregnancy and change little 
during the first 8-10 weeks of gestation unless the pregnancy fails [33].  Several 
studies [39-41], including a meta-analysis [42], have shown serum 
progesterone levels less than 25nmol/l to be associated with non-viability 
although a small proportion (0.3%) of viable pregnancies have been reported 
with initial levels <15.9nmol/l [107] .  Levels less than 20nmol/l have a positive 
predictive value of more than 95% at predicting a failing pregnancy, and this 
compares favourably with complex multi-parameter diagnostic models [40].  
Progesterone is therefore a useful marker of pregnancy viability. 
 
Unfortunately however, progesterone is a less useful indicator of pregnancy 
location.  Although a low progesterone concentration has been associated 
with ectopic pregnancy since the late 1970s, there is currently no well-
established cut-off to discriminate between intra and extra-uterine 
pregnancies.  Furthermore, a small proportion (2.6%) of ectopic pregnancies 
have been reported with a serum progesterone concentration of more than 
60nmol/l [42].  A meta-analysis [42] of twenty six studies assessing the accuracy 
of a single serum progesterone measurement in the diagnosis of an ectopic 
pregnancy concluded that a single serum progesterone measurement can 
identify patients at risk of ectopic pregnancy who need further evaluation, but 
its discriminative capacity is insufficient to diagnose ectopic pregnancy with 
certainty.   
 
In summary so far then, although a suboptimal increase or decrease in serum 
hCG over a 48-hour period may be indicative of abnormal early pregnancy 
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development, it is unfortunately not diagnostic of either a miscarriage or an 
ectopic pregnancy.  Furthermore, whilst a low serum progesterone level may 
be suggestive of abnormal early pregnancy development with regards to 
viability, unfortunately its ability to predict a failing pregnancy is not 100% 
specific and therefore it cannot be solely relied upon in clinical practice.   
 
2.4  Summary 
 
This chapter has introduced the common clinical problems of miscarriage and 
ectopic pregnancy.  It has described the ultrasonographic appearances of 
abnormal early pregnancies including miscarriage and various different types 
of ectopic pregnancies.  The role of hCG and progesterone in diagnosing 
abnormal early pregnancy development has also been discussed.  Having 
briefly described both normal and abnormal early pregnancy development, 
we can now move on to discuss diagnostic uncertainties in early pregnancy, 
which is the focus of the remainder of this thesis.   
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3. Diagnostic Uncertainties In 
Early Pregnancy 
 
3.1 Introduction 
 
Abdominal pain and/or vaginal bleeding in early pregnancy is common and 
nowadays women are able to find out they are pregnant before they even 
miss a menstrual period.  This means that an increasing number of women are 
presenting to Emergency Departments and Early Pregnancy Assessment Units 
in the very early stages of pregnancy.   
 
If a woman presents during very early pregnancy therefore and an ultrasound 
scan is performed, it is possible that the findings will be inconclusive and a 
definitive diagnosis cannot be provided at that time.  Depending on the exact 
findings during the ultrasound examination, the woman will be given one of 
two possible interim ‘diagnoses’, both of which reflect an ‘uncertainty’ in early 
pregnancy, either in location or viability. 
 
These uncertainties are hazardous in many ways.  Firstly they are likely to cause 
a considerable amount of anxiety for the pregnant woman and her partner.  
Secondly they contribute a significant part of the workload for Early 
Pregnancy Assessment Units which has associated cost and time implications 
(serial blood tests, follow-up ultrasound scans, counseling and occasionally 
admission to hospital and surgery) and finally, perhaps most importantly, 
during the time it takes to make a definite diagnosis, a haemodynamically 
stable woman with an unknown miscarriage or ectopic pregnancy, may 
deteriorate and become unstable and need immediate resuscitation, blood 
transfusion and/or emergency life-saving surgical intervention as opposed to 
more conservative forms of management which could have been utilized if 
the diagnosis had been made whilst in a stable condition.   
 
3.2 Pregnancies of Unknown Location 
 
A pregnancy of unknown location is the descriptive term used to describe the 
situation when a woman has a positive pregnancy test but there are no signs 
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of an intra- or extra-uterine pregnancy or retained products of conception on 
ultrasound scan [108]. 
 
There are four potential reasons why a pregnant woman may have an empty 
uterus on transvaginal ultrasound scan.  Firstly the woman may not be 
pregnant.  It is therefore important that whenever an empty uterus is identified 
during an ultrasound that a pregnancy test is performed.  Other conditions, for 
example germ cell tumours, can lead to elevated hCG levels and although 
these are extremely rare, they must be excluded.  Secondly, the woman may 
be pregnant and the pregnancy may be intrauterine but it may be too early 
in the pregnancy to identify any pregnancy related structures.  A gestation 
sac is not visible on ultrasound until at least day 28-31 [12] and so if a woman 
presents before this time she will be given an interim diagnosis of a pregnancy 
of unknown location.  Thirdly, the woman may have experienced a complete 
miscarriage.  This will usually be indicated by a history of heavy vaginal 
bleeding with or without crampy abdominal pain.  The serum hCG remains 
elevated often for several weeks after a miscarriage.  However, as 6% of 
women with such a history are subsequently diagnosed with an ectopic 
pregnancy [109], it is important not to assume, even with such a history, that a 
miscarriage has occurred and hence the woman should be given an interim 
diagnosis of a pregnancy of unknown location and followed up accordingly 
(unless an intrauterine pregnancy has been visualized previously).  The fourth 
possibility is that uterus is empty because the pregnancy is ectopic and is 
either too small to be visualized at that time, the adnexa have not been 
assessed thoroughly or the ectopic is outside the pelvis.   
 
Even with expert use of transvaginal ultrasound using agreed criteria, it may 
not be possible to confirm if a pregnancy is intra- or extra-uterine in 8-31% of 
cases at the first visit [43].  However, in specialized scanning units, the overall 
incidence of pregnancies of unknown location is as low as 8-10%.  There is a 
consensus that modern early pregnancy units should strive to maintain a 
pregnancy of unknown location rate of 15% or less [110]. 
 
Of women given an initial diagnosis of a pregnancy of unknown location, 50-
70% will have a final diagnosis of a resolving pregnancy/failing pregnancy of 
unknown location, 30-50% will be diagnosed with an intrauterine pregnancy 
on subsequent ultrasound scan, 7-20% of women will be diagnosed with an 
ectopic pregnancy and less than 5% of women will have a persistent 
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pregnancy of unknown location [39, 111-113].  A persistent pregnancy of 
unknown location is when the serum hCG levels fail to decline and no 
evidence of a pregnancy is ever identified on transvaginal ultrasound, 
diagnostic laparoscopy or uterine curettage [109]. 
 
All women with a pregnancy of unknown location are rigorously followed-up 
until a definite diagnosis has been made.  This at least requires one additional 
serum hCG and transvaginal ultrasound scan.  As intervention is only required 
in the minority of women with a pregnancy of unknown location (those with 
an ectopic pregnancy or a persistent pregnancy of unknown location), limited 
resources are expended and significant anxiety inflicted upon a large 
proportion of women unnecessarily.  It would therefore be preferable if the 
proportion of women being given a diagnosis of a pregnancy of unknown 
location was minimised or, at the very least, if there was some way of 
differentiating women with a pregnancy of unknown location who are at high 
risk of an ectopic pregnancy from those who are at low risk of an ectopic 
pregnancy and rationalising follow-up appropriately.  
 
Minimising the Diagnosis of Pregnancy of Unknown 
Location 
 
The ideal would be to minimise the diagnosis of a pregnancy of unknown 
location in the first instance as this would minimise anxiety for women and 
would also enable limited hospital resources to be more appropriately utilized.  
There appear to be two main issues to consider: 
 
Ultrasound Technology 
 
The incidence of pregnancy of unknown location in some early pregnancy 
units is as high as 31% but in other units it may be as low as 8% [43].  The relative 
proportions of pregnancy of unknown location are determined by many 
factors, but the quality of ultrasound examination is probably the most 
important one.  As already discussed, the diagnostic capability of ultrasound 
in early pregnancy increased dramatically following the introduction of 
transvaginal ultrasound and it continues to increase with the development of 
higher frequency transvaginal transducers [15].   Threshold values and 
discriminatory sizes used to distinguish normal and abnormal pregnancies are 
smaller on higher frequency than lower frequency imaging.      
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Ultrasonographer Expertise 
 
Even if using the latest in ultrasound technology, the ability of the machine to 
produce good quality images is critically dependent on the capability of the 
ultrasonographer performing the examination.   
 
Obviously if a woman has no evidence of an intra- or extra-uterine pregnancy 
on ultrasound scan and definitely has a positive pregnancy test then she has, 
until proven otherwise, a pregnancy of unknown location.  This is 
uncontroversial.  However, anecdotally many women are given the diagnosis 
of a pregnancy of unknown location when there is ultrasonographic evidence 
of an intrauterine fluid collection within the uterus and it is these ‘pregnancies 
of unknown location’ that have the potential to become pregnancies of 
uncertain viability.   
 
As already discussed, the yolk sac is currently the first incontrovertible 
ultrasonographic sign of an intrauterine pregnancy.  Many ultrasonographers 
therefore choose to wait until a yolk sac is visible before confirming that the 
intrauterine fluid collection that they have detected on ultrasound is indeed a 
true gestational sac and not a pseudosac.  A pseudosac is seen in up to 15% 
of ectopic pregnancies and caused by the presence of an intrauterine fluid 
collection surrounded by a thick decidual reaction or a detached decidual 
reaction (decidual cast) containing fluid.  This may appear to be a sensible 
approach as it is obviously important not to misdiagnose an ectopic 
pregnancy as an intrauterine pregnancy and vice versa, but, according to 
experts, using transvaginal ultrasound it is not difficult to differentiate a true 
gestation sac, which is eccentrically located and surrounded by two layers, 
from a pseudosac, which is centrally located and only surrounded by one 
layer [114].   
 
Understandably ultrasonographers may not want or feel able to comment on 
the origin of the intrauterine fluid collection that they have visualized.  They 
may not be fully aware of the clinical history of the patient and even if they 
are, they may not be able to interpret the significance of such information.  
Ultrasonographers therefore need to comment in their report not only on the 
size of the intrauterine fluid collection that they have seen, and whether or not 
it has any contents, for example a yolk sac or a fetal pole, but also on its 
precise location within the cavity and the number of surrounding layers, so 
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that clinicians can interpret these findings in combination with the clinical 
picture and are then better equipped to make the distinction between a true 
gestation sac of an intrauterine pregnancy and a pseudosac of an ectopic 
pregnancy.  If this can be successfully accomplished then the number of 
women that are given the diagnosis of a pregnancy of unknown location will 
be significantly reduced.     
 
Rationalising Follow-up of Pregnancies of Unknown 
Location 
 
When a diagnosis of a pregnancy of unknown location is made, it is essential 
to follow women up until a definite diagnosis has been made and although 
follow-up strategies vary between and within units, most involve the use of 
hCG with or without progesterone, repeat transvaginal ultrasound 
examinations and possibly even occasional surgical intervention.  The timing of 
further serum hCG estimations and repeat ultrasound examinations and 
possible surgery is very ad-hoc and clinician dependent and women can 
therefore experience a very protracted period of follow-up with multiple clinic 
visits and possible unnecessary investigations.  This would perhaps be 
acceptable if the majority of women with a pregnancy of unknown location 
had an adverse outcome but, as already discussed, they do not and it would 
therefore be preferable to differentiate those women with a pregnancy of 
unknown location at high risk of having an ectopic pregnancy from those 
women that are low risk so that follow-up, and limited resources, can be more 
appropriately rationed.  Several different methods have been proposed in an 
attempt to accomplish this, some incorporating different blood tests, other 
utilizing mathematical models and a small proportion involving surgical 
intervention.  These shall now be discussed in more detail. 
 
Serology 
 
Human Chorionic Gonadotropin (hCG) 
 
A single serum hCG in the management of pregnancies of unknown location 
is of limited value.  If the serum hCG is above the discriminatory level (usually 
around 1500iu/l but this can vary) and no intrauterine pregnancy is visualized 
on ultrasound, some may assume that the woman has an ectopic pregnancy 
and a diagnostic laparoscopy is subsequently performed.  However, this 
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practice can lead to the performance of unnecessary surgical procedures (in 
women subsequently found to have a failing pregnancy of unknown location 
or an intrauterine pregnancy) and may fail to diagnose ectopic pregnancies, 
as studies have shown that more than 50% of ectopic pregnancies in the 
pregnancy of unknown location population will have initial serum hCG levels 
below the discriminatory level [109].  Furthermore, even if these women do 
have ectopic pregnancies, as their serum hCG is low, they may be suitable 
candidates for non-surgical management and adopting a wait and see 
approach and monitoring their hCG rather than immediately resorting to 
surgery may have its benefits.  It is essential however that women with a 
pregnancy of unknown location are not given methotrexate (even if the hCG 
is above the discriminatory zone and no intrauterine pregnancy has been 
seen on scan) unless a viable intrauterine pregnancy has been confidently 
excluded.   
 
Serial serum hCG measurements have also been used to help predict the 
outcome in women with pregnancies of unknown location.  In a study of 389 
women with a pregnancy of unknown location, a hCG ratio (serum hCG at 
48hrs/serum hCG at 0hrs) of less than 0.87 predicted a failing pregnancy with a 
sensitivity and specificity of 93.1% (95% CI 85.9-97.0&) and 90.8% (95% CI 90.0-
99.1%) respectively [115].  Whilst the hCG ratio is of more use than a single 
serum hCG level in the management of pregnancies of unknown location, 
even that is prone to error and hence caution is required.  Solely using serial 
hCG values to predict the likelihood of ectopic pregnancy in women with a 
pregnancy of unknown location can result in misdiagnosis as approximately 
20% of ectopic pregnancies have a doubling time similar to that of intrauterine 
pregnancies [34, 106] and 10% will have decreasing hCG levels similar to 
spontaneous miscarriages [38, 106].  Clinical judgement should trump 
prediction rules and continued surveillance with a third hCG may be prudent, 
especially when initial values are low or when values are near suggested 
thresholds [116].   
 
Progesterone 
 
Serum progesterone can help predict the outcome of pregnancies of 
unknown location although it is of more use in predicting viability than 
location.  However, a low serum progesterone suggestive of pregnancy failure 
could be used to help rationalise the follow-up of women with pregnancies of 
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unknown location.  In a study of 1110 women with a pregnancy of unknown 
location, women with a progesterone of less than or equal to 10nmol/L at 
presentation were at low (2.1%) risk of requiring medical intervention.  If the 
hCG was also less than 450iu/l, the intervention rate was even lower (1.3%).  
Such women may not benefit from attending routine follow-up visits [117]. 
 
Cancer Antigen 125  
 
Cancer Antigen 125 (CA125) is thought to originate from decidual cells 
affected by chorionic invasion or placental separation.  Levels peak during 
the first trimester of pregnancy and drop to non-pregnant levels in the second 
and third trimester.  Although there is evidence to suggest that CA125 levels 
do not predict spontaneous miscarriage in the first trimester of pregnancy, 
there is conflicting evidence regarding the use of CA125 to differentiate 
between intrauterine pregnancies and ectopic pregnancies.  Serum CA125 
levels have been reported to be significantly lower in ectopic pregnancies 
compared to intrauterine pregnancies [118] but in a larger, more recent study 
[119], single serum measurements of CA125 failed to accurately differentiate 
between a viable intrauterine pregnancy, spontaneous miscarriage or 
ectopic pregnancy. The CA125 ratio however (CA125 at 48hrs/CA125 at 0hrs) 
can distinguish a failing pregnancy of unknown location from an intrauterine 
pregnancy but unfortunately is not able to detect an ectopic pregnancy, 
rendering it of limited use in the clinical setting [120].   
 
Creatine Kinase 
 
Creatine Kinase is a key enzyme for energy metabolism of contraction and 
relaxation in both striated and smooth muscle.  It has been found in all smooth 
muscles studied to date including the fallopian tube.  One theory is that 
damage to the fallopian tube in an ectopic pregnancy is sufficient to cause 
an increase in serum creatine kinase.  Although some studies [121, 122] have 
demonstrated that maternal creatine kinase levels can be an important 
biochemical marker for the diagnosis of an ectopic pregnancy, the general 
consensus is that maternal serum creatine kinase levels do not reliably predict 
ectopic pregnancy [123-126].   
 
Chapter 3 
- 44 - 
 
Activin A and Inhibin A 
 
Activin A and inhibin A are glycoproteins secreted by the feto-placental unit.  
Their levels have been used to predict miscarriage in women with a history of 
recurrent miscarriage [43] and to predict the outcome in women with a 
pregnancy of unknown location [127].  In a study of 141 women with a 
pregnancy of unknown location, serum concentrations of activin A and inhibin 
A were measured at 0 and 48 hours.  Activin A levels at 0 and 48hrs were 
found to be unhelpful in predicting the outcome of pregnancies of unknown 
location as levels were not significantly different between the various outcome 
groups.  Serum inhibin A levels however were significantly lower in the failing 
pregnancy of unknown location group but they did not perform as well as 
serial serum hCG levels and are therefore of little use in this clinical context.   
 
Serum hCG, progesterone, inhibin A, inhibin pro-αC-related immunoreactivity, 
and insulin like growth factor binding protein 1 (IGFBP-1) were measured in 109 
women with a pregnancy of unknown location [128].  Progesterone and 
inhibin A were significantly lower and IGFBP-1 significantly higher in failing 
pregnancies than in those that required further intervention.  In decision tree 
analysis, the novel markers were less useful than progesterone and hCG in 
predicting failing pregnancies of unknown location.  Inhibin pro-αC-RI and 
IFGBP-1 were not at all useful in the prediction of failing pregnancies of 
unknown location.  Inhibin A on the other hand was found to be more 
predictive than hCG alone, but serum progesterone was still considered to be 
the best single marker and progesterone and hCG combined continue to be 
the best way of predicting failing pregnancies of unknown location. 
 
Disintegrin and Metalloprotease Protein-12  
 
When measured in isolation, disintegrin and metalloproteases protein-12 levels 
had limited value as a diagnostic biomarker for ectopic pregnancy in 120 
women with a pregnancy of unknown location [129] 
 
Unfortunately therefore, at present, no single factor has been identified to 
accurately predict the outcome of a pregnancy of unknown location.   
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Mathematical Models 
 
A number of mathematical models have consequently been developed in an 
attempt to predict the outcome of pregnancies of unknown location.  The 
main advantage of mathematical models in general is that they do not 
require any understanding of clinical biochemistry in early pregnancy and 
their use is independent of clinical experience.   
 
In 2004, three logistic regression models to predict the outcome of 
pregnancies of unknown location were created from simple demographic 
and hormonal data and subsequently tested on 185 women with a pregnancy 
of unknown location [130].   The first model, M1 involved the hCG ratio (hCG 
at 48hrs/hCG at 0hrs).  The second model, M2, incorporated the average 
progesterone level ((progesterone at 0hrs + progesterone at 48hrs)/2) and the 
final model, M3, simply utilized the patient’s age.  When tested prospectively, 
M1 out-performed M2 and M3.  It had an area under the curve (AUC) of 0.975, 
0.966 and 0.885 for a failing pregnancy of unknown location, intrauterine 
pregnancy and ectopic pregnancy respectively.  Furthermore, M1 had a 
sensitivity of 91.7%, specificity of 84.2%, positive likelihood ratio of 5.8, positive 
predictive value of 27.5% and negative predictive value of 99.4% for the 
detection of ectopic pregnancy.  Although promising, multi-centre trials are 
needed to test the reproducibility and validity of this model before it is 
adopted in the clinical setting.   
 
In 2006, Gevaert attempted to develop Bayesian networks to predict ectopic 
pregnancies in the pregnancy of unknown location population [131].  
Variables such as age, abdominal pain, vaginal bleeding, gestational age, 
endometrial thickness, midline echo, free fluid, hCG ratio, progesterone levels 
at 0 and 48 hours and the clinical outcome of the pregnancy of unknown 
location were investigated.  The best Bayesian network used the gestational 
age, the hCG ratio and the progesterone level at 48 hours and had an AUC of 
0.88 for predicting ectopic pregnancies when tested prospectively.  However 
these complex models need to be validated, ideally using prospective multi-
centre studies, before being relied upon in clinical practice.   
 
In 2007, Condous devised and tested three different models in an attempt to 
predict pregnancy failure in the pregnancy of unknown location population.  
The first, M1, was a logistic regression model incorporating vaginal bleeding, 
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endometrial thickness, initial serum progesterone and hCG levels.  The second, 
M2, utilized the serum progesterone at presentation only and the third model, 
M3 involved the serum hCG ratio (i.e. serum hCG at 48hrs/serum hCG at 0hrs) 
[132].  The hCG ratio was found to be the optimal test for the prediction of 
pregnancy failure in the pregnancy of unknown location population as it had 
an AUC of 0.980 (SE 0.004) compared to M1 which had an AUC of 0.907 (SE 
0.015) and M2 which had an AUC of 0.952 (SE 0.010).  The difference between 
M3 and M1 and M2 was statistically significant (p<0.0001 and p=0.0076 
respectively).   
 
In an attempt to improve on the performance of the M3 model, a new model, 
M4, was devised and tested against the hCG ratio [133].  This new model 
involved a multinomial logistic regression model containing the log of the hCG 
average, the hCG ratio and its quadratic effect.  In the prediction of ectopic 
pregnancy, this new model, M4, gave an AUC of 0.9 compared to M3, which 
had an AUC of 0.842.  Although this difference was found to be statistically 
significant (p=0.0303), in clinical terms, it did not result in substantially more 
pregnancies being classified correctly as developing ectopic pregnancies.  
Furthermore, when tested in a cohort in the United States, the M4 model 
performed less well [134] highlighting that caution is required when applying 
algorithms from one centre to another, where the definitions of pathology may 
differ.   
 
The effectiveness of these different models are difficult to compare as they are 
not all aiming to predict the same outcome.  Some are interested in predicting 
pregnancy failure [132] presumably so that these women can be followed-up 
less closely or even discharged, whilst others are interested in identifying 
women at high risk of an ectopic pregnancy that need closer surveillance 
[131, 133].  Only one looks at predicting all pregnancy of unknown location 
outcomes [130].  A further disadvantage of all of these models is that 
unfortunately they require multiple visits in order to be able to collect the data 
that is needed to be input into the calculation.   
 
Single Visit Strategies 
 
The possibility of whether women with a pregnancy of unknown location could 
be safely excluded from potentially unnecessary multiple clinic visits has also 
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been assessed [135].  A single visit protocol was developed based on data 
from 200 women.  Pregnancies of unknown location were divided into groups 
according to their probable risk of an ectopic pregnancy.  Women were 
considered to be at low risk if they were thought to have a failing pregnancy 
of unknown location (i.e. they had an initial serum progesterone of ≤10nmol/l 
or an initial serum hCG of ≤25iu/l) or a probable intrauterine pregnancy (i.e. an 
initial serum progesterone of >50nmol/l regardless of the serum hCG).   Women 
with a pregnancy of unknown location and an initial serum progesterone of 
between 10 and 50nmol/l or an initial serum hCG of >25iu/l were considered 
to be at high risk of an ectopic pregnancy.  This protocol was then tested on 
318 consecutive women with an ultrasonographic diagnosis of a pregnancy of 
unknown location.  The sensitivity, specificity, positive predictive value and 
negative predictive value of this single visit strategy to detect women with a 
pregnancy of unknown location at low risk of an ectopic pregnancy was 84%, 
33%, 96% and 9.4% respectively.  In conclusion therefore, although this strategy 
eliminates 84% of non-ectopic pregnancies correctly from the system, 67% of 
ectopic pregnancies are discharged without adequate follow-up rendering 
this single visit strategy inappropriate for the management of women with 
pregnancies of unknown location.   
 
More recently, the efficacy and safety of a modified clinical protocol using 
serum progesterone for the management of women with a pregnancy of 
unknown location has been prospectively evaluated [136].  Two hundred and 
fifty two women with a pregnancy of unknown location and a serum 
progesterone of ≤10nmol/l were discharged after their initial visit and followed-
up via telephone four weeks later.  These women accounted for 37% of the 
total pregnancy of unknown location population.  Follow-up was complete in 
227 of the 252 women (90%).  The pregnancy resolved without any 
complications in 212 of the 227 women (93.4%).  Fifteen women (6.6%) re-
attended with persistent or worsening symptoms.  Five women (2.2%) were 
diagnosed with an ectopic pregnancy following a subsequent ultrasound 
examination.  Of these, two had surgery and three were managed 
conservatively.  Another two women had surgery.  One had a negative 
laparoscopy and an evacuation of retained products of conception but no 
products of conception were found and another was diagnosed with an 
incomplete miscarriage and had an evacuation of retained products of 
conception in which histology confirmed an intrauterine pregnancy.  
Therefore only four women (1.8%) needed surgical intervention.  The positive 
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predictive value of a serum progesterone of ≤10nmol/l for diagnosing a 
spontaneously resolving pregnancy was therefore found to be 98.2% (95% CI 
96.8-99.7%) and it was concluded that a clinical protocol based on a single 
serum progesterone measurement is effective for triaging women with 
pregnancies of unknown location as it reduces the need for follow-up of these 
women without compromising safety.   
 
It therefore appears possible to triage women with a pregnancy of unknown 
location at low risk of an ectopic pregnancy so that they can receive less 
intensive or even no follow-up but the clinically important identification of 
women with a pregnancy of unknown location at high risk of ectopic 
pregnancy remains elusive following a single visit strategy.   
 
Surgery 
 
Uterine curettage and diagnostic laparoscopy are occasionally used in the 
management of women with a pregnancy of unknown location.  One 
commonly used algorithm to diagnose ectopic pregnancy is based on the use 
of transvaginal ultrasound to demonstrate the absence of an intrauterine 
gestation sac followed by uterine curettage if a viable intrauterine pregnancy 
has first been excluded either on the basis of a low progesterone level or a 
suboptimal rise in hCG over 48 hours.  Following curettage, if the hCG 
decreases by less than 15% or increases, a diagnosis of ectopic pregnancy is 
assumed.  This protocol could however result in the inadvertent termination of 
viable intrauterine pregnancies as we have already explained the diagnostic 
limitations of using progesterone and/or hCG to determine pregnancy 
location.   Uterine curettage should therefore not have a routine place in the 
management of women with pregnancies of unknown location although it 
may have a role in identifying the location of the pregnancy after the 
possibility of a viable pregnancy has been excluded.  This may be important 
because it can help advise on future pregnancies.    
 
Similarly, diagnostic laparoscopy should not be used in the routine 
management of women with a pregnancy of unknown location.  In some 
units, as already mentioned, it is performed when there is no intrauterine 
pregnancy visible on ultrasound and the hCG is above the discriminatory 
level.  This may not only lead to the performance of unnecessary surgery (in 
women subsequently found to have a failing pregnancy of unknown location 
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or an intrauterine pregnancy) but it may also falsely reassure clinicians as 
many women with ectopic pregnancies have serum hCG levels below even 
the lowest used discriminatory levels.  Similarly, some women with failing 
pregnancies of unknown location and early intrauterine pregnancies have 
very high serum hCG levels and may therefore undergo unnecessary surgery 
with its associated risks.   
 
3.3 Pregnancies of Uncertain Viability 
 
As eluded to in chapter two, the definition of a pregnancy of uncertain 
viability is when there is an intrauterine gestation sac less of than 25mm mean 
diameter with no obvious yolk sac or fetal pole or a fetal pole of less than 7mm 
with no obvious fetal heart activity. 
 
The visualization of a small intrauterine gestation sac without a fetal pole, or a 
small fetal pole without fetal heart pulsation is not an uncommon finding 
during a transvaginal ultrasound scan in very early pregnancy [137].  In cases 
of known intrauterine location, viability will be uncertain in approximately 10% 
of women at their first visit to the Early Pregnancy Assessment Unit ([138].  It 
may represent a normal early pregnancy of between four and six weeks’ 
gestation or it may be a failed or failing pregnancy with arrested 
development, which is destined to miscarry.   
 
It is therefore not difficult to conceive that erroneous diagnoses of early fetal 
demise can occur in this situation, which may subsequently lead to the 
unintentional termination of a viable pregnancy.  Reports of such diagnostic 
errors prompted a national enquiry in the UK in the mid-1990s [139].  The 
diagnostic guidelines, which were issued as a result, state that no ultrasound 
diagnosis of early fetal demise should be made at the initial visit.  In order to 
confirm or refute viability, a repeat scan at a minimal interval of one week is 
recommended [140] and in cases of an empty sac of less than 15mm in 
diameter, the guideline requires that a follow-up scan be organized two 
weeks later.  This policy, whilst minimising the risk of diagnostic errors, 
contributes greatly to the workload of often already under-resourced Early 
Pregnancy Assessment Units, not to mention causing a tremendous amount of 
anxiety for women and their partners.  Some authors therefore, whilst 
acknowledging the value of time and serial observation,  do not agree with 
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these diagnostic guidelines, preferring to spare women from unnecessary 
follow-up examinations when a failed pregnancy has been reliably diagnosed 
[141].   
 
The prediction of outcome in cases of pregnancies of uncertain viability is 
challenging [139, 141].  Failure to identify certain landmarks 
ultrasonographically by a certain gestation should not be used to reliably 
diagnose pregnancy failure because true gestational age cannot be 
confirmed in the majority of cases as the reported date of the last menstrual 
period is notoriously unreliable [142-144].  Furthermore, growth in the first 
trimester is variable [145-148] and not, as was previously assumed, uniform 
[149]. 
 
Several studies have attempted to establish methods of differentiating viable 
from non-viable pregnancies in cases of pregnancies of uncertain viability.   
 
Predicting Outcome  
 
Serology 
 
The measurement of serum hCG and progesterone have been used in the 
past in an attempt to discriminate between various pregnancy complications.  
Although there is some evidence that measuring serum hCG is helpful in the 
diagnosis of ectopic pregnancy, most studies have concluded that it cannot 
reliably discriminate between viable and non-viable pregnancies [150].  For 
example, in a study of 200 women with a pregnancy of uncertain viability, 
serum hCG levels were not significantly different between the women that 
subsequently miscarried (n=82) and those that did not (3556iu/L versus 
3974iu/L) [151]. 
 
Having said that, an increase in hCG of at least 66% in forty eight hours is 
associated with an intrauterine pregnancy with a positive predictive value of 
96.5% [34] and a decrease in hCG of at least 15% in a forty eight hour period is 
most usually associated with a failing pregnancy [33] although a similar 
decline is seen in approximately 8% of ectopic pregnancies [38, 106]. 
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The inability of hCG to differentiate viable from non-viable pregnancies with 
certainty is in part due to the wide range of hCG levels recorded in normal 
pregnancy and the long half-life in blood following fetal demise.     
 
Serum progesterone levels are elevated during pregnancy and change little 
during the first 8-10 weeks of gestation unless the pregnancy fails [33].  Several 
studies [39-41], including a meta-analysis [42], have shown serum 
progesterone levels less than 25nmol/l to be associated with non-viability 
although a small proportion (0.3%) of viable pregnancies have been reported 
with initial levels <15.9nmol/l [152].  Levels less than 20nmol/l have a positive 
predictive value of more than 95% at predicting a failing pregnancy, and this 
compares favourably with complex multi-parameter diagnostic models [40].  
Progesterone, whilst useful, is not diagnostic and therefore cannot be relied 
upon in clinical practice.  
 
Ultrasonography 
 
Various authors have attempted to predict the outcome of pregnancies of 
unknown viability following a single ultrasound scan.  The benefit of this 
approach is that it minimises additional workload for Early Pregnancy 
Assessment Units and does not cause undue anxiety for the couple.  
 
Single Visit Strategies 
 
A study by Tongsong et al [153] concluded that it was possible using 
transvaginal ultrasound to distinguish viable and non-viable empty gestational 
sacs at a single examination in the majority (73%) of cases.  They found that in 
a study of 211 women with threatened miscarriage and an empty gestation 
sac on ultrasound, a mean sac diameter was the most useful criterion for 
determining non-viability.  A gestational sac with a mean diameter of 17mm or 
more without an embryo or a gestational sac with a mean diameter of 13mm 
or more without a yolk sac were reliable predictors of non-viability with both a 
specificity and positive predictive value of 100%.  A gestational sac with a 
mean diameter of 13mm or more without a yolk sac had the greatest 
sensitivity.   
 
In another study the relationship between maternal age, menstrual age, mean 
gestation sac diameter, presence or absence of a yolk sac and/or sub-
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chorionic haematoma and serum hCG levels and pregnancy outcome was 
investigated in 50 women with vaginal bleeding in the first trimester and an 
ultrasound scan showing a gestation sac with a mean sac diameter of 16mm 
or less and no visible fetal pole [147].  64% of women subsequently miscarried 
prior to 22 weeks gestation.  A yolk sac was visualized in 72.2% of the viable 
pregnancies but only 40.6% of the non-viable pregnancies suggesting that 
failure to visualize the yolk is a risk factor for pregnancy failure.  Sub-chorionic 
haematomas were not found to be of any prognostic significance.  Maternal 
age, menstrual age, mean gestation sac diameter standard deviation score 
(defined as the number of standard deviations from the expected mean) and 
serum hCG level were significantly correlated with subsequent miscarriage 
with AUCs of 0.73, 0.84, 0.91 and 0.66 respectively.  In particular, all women 
over 35 years of age, or with a serum hCG of less than 1200mUI/l or a 
gestational age of more than 7 weeks or a mean gestation sac diameter more 
than 1.64 standard deviations below the mean underwent a miscarriage.  
However when these variables were entered into a multiple logistic regression 
analysis, only the mean gestation sac standard deviation score was found to 
be independently associated with miscarriage.   
 
Other features in addition to mean gestation sac diameter have been 
proposed in an attempt to predict the subsequent outcome of pregnancies 
with initially uncertain viability.  In the aforementioned study by Tongsong, 
deformed gestational sac shape, a low position within the uterine cavity and a 
thin decidual reaction were all shown to be strongly suggestive of non-viability 
but were not 100% accurate [153] and therefore these features should not be 
relied upon in clinical practice. 
 
Another study involving thirty five women with either an empty gestational sac 
or a gestational sac containing a yolk sac but no fetal pole looked at the size 
and shape of the gestation sac, the prominence of the trophoblastic reaction 
and the continuity of the reaction around the sac in an attempt to determine 
if any of these features could be used to help predict outcome in pregnancies 
of uncertain viability [154].  Fifteen pregnancies (42%) were subsequently 
proven to be viable, whilst the remainder (n=20) were non-viable.  The 
average diameter of the gestational sac in the viable pregnancies was 13mm 
compared to 18mm in the non-viable pregnancies.  There was however 
considerable overlap in the sac size between the two groups to enable 
accurate differentiation between the two.  Furthermore, although 80% of non-
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viable pregnancies had a pointed sac, 53% of viable pregnancies also 
exhibited this peculiarity rendering sac shape an inaccurate predictor of 
pregnancy outcome.  With regards to the quality of the trophoblastic 
reaction, although 100% of the viable pregnancies had a good or fair 
reaction, 63% of the failing pregnancies also demonstrated similar findings.  
87% of the viable pregnancies had a continuous trophoblastic reaction 
around the gestational sac compared to only 50% of the non-viable 
pregnancies but again there was considerable overlap between the two 
groups rendering this sign of little use clinically.  However, 67% of the viable 
pregnancies had a good ring of continuous trophoblast compared to only 
12.5% of the non-viable pregnancies.  Thus this combination of these two 
features has a higher degree of accuracy in predicting pregnancy outcome 
than either factor alone.   
 
In addition to the gestation sac, the appearance and volume of the yolk sac 
has been extensively assessed but its relationship with pregnancy outcome 
remains controversial. 
 
In a study of 250 asymptomatic first trimester pregnancies, an abnormal yolk 
sac shape was found in 29% (n=31) of pregnancies that subsequently 
miscarried compared to only 4.6% (n=219) in pregnancies that continued 
beyond the first trimester [155].  An abnormal yolk sac shape was found to 
predict adverse pregnancy outcome with a sensitivity of 29%, specificity of 
95%, positive predictive value of 47% and negative predictive value of 90.5%.   
 
In the same study, the diameter of the yolk sac was also assessed.  It was 
found to strongly correlate with both menstrual age (R=0.958) and crown rump 
length (R=0.943).  Pregnancies that miscarried within the first trimester were 
more likely to have a yolk sac diameter greater than two standard deviations 
from the mean than pregnancies that continued beyond the first trimester 
(64.5% versus 3.7%).  Using two standard deviations as the cut off, abnormal 
pregnancy outcome was predicted with a sensitivity, specificity, positive 
predictive value and negative predictive value of 65%, 97%, 71% and 95% 
respectively [155].  Hence, yolk sac diameter was shown, in this study at least, 
to be a better predictor of adverse pregnancy outcome than yolk sac shape.   
 
Conversely, a much more recent study [156] involving 62 early first trimester 
pregnancies found the yolk sac volume to be poorly correlated with both 
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gestational age (R=0.188) and crown rump length (R=0.203). This may be due 
to differences in caliper placement and measurement technique between 
the various studies however. 
 
The relative development of the yolk sac to the gestation sac has also been 
investigated as a prognostic marker for pregnancy outcome [157].  In a study 
of 49 pregnancies conceived following IVF, three-dimensional measurements 
of the gestation sac, yolk sac and crown rump length were used to form 
nomograms in the pregnancies where there were normal outcomes.  
Measurements from the abnormal pregnancies were then compared with 
these nomograms.  The embryo volumes and gestation sac volumes were 
shown to have a good predictive value for adverse pregnancy outcome 
(p<0.05) but the yolk sac volumes were not found to differ significantly 
between viable and non-viable pregnancies.   The yolk sac volume:gestation 
sac volume ratio was however found to have a good predictive value but this 
is likely to be a function of the effect of gestation sac volume alone.   
 
In another study however [158], the mean diameter and volume of the yolk 
sac and gestational sac, fetal heart rate, maternal age, gestational age and 
presence of a subchorionic haematoma were recorded in 125 asymptomatic 
women with a singleton pregnancy.  Twenty-five women were included at 
each gestational age between six and ten weeks and nomograms were 
constructed for volumes, mean diameters and fetal heart rate.  The main 
outcome measure was miscarriage before 20 weeks gestation.  Regression 
analysis demonstrated that the only variables that were significantly 
associated with spontaneous miscarriage were maternal age more than 34 
years, gestational sac mean diameter less than the 5th percentile and a fetal 
heart rate less than the 5th or more than the 95th percentiles.   The authors 
therefore concluded that new three-dimensional parameters were of no 
additional clinical benefit in predicting miscarriage in asymptomatic first 
trimester pregnancies. 
 
Some pregnancies of uncertain viability however have a visible fetal pole but 
no visible fetal heart pulsation.  There are multiple references in the literature to 
the ultrasonographic detection of early embryos before the onset of cardiac 
contractility [23, 25, 159-161].  Therefore it is possible that early embryos without 
visible heart pulsations are actually alive but their hearts have simply not yet 
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begun to beat.  Equally it is possible that such embryos represent failing 
pregnancies.   
 
The ‘yolk stalk sign’ has been proposed to help differentiate between the two 
possible diagnoses [162].  In early embryonic development, the yolk stalk has 
not yet developed.  Thus the embryo is detected immediately adjacent to the 
yolk sac, producing the so-called ‘signet ring’ appearance (Figure 1.3c).  If the 
embryo is separated from the yolk sac, the separation is due to the 
development of the yolk stalk.  As the yolk stalk lengthens, the distance 
between the embryo and the yolk sac increases.  For small embryos (less than 
5mm), there should be no separation between the embryo and the yolk sac 
because the yolk stalk has not yet developed.  The depiction of separation of 
an embryo with a crown rump length of 5mm or less from the yolk sac 
indicates development of a yolk stalk and thus a more advanced stage of 
gestation than would have been deduced from the crown rump length alone.   
 
In a retrospective study of 159 pregnancies with a crown rump length of 
5.4mm or less with no visible heartbeat, 21 (13.2%) demonstrated this yolk stalk 
sign.  All of these cases were subsequently proven to be failed pregnancies, 
thus the positive predictive value of this sign in determining early pregnancy 
failure was 100% in this cohort.  As it was a retrospective study, no effort was 
made during the ultrasound examination to demonstrate this finding, hence 
the sensitivity of the yolk stalk sign for predicting miscarriage was not 
calculated [162].   
 
In addition to the size and appearance of the gestation sac and yolk sac, 
single measurements of fetal size below expected for gestational age can also 
help predict subsequent miscarriage.  In 1991, Koornstra et al [163] suggested 
a link between first trimester growth restriction and subsequent miscarriage.  
Using customized first trimester growth charts, the authors calculated the 
difference between the observed crown rump length of 403 singleton 
pregnancies and the expected crown rump length based on the duration of 
amenorrhoea.  When the observed crown rump length was 7 or more days 
less than the expected crown rump length, the risk of miscarriage was 16%, 
compared to only 5% when the difference was less than 7 days (p<0.001). 
   
Similarly, in a study of 292 women with certain menstrual dates and a single 
viable fetus, the initial crown rump length of the 14% who subsequently 
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miscarried was below the expected mean for gestational age.  In 61% of those 
that miscarried, the crown rump length was at least two standard deviations 
below expected [145]. 
 
Multiple Visit Strategies 
 
Other studies, involving multiple visits and serial ultrasound scans, have looked 
at the growth rate of various structures in an attempt to establish cut off values 
that could be used to definitively confirm or refute viability.  Such information 
would be extremely useful clinically.  Although it is recommended that when a 
pregnancy of uncertain viability is diagnosed a repeat ultrasound scan at a 
minimum period of one week is required, few, if any protocols define how the 
ultrasound findings are expected to change over that period of time.  This lack 
of clarity leads to both unnecessary protracted follow-up and potentially 
inappropriate intervention.   
 
In a study of 83 women [164], those that had a viable pregnancy (n=53) had a 
mean gestation sac growth velocity of 1.13mm/day (range 0.71-1.75mm) 
compared to 0.70mm/day (range 0.14-1.71mm/day) which was observed in 
women that were subsequently proven to have a non-viable pregnancy 
(n=30).  The authors concluded that a mean gestational sac growth of less 
than 0.6mm per day is associated with an abnormal outcome. However, as 
there is considerable overlap between the ranges in the two groups, this 
should be interpreted with caution.   
 
In 2007, the crown rump length growth rate in viable pregnancies that 
continue beyond the first trimester was compared to that of viable 
pregnancies that subsequently miscarry in the first trimester [165].  Using 
functional linear discriminant analysis (FLDA), the crown rump length growth 
rate was found to be significantly lower (p<0.001) in the group that miscarried.   
FLDA was found to differentiate between normal and abnormal growth and 
thus predict miscarriage with a much higher specificity than a single measure 
of crown rump length (93.1% versus 72.2%). 
 
A multi-centre study looking at changes in both mean gestational sac 
diameter and embryonic crown rump length in women initially diagnosed with 
a pregnancy of unknown viability and correlating these with subsequent 
pregnancy outcome found that both the mean gestational sac diameter 
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growth and crown-rump length growth was significantly higher in viable 
pregnancies compared to non-viable pregnancies (1.003 versus 0.503mm/day 
and 0.673 versus 0.148mm/day respectively) [166].    However, there was an 
overlap in mean sac diameter growth rate between ultimately viable and 
non-viable pregnancies of uncertain viability and no cut off was found below 
which a viable pregnancy could be confidently excluded making it of little 
use in clinical practice.  However a crown rump length growth rate of 
0.2mm/day or less was always associated with a miscarriage and the finding 
of an empty gestational sac on two scans more than a week apart was highly 
suggestive of miscarriage, irrespective of sac growth.  
 
Mathematical Models 
 
As we have seen, it is difficult using solitary features to be able to predict with 
certainty the eventual outcome of pregnancies of uncertain viability.  Various 
authors have therefore investigated the use of mathematical models in an 
attempt to identify any clinical, ultrasonographic or biochemical parameters 
that may be of clinical benefit. 
 
A prospective observational study of 200 pregnant women with an initial 
transvaginal ultrasound finding of a gestation sac of less than 20mm and no 
obvious fetal pole was undertaken [151].  Information was collected including 
maternal age, gestational age, symptomatology, mean gestational sac 
diameter and serum progesterone and hCG levels.  A repeat ultrasound was 
performed one to two weeks after the initial scan.  Of the 200 women 
included, miscarriage was confirmed in 82 (41%) at the time of the repeat 
ultrasound examination.  Women that miscarried were significantly older (32.3 
years versus 29.3 years), more likely to have experienced vaginal bleeding 
(76.8% versus 34.7%), have a larger mean gestation sac diameter (10.7mm 
versus 6.8mm) and a lower serum progesterone level (31nmol/L versus 
84nmol/L) than women who did not miscarry.   
 
Using a regression equation derived from the forward stepwise selection of 
variables, maternal age, mean gestation sac diameter and serum 
progesterone were found to be independent with statistically significant 
coefficients and were therefore included in a logistic regression model.  Using 
this model, at a cut-off value of 10% probability, the diagnosis of a viable 
intrauterine pregnancy could be made with 99.2% (95% CI 95.8-99.97) 
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sensitivity and 70.7% (95% CI 61.3-78.9) specificity.  A comparison of receiver 
operating characteristic (ROC) curves showed that for the logistic regression 
model, the AUC was 0.9693, which was significantly better than all the other 
parameters (gestational age, mean gestation sac diameter, maternal age 
and serum hCG) except serum progesterone, which had an AUC of 0.9493.    
 
However, in order to ensure no cases of viable pregnancy were wrongly 
classified as non-viable, the cut-off value of probability had to be decreased 
to 1%.  At this level the sensitivity is 100% (95% CI 97.5-100) but the specificity 
decreases to 43.9% (95% CI 34.6-53.6).  This makes the model less useful 
clinically, especially since an almost identical result could be achieved using a 
serum progesterone cut-off level of 25nmol/L, in which viable pregnancies 
could be diagnosed with 100% sensitivity (95% CI 96.8-100) and 40.2% 
specificity (95% CI 31.1-50.0).  In addition, the model is complex to use and 
therefore necessitates the use of an electronic calculator or computer, which 
may or may not be readily available. It does however give a numerical 
probability of the pregnancy being viable, which improves counseling of 
women.  The use of the logistic regression model expresses the degree of 
diagnostic uncertainty and gives the opportunity to patients and physicians to 
decide at what level of probability the treatment for the presumed medical 
condition may be initiated.      
 
Similarly, in a prospective study of 493 women, an attempt was made to 
define the incidence and outcome of pregnancies of uncertain viability and 
identify any maternal demographic, ultrasound and symptom variables which 
could help to predict first trimester outcome, using a mathematical model or 
scoring system [167].  Demographic details, obstetric history and pregnancy 
symptoms were sought prior to undertaking a transvaginal ultrasound scan in 
which the gestation sac, yolk sac and fetal pole were measured (if present).  
The presence or absence of a subchorionic haematoma was also noted.  A 
repeat ultrasound was performed one to two weeks later and the outcome 
recorded.  If the outcome at that stage was a viable pregnancy, a further 
ultrasound scan was performed at the end of the first trimester to confirm 
ongoing viability.   
 
Two hundred and ninety eight (60.4%) women had an empty gestational sac 
during the first ultrasound scan.  Of these, 178 (59.7%) had a viable pregnancy 
confirmed at the follow-up scan one to two weeks later.  165 (33.5%) women 
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had a gestational sac containing a yolk sac but no fetal pole at the initial scan 
and of these, 127 (95.2%) had a viable pregnancy confirmed during the 
follow-up scan.  The remaining women (n=30) had a small fetal pole on the 
initial ultrasound scan but no visible fetal heartbeat.  Of these, only two (6.7%) 
had a viable pregnancy confirmed during the subsequent scan.  In this cohort 
therefore, 37.7% of women given an initial diagnosis of a pregnancy of 
uncertain viability were confirmed to have miscarried within two weeks.   
 
Of the 307 pregnancies that were deemed viable after one to two weeks, first 
trimester outcome data was available for 258 (84.0%).  Of these, 225 (87.2%) 
remained viable and the remainder miscarried by the end of the first trimester.  
In the group with no embryonic structures visible on initial scan, 44.4% had a 
pregnancy which progressed into the second trimester.  In the group with a 
yolk sac but no fetal pole visible initially, 71.0% continued beyond the first 
trimester and in the group with a small fetal pole on the initial ultrasound scan 
but no visible fetal heartbeat, all that were viable at the initial follow-up 
ultrasound scan progressed into the second trimester.  Therefore, although 
almost two thirds of women with a pregnancy of uncertain viability may have 
a viable pregnancy confirmed at the initial follow-up scan, ultimately only half 
will have pregnancies that progress into the second trimester and beyond.     
 
Univariable analysis showed that pain, previous miscarriage, parity and the 
presence of a sub-chorionic haematoma were not associated with 
miscarriage.  Advanced maternal age, gestational age, heavy vaginal 
bleeding, increasing deviation of the mean gestation sac diameter above or 
below 7mm, absence of a yolk sac and mean yolk sac diameter deviation 
above 4mm on the other hand were all associated with miscarriage at one to 
two weeks and at the end of the first trimester.  In the multivariable model, only 
maternal age, gestational age, bleeding score, increasing mean gestation 
sac diameter deviation from 7mm and presence of a yolk sac remained 
significant.  Logistic regression models provided the estimated probability of 
viability at the initial one to two weeks follow-up scan and at the end of the 
first trimester for a woman with a pregnancy of uncertain viability and gave 
AUCs of 0.821 (95% CI 0.756-0.885) and 0.774 (95% CI 0.701-0.848) respectively. 
 
This study concludes that in women with a pregnancy of uncertain viability, 
whilst definitive prediction of pregnancy outcome with 100% accuracy might 
not be possible, it could be predicted with reasonable accuracy using 
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mathematical models.  This information could be used in order to prepare 
couples for the predicted likely outcome and time follow-up scans 
accordingly.  There is evidence to suggest that women would benefit 
psychologically from this type of information, even if it is not absolute [168]. 
 
3.4 The Optimal Timing of an Ultrasound Scan 
 
Whilst performing an ultrasound scan too early in pregnancy may lead to the 
diagnosis of a pregnancy of unknown location or a pregnancy of uncertain 
viability which has its associated hazards, deferring an ultrasound scan based 
on arbitrary limits for gestation (especially when as many as 45% of pregnant 
women have a suspect menstrual history [169]) may also be associated with 
physical and psychological morbidity or mortality due to a delay in the 
diagnosis of a miscarriage [170] or ectopic pregnancy [171].    
 
Based on a study of 1442 women [172], the commonest transvaginal 
ultrasound finding prior to 35 days gestation was a pregnancy of unknown 
location and from 42 days gestation it was a viable intrauterine pregnancy 
although the chance of confirming viability increased rapidly per day of 
gestation until 49 days and thereafter plateaued.  A miscarriage could not be 
diagnosed on initial transvaginal ultrasound prior to 35 days gestation.  
Between 35 and 41 days gestation the commonest transvaginal ultrasound 
finding was a pregnancy of uncertain viability.  It was concluded therefore 
that in asymptomatic women, with no previous ectopic pregnancy, 
transvaginal ultrasound could be delayed until 49 days gestation, which would 
decrease the number of inconclusive ultrasound scans performed, without an 
associated increase in morbidity from missed ectopic pregnancy.  
Symptomatic women however should not have an ultrasound scan deferred, 
regardless of gestation, due to the risk of serious morbidity associated with a 
missed diagnosis of an ectopic pregnancy.   
 
3.5 Summary 
 
This chapter has introduced the concept of diagnostic uncertainties in early 
pregnancy, namely pregnancies of uncertain location and pregnancies of 
unknown viability, and the clinical difficulties associated with them.  It has 
outlined strategies to minimise the diagnosis of pregnancies of unknown 
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location (including advancements in ultrasound technology and 
improvements in ultrasonographer training) and methods to rationalise the 
follow-up if a pregnancy of unknown location diagnosis cannot be avoided 
(including multiple serological markers, mathematical models, single visit 
strategies and surgical intervention).  This chapter has also discussed methods 
of predicting pregnancy outcome when a pregnancy of uncertain viability 
diagnosis has been made (including serological markers, ultrasonographic 
findings and mathematical models) and the optimal timing of an ultrasound 
scan in asymptomatic women to avoid diagnostic uncertainties in early 
pregnancy.    
 
3.6 Rationale for Research 
 
As we have discussed, diagnostic uncertainties in early pregnancy are a 
relatively common phenomenon. At present, all methods to differentiate 
viable from non-viable pregnancies in pregnancies of uncertain viability, and 
intrauterine from ectopic pregnancies in pregnancies of unknown location, 
lack the required levels of diagnostic accuracy.    
 
In addition to this, diagnostic uncertainties in early pregnancy are associated 
with many hazards.  Firstly, it is likely that they generate considerable anxiety 
for women and their partners.  Secondly, the follow-up of women with 
uncertain diagnoses contributes a significant part of the workload of Early 
Pregnancy Assessment Units, taking precious time and utilizing valuable and 
limited resources.  Delayed diagnosis of early pregnancy complications such 
as non-viable and ectopic pregnancies can have catastrophic 
consequences, not only for a woman’s health, but also her future fertility. 
 Whilst waiting for a definitive diagnosis, a stable woman with an unknown 
miscarriage or ectopic pregnancy, may deteriorate and become unstable 
and require immediate resuscitation, life-saving blood transfusion and/or 
emergency surgery.  Therefore, minimising the number of women given these 
uncertain diagnoses in early pregnancy, or at the very least, minimising the 
duration of uncertainty when the diagnosis is unavoidable, would be 
preferable.  This rationale forms the premise for the research projects 
undertaken as part of this thesis.   
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4. Anxiety Associated With 
Diagnostic Uncertainties In 
Early Pregnancy 
 
NB: An abridged version of this chapter has been published in the journal, 
Ultrasound in Obstetrics and Gynaecology [173] 
 
4.1 Introduction 
 
Approximately one in five women experience abdominal pain and/or vaginal 
bleeding in early pregnancy.  This usually prompts referral to an Early 
Pregnancy Assessment Unit.  Following a pelvic ultrasound, women may be 
given one of five possible diagnoses, which may be certain or uncertain.  
Certain diagnoses may be positive i.e. a viable intrauterine pregnancy or 
negative i.e. a non-viable intrauterine pregnancy or an ectopic pregnancy.  
Uncertain diagnoses include pregnancies of unknown location or uncertain 
viability.  Pregnancies of uncertain viability are diagnosed in approximately 
10% of women attending an Early Pregnancy Assessment Unit and a further 8-
31% of women are diagnosed with a pregnancy of unknown location [43, 
109].  All women with uncertain diagnoses need to be followed up until a 
definitive diagnosis is made. Follow-up of these uncertainties utilizes limited 
resources and is often haphazard and protracted and women may 
deteriorate clinically during the process.   
 
In medicine, diagnostic tests, such as ultrasound, inherently harbor uncertainty. 
Uncertainty, defined as a cognitive state created when an event cannot be 
adequately structured or categorized because sufficient cues are lacking 
[174], occurs when the decision-maker is unable to assign definite values to 
objects and events and/or is unable to accurately predict outcomes [175]. It is 
generated by events characterized as vague, ambiguous, unpredictable, 
unfamiliar, inconsistent, or lacking information [176].  Uncertainty in medicine 
causes stress [177] and has been linked to poor coping with health-related 
issues, as well as poor adaptation and recovery [176]. 
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Enduring negative affect styles such as stress, anxiety and depression have 
been found to be associated with greater morbidity and mortality in a range 
of clinical contexts including chronic heart disease [178], autoimmune disease 
[179], multiple sclerosis [180], upper respiratory tract infection [181], human 
immunodeficiency virus [182] and cancer [183].  In early pregnancy 
specifically, women who feel stressed, anxious, depressed, out of control 
and/or overwhelmed in the first trimester have a higher risk of miscarriage than 
those who feel happy, relaxed and in control (OR 2.47; 95% CI, 2.02-3.02) [184].   
 
The Transactional Model of Stress suggests that stress is the result of an 
interaction between a person and their environment [185].  When an 
individual finds the environmental demands taxing and/or threatening, and 
simultaneously feels insufficiently equipped to cope with them due to a lack 
(actual or perceived) of personal or environmental resources, stress is 
experienced.  Biological, psychological and/or behavioral stress responses 
then ensue depending on the level of perceived threat.  This implies therefore 
that different people may experience the same event in a completely 
different way based on their individual appraisal of the situation.  In the early 
pregnancy setting therefore, a woman who has had several miscarriages 
previously or who took a long time to conceive might perceive the experience 
of abdominal pain and/or vaginal bleeding to be a greater threat than a 
woman who is contemplating termination of pregnancy.   
 
Whilst there is an abundance of evidence in the literature regarding the 
psychological sequelae following miscarriage and, to a lesser extent, ectopic 
pregnancy [186-193], very little is known about how uncertain diagnoses in 
early pregnancy affect women.    
 
4.2 Aims 
 
The aim of this study therefore was to determine anxiety levels of women 
presenting to Early Pregnancy Assessment Units with abdominal pain and/or 
vaginal bleeding and assess how these change over time and according to 
ultrasonographic diagnosis (viable and non-viable intrauterine pregnancies, 
ectopic pregnancies and pregnancies of unknown location and uncertain 
viability).   
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4.3 Hypotheses 
 
x Amongst women with viable and non-viable intrauterine pregnancies, 
ectopic pregnancies and pregnancies of unknown location or uncertain 
viability, there would be no significant difference in the level of trait anxiety 
x Amongst women with viable and non-viable intrauterine pregnancies, 
ectopic pregnancies and pregnancies of unknown location or uncertain 
viability, there would be no significant difference in the level of state 
anxiety prior to the ultrasound scan 
x Immediately after the ultrasound scan, women with a certain positive 
diagnosis i.e. a viable intrauterine pregnancy, would have the lowest levels 
of state anxiety compared to any other group 
x Women with a certain diagnosis would have lower levels of anxiety than 
women with an uncertain diagnosis 48-72 hours after the ultrasound scan 
x Anxiety levels would decrease over time for women with certain 
diagnoses, especially if they were also positive, and increase over time for 
women with uncertain diagnoses 
 
4.4 Methods 
 
Ethical Approval 
 
Ethical approval for this study was obtained from Nottingham 1 Research 
Ethics Committee (13-EM-0081) (Appendix 1). 
 
Assessment of Anxiety 
 
Anxiety, defined as a negative emotional state characterized by subjective 
feelings of tension, apprehension and nervousness, may occur as a transitory 
state, existing at a given moment in time or in response to a particular situation 
i.e. state anxiety, or as a stable disposition i.e. trait anxiety.   
 
Two different measures of anxiety were considered for the assessment of 
anxiety in this study: Spielberger’s State-Trait Anxiety Inventory (STAI) [194] and 
the Beck Anxiety Inventory (BAI) [195].  Although there are numerous measures 
of anxiety in existence, these two were selected initially because they fulfilled 
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certain pre-defined criteria, specifically they were both considered to be: 
measures of general anxiety (rather than specific anxiety disorders such as 
panic disorder, obsessive-compulsive disorder and post-traumatic stress 
disorder) and the severity of anxiety symptoms; administered by self-report; 
and supported by adequate psychometric data.   
 
The purpose of the STAI is to measure the presence and severity of current 
symptoms of anxiety (state anxiety) and a generalized propensity to be 
anxious (trait anxiety).  As the STAI provides operational measures of both state 
and trait anxiety, it consists of two self-report questionnaires, one for assessing 
state anxiety and the other for determining trait-anxiety.  The different anxieties 
are deliberately separated so that both questionnaires are reliable in their own 
right. 
   
The state anxiety scale evaluates the current state of anxiety, asking how a 
respondent feels ‘right now’ using items that measure subjective feelings of 
apprehension, tension, nervousness, worry and activation/arousal of the 
autonomic nervous system.  Responses for the state anxiety scale assess the 
intensity of feelings ‘at this moment’ and include: (1) not at all (2) somewhat 
(3) moderately so and (4) very much so.   
 
The trait anxiety scale evaluates relatively stable aspects of ‘anxiety 
proneness’ including general states of calmness, confidence and security.  The 
questionnaire consists of 20 questions, including anxiety-present and anxiety-
absent questions and are rated using a 4-point Likert scale. Responses assess 
the frequency of feelings ‘in general’ and include: (1) almost never (2) 
sometimes (3) often and (4) almost always.   
 
For each scale, the item scores are added.  Scoring is reversed for anxiety 
absent items.  Scores range from 20 to 80 and higher scores represent greater 
levels of anxiety.  A cut-off of 39-40 has been suggested to detect clinically 
significant symptoms of state anxiety [196, 197], although a higher cut-off of 
54-55 has been suggested for older adults [198]. 
 
The BAI is a brief measure of anxiety that focuses on the somatic and, to a 
lesser extent, cognitive symptoms of anxiety.  The cognitive subscale provides 
a measure of fearful thoughts and impaired cognitive functioning, for 
example, fear of losing control, of the worst happening or of dying, and the 
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somatic subscale measures the symptoms of physiological arousal such as 
numbness, light-headedness and palpitations.  It has a total of 21 items in 
which respondents indicate how much they have been bothered by each 
symptom over the past week.  Responses are rated on a 4-point Likert scale 
and include: (0) not at all (1) mildly, it did not bother me much (2) moderately, 
it wasn’t pleasant at times and (3) severely, it bothered me a lot. 
 
Scoring is easily accomplished by summing the scores of each item.  Scores 
range from 0 to 63. The following guidelines are recommended for the 
interpretation of scores: 0-7, normal or no anxiety; 8-15, mild to moderate 
anxiety; 16-25, moderate to severe anxiety; and 26-63, severe anxiety. 
   
Both the STAI and the BAI have been shown to have good reliability.  Test-
retest coefficients range from 0.31 to 0.86 (with intervals ranging from one hour 
to 104 days) for the STAI and 0.62 to 0.93 (with intervals ranging from one to 
seven weeks) for the BAI [194, 199-201].  Similarly, internal consistency alpha 
coefficients were also high for both inventories, ranging from 0.86 to 0.95 and 
0.90 to 0.94 for the STAI and BAI respectively [194, 199-201].  The validity of both 
the STAI and the BAI is considered to be moderate although both are 
somewhat limited in being able to discriminate anxiety from depression [202-
205].   
 
The BAI has been demonstrated to be responsive to change over time [206, 
207] as has the state anxiety subscale of the STAI.  The intention of the trait 
anxiety subscale of the STAI is to characterize anxiety proneness as a 
longstanding trait or characteristic and as such it is less responsive to change.   
 
Both the STAI and the BAI are brief to administer (taking approximately 5-10 
minutes to complete) and simple to interpret.  They have both been translated 
into multiple different languages and have both been used in a variety of 
clinical and research settings. 
 
The STAI was ultimately selected for use in this study primarily because, in 
addition to the twenty item subscale for assessing state anxiety, there also 
exists a standardized short form (SSF) of the inventory [208], which consists of 
only six questions and produces scores ranging from six to 24.  This shortened 
version of the state anxiety subscale is therefore even less burdensome for the 
respondent to complete.  The STAI-SSF has acceptable reliability and produces 
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scores that are similar to those produced with the full-form across subject 
groups manifesting normal and raised levels of anxiety.  Two of the three 
anxiety-absent items it contains are those identified by Spielberger to be 
particularly sensitive to low stressors whilst all three of the anxiety-present items 
included he reported as being particularly sensitive to high stressors.  When 
compared with the full-form of the inventory, the six-item short form offers a 
briefer and more acceptable scale for subjects whilst maintaining results that 
are comparable to those obtained from the full-form and remains sensitive to 
different degrees of anxiety.  Further benefits of the abridged inventory are 
that it is likely to maximize response rates and minimise the number of response 
errors and unanswered items thus improving the validity and generalizability of 
any findings [208].  
  
Furthermore, as the BAI measures symptoms experienced in the preceding 
seven days, it is more a measure of prolonged state anxiety rather than 
current state or background trait anxiety.  It was felt that an assessment of 
prolonged state anxiety might be less sensitive to change over a relatively 
brief encounter than the state subscale of the STAI.  There was also the 
concern that the BAI might be interpreted in different ways by different 
individuals, for example, should the highest rating on the scale be marked by 
the respondent even if the symptom was only bothersome very transiently or 
should a general state or indeed an average state be recorded?  The 
assessment of feelings ‘right now’ and ‘at this moment,’ as in the state 
subscale of the STAI, was therefore considered to be less ambiguous.   
  
Another limitation of the BAI is that it focuses primarily on the somatic 
symptoms of anxiety. With fifteen of the 21 items included measuring 
physiological symptoms, many of which overlap with some of the typical 
physical symptoms experienced in normal early pregnancy, for example, 
palpitations, dizziness, indigestion and facial flushing, scores may be increased 
for reasons other than anxiety in some individuals. 
 
Study Design 
  
All women presenting to the Early Pregnancy Assessment Unit at the Queen’s 
Medical Centre, Nottingham with abdominal pain and/or vaginal bleeding 
between 6th February 2015 and 30th April 2015 were eligible to take part in the 
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study.  Upon arrival to the Unit, a brief history was taken using a standardized 
clerking proforma by a nurse specialist.  A pelvic ultrasound scan, performed 
either transabdominally or transvaginally depending on the estimated 
gestational age, was then conducted by a trained ultrasonographer.  
Following the ultrasound, a diagnosis of a viable intrauterine pregnancy, non-
viable intrauterine pregnancy, ectopic pregnancy, pregnancy of unknown 
location or pregnancy of uncertain viability was made.  A viable intrauterine 
pregnancy was confirmed by the presence of an intrauterine gestation sac 
with a fetal pole of any length with demonstrable fetal heart pulsations.  A 
non-viable intrauterine pregnancy was diagnosed when either there was an 
empty intrauterine gestation sac with mean sac diameter greater than 25mm 
or an intrauterine gestation sac containing a fetal pole with crown rump 
length greater than 7mm with no demonstrable fetal heart pulsations or, in the 
absence of a viable embryo, there was no significant growth of the gestation 
sac or fetal pole on two ultrasound scans performed more than seven days 
apart.  Ultrasonographic appearances strongly suggestive of an ectopic 
pregnancy included an empty endometrial cavity with either an 
inhomogeneous adnexal mass or an empty extra-uterine sac or a yolk sac or 
fetal pole with or without cardiac activity in an extra-uterine sac.  A 
pregnancy of unknown location was reported when, in the presence of a 
positive urinary pregnancy test, there was no ultrasonographic evidence of an 
intra- or extra-uterine pregnancy or retained products of conception.  A 
pregnancy of uncertain viability was defined as the presence of an 
intrauterine gestation sac of less than 25mm mean diameter with no obvious 
yolk sac or fetal pole or an intrauterine gestation sac containing a fetal pole of 
less than 7mm with no obvious fetal heart pulsations.  
 
Following the ultrasound, women were reviewed by a nurse specialist or a 
gynaecology doctor, and, if necessary, a plan for further management made 
according to departmental protocols: women with viable intrauterine 
pregnancies were reassured and discharged back to the care of their general 
practitioner; women with non-viable or ectopic pregnancies were given the 
options of conservative, medical or surgical management, which was usually 
carried out within the next 24-72 hours; women with pregnancies of uncertain 
viability were given an appointment for a repeat ultrasound scan after an 
interval of no less than seven days; and women with pregnancies of unknown 
location had their serum hCG concentrations measured at 0 and 48 hours 
after the scan and were then reviewed back in the Early Pregnancy 
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Assessment Unit with the results. At that time, if the serial serum hCG 
concentration had increased by at least 66%, the anticipation was of a viable 
intrauterine pregnancy and hence a repeat ultrasound scan was performed 
after an interval of at least seven days; if the serial serum hCG concentration 
had decreased by at least 15%, the pregnancy of unknown location was 
considered to be resolving and weekly serum hCG measurements were 
recommended until the concentration was less than 25iu/L; if the serial serum 
hCG concentration had decreased by less than 15% or increased by less than 
66%, an ectopic pregnancy was suspected and either surgery, in the form of a 
laparoscopy with or without definitive treatment of an ectopic pregnancy if 
identified, or a repeat ultrasound scan was performed, depending on the 
specific combination of clinical, ultrasonographic and serological findings 
(Appendix 2).   
 
Women were excluded from the study if they had attended the Unit previously 
in the same pregnancy; if they were unable to comprehend the questions 
asked of them; if they failed to answer all of the questions on all of the 
questionnaires: or if they were unable or unwilling to give consent. 
 
Timing of Assessments of Anxiety 
 
Women were asked to complete the trait anxiety questionnaire (Figure 4.1) 
and the first of three STAI-SSF questionnaires (Figure 4.2) upon arrival to the 
Early Pregnancy Assessment Unit (State 1).  The second STAI-SSF questionnaire 
was completed immediately after the ultrasound scan or as soon after as was 
considered practical (but always prior to leaving the unit) (State 2).  At this 
point the questionnaires were returned to a member of the Early Pregnancy 
Assessment Unit staff and the ultrasonographic diagnosis recorded.  Women 
were contacted by one of the investigators 48-72 hours later via telephone or 
e-mail using contact information provided exclusively for the purpose by the 
woman to complete the third and final STAI-SSF questionnaire (State 3) 
(Appendix 3).   
 
Questionnaires were confidential but not completely anonymous although 
identifying information was kept to an absolute minimum (appointment date 
and time) and only used for the purpose of correlating the correct 
ultrasonographic diagnosis to each woman. 
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Figure 4.1: Spielberger’s trait anxiety inventory 
 
 
Figure 4.2: The standardized short form of Spielberger’s state anxiety inventory 
 
 
Statistical Analysis 
 
The reliability of the questionnaires was assessed using Cronbach’s α.  This is a 
measure of the internal consistency used to determine how much the items on 
a scale are measuring the same construct [209]. It is commonly used when 
there are multiple Likert questions in a survey/questionnaire that form a scale 
or subscale, and it is necessary to determine if the scale is reliable.  It is 
expressed as a number between 0 and 1.  There are different reports about 
the acceptable values of α, ranging from 0.70 to 0.95 [210-212]. 
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The Cronbach’s α and the corresponding levels of internal consistency for the 
trait anxiety questionnaire and the three state anxiety questionnaires are 
illustrated in Table 4.1.  In the state 1 questionnaire, questions 1 (I feel calm), 4 (I 
am relaxed) and 5 (I feel content) had zero variance and were removed from 
the scale resulting in an unacceptable level of internal consistency.  This is 
because α is affected by the length of the test and if this is too short, the value 
is reduced.  Additionally, α is grounded in the ‘tau equivalent model’, which 
assumes that each test item measures the same latent trait on the same scale.  
If the number of test items is too small it will also violate the assumption of tau-
equivalence and will underestimate reliability [213]. 
 
Table 4.1: Internal consistency associated with each of the questionnaires 
 Cronbach’s α No. of Items Internal Consistency 
Trait 0.94 20 Excellent 
State 1 0.46 3 Unacceptable 
State 2 0.96 6 Excellent 
State 3 0.94 6 Excellent 
 
To determine if trait anxiety levels were statistically significantly different 
amongst the different groups, a one-way ANOVA was conducted after 
assessment of outliers, normality and homogeneity of variances.   
 
To determine if state anxiety levels were statistically significantly different 
amongst the different groups at the three different time points, a mixed 
ANOVA was conducted after assessment of outliers, normality, homogeneity 
of variances and sphericity.   
 
A post-hoc Tukey-Kramer test was carried out for any statistically significant 
findings from the ANOVAs. Data are presented as mean ± standard deviation 
unless otherwise indicated. p-values of <0.05 were considered to be 
statistically significant for all tests.   
 
4.5 Results 
 
Between 1st February 2015 and 30th April 2015, 1553 women attended the Early 
Pregnancy Assessment Unit at the Queen’s Medical Centre, Nottingham.  381 
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(25%) women were excluded because they had visited the Unit previously 
during the same pregnancy and a further 57 (3.7%) were excluded because 
they were unable to understand the questions. Of the 1115 women who were 
eligible to take part in the study: 670 (60%) did not return any completed 
questionnaires; 203 (18%) only completed the trait and state 1 questionnaire; 
82 (7.4%) only completed the trait, state 1 and state 2 questionnaires. One 
hundred and sixty women (14%) completed all four questionnaires and formed 
our study sample (Figure 4.3).   
 
Figure 4.3: A flow chart to demonstrate movement of participants through the 
different phases of the study 
 
Of these 160 women, 64 (40%) had a viable intrauterine pregnancy, 48 (30%) a 
non-viable intrauterine pregnancy, 16 (10%) an ectopic pregnancy, 13 (8.1%) 
a pregnancy of unknown location and 19 (12%) a pregnancy of uncertain 
viability diagnosed following the ultrasound.  One hundred and twenty-eight 
(80%) women therefore had a certain diagnosis (viable intrauterine, non-viable 
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intrauterine or ectopic pregnancy) and 32 (20%) women had an uncertain 
diagnosis (pregnancy of unknown location or uncertain viability).  Of those 
with a certain diagnosis, 64 (50%) women had a positive diagnosis (viable 
intrauterine pregnancy) and a further 64 women had a negative diagnosis 
(non-viable intrauterine or ectopic pregnancy).  The relative frequencies of 
the different diagnoses were not significantly different amongst women that 
completed all four questionnaires (i.e. those that formed the final study 
sample) and women that only completed two (trait and state 1) or three (trait, 
state 1 and state 2) questionnaires (Table 4.2).   
 
Table 4.2: Relative frequencies of the different diagnoses according to the 
number of questionnaires completed  
Diagnosis 
n(%) 
p-value$ 
Excluded Included 
2* complete 
(n=203) 
3¥ complete 
(n=82) 
4§ complete 
(n=160) 
Viable IUP 71 (35) 36 (44) 64 (40) 0.33 
Non-viable IUP 71 (35) 19 (23) 48 (30) 0.14 
EP 17 (8.4) 4 (4.9) 16 (10) 0.39 
PUL 18 (8.9) 10 (12) 13 (8.1) 0.63 
PUV 26 (13) 13 (16) 19 (12) 0.68 
Certain 159 (78) 59 (72) 128 (80) 0.35 
Uncertain 44 (22) 23 (28) 32 (20) 0.35 
Positive 71 (35) 36 (44) 64 (40) 0.33 
Negative 88 (43) 23 (28) 64 (40) 0.56 
*Trait and State 1; ¥Trait, State 1 and State 2; §Trait, State 1, State 2 and State 3; $Chi-squared test  
 
Similarly, irrespective of the diagnosis, there were no significant differences in 
the levels of trait or state anxiety amongst those that were included in the final 
study sample and those that were excluded due to failure to complete all four 
questionnaires (Table 4.3).   
 
Trait Anxiety Levels in Women Attending The Early 
Pregnancy Assessment Unit With Abdominal Pain 
And/Or Vaginal Bleeding  
 
We first examined whether there were any differences between the groups in 
the level of trait anxiety.  This was  accomplished  by  conducting  a  one-way 
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Table 4.3: Anxiety levels according to diagnosis, timing of assessment and 
number of questionnaires completed 
Diagnosis 
Timing of 
Assessment  
 
Level of Anxiety (mean±SD) 
p-value$ 
Excluded Included 
2* 
complete 
3¥ 
complete 
4§  
complete 
Overall 
Trait 33±7.1 34±3.9 33±7.1 0.88 
State 1 22±1.2 22±1.0 22±1.1 0.90 
State 2  16±7.1 16±6.8 0.72 
Viable IUP 
Trait 34±6.8 33±7.5 34±8.3 0.79 
State 1 22±1.1 22±1.1 22±1.1 0.76 
State 2  7.7±1.3 7.8±1.1 0.91 
Non-
viable IUP 
Trait 34±7.7 33±5.9 33±7.8 0.89 
State 1 22±1.1 22±1.2 22±1.1 0.66 
State 2  20±1.0 20±1.1 0.56 
EP 
Trait 32±6.2 31±7.9 35±9.2 0.56 
State 1 22±1.3 22±0.50 22±1.2 0.96 
State 2  22±0.50 23±0.7 0.53 
PUL 
Trait 32±7.8 35±5.3 36±8.7 0.52 
State 1 22±1.3 22±1.0 22±1.1 0.53 
State 2  23±0.67 23±0.58 1.0 
PUV 
Trait 34±6.1 37±7.3 35±8.7 0.43 
State 1 22±1.2 22±0.86 22±1.1 0.97 
State 2  23±0.80 23±0.92 0.85 
Certain 
Trait 33±7.2 33±7.0 34±8.2 0.89 
State 1 22±1.1 22±1.1 22±1.1 0.62 
State 2  13±6.4 14±6.55 0.16 
Uncertain 
Trait 33±6.8 36±6.4 36±8.5 0.30 
State 1 22±1.3 22±0.90 22±1.09 0.74 
State 2  23±0.73 223±0.79 0.85 
Positive 
Trait 33±7.1 33±7.5 34±8.3 0.79 
State 1 22±1.2 22±1.1 22±1.1 0.80 
State 2  7.7±1.3 7.8±1.1 0.91 
Negative 
Trait 33±7.4 32±6.1 34±8.1 0.92 
State 1 22±1.1 22±1.1 22±1.1 0.63 
State 2  20±1.3 21±1.5 0.80 
*Trait and State 1; ¥Trait, State 1 and State 2; §Trait, State 1, State 2 and State 3; $one-way ANOVA.  
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ANOVA.  There were no significant outliers, as assessed by boxplot; data was 
approximately normally distributed as assessed by the Shapiro-Wilk test 
(p>0.05) when the sample size was small and Normal Q-Q plots when the 
sample size was large; and there was homogeneity of variances, as assessed 
by Levene’s test (p>0.05).   
 
Trait anxiety levels amongst women presenting to the Early Pregnancy 
Assessment Unit with abdominal pain and/or vaginal bleeding were generally 
fairly low (33±7.1).  Trait anxiety levels increased from 32±6.2 in women with 
non-viable intrauterine pregnancies, to 33±7.2 in women with viable 
intrauterine pregnancies, to 34±7.5 in women with pregnancies of uncertain 
viability, to 35±8.6 in women with ectopic pregnancies, to 35±8.0 in women 
with pregnancies of unknown location, but the differences in trait anxiety 
levels between the groups were not statistically significant, F(4, 155)=0.74, 
p=0.57. 
 
State Anxiety Levels According To Certainty Of 
Ultrasonographic Diagnosis And Timing Of Assessment 
 
There was a statistically significant interaction between the level of certainty of 
the diagnosis (i.e. certain and uncertain) and time on the level of state 
anxiety, F(2, 316)=102, p<0.0005, partial η2=0.39. 
 
Simple Main Effect for Group 
 
Prior to the ultrasound scan (state 1), the mean level of state anxiety was 
22±1.1.  State anxiety levels were 22±1.1 in women with a certain and 
uncertain diagnosis.  Immediately after the ultrasound scan (state 2), the 
mean level of state anxiety was 16±6.8.  State anxiety levels ranged from 
14±6.6 in women with a certain diagnosis to 23±0.79 in women with an 
uncertain diagnosis.  48-72 hours after the ultrasound scan (state 3), the mean 
level of state anxiety was 13±6.3.  State anxiety levels ranged from 11±4.3 in 
women with a certain diagnosis to 23±1.7 in women with an uncertain 
diagnosis (Table 4.4 and Figure 4.4).   
 
There was no statistically significant difference in the level of state anxiety 
between the two groups (certain and uncertain) prior to the ultrasound scan 
being undertaken (state 1), F(1, 158)=0.080, p=0.78, partial η2=0.001 but there 
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was a statistically significant difference in the level of state anxiety between 
the two groups both immediately after (state 2), F(1, 158)=56, p<0.005, partial 
η2=0.26 and 48-72 hours after (state 3), F(1, 158)=246, p<0.005, partial η2=0.61 
the ultrasound scan (Table 4.4 and Figure 4.4). 
 
Table 4.4: State anxiety levels according to certainty of diagnosis and timing of 
assessment 
 
State Anxiety Level (mean±SD) 
p-value 
(group) 
Certain 
(n=128) 
Uncertain 
(n=32) 
State 1 22±1.1 22±1.1 ns 
State 2 14±6.6 23±0.79 <0.005 
State 3 11±4.3 23±1.7 <0.005 
p-value (time) <0.0005 <0.001  
 
Figure 4.4: State anxiety levels according to certainty of diagnosis and timing 
of assessment 
 
 
Simple Main Effect for Time 
 
In women with a certain diagnosis, state anxiety levels were highest (22±0.10) 
before the ultrasound scan (state 1) and lowest (11±0.35) 48-72 hours after the 
ultrasound scan (state 3).  Immediately after the ultrasound scan (state 2), 
state anxiety levels were 14±0.52.  In women with an uncertain diagnosis, state 
anxiety levels were highest (23±0.69) 48-72 hours after the ultrasound (state 3) 
and lowest (22±0.20) before the ultrasound scan (state 1).  Immediately after 
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the ultrasound scan (state 2), state anxiety levels were 23±1.0) (Table 4.4 and 
Figure 4.4).   
 
There was a statistically significant effect of time on the level of state anxiety 
for women with both a certain, F(2, 254)=351, p<0.0005, partial η2=0.73 and 
uncertain, F(2, 62)=7.3, p=0.001, partial η2=0.19 diagnosis (Table 4.4 and Figure 
4.4).   
 
For women with a certain diagnosis, the level of state anxiety was statistically 
significantly lower (M=-7.8, SE=0.59, p<0.001) immediately following the 
ultrasound scan (state 2) compared to prior to the ultrasound scan (state 1).  
Similarly, the level of state anxiety was statistically significantly lower (M=-3.4, 
SE=0.22, p<0.001) 48-72 hours following the ultrasound scan (state 3) 
compared to immediately after the ultrasound scan (state 2).   
 
For women with an uncertain diagnosis, the level of state anxiety was 
statistically significantly higher (M=0.97, SE=0.25, p=0.002) immediately 
following the ultrasound scan (state 2) compared to prior to the ultrasound 
scan (state 1).  The level of state anxiety was slightly, but not statistically 
significantly, higher (M=0.063, SE=0.32, p>0.05) 48-72hrs after the ultrasound 
scan (state 3) than it had been immediately after the ultrasound scan (state 
2). 
 
State Anxiety Levels According To Type Of 
Ultrasonographic Diagnosis And Timing Of Assessment 
 
There was a statistically significant interaction between the type of diagnosis 
(i.e. positive, negative or uncertain) and time on the level of state anxiety, 
F(4,314)=916, p<0.0001, partial η2= 0.92. 
 
Simple Main Effect for Group 
 
Prior to the ultrasound scan (state 1), the mean level of state anxiety was 
22±1.1.  State anxiety levels ranged from 22±1.1 in women with an uncertain 
diagnosis to 22±1.1 in women with a positive diagnosis.  State anxiety levels in 
women with a negative diagnosis were 22±1.1.  Immediately after the 
ultrasound scan (state 2), the mean level of state anxiety was 16±6.8.  At this 
time, state anxiety levels were lowest (7.8±1.1) in women with a positive 
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diagnosis and highest (23±0.79) in women with an uncertain diagnosis. State 
anxiety levels in women with a negative diagnosis were 21±1.5.  48-72 hours 
after the ultrasound scan (state 3) the mean level of state anxiety was 13±6.3.  
At this time, state anxiety levels ranged from 6.7±0.59 in women with a positive 
diagnosis to 23±1.7 in women with an uncertain diagnosis.  State anxiety levels 
in women with a negative diagnosis were 15±1.7 (Table 4.5 and Figure 4.5). 
 
There was no statistically significant difference in the level of state anxiety 
between the different types of diagnosis prior to the ultrasound scan being 
performed (state 1) F(2, 157)=0.24, p>0.05, partial η2=0.003 (Table 4.5 and 
Figure 4.5). 
 
Immediately after the ultrasound scan (state 2) there was a statistically 
significant difference in the level of state anxiety between the different types 
of diagnosis, F(2, 157)=2278, p<0.001, partial η2=0.97 (Table 4.5 and Figure 4.5).  
At this time, state anxiety levels were significantly higher (M=2.3, SE=0.27, 
p<0.001) in women with an uncertain diagnosis compared to women with a 
negative diagnosis. Similarly, state anxiety levels were significantly higher 
(M=13, SE=0.22, p<0.001) in women with a negative diagnosis compared to 
women with a positive diagnosis. 
 
Table 4.5: State anxiety levels according to type of diagnosis and timing of 
assessment 
 State Anxiety Level (mean±SD) 
p-value 
(group) 
Certain 
Uncertain 
(n=32) 
Positive 
(n=64) 
Negative 
(n=64) 
State 1 22±1.1 22±1.1 22±1.1 ns 
State 2 7.8±1.1 20.53±1.53 23±0.79 <0.001 
State 3 6.7±0.59 15±1.7 23±1.7 <0.001 
p-value 
(time) 
<0.0005 <0.0005 <0.001  
 
 
Similarly there was a statistically significant difference in the level of state 
anxiety between the different types of diagnosis 48-72hrs after the ultrasound 
scan (state 3), F(2, 157)=1660, p<0.001, partial η2=0.96 (Table 4.5 and Figure 
4.5).  At this time, state anxiety levels were significantly higher (M=8.1, SE=0.29, 
p<0.001) in women with an uncertain diagnosis compared to women with a 
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negative diagnosis. Similarly, state anxiety levels were significantly higher 
(M=8.2, SE=0.24, p<0.001) in women with a negative diagnosis compared to 
women with a positive diagnosis. 
 
Figure 4.5: State anxiety levels according to type of diagnosis and timing of 
assessment 
 
 
Simple Main Effect for Time 
 
In women with a positive diagnosis, state anxiety levels were highest (22±0.14) 
immediately before the ultrasound scan (state 1) and lowest (6.7±0.17) 48-72 
hours later (state 3).  State anxiety levels were 7.8±0.16 immediately after the 
ultrasound scan (state 2).  Similarly, in women with a negative diagnosis, state 
anxiety levels were highest (22±0.14) immediately before the ultrasound scan 
(state 1) and lowest (15±0.17) 48-72 hours later (state 3).  State anxiety levels 
were 21±0.16 immediately after the ultrasound scan (state 2).  Conversely, in 
women with an uncertain diagnosis, state anxiety levels were lowest (22±0.20) 
immediately before the ultrasound scan (state 1) and highest (23±0.24) 48-72 
hours later (state 3).  State anxiety levels were 23±0.22 immediately after the 
ultrasound scan (state 2) (Table 4.5 and Figure 4.5). 
 
There was a statistically significant effect of time on state anxiety levels for 
women with a positive diagnosis, F(2, 126)=6084, p<0.0005, partial η2=0.99 
(Table 4.5 and Figure 4.5).  In women with a positive diagnosis, state anxiety 
levels were statistically significantly lower (M=-14, SE=0.17, p<0.001) 
immediately after the ultrasound scan (state 2) compared to state anxiety 
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levels prior to the ultrasound scan (state 1).  State anxiety levels were also 
statistically significantly lower (M=-1.1, SE=0.14, p<0.001) 48-72 hours after the 
ultrasound scan (state 3) compared to immediately after the ultrasound scan 
(state 2). 
 
There was a statistically significant effect of time on state anxiety levels for 
women with a negative diagnosis, F(2, 126)=508, p<0.0005, partial η2=0.89 
(Table 4.5 and Figure 4.5).  In women with a negative diagnosis, state anxiety 
levels were statistically significantly lower (M=-1.4, SE=0.26, p<0.001) 
immediately after the ultrasound scan (state 2) compared to state anxiety 
levels prior to the ultrasound scan (state 1).  State anxiety levels were also 
statistically significantly lower (M=-5.7, SE=0.12, p<0.001) 48-72 hours after the 
ultrasound scan (state 3) compared to immediately after the ultrasound scan 
(state 2). 
 
There was a statistically significant effect of time on state anxiety levels for 
women with an uncertain diagnosis, F(2, 62)=7.3, p=0.001, partial η2=0.19 
(Table 4.5 and Figure 4.5).  In women with an uncertain diagnosis, state anxiety 
levels were statistically significantly higher (M=0.97, SE=0.25, p=0.002) 
immediately after (state 2) the ultrasound scan compared to state anxiety 
levels prior to the ultrasound scan (state 1).  State anxiety levels were slightly, 
but not statistically significantly, higher (M=0.063, SE=0.32, p>0.05) 48-72 hours 
after the ultrasound scan (state 3) than they were immediately after the 
ultrasound scan (state 2). 
 
State Anxiety Levels According To Specific 
Ultrasonographic Diagnosis And Timing Of Assessment 
 
There was a statistically significant interaction between the specific 
ultrasonographic diagnosis (viable IUP, non-viable IUP, EP, PUL and PUV) and 
time on the level of state anxiety, F(8,310)=605, p<0.0005, partial ƞ2 = 0.94. 
 
Simple Main Effect For Group 
 
Prior to the ultrasound scan (state 1), the mean level of state anxiety was 
22±1.1.  State anxiety levels ranged from 22±1.1 in women with a pregnancy of 
uncertain viability to 22±1.1 in women with a viable intrauterine pregnancy.  
State anxiety levels in women with a non-viable intrauterine pregnancy, 
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ectopic pregnancy and pregnancy of unknown location were 21±1.1, 22±1.1 
and 22±1.1 respectively.  Immediately after the ultrasound scan (state 2), the 
mean level of state anxiety was 16±6.8.  At this time, state anxiety levels were 
lowest (7.8±1.1) in women with a viable intrauterine pregnancy and highest 
(23±0.58) in women with a pregnancy of unknown location. State anxiety 
levels in women with a non-viable intrauterine pregnancy were 20±1.1, 
ectopic pregnancy 23±0.73 and pregnancy of uncertain viability 23±0.92.  48-
72 hours after the ultrasound scan (state 3), the mean level of state anxiety 
was 13±6.3.  At this time state anxiety levels ranged from 6.7±0.59 in women 
with a viable intrauterine pregnancy to 24±0.32 in women with a pregnancy of 
uncertain viability.  State anxiety levels in women with a non-viable intrauterine 
pregnancy, ectopic pregnancy and pregnancy of unknown location were 
14±1.072, 17±1.1 and 22±1.8 respectively (Table 4.6 and Figure 4.6).   
 
Prior to the ultrasound scan (state 1) there was no statistically significant 
difference in the level of state anxiety between the specific diagnoses, 
F(4,155)=0.16, p=0.96, partial ƞ2=0.004 (Table 4.6 and Figure 4.6). 
 
Table 4.6: State anxiety levels according to specific ultrasonographic 
diagnosis and timing of assessment 
 State Anxiety Level (mean±SD) 
 
p-value 
(group) 
Certain Uncertain 
Viable IUP 
(n=64) 
Non-
viable IUP 
(n=48) 
EP 
(n=16) 
PUL 
(n=13) 
PUV 
(n=19) 
State 1 22±1.1 22±1.1 22±1.1 22±1.1 22±1.1 ns 
State 2 7.8±1.1 20±1.1 23±0.73 23±0.58 23±0.92 <0.005 
State 3 6.7±0.59 14±1.1 17±1.1 22±1.8 24±0.32 <0.005 
p-value 
(time) 
<0.005 <0.005 <0.005 <0.05 <0.005  
 
There was a statistically significant difference however in the level of state 
anxiety between the specific diagnoses immediately after the ultrasound scan 
(state 2), F(4,155)=1712, p<0.005, partial ƞ2=0.98 (Table 4.4 and Figure 4.4).  At 
this time, state anxiety levels were significantly higher (M=12, SE=0.20, p<0.005) 
in women with a non-viable intrauterine pregnancy compared to women with 
a viable intrauterine pregnancy.  State anxiety levels were also significantly 
higher (M=2.6, SE=0.30, p<0.005) in women with ectopic pregnancy compared 
to women with a non-viable intrauterine pregnancy.  State anxiety levels were 
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slightly (but not statistically significantly) higher (M=0.29, SE=0.35, p=0.92) in 
women with a pregnancy of uncertain viability compared to women with an 
ectopic pregnancy.  Similarly, state anxiety levels were slightly (but not 
statistically significantly) higher (M=0.21, SE=0.37, p=0.98) in women with a 
pregnancy of unknown location compared to women with a pregnancy of 
uncertain viability. 
 
Figure 4.6: State anxiety levels according to specific ultrasonographic 
diagnosis and timing of assessment 
 
 
48-72 hours after the ultrasound scan (state 3) there was a statistically 
significant difference in the level of state anxiety between the five different 
specific diagnoses, F(4,155)=1734, p<0.005, partial ƞ2 = 0.98 (Table 4.4 and 
Figure 4.4).  At this time, state anxiety levels were significantly higher (M=7.5, 
SE=0.18, p<0.005) in women with a non-viable intrauterine pregnancy 
compared to women with a viable intrauterine pregnancy.  Similarly, state 
anxiety levels were significantly higher (M=2.9, SE=0.27, p<0.005) in women with 
an ectopic pregnancy compared to women with a non-viable intrauterine 
pregnancy.  Unlike immediately after the ultrasound scan (state 2), 48-72 hours 
after the ultrasound scan (state 3), state anxiety levels were significantly higher 
(M=4.5, SE=0.35, p<0.005) in women with a pregnancy of unknown location 
compared to women with an ectopic pregnancy and furthermore, those with 
a pregnancy of uncertain viability were significantly more anxious (M=2.4, 
SE=0.34, p<0.005) than those with a pregnancy of unknown location.   
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Simple Main Effect For Time 
 
In women with a viable intrauterine pregnancy, state anxiety levels were 
highest (22±1.1) prior to the ultrasound scan (state 1) and lowest (6.7±0.59) 48-
72 hours after the ultrasound (state 3).  State anxiety levels were 7.8±1.1 
immediately after the ultrasound scan (state 2).  Similarly, in women with a 
non-viable intrauterine pregnancy, state anxiety levels were highest 
(21.92±1.13) prior to the ultrasound scan (state 1) and lowest (14±1.1) 48-72 
hours after the ultrasound (state 3).  State anxiety levels were 20±1.1 
immediately after the ultrasound scan (state 2).  In women with an ectopic 
pregnancy, state anxiety levels were highest (23±0.73) immediately after the 
ultrasound scan (state 2) and lowest (17±1.1) 48-72 hours after the ultrasound 
scan (state 3).  State anxiety levels were 22±1.2 before the ultrasound scan 
(state 1).  Similarly in women with a pregnancy of unknown location, state 
anxiety levels were highest (23±0.58) immediately after the ultrasound scan 
(state 2) and lowest (22±1.8) 48-72 hours after the ultrasound scan (state 3).  
State anxiety levels were 22±1.1 before the ultrasound scan (state 1).  In 
women with a pregnancy of uncertain viability, state anxiety levels were 
lowest (22±1.1) before the ultrasound scan (state 1) and highest (24±0.32) 48-
72 hours after the ultrasound scan (state 3).  State anxiety levels were 23±0.92 
immediately after the ultrasound scan (state 2) (Table 4.6 and Figure 4.6). 
 
There was a statistically significant effect of time on state anxiety levels for 
women with a viable intrauterine pregnancy, F(2, 126)=6084, p<0.0005, partial 
η2=0.990 (Table 4.4 and Figure 4.4).  In women with a viable intrauterine 
pregnancy, state anxiety levels were significantly lower (M=-14, SE = 0.17, 
p<0.001) immediately after the ultrasound scan (state 2) compared to state 
anxiety levels prior to the ultrasound scan (state 1).  State anxiety levels were 
also statistically significantly lower (M=-1.1, SE=0.14, p<0.001) 48-72 hours after 
the ultrasound scan (state 3) compared to immediately after the ultrasound 
scan  (state 2). 
 
There was a statistically significant effect of time on state anxiety levels for 
women with a non-viable intrauterine pregnancy, F(2,94)=604, p<0.005, partial 
ƞ2=0.93 (Table 4.4 and Figure 4.4). In women with a non-viable intrauterine 
pregnancy, state anxiety levels were significantly lower (M=-2.0, SE=0.26, 
p<0.005) immediately after the ultrasound scan (state 2) compared to state 
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anxiety levels prior to the ultrasound scan (state 1).  State anxiety levels were 
also significantly lower (M=-5.7, SE=0.13, p<0.005) 48-72 hours after the 
ultrasound scan (state 3) compared to immediately after the ultrasound scan 
(state 2). 
 
There was a statistically significant effect of time on state anxiety levels for 
women with an ectopic pregnancy, F(2,30)=120, p<0.005, partial ƞ2=0.89 
(Table 4.4 and Figure 4.4).  In women with an ectopic pregnancy, state anxiety 
levels were not statistically significantly different (M=0.63, SE=0.38, p<0.35) 
immediately following the ultrasound scan (state 2) compared to before the 
ultrasound scan (state 1) but 48-72 hours after the ultrasound scan (state 3), 
state anxiety levels were statistically significantly lower (M=-5.4, SE=0.29, 
p<0.005) than immediately after the ultrasound scan (state 2).   
 
There was a statistically significant effect of time on the level of state anxiety 
for women with a pregnancy of unknown location, F(2,24)=5.5, p<0.05, partial 
ƞ2=0.32 (Table 4.4 and Figure 4.4).  In women with a pregnancy of unknown 
location, state anxiety levels were slightly, (but not statistically significantly), 
higher (M=1.0, SE=0.38, p=0.062) immediately following the ultrasound scan 
(state 2) compared to before the ultrasound scan (state 1). 48-72 hours after 
the ultrasound scan (state 3), state anxiety levels were statistically significantly 
lower (M=-1.5, SE=0.46, p<0.05) than they had been immediately after the 
ultrasound scan (state 2).  State anxiety levels were not however statistically 
significantly different (M=-0.46, SE=0.50, p=1.0) 48-72 hours after the ultrasound 
scan (state 3) than they had been before it (state 1). 
 
There was a statistically significant effect of time on the level of state anxiety 
for women with a pregnancy of uncertain viability, F(2,36)=27, p<0.005, partial 
ƞ2=0.60 (Table 4.4 and Figure 4.4).  In women with a pregnancy of uncertain 
viability, state anxiety levels were statistically significantly higher (M=0.95, 
SE=0.35, p<0.05) immediately following the ultrasound scan (state 2) 
compared to before the ultrasound scan (state 1).  Similarly, the level of state 
anxiety was statistically significantly higher (M=1.1, SE=0.22, p<0.005) 48-72 
hours after the ultrasound scan (state 3) compared to immediately after the 
ultrasound scan (state 2). 
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4.6  Discussion 
 
Our results demonstrate that the propensity for anxiety, as measured by 
Spielberger’s trait anxiety subscale, in women presenting to Early Pregnancy 
Assessment Units with abdominal pain and/or vaginal bleeding, was fairly low, 
reflected by a mean score on the trait anxiety inventory of 33.28±7.13 (the 
maximum score being 80).  Of interest however is that despite this general 
tendency towards low levels of anxiety, very high levels of state anxiety 
(21.96±1.11) were reported by women in all groups prior to the ultrasound  (the 
maximum score being 24). All women scored 20 or more at this time indicating 
that the experience of abdominal pain and/or vaginal bleeding in early 
pregnancy is highly anxiogenic.  For women with certain diagnoses following 
the ultrasound, whether associated with positive or negative connotations, 
anxiety levels significantly decreased but for women with uncertain diagnoses, 
especially a pregnancy of uncertain viability, anxiety levels increased.  Hence 
it appears to be the certainty of diagnosis that affects anxiety levels rather 
than the positive or negative connotations associated with it per se.  
Accordingly we can accept all of the aforementioned hypotheses. 
 
With regards to the viable intrauterine pregnancy group, it is unsurprising that 
anxiety levels significantly decreased immediately following the ultrasound 
scan and continued to do so with time.  It is important to note that the 
minimum score on the STAI-SSF is six (not zero), hence in our study, most 
women who presented to the Early Pregnancy Assessment Unit with 
abdominal pain and/or vaginal bleeding but who were subsequently 
diagnosed with a viable intrauterine pregnancy report feeling only very slightly 
anxious 48-72 hours after the ultrasound scan (6.67±0.59). 
 
It is interesting that in the non-viable intrauterine pregnancy group, state 
anxiety levels also decreased following the ultrasound.  However, Spielberger’s 
STAI only measures anxiety and not other constructs.  The high Cronbach α 
coefficient reflects this.   The fact that these women have been given a 
certain diagnosis, albeit a negative one, appears to have abated their initial 
anxiety, which has perhaps been replaced by other feelings, for example 
grief, sadness and depression, which are well-documented amongst women 
who have miscarried [186-191].   
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Given the threats to health and future fertility, it is unsurprising that state 
anxiety levels in the ectopic pregnancy group increased following the 
ultrasound.  What is surprising is that this increase in anxiety was not significant.  
This may be because there were only sixteen women in this group and their 
anxiety levels were already high, or it may be indicative of the general naivety 
of the population towards the diagnosis, or a reflection of the communication 
skills of those imparting the diagnosis.  Most ectopic pregnancies are treated 
within 48-72 hours of diagnosis, which explains the significant decrease in 
anxiety levels observed at this time.  Again, it is worth remembering that the 
STAI does not measure constructs such as sadness and depression. There is 
very little evidence regarding the psychological sequelae following an 
ectopic pregnancy [193], which, for many women is considered in the same 
light as a miscarriage.  It is, after all, a pregnancy that will never result in a 
child. 
 
In the pregnancy of unknown location group, anxiety levels were shown to 
increase slightly following the ultrasound scan.  Although this increase was not 
found to be statistically significant, this can perhaps be explained by the fact 
that anxiety levels before the scan were already high (22.00±1.08) and the 
maximum score obtainable on the scale is 24.  Anxiety levels then decreased 
significantly over the next 48-72 hours, most likely because serial serum βhCGs 
were taken, the results of which may have provided clarification on the 
situation one way or another.  However, whilst anxiety levels significantly 
decreased, they were still high (21.54±1.81). 
 
In women with a pregnancy of uncertain viability, there was a significant 
increase in anxiety levels immediately after the ultrasound and again 48-72 
hours after.  In the UK, pregnancy of uncertain viability management protocols 
advocate a repeat ultrasound 7-10 days after the initial scan [138].  Since no 
other investigations were performed, no additional information was available 
to alter anxiety levels.  Even if further investigations are not definitive, there is 
evidence to suggest that women would benefit psychologically from tests that 
give them an indication of what a subsequent ultrasound might show [168].   
 
It is extremely important that the psychological wellbeing of women 
undergoing investigation for abdominal pain and/or vaginal bleeding in early 
pregnancy is not overlooked. Our study has demonstrated that the 
experience of these symptoms alone is highly anxiogenic and that for some 
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women, particularly those given uncertain diagnoses, anxiety levels remain 
elevated for at least 48-72 hours.  This is concerning since women who feel 
anxious in the first trimester of pregnancy have a much higher risk of 
miscarriage than those who do not [184]. 
 
This is the first study to assess anxiety levels of women presenting to Early 
Pregnancy Assessment Units with abdominal pain and/or vaginal bleeding 
and to determine how this changes over time with different types of 
diagnoses. The study was prospective, included a considerable number of 
women and utilized a widely adopted, validated and reliable measure of 
anxiety.  
 
Although only 14.3% of eligible women were sampled, the proportions of the 
different diagnoses were representative of the population hence there should 
not be any sampling bias.  Additionally, due to the relative rarity of diagnosis, 
the numbers of women in the ectopic pregnancy, pregnancy of unknown 
location and pregnancy of uncertain viability groups were small.  However, 
since the statistical analyses took this into consideration and the results were 
extremely significant reflected by p-values of <0.005, this should not affect the 
validity of our results or conclusions drawn. 
Whilst we collected very little specific demographic and clinical data, all 
participants were of reproductive age and presented with abdominal pain 
and/or vaginal bleeding in early pregnancy.  Although perhaps interesting to 
collect more data, our remit was to determine how anxious women were, not 
why they were this anxious.  Furthermore, we wanted to make the 
questionnaires as brief as possible to encourage participation. 
 
A further weakness of our study is that follow-up was only for 48-72 hours.  This is 
because we wanted to focus on the impact of the diagnosis itself on anxiety 
levels and felt that with longer follow-up other factors might come into play for 
example, anxiety about further management and future reproductive 
performance.  Longer follow-up would however enable us to assess how 
anxiety levels in women diagnosed with a viable, non-viable or ectopic 
pregnancy after a period of uncertainty compare to those given a certain 
diagnosis at the outset – does an initial uncertain diagnosis reduce the 
psychological burden of a subsequent negative diagnosis or does it cause 
women to remain anxious for the rest of an ongoing pregnancy? 
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4.7 Conclusion 
 
In conclusion, this study has proven that women who present to Early 
Pregnancy Assessment Units with abdominal pain and/or vaginal bleeding in 
early pregnancy and who are subsequently given an uncertain diagnosis 
have significantly higher levels of anxiety than their counterparts who are 
given certain diagnoses, even if those certain diagnoses are not associated 
with an ongoing pregnancy. Healthcare providers should be aware of this 
when communicating uncertain diagnoses. Women with non-viable 
intrauterine pregnancies, and to a lesser extent those with ectopic 
pregnancies, have access to different support groups.  Women with uncertain 
diagnoses have no such psychological support and this must be addressed if 
we are to improve the holistic nature of care provided to women with 
complications of early pregnancy.  Further research should focus on reducing 
the number of women given uncertain diagnoses in early pregnancy and/or 
minimising the duration of uncertainty so that we can: reduce anxiety levels for 
women and their partners; redistribute valuable and limited NHS resources; 
decrease the number of women presenting to hospital in a state of 
haemodynamic compromise following delayed diagnosis of early pregnancy 
complications; and enable women to choose more conservative forms of 
management for non-viable intrauterine and ectopic pregnancies if they wish. 
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5. Accuracy Of First Trimester 
Ultrasound In The Diagnosis 
Of An Intrauterine Pregnancy 
Prior To Visualization Of The 
Yolk Sac 
 
NB; An abridged version of this chapter has been published in the journal 
Ultrasound in Obstetrics and Gynaecology [214] 
 
5.1 Introduction 
 
Having established in the previous chapter that uncertain diagnoses in early 
pregnancy generate considerable anxiety for women, we can now move on 
to attempting to minimise the number of women given uncertain diagnoses in 
early pregnancy, which is the focus of the remainder of this thesis.  As 
discussed in chapter one, the earliest reliable ultrasonographic sign of an 
intrauterine pregnancy is visualization of the gestation sac.  This is first seen as a 
uniformly round, hypoechoic ring-like structure with an echogenic rim.  It can 
be identified using transvaginal ultrasound from 28 days’ gestation [12].  
Initially, the structure does not contain any internal echoes and at this stage 
can be difficult to differentiate from a pseudosac, that is, an intrauterine fluid 
collection, that occurs in up to 15% of ectopic pregnancies [215].   
 
The yolk sac is the first structure to appear within the gestation sac, and 
indicates an intrauterine pregnancy with a positive predictive value of 100% 
[216].  Identification of the yolk sac therefore excludes the possibility of an 
ectopic pregnancy in most cases with the very rare exception of a 
heterotopic pregnancy.  The yolk sac is first visualized with transvaginal 
ultrasound from around 35 days gestation [19] appearing as a spherical 
hyperechoic ring situated eccentrically within the gestation sac.  It increases in 
size to a maximum diameter of 6mm at ten weeks gestation and then begins 
to regress, usually disappearing completely by twelve weeks gestation [217]. 
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Many health care professionals opt to wait until the yolk sac is visualized 
before confirming the presence of a true gestation sac.  This may improve the 
accuracy of ultrasound for the detection of an intrauterine pregnancy, but 
there is a distinct interval of at least seven days during which a gestation sac 
may be visible but a yolk sac may not.  The potential diagnoses that could be 
made during this interval are an early intrauterine pregnancy, which could be 
viable or non-viable, or an ectopic pregnancy, whereby the ‘sac’ visualized is 
actually a pseudosac.  Prompt differentiation between these two would be 
preferable, as it would minimise the level of anxiety for women, prevent 
unnecessary investigations for those with intrauterine pregnancies and permit 
earlier, potentially less invasive intervention for women with ectopic 
pregnancies.   
 
Several different ultrasonographic signs have been proposed to help 
differentiate a true gestation sac from a pseudosac prior to development of 
the yolk sac including the intradecidual [218], double decidual sac [219] and 
chorionic rim [220] signs.  The intradecidual sign consists of a well-defined 
endometrial stripe with an echogenic area eccentrically embedded into the 
thickened decidua on one side of the uterine cavity [218].  This differs from 
that of a pseudosac, which appears as fluid, surrounded by the echogenic 
endometrial lining only.  The double decidual sac sign appears as an intra-
endometrial fluid collection with two surrounding concentric echogenic rings 
that impress upon the endometrial stripe in a normal early pregnancy [219]. In 
an ectopic pregnancy, the decidual reaction consists of only a single ring 
around the fluid collection [19].  The chorionic rim sign consists of a curvilinear 
echogenic rim separate from the underlying decidua bordering an outwardly 
convex fluid collection [220].  In clinical practice however, due to varying 
degrees of accuracy reported in individual studies, none of these signs are 
relied upon to confirm pregnancy location. 
 
5.2 Aims 
 
We therefore undertook a systematic review of the literature and meta-
analysis to determine the accuracy of these first trimester ultrasonographic 
signs in the diagnosis of an intrauterine pregnancy prior to the appearance of 
a yolk sac, in women with or without symptoms of abdominal pain and/or 
vaginal bleeding in early pregnancy. 
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5.3 Methods 
 
Protocol and Registration 
 
Search methods, criteria for inclusion and outcomes were specified in 
advance and documented in the protocol, which was registered with 
PROSPERO (http://www.crd.york.ac.uk/PROSPERO) on 4th October 2012. The 
registration number is CRD42012003046.  Prospero is an international database 
of prospectively registered systematic reviews in health and social care, 
welfare, public health, education, crime, justice and international 
development, where there is a health related outcome.  Key features from the 
review protocol are recorded and maintained as a permanent record.  
PROSPERO aims to provide a comprehensive listing of systematic reviews 
registered at inception to help avoid duplication and reduce opportunity for 
reporting bias by enabling comparison of the complete review with what was 
planned in the protocol.  PROSPERO is produced by the Centre for Reviews 
and Dissemination and funded by the National Institute for Health Research.   
 
Transparent and complete reporting of the systematic review and meta-
analysis was ensured by adhering to the recommendations set out in the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
checklist [221].   PRISMA is an evidence-based minimum set of items for 
reporting in systematic reviews and meta-analyses.  As with all research, the 
value of a systematic review depends on what was done, what was found 
and the clarity of reporting. As with other publications, the reporting quality of 
systematic reviews varies, limiting readers’ ability to assess the strengths and 
weaknesses of those reviews.  Several studies have evaluated the quality of 
systematic review reports and found them lacking [222, 223].   
 
In 1999, to address the suboptimal reporting of meta-analyses, an international 
group developed a guidance called the QUOROM Statement (Quality Of 
Reporting Of Meta-analyses), which focused on the reporting of meta-
analyses of randomized controlled trials [224].  In 2009, the guideline was 
updated to address several conceptual and practical advances in the 
science of systematic reviews, and was renamed PRISMA.  The PRISMA 
Statement consists of a checklist, which contains 27 items, which pertain to the 
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content of a systematic review and meta-analysis including the title, abstract, 
methods, results, discussion and funding, and a flow diagram, which depicts 
the flow of information through the different phases of a systematic review.  It 
maps out the number of records identified, included and excluded and the 
reasons for exclusions (Appendix 11).   
 
Information Sources 
 
The following databases were searched electronically for relevant citations: 
MEDLINE (1951-March week 3 2013), Embase (1980-2013 week 11) and the 
Cochrane Library (2013).  We used a combination of text words, Medical 
Subject and Emree Headings to generate two subsets of citations, one 
indexing ultrasound (‘ultraso$’ OR ‘sonograph$’) and the other indexing terms 
related to early pregnancy location or viability (‘ectopic pregnancy’ OR 
‘tubal pregnancy’ OR ‘viab$ pregnancy’ OR ‘failing pregnancy’ OR ‘miscarr$’ 
OR ‘abort$’ OR ‘intrauterine pregnancy’) or ultrasonographic signs of either an 
intrauterine pregnancy (‘gestation$ sac’ OR ‘yolk sac’ OR ‘f$etal pole’ OR 
‘intradecidual sign’ OR ‘double decidual sac sign’ OR ‘double decidual sac’ 
OR ‘double decidual sign’ OR ‘chorionic rim sign’ OR ‘chorionic rim’) or an 
ectopic pregnancy (‘empty uterus’ OR ‘pseudosac’ ‘free fluid’ OR ‘cul de sac 
fluid’ OR ‘adnexal mass’ OR ‘tubal ring’ OR ‘donut sign’ OR ‘doughnut sign’).  
These two subsets were then combined with ‘AND’ to generate a subset of 
citations relevant to the research question.  The search was limited to human 
subjects and the English language.  Duplicates were removed during the 
process of assessing the full text articles for eligibility. The search was last run on 
3rd July 2014.  Further relevant papers were searched by examination of the 
reference lists of all included studies, reviews and other previously identified 
papers.  A comprehensive database of relevant articles was constructed.   
 
Study Selection 
 
Primary studies that reported original data regarding the ultrasonographic 
diagnosis of either an intrauterine (viable or non-viable) pregnancy were 
included.  Case reports and case studies where the sample size was less than 
10 were excluded due to the high risk of bias.  Commentaries, narrative 
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reviews and letters were also excluded.  There was no limitation on publication 
date or publication status. 
 
Studies were selected in a two-stage process.  Firstly, two reviewers 
independently examined the titles and abstracts of all of the citations 
produced by the electronic searches.  The full manuscripts of citations that 
met the predefined selection criteria were then obtained.  Secondly, 
examination of the full manuscripts led to a final decision regarding inclusion 
or exclusion.  In cases of duplicates, the most recent version was selected.  
Any disagreements concerning selection were resolved by consensus or 
arbitration by a third reviewer. 
 
Data Collection Process 
 
Two review authors independently extracted the data from included studies 
using a data extraction form designed and pilot-tested by the authors. One 
reviewer independently checked the extracted data. If there were data 
queries the corresponding author of the study was contacted. Disagreements 
were resolved by consensus. The names of article authors and titles of the 
included studies were juxtaposed to identify duplicate publications; in case of 
duplicates both articles were considered as a unique study.  
 
Data Items 
 
The following data were extracted from included studies using a standardized 
data extraction form, designed and pilot-tested by the authors: study 
characteristics (first author, year of publication, population, age group, 
inclusion and exclusion criteria); study methodology (study design, study 
period, recruitment method); details of the intervention (ultrasound approach 
i.e. transabdominal or transvaginal, frequency/resolution of ultrasound 
machine, operator; ultrasonographic feature under evaluation i.e. 
intradecidual sign, double decidual sac sign, chorionic rim sign, gestation sac, 
yolk sac); outcome investigated (intrauterine pregnancy, ectopic pregnancy) 
and the quality and accuracy of the results.  Accuracy data were used to 
construct 2x2 tables of ultrasonographic findings and pregnancy location. 
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Risk of Bias in Individual Studies 
 
One reviewer completed the quality assessment using the Quality Assessment 
of Diagnostic Accuracy Studies (QUADAS)-2 checklist (Appendix 12) [225].  This 
checklist is designed to assess the quality of primary diagnostic accuracy 
studies and consists of four key domains covering patient selection, the index 
test, the reference standard and flow of patients through the study and timing 
of the index test(s) and reference standard.  The tool is completed in four 
phases: 1) state the review question; 2) develop review specific guidance; 3) 
review the published flow diagram for the primary study or construct a flow 
diagram if none is reported; 4) judgement of bias and applicability. Each 
domain is assessed in terms of the risk of bias and the first three are also 
assessed in terms of concerns regarding applicability. To help reach a 
judgement on the risk of bias, signaling questions are included. These flag 
aspects of study design related to the potential for bias and aim to help 
reviewers make risk of bias judgements. 
 
Summary Measures 
 
All data were inserted into the Review Manager 5.1 (The Nordic Cochrane 
Centre, The Cochrane Collaboration, Copenhagen, Denmark, 2011) for 
producing summary tables.  Accuracy measures of the various different 
ultrasonographic signs were calculated, including sensitivity, specificity and 
likelihood ratios.  When there were more than three studies reporting on the 
ultrasonographic sign, meta-analysis was performed.  Individual study 
estimates of sensitivities and specificities were plotted in summary receiver 
operating characteristic (ROC) space and forest plots for visual examination of 
heterogeneity. We used the statistical package STATA version 12 (College 
Station, TX, USA) to meta-analyze the sensitivity and specificity from each 
included study using the hierarchical summary ROC (HSROC) approach [226, 
227]. This approach estimates the position and shape of the summary ROC 
curve and takes into account both within and between study variations.  The 
summary ROC curve includes the pairs of sensitivity and specificity for 
individual studies showing the differences in precision between them and the 
overall sensitivity and specificity for the test when all studies are pooled 
together. When all the parameters of the HSROC model could not be 
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estimated due to limited number of studies, it was simplified by assuming a 
symmetrical shape for the summary ROC curve. When only one study was 
available we calculated the sensitivities, specificities, 95% confidence intervals, 
likelihood ratios and pre-test with post-test probabilities for that study. Post-test 
probabilities were calculated using the summary likelihood ratios and the 
median prevalence values with their ranges as the pre-test probabilities.  
 
Risk of Bias Across Studies 
 
The potential impact of publication and reporting bias were minimised by 
performing a comprehensive search for eligible studies and by looking for 
duplication of data. 
 
5.4 Results 
 
Study Selection 
 
The search identified 19,959 potential papers.  Following review of the titles 
and abstracts, 294 full-text papers were selected for further examination and 
subsequently 277 of these studies were excluded (Figure 5.1). Seventeen 
studies [218-220, 228-241], including 2564 women, met the inclusion criteria 
and were incorporated into the systematic review. The characteristics of the 
included studies are shown in Table 5.1. 
 
Diagnostic Accuracy Of The Gestation Sac For 
Predicting An Intrauterine Pregnancy 
 
Twelve cohort studies [228, 229, 231-240], including 1920 women in early 
pregnancy, evaluated the diagnostic accuracy of visualization of a gestation 
sac on ultrasound examination to predict the likelihood of an intrauterine 
pregnancy. Figure 5.2 shows the sensitivities and specificities of the presence 
of a gestation sac for predicting an intrauterine pregnancy in the individual 
studies.  The precision estimates for each of the studies and the estimated 
summary sensitivity and specificity for differentiating between an intrauterine 
and an extra-uterine pregnancy are shown in Figure 5.3 and Table 5.2. 
Following meta-analysis of these twelve studies we found that the presence of 
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a gestation sac predicts an intrauterine pregnancy with a pooled sensitivity of 
53% (95% CI, 38–67%), specificity of 98% (95% CI, 94–99%), positive likelihood 
ratio of 22 (95% CI, 9.8–51) and negative likelihood ratio of 0.48 (95% CI, 0.36–
0.66). Of the studies included in this meta-analysis, the median prevalence of 
an intrauterine pregnancy was 68% (range, 30–88%), however if the 
gestational sac was present the probability of an intrauterine pregnancy was 
as high as 98% (range, 96–99%) compared with 50% (range, 48–52%) if the 
gestational sac was absent. 
 
Figure 5.1: Flow chart summarizing study selection of papers on first-trimester 
ultrasound signs in the diagnosis of intrauterine pregnancy prior to visualization 
of the yolk sac 
 
 
Diagnostic Accuracy Of The Double Decidual Sac Sign 
For Predicting An Intrauterine Pregnancy 
 
Six cohort studies [218-220, 238, 239, 241], including 571 women in early 
pregnancy, evaluated the diagnostic accuracy of the double decidual sac 
sign for predicting the likelihood of an intrauterine pregnancy. Figure 5.2 shows 
the sensitivities and specificities of the double decidual sac sign to predict an 
intrauterine pregnancy in the individual studies.  The precision estimates for 
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each of the studies and the estimated summary sensitivity and specificity for 
differentiating between an intrauterine and an extra-uterine pregnancy are 
shown in Figure 5.3 and Table 5.2. Following meta-analysis of these six studies 
we found that the presence of the double decidual sac sign predicts an 
intrauterine pregnancy with a pooled sensitivity of 82% (95% CI, 68-90%), 
specificity of 97% (95% CI, 76-100%), positive likelihood ratio of 30 (95% CI, 2.8-
331) and negative likelihood ratio of 0.19 (95% CI, 0.10-0.35). In the studies 
included in this meta-analysis the median prevalence of an intrauterine 
pregnancy was 89% (range, 49-91%), but if the double decidual sac sign was 
present the probability of an intrauterine pregnancy was as high as 100% 
(range, 97-100%) compared with 61% (range, 15%-64%) probability if the 
double decidual sac sign was absent. 
 
Figure 5.2: Forest plots for the performance of each ultrasonographic sign for 
predicting an intrauterine pregnancy 
 
 
Diagnostic Accuracy Of The Intradecidual Sign For 
Predicting An Intrauterine Pregnancy 
 
Two cohort studies [218, 230], including 228 women in early pregnancy, 
evaluated the diagnostic accuracy of the intradecidual sign for predicting the 
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likelihood of an intrauterine pregnancy.  Figure 5.2 shows the sensitivities and 
specificities of an intradecidual sign to predict an intrauterine pregnancy in 
the individual studies.  The precision estimates for each of the studies and the 
estimated summary sensitivity and specificity for differentiating between an 
intrauterine and an extra-uterine pregnancy are shown in Table 5.2.  Following 
meta-analysis of these two studies we found that the presence of the 
intradecidual sign predicts an intrauterine pregnancy with a pooled sensitivity 
of 66% (95% CI, 59-73%), specificity of 100% (95% CI, 91-100%), positive 
likelihood ratio of 21 (95% CI, 3.1-141) and negative likelihood ratio of 0.22 (95% 
CI, 0.06-0.88). The median prevalence of an intrauterine pregnancy was 85%, 
but if the intradecidual sign was present the probability of an intrauterine 
pregnancy was as high as 99% compared with 56% if the intradecidual sign 
was absent.  
 
Figure 5.3: Summary receiver operating characteristics (ROC) plot of the ability 
of a gestation sac (a) and the double decidual sac sign (b) to predict an 
intrauterine pregnancy.  
 
 
o, Study estimate; −−−−, hierarchal summary ROC curve; -----, 95% prediction region; , summary 
point; − − −, 95% confidence region 
 
Diagnostic Accuracy Of The Chorionic Rim Sign For 
Predicting An Intrauterine Pregnancy 
 
One cohort study [220], including 238 women in early pregnancy, evaluated 
the diagnostic accuracy of the chorionic rim sign for predicting the likelihood 
of an intrauterine pregnancy. The estimated summary sensitivity and specificity 
for differentiating an intrauterine from an extra-uterine pregnancy are shown 
in Figure 5.2 and Table 5.2. This study found that the presence of the chorionic 
rim sign predicts an intrauterine pregnancy with a sensitivity of 80% (95% CI, 73-
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86%), specificity of 97% (95% CI, 90-100%), positive likelihood ratio of 28 (95% CI, 
7.0-108) and negative likelihood ratio of 0.21 (95% CI, 0.15-0.28). In the study 
the prevalence of an intrauterine pregnancy was 71%, but if the chorionic rim 
sign was present the probability of an intrauterine pregnancy was as high as 
99% compared with 66% if the chorionic rim sign was absent. 
 
Diagnostic Accuracy Of The Yolk Sac For Predicting An 
Intrauterine Pregnancy 
 
One cohort study [239], including 51 women in early pregnancy, evaluated 
the diagnostic accuracy of the presence of the yolk sac for predicting the 
likelihood of an intrauterine pregnancy. The estimated summary sensitivity and 
specificity for differentiating an intrauterine from an extra-uterine pregnancy 
are shown in Figure 5.2 and Table 5.2. This study found that the presence of a 
yolk sac predicts an intrauterine pregnancy with a sensitivity of 42% (95% CI, 
28-58%), specificity of 100% (95% CI, 54%-100%), positive likelihood ratio was 
infinite and negative likelihood ratio of 0.58 (95% CI, 0.45-0.74). In this study the 
prevalence of an intrauterine pregnancy was 88%, but if a yolk sac was 
present the probability of an intrauterine pregnancy was 100% compared with 
19% probability if a yolk sac was absent. 
 
Risk Of Bias Within Studies 
 
Figure 5.4 summarizes the risks of bias and applicability concerns of studies 
based on QUADAS-2 (the assessment of each individual study is presented in 
Table 5.3).  Although some high quality studies were included in the systematic 
review [220, 230, 236], the quality of most of the studies was considered 
mediocre.  Six studies were retrospective in nature [219, 230, 232, 236, 237, 
241], five were small (including fewer than 100 participants) [218, 219, 232, 235, 
240], and twelve studies were undertaken more than 20 years ago [219, 228, 
229, 231-235, 238-241].  Many studies did not fully describe the methods of 
patient selection, most notably with respect to whether a consecutive or 
random sample of patients was selected, and hence it is unclear whether the 
selection of patients could have introduced bias[229, 231, 233, 234, 238-240].   
 
The inclusion criteria for the different studies were also variable.  In some 
studies the only inclusion criteria appeared to be that of a positive pregnancy 
test [219, 234, 239] whilst most others additionally required symptoms 
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suggestive of an ectopic or failing pregnancy namely abdominal pain and/or 
vaginal bleeding [218, 220, 228, 229, 231-233, 235, 236, 238, 240].  Other studies 
had more specific inclusion criteria. The study by Chiang et al., [230], for 
example, included patients who were pregnant and whose ultrasonographic 
findings revealed the presence of either an intrauterine fluid collection 
associated with an early intrauterine pregnancy of less than 5.5 weeks’ 
gestation (defined as a mean sac diameter of less than or equal to 8mm) or 
an ectopic pregnancy. In contrast, Dart et al., [237] included symptomatic 
pregnant women with indeterminate transvaginal ultrasound scans and either 
a serum human Chorionic Gonadotropin (hCG) level of greater than 
3000mIU/ml or women whose last menstrual period was more than 38 days 
before examination. The results of these studies with more specific inclusion 
criteria may be less generalizable. 
 
Figure 5.4: Risk of bias and applicability concerns based on quality assessment 
of diagnostic accuracy studies (QUADAS)-2 across included studies 
 
The degree of blinding in the studies was also unclear. Many studies did not 
explicitly state whether the ultrasound images were interpreted without 
knowledge of the final diagnosis.  In the prospective studies, it is probable that 
this was the case owing to the inevitable passage of time that occurred whilst 
waiting for the clinical follow-up (reference standard) to occur.  It is less clear 
in the retrospective studies [219, 230, 232, 236, 237, 241].  Furthermore three 
studies did not clearly define the ultrasonographic feature under surveillance 
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[228, 232, 235] and in those studies that did give a clear definition, there were 
often considerable differences between the studies. Most studies that 
investigated the accuracy of a gestation sac defined a gestation sac as 
being an anechoic intrauterine fluid collection surrounded by an echogenic 
border [229, 233, 238-240] but two studies included the presence of internal 
echoes in the definition [231, 234] and two others incorporated a size limitation 
[236, 237].  Therefore the conduct and/or interpretation of the index test could 
have introduced bias.  Some of the older studies utilized transabdominal 
ultrasound [219, 232, 233, 238, 239] and the ultrasound approach was not 
stated in others [235] and hence their results may not be applicable to current 
practice.  Seven studies [218, 219, 232-234, 236, 237] did not clearly define the 
reference standard and in the majority of studies it was unclear if the results of 
the reference standard were interpreted without knowledge of the index test.  
Patient flow was considered to be appropriate in all the studies. 
 
5.5 Discussion 
 
Summary of Evidence 
 
This systematic review and meta-analysis summarizes the diagnostic accuracy 
of commonly used ultrasonographic signs for indicating the location of a 
pregnancy, and shows that the presence of any of the ultrasonographic 
features evaluated, namely a gestation sac, double decidual sac sign, 
intradecidual sign or chorionic rim sign, increases substantially the probability 
that a pregnancy is of intrauterine location. Therefore, the presence of these 
signs indicates an intrauterine pregnancy and can be used to guide clinical 
practice. The exception to this is the use of the presence of the gestation sac 
as this test is slightly less specific than the others for predicting an intrauterine 
pregnancy. The absence of these signs does not exclude the diagnosis of an 
intrauterine pregnancy, and a negative test result therefore cannot be relied 
upon to inform clinical practice.   
 
Strengths and Weaknesses of Study  
 
We conducted a prospective and extensive systematic search of electronic 
databases using a predefined protocol which was registered with PROSPERO. 
The high number of included studies in our meta-analyses for a gestation sac 
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and the double decidual sac sign strengthened the power of these 
conclusions and enabled us to define the diagnostic accuracy of these signs 
in confirming an intrauterine pregnancy with relative precision. Our findings for 
the other ultrasonographic features i.e. the intradecidual sign, chorionic rim 
sign and yolk sac, were, however, limited by the small number of included 
studies.   
 
An additional strength is that we performed an assessment of quality of the 
included studies. However, the quality of the included studies was relatively 
poor as there was a substantial risk of bias and concerns regarding the 
applicability to current clinical practice.  Furthermore, many of the studies 
reported a different prevalence of pregnancy outcomes compared with 
more recent studies, which may affect the generalizability of the findings to 
clinical practice in a variety of settings.   
 
The main limitation of our study is that our conclusions with regard to 
evaluating the accuracy of visualization of a yolk sac for determining the 
location of an intrauterine pregnancy have been drawn from one small study.  
Other studies investigating the significance of a yolk sac in early pregnancy 
were identified by the search strategy but these did not meet the pre-
specified inclusion criteria. These studies were largely considered to be 
irrelevant, as they were more concerned with the relative size, shape or 
position of the yolk sac with regard to predicting pregnancy viability than with 
the actual presence of the yolk sac confirming identification of a true 
gestation sac and, ultimately, an intrauterine pregnancy, which was the focus 
of our review.  It is surprising that no other studies have been conducted to 
investigate the performance of visualization of the yolk sac on ultrasound for 
determining the true nature of an intrauterine fluid collection.  It can be 
speculated that this may be because, embryologically, the yolk sac is derived 
from migrating hypoblast cells of the inner cell mass and could therefore only 
occur within a true gestation sac.  In the case of a pseudosac, which is merely 
a fluid filled space with no gestational tissue, there is no potential to develop a 
yolk sac.  Given this fact and the 100% specificity found in the one included 
study, further studies to investigate the accuracy of a yolk sac for predicting 
an intrauterine pregnancy may have been considered unnecessary. 
 
A further limitation of our study is that there is wide variation in sensitivity and 
specificity between studies reporting on the same ultrasonographic sign.  For 
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example, the sensitivity of a gestation sac for predicting an intrauterine 
pregnancy ranged from 14% in the study by Dart et al [237] to 100% in the 
study by Weckstein et al [235].  This is probably because of the considerable 
population heterogeneity between the studies. Dart et al [237] included only 
pregnant women with abdominal pain and/or vaginal bleeding with an 
indeterminate ultrasound scan who had either a serum hCG level greater than 
3000iu/l or whose last menstrual period was more than 38 days before 
examination. It was conducted using transvaginal ultrasound and a gestation 
sac was defined as an empty anechoic intrauterine fluid collection with a 
hyperechoic border and mean sac diameter of less than 10mm.  In contrast, 
Weckstein et al [235] included a less specific group of patients, a broader 
definition of what constitutes a gestation sac and a less accurate 
ultrasonographic approach.  It is therefore of no surprise that these studies, 
with their inherent differences in study design, have yielded considerably 
different accuracy measures.  
 
A final limitation of this study is that no information regarding pregnancy 
viability can be inferred from the results.  The finding of the double decidual 
sac sign, for example, suggests an intrauterine pregnancy with a sensitivity of 
82% and specificity of 97%, whether that pregnancy is viable or not cannot be 
concluded from our results.  However it was the aim of this systematic review 
to determine the accuracy of first trimester ultrasonographic signs in predicting 
intrauterine pregnancy location, and this has been accomplished.  In order to 
achieve this, of studies that considered three separate outcomes including 
viable intrauterine, non-viable intrauterine and ectopic pregnancies, all 
intrauterine pregnancies were combined prior to construction of the 2x2 tables 
[219, 229-234, 236, 237, 239-241].  Of studies that did not differentiate between 
viable and non-viable intrauterine pregnancies no such combination was 
required [218, 220, 228, 235, 238].   
 
5.6 Conclusion  
 
This review is the first to comprehensively collate evidence of the accuracy of 
various different ultrasonographic features for predicting an intrauterine 
pregnancy prior to ultrasonographic visualization of the yolk sac. The findings 
are limited by the relatively small number and poor quality of the included 
studies and by the heterogeneity seen between the tests and outcome 
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assessment. An appropriately powered study following STARD guidelines [242] 
using transvaginal ultrasound and an appropriate reference standard, is 
required to establish standards for the accurate prediction of an intrauterine 
pregnancy.  In the interim, it would be prudent to continue the current 
practice of waiting until a yolk sac is visualized before confirming that a 
pregnancy is intrauterine. 
   

  
 
Table 5.1: Characteristics of studies included in the systematic review and meta-analysis 
Study Type of Study Inclusion Criteria Exclusion Criteria US Details Sign Definition Outcomes Measured 
Ankum, 1993 
(n=208)[228] 
Prospective  Positive UPT, pain 
+/- PVB, risk 
factors for EP 
 TV 5.5-7.5MHz GS Not stated IUP: uneventful clinical course 
EP: all were confirmed surgically 
Bateman, 1990 
(n=126)[229] 
Prospective  Suspected EP  TV 5MHz GS Anechoic intrauterine fluid 
collection with mean sac 
diameter <10mm and a 
regular echogenic border 
Normal IUP: normal progression into the 
second trimester 
EP: documented surgically 
SA: terminated before 12 weeks gestation 
Bradley, 1982 
(n=50)[219] 
Retrospective  Positive UPT Fetal pole or 
abnormal GS; lost 
to follow-up 
TA 3.5-5MHz DDSS Two concentric rings within 
the endometrial cavity 
Normal IUP, abnormal IUP or EP: 
determined from medical records 
Chiang, 2004 
(n=187)[230] 
Retrospective  Intrauterine fluid 
collection with 
mean sac 
diameter <8mm 
or suspected EP 
No intrauterine 
fluid collection or 
fluid collection 
with a DDSS, YS or 
fetal pole; 
heterotopic 
pregnancy; no TV 
US; Lost to follow 
up 
TV 5-9MHz IDS Echogenic area 
embedded in thickened 
decidua that is 
eccentrically located on 
one side of the uterine 
cavity which appears as a 
well-defined endometrial 
stripe 
Normal IUP: subsequent US shows fetal 
heart or a hospital record reported 
delivery of a live infant corresponding to 
the index pregnancy 
Abnormal IUP: histology shows chorionic 
villi 
EP: surgical records show an EP or if the US 
findings show classic findings of an EP with 
an extra-ovarian adnexal mass in patients 
treated with methotrexate or showed free 
fluid with debris with follow-up and hCG 
levels showing inappropriate increases 
over >7 days 
Dart, 1997 
(n=163)[237] 
Retrospective  hCG>3000iu/l 
and/or LMP>38 
days ago with 
pain ± PVB and 
positive UPT and 
indeterminate US 
Recent 
ERPC/delivery; 
hCG or LMP 
unknown; final 
diagnosis unknown 
TV 5MHz GS An empty anechoic 
intrauterine fluid collection 
with a hyperechoic border 
and a mean sac diameter 
<10mm 
Normal IUP, abnormal IUP and EP: 
determined from hospital records and 
results from radiology, laboratory and 
pathology department databases  
Dart, 1998 
(n=228)[236] 
Retrospective  Positive UPT, pain 
± PVB, 
indeterminate 
TVUS 
Recent 
ERPC/delivery; 
hCG or LMP 
unknown; final 
diagnosis unknown 
TV 5MHz GS An empty anechoic 
intrauterine fluid collection 
with hyperechoic border 
and mean sac diameter 
<10mm 
Normal IUP, abnormal IUP and EP: 
determined from hospital records and 
results from radiology, laboratory and 
pathology department databases 
 
  
 
  
  
 
 
Study Type of Study Inclusion Criteria Exclusion Criteria US Details Sign Definition Outcomes Measured 
Enk, 1990 
(n=107)[231] 
Prospective  Positive UPT, pain 
± PVB, risk factors 
for EP 
Repeat US TV 7MHz GS Hypoechoic area 
including internal echoes  
Normal IUP: ultrasonographic evidence of 
normal fetal development in utero 
SA: absence of ultrasonographic evidence 
of fetal development with histopathological 
confirmation of trophoblasts in curettage 
material 
EP: Histopathological confirmation of extra-
uterine trophoblasts obtained at 
laparotomy/laparoscopy 
Kadar, 1981 
(n=97)[232] 
Retrospective  Suspected EP hCG>25000mIU/ml TA GS Not stated Normal IUP, abnormal IUP and EP: not stated 
Nyberg, 1983 
(n=128)[241] 
Retrospective  Intrauterine fluid 
collection 
associated with 
pregnancy or 
suspected EP 
Fetal pole visible 
on US; inadequate 
US; Lost to follow 
up 
TA 3.5-5MHz DDSS Two concentric rings 
surrounding a portion of 
the gestational sac 
Normal IUP: patients carried the gestation to 
term or had a living intrauterine fetus 
confirmed subsequently 
Abnormal IUP: presence of chorionic villi on 
histopathology 
EP: all confirmed surgically 
Nyberg, 1987 
(n=63/150 
DDSS/GS)[238] 
Prospective  Pain ± PVB, TVS 
and hCG 
IUP on US; 
subsequent non-
viable IUP; repeat 
US 
TA 3.5MHz DDSS 
GS 
Not stated 
Central sonolucency 
surrounded by an 
echogenic ring 
IUP: shown to have normal outcome by 
follow-up sonograms or clinical evaluation 
EP: all confirmed surgically 
Nyberg, 1988 
(n=51/136 
DDSS&YS/GS) 
[240] 
Prospective  Positive UPT Lost to follow up TA DDSS 
 
 
GS 
 
 
YS 
Two concentric rings 
surrounding portion of GS 
Intrauterine fluid 
collection surrounded by 
echogenic ring 
Sonolucent rounded sac 
like structure within the GS 
Normal IUP: repeat sonograms and/or 
clinical evaluation demonstrated normal 
growth of a living fetus 
Abnormal IUP: failure of normal growth and 
development on follow-up sonograms or 
clinical examination usually supported by 
declining serum hCG levels 
EP: all confirmed surgically 
 
  
  
  
  
 
 
Study Type of Study Inclusion Criteria Exclusion Criteria US Details Sign Definition Outcomes Measured 
Nyberg, 1988 
(n=84)[243] 
Prospective  Positive UPT, pain 
± PVB 
Fetal heart on US, 
repeat US 
TA 3.5-5MHz 
TV5-7.5MHz 
GS Intrauterine fluid 
collection surrounded by 
echogenic ring 
Normal IUP: normal gestational growth on 
clinical examination or demonstration of a 
living fetus >10 weeks gestation 
Abnormal IUP: lack of normal growth 
demonstrated clinically or by later 
ultrasonographic examination usually 
accompanied by declining serial hCG levels 
EP: all confirmed surgically  
Parvey, 1996 
(n=238)[220] 
Prospective  Positive UPT, pain 
± PVB 
Fetal heart on US TA 5MHz   
TV 5-7 MHz 
CRS 
 
 
DDSS 
Single concentric 
echogenic ring around an 
early intrauterine GS 
Two concentric 
echogenic rings around 
an early intrauterine GS 
Live IUP: repeat sonogram showing YS or 
fetal pole ± fetal heart or documented term 
delivery of a live infant 
Abnormal IUP: pathological examination 
after curettage 
EP: surgical and pathological confirmation 
of products of conception in the fallopian 
tube 
Romero, 1985 
(n=383)[233] 
Prospective  Positive UPT, 
Suspected EP 
 TA 3.5MHz GS Hypoechogenic area 
surrounded by an 
echogenic rim 
Normal IUP: resulting in a viable infant 
Abnormal IUP: not stated 
EP: not stated 
Tongsong, 
1993 
(n=201)[234] 
Prospective  Haemodynamic
ally stable, 
known hCG,  
Repeat US; lost to 
follow up 
TV 5MHz GS GS with a fetal pole+/-
fetal heart or DDSS 
Normal IUP, abnormal IUP or EP: determined 
following review of surgical and clinical 
records 
Weckstein, 
1985 
(n=37)[235] 
Prospective  Positive UPT, pain Haemodynamicall
y unstable; febrile 
Not stated GS Not stated IUP: not stated 
EP: confirmed surgically 
Yeh, 1986 
(n=41)[218] 
Prospective  Suspected EP  TA 3.5MHz DDSS 
IDS 
Not stated 
GS or echogenic area of 
early implantation, 
remains within thickened 
decidua on one side of 
the uterine cavity which is 
relatively undisturbed and 
appears as a straight line  
IUP or EP: proven by subsequent scanning, 
clinical follow-up, delivery, curettage or 
surgery 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 5.2: Summary estimates of each ultrasonographic sign for predicting an intrauterine pregnancy 
Ultrasonographic 
Sign 
Studies 
n [N] 
Sensitivity 
(95% CI)(%) 
Specificity 
(95% CI)(%) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
Pre- and post-test probability (range)(%) 
Pre-test Post-test if 
test positive 
Post-test if 
test negative 
GS 12 (1920) 53 
(38-67) 
98 
(94-99) 
22 
(9.8-51) 
0.48 
(0.36-0.66) 
68 
(30-88.) 
98 
(96-99) 
50 
(48-52) 
DDSS 6 (571) 82 
(68-90) 
97 
(76-100) 
30 
(2.8-331) 
0.19 
(0.10-0.35) 
89 
(49-91) 
100 
(97-100) 
61 
(15-64) 
IDS* 2 (228) 66 
(59-73) 
100 
(91-100) 
21 
(3.1-141) 
0.22 
(0.06-0.88) 
85 99 56 
CRS* 1 (238) 80 
(73-86) 
97 
(90-100) 
28 
(7.0-108) 
0.21 
(0.15-0.28) 
71 99 66 
YS* 1 (51) 42 
(27-58) 
100 
(54-100) 
∞ 0.58 
(0.45-0.74) 
88 100 19 
*Probability ranges not applicable for ultrasonographic signs with fewer than three studies. n[N], number of studies [number of women]  
  
  
  
 
Table 5.3: Quality assessment of included studies in the systematic review using quality assessment of diagnostic accuracy studies (QUADAS)-2 
Study Risk of Bias Applicability Concerns 
Patient 
Selection 
Index 
Test 
Reference 
Standard 
Flow and 
Timing 
Patient 
Selection 
Index 
Test 
Reference 
Standard 
Ankum (1993)[228] Low Unclear Unclear Low Low Low Low 
Bateman (1990)[229]  Unclear Low Low Low Unclear Low Low 
Bradley (1982)[219] Low Unclear Unclear Low Low High Unclear 
Chiang (2004)[230] Low Low Low Low Low Low Low 
Dart (1997)[237] Unclear Low Low Low High Low Low 
Dart (1998) [236] Low Low Low Low Low Low Low 
Enk (1990)[231] Unclear Low Low Low Low Low Low 
Kadar (1981)[232] Low Unclear Unclear Unclear Unclear High Unclear 
Nyberg (1983)[241] Low High Unclear Low Low High Low 
Nyberg (1987)[238] Unclear Low Low Low Low High Low 
Nyberg (1988)[240]  Unclear Low Low Low Low High Low 
Nyberg (1988)[243] Unclear Low Low Low Low Low Low 
Parvey (1996)[220] Low Low Low Low Low Low Low 
Romero (1985)[233] Unclear Low Low Low Low High Unclear 
Tongsong (1993)[234] Unclear Low Low Low Low Low Low 
Weckstein (1985)[235] Low Unclear Unclear Low Low High Low 
Yeh (1986)[218] Low Low Unclear Low Low High Low 
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6. Accuracy Of First Trimester 
Ultrasound For Diagnosis Of 
Tubal Ectopic Pregnancy In 
The Absence Of An Obvious 
Extra-Uterine Embryo 
 
NB; An abridged version of this chapter has been published in the journal 
Ultrasound in Obstetrics and Gynaecology [244] 
 
6.1 Introduction 
 
The incidence of ectopic pregnancy has risen over the last few decades.  
Fortunately both maternal morbidity and mortality associated with the 
condition has declined during this period, largely owing to greater awareness 
and earlier diagnosis (Figure 2.3).  Despite this, ectopic pregnancy still 
accounts for 3.4% of maternal mortality in the UK [245].  Early diagnosis of 
ectopic pregnancy is essential for reducing maternal mortality.  Although 
diagnostic laparoscopy is considered the gold standard, it has a false positive 
rate of 5% and a false negative rate of 3-4% [77].  The advent of high-
resolution transvaginal ultrasound has revolutionized the diagnosis of ectopic 
pregnancy.   
 
Unfortunately, the ultrasonographic appearances of ectopic pregnancies 
vary considerably.  Diagnosis should be based on the positive visualization of 
an extra-uterine mass rather than the inability to recognize an intrauterine 
pregnancy [114].  As discussed in chapter two, a living embryo located 
outside the uterus is the only pathognomonic sign of an ectopic pregnancy 
but is only reported in 8-26% of ectopic pregnancies detected on transvaginal 
ultrasound [77].  In the absence of an obvious ectopic pregnancy, several 
different ultrasonographic signs have been proposed to help detect ectopic 
pregnancy, with variable sensitivities and specificities.  These include an empty 
uterus (i.e. one that does not contain a gestation sac, pseudosac or retained 
products of conception), a pseudosac, free fluid, and an adnexal mass [3].  
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An empty uterus is a non-specific finding, which not only occurs in an ectopic 
pregnancy but also in a very early intrauterine pregnancy, following a 
complete miscarriage and in a non-pregnant woman. 
 
A pseudosac represents a thickened decidual reaction surrounding an 
intrauterine fluid collection.  They occur in up to 15% of ectopic pregnancies 
[215].  They can be difficult to differentiate from a true gestation sac.  The 
presence of a pseudosac alone cannot be used to diagnose an ectopic 
pregnancy.  Indeed, when an intrauterine smooth-walled anechoic cystic 
structure is the only ultrasonographic finding in a woman with a positive 
pregnancy test, the probability of a tubal ectopic pregnancy is, according to 
one study, only 0.02% [246], hence a small intrauterine anechoic cystic 
structure is actually more likely to be an early gestation sac than a pseudosac. 
 
An adnexal mass that is separate from the ovary is the most common finding 
of a tubal ectopic pregnancy and is seen in as many as 89-100% of patients 
[164, 247].  In a meta-analysis of ten studies [248], a non-cystic or 
inhomogeneous mass was the most appropriate criterion on which to 
diagnose an ectopic pregnancy with a specificity of 99%, sensitivity of 84%, 
positive predictive value of 96% and negative predictive value of 95%.  
However, in addition to being non-discriminatory (occurring in other conditions 
such as ruptured corpus lutea, haemorrhagic cysts, pelvic inflammatory 
disease and endometriosis), adnexal masses are also non-existent in 15-35% of 
patients with an ectopic pregnancy [249]. 
 
Free fluid may be visible on ultrasound but this is also a non-specific finding 
and can occur in other pathologies, for example, ruptured ovarian cysts, 
pelvic inflammatory disease, ovarian torsion and miscarriage.  Transvaginal 
ultrasound has detected free fluid in up to 63% of ectopic pregnancies but it 
also occurs in 25-31% of intrauterine pregnancies [77].  Echogenic fluid has 
been reported in 28-56% of ectopic pregnancies [215, 250].  It may signify 
tubal rupture but most commonly is due to blood leaking from the fimbrial end 
of a fallopian tube.   The presence of free fluid however may help confirm a 
suspicion of an ectopic pregnancy in lieu of, or in combination with, other 
ultrasonographic findings. 
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6.2 Aims 
 
We performed a systematic review and meta-analysis of the literature to 
determine the accuracy of these commonly described, non-specific 
ultrasonographic signs in the diagnosis of a tubal ectopic pregnancy in the 
absence of a living embryo located outside the uterus, in women with or 
without symptoms of abdominal pain and/or vaginal bleeding in early 
pregnancy. 
 
6.3 Methods 
 
The protocol was registered with PROSPERO on 4th October 2012 available 
from http://www.crd.york.ac.uk/PROSPERO (registration number: 
CRD42012003046).  The systematic review and meta-analysis was carried out 
according to the methodology described in chapter 5 .3.  
 
6.4 Results  
 
Study Selection 
 
The search identified 19,959 potential papers.  Following review of the titles 
and abstracts, 294 full-text papers were selected for further examination and 
subsequently 263 of these studies were subsequently excluded (Figure 6.1)).  
Thirty-one studies [73, 229, 234-236, 239, 240, 250-274], including 5858 women, 
met the inclusion criteria and were incorporated into the systematic review. 
The characteristics of the included studies are shown in Table 6.1. 
 
Diagnostic Accuracy Of An Empty Uterus For The 
Prediction Of Tubal Ectopic Pregnancy 
 
Thirteen cohort studies [234, 236, 239, 251, 255-257, 259, 261, 262, 265, 274], 
including 2499 women in early pregnancy, evaluated the diagnostic 
accuracy of an empty uterus on ultrasound examination to predict the 
likelihood of an ectopic pregnancy. Figure 6.2 shows the sensitivities and 
specificities of the presence of an empty uterus for predicting an ectopic 
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pregnancy in the individual studies.  The precision estimates for each of the 
studies and the estimated summary sensitivity and specificity for differentiating 
between an ectopic and an intrauterine pregnancy are shown in Figure 6.3a 
and Table 6.2.  Following meta-analysis of these thirteen studies we found that 
the presence of an empty uterus predicts an ectopic pregnancy with a 
pooled sensitivity of 32% (95% CI, 20-48%), specificity of 93% (95% CI, 85-97%), 
positive likelihood ratio of 4.8 (95% CI, 1.6-15) and negative likelihood ratio of 
0.72 (95% CI, 0.57-0.93). Of the studies included in this meta-analysis, the 
median prevalence of an ectopic pregnancy was 34% (range, 7.2% to 78%), 
however if an empty uterus was present the probability of an ectopic 
pregnancy was as high as 71% (range, 38% to 94%) compared with 27% 
(range, 5.3% to 72%) if the uterus was not empty. 
  
Figure 6.1: Flow chart summarizing study selection of papers on first-trimester 
ultrasound in the diagnosis of tubal ectopic pregnancy in the absence of an 
obvious extra-uterine embryo 
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Figure 6.2: Forest plot for the performance of an empty uterus, a pseudosac 
and an adnexal mass for predicting a tubal ectopic pregnancy 
 
Diagnostic Accuracy Of A Pseudosac For The Prediction 
Of Tubal Ectopic Pregnancy 
 
Eight cohort studies [234, 236, 251, 252, 259, 261, 264, 267], including 1838 
women in early pregnancy, evaluated the diagnostic accuracy of a 
pseudosac on ultrasound to predict the likelihood of an ectopic pregnancy. 
Figure 6.2 shows the sensitivities and specificities of a pseudosac to predict an 
ectopic pregnancy in the individual studies.  The precision estimates for each 
of the studies and the estimated summary sensitivity and specificity for 
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differentiating between an ectopic pregnancy and an intrauterine pregnancy 
are shown in Figure 6.3 b and Table 6.2.  
 
Figure 6.3: Summary receiver operating characteristics (ROC) plot of the ability 
of an empty uterus (a), pseudosac (b), adnexal mass (c), free fluid (d) and the 
combination of an adnexal mass and free fluid (e) to predict tubal ectopic 
pregnancy.  
 
o, Study estimate; −−−−, hierarchal summary ROC curve; -----, 95% prediction region; , summary 
point; − − −, 95% confidence region 
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Following meta-analysis of these eight studies we found that the presence of a 
pseudosac predicts an ectopic pregnancy with a pooled sensitivity of 5,5% 
(95% CI, 3.3-9.0%), specificity of 94% (95% CI, 76-99%), positive likelihood ratio of 
0.96 (95% CI, 0.26-3.5) and negative likelihood ratio of 1.0 (95% CI, 0.93-1.1). Of 
the studies included in this meta-analysis the median prevalence of an 
ectopic pregnancy was 32% (range, 7.2-69%), however if a pseudosac was 
present the probability of an ectopic pregnancy fell to 12% (range, 8-16%) 
compared to staying fairly static (35% (range, 34-35%) probability) if a 
pseudosac was absent. 
 
Diagnostic Accuracy Of An Adnexal Mass For The 
Prediction Of Tubal Pregnancy 
 
Twenty-one cohort studies [73, 234, 235, 240, 250, 251, 253-256, 258, 262, 263, 
265-268, 270-274], including 2787 women in early pregnancy, evaluated the 
diagnostic accuracy of an adnexal mass for predicting the likelihood of an 
ectopic pregnancy. Figure 6.2 shows the sensitivities and specificities of an 
adnexal mass to predict an ectopic pregnancy in the individual studies.  The 
precision estimates for each of the studies and the estimated summary 
sensitivity and specificity for differentiating between an ectopic pregnancy 
and an intrauterine pregnancy are shown in Figure 6.3c and Table 6.2. 
Following meta-analysis of these 21 studies we found that the presence of an 
adnexal mass predicts an ectopic pregnancy with a pooled sensitivity of 64% 
(95% CI, 49-76%), specificity of 91% (95% CI, 84-96%), positive likelihood ratio of 
7.4 (95% CI, 3.6-15) and negative likelihood ratio of 0.40 (95% CI, 0.27 to 0.59). 
Of the studies included in this meta-analysis, the median prevalence of an 
ectopic pregnancy was 39% (range, 24-88%), however if an adnexal mass was 
present the probability of an ectopic pregnancy was as high as 83% (range, 
80-85%) compared with 21% (range, 19-22%) if there was no evidence of an 
adnexal mass. 
 
Diagnostic Accuracy Of Free Fluid For The Prediction Of 
Tubal Pregnancy 
 
Nineteen cohort studies [229, 234, 235, 240, 250, 251, 253, 258, 260, 262, 263, 
265, 267-272, 274] including 3232 women in early pregnancy, evaluated the 
diagnostic accuracy of free fluid to predict the likelihood of an ectopic 
pregnancy. Figure 6.4 shows the sensitivities and specificities of free fluid to 
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predict an ectopic pregnancy in the individual studies.  The estimated 
summary sensitivity and specificity for differentiating between an ectopic 
pregnancy and an intrauterine pregnancy are shown in Figure 6.3d and Table 
6.2.  Following meta-analysis of these nineteen studies we found that the 
presence of free fluid predicts an ectopic pregnancy with a pooled sensitivity 
of 47% (95% CI, 33-62%), specificity of 92% (95% CI, 86-96%), positive likelihood 
ratio of 6.1 (95% CI, 3.1-12.) and negative likelihood ratio of 0.57 (95% CI, 0.43-
0.76). Of the studies included in this meta-analysis, the median prevalence of 
an ectopic pregnancy was 31% (range, 5.2-78%), but if free fluid was present 
the probability of an ectopic pregnancy was as high as 73% (range, 70-76%) 
compared with 20% (range, 19-21%) if there was no free fluid. 
 
Figure 6.4: Forest plot for the performance of free fluid, the combination of an 
adnexal mass and free fluid, the combination of a pseudosac and an adnexal 
mass, the combination of a pseudosac and free fluid and the combination of a 
pseudosac, adnexal mass and free fluid for predicting tubal ectopic 
pregnancy 
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Diagnostic Accuracy Of The Combination Of An 
Adnexal Mass And Free Fluid For The Prediction Of Tubal 
ectopic Pregnancy 
 
Seven cohort studies [234, 258, 265, 267, 270, 271, 274] including 1023 women 
in early pregnancy, evaluated the diagnostic accuracy of the combination of 
an adnexal mass and free fluid to predict the likelihood of an ectopic 
pregnancy. Figure 6.4 shows the sensitivities and specificities of the 
combination of an adnexal mass and free fluid to predict an ectopic 
pregnancy in the individual studies. The estimated summary sensitivity and 
specificity for differentiating between an ectopic pregnancy and an 
intrauterine pregnancy are shown in Figure 6.3e and Table 6.2.  Following 
meta-analysis of these seven studies we found that the presence of the 
combination of an adnexal mass and free fluid predicts an ectopic 
pregnancy with a pooled sensitivity of 45% (95% CI 34-57%), specificity of 97% 
(95% CI, 93% to 98%), positive likelihood ratio of 12 (95% CI, 5.9-24) and 
negative likelihood ratio of 0.57 (95% CI, 0.46-0.71). Of the studies included in 
this meta-analysis the median prevalence of an ectopic pregnancy was 54% 
(range, 33-78%), but if the combination of an adnexal mass and free fluid was 
present the probability of an ectopic pregnancy was as high as 94% (range, 
89% to 98%) compared with 40% (range, 38% to 42%) if the combination of an 
adnexal mass and free fluid was absent. 
 
Diagnostic Accuracy Of The Combination Of An 
Adnexal Mass And Pseudosac For The Prediction Of 
Tubal Pregnancy 
 
One cohort study [265] including 265 women in early pregnancy, evaluated 
the diagnostic accuracy of the combination of an adnexal mass and 
pseudosac to predict the likelihood of an ectopic pregnancy. Figure 6.4 shows 
the sensitivities and specificities of the combination of a pseudosac and 
adnexal mass to predict an ectopic pregnancy in the individual studies.  The 
estimated summary sensitivity and specificity for differentiating between an 
ectopic pregnancy and an intrauterine pregnancy are shown in Table 6.2. This 
study found that the presence of both an adnexal mass and pseudosac 
predicts an ectopic pregnancy with a pooled sensitivity of 2.9% (95% CI, 1.1-
6.2%), specificity of 100% (95% CI, 93-100%), positive likelihood ratio of infinity 
and negative likelihood ratio of 0.97 (95% CI, 0.95-0.99). In this study the 
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median prevalence of an ectopic pregnancy was 78%, but if the combination 
of an adnexal mass and pseudosac were present the probability of an 
ectopic pregnancy was as high as 100% compared with 23% if the 
combination of an adnexal mass and pseudosac were absent. 
 
Diagnostic Accuracy Of The Combination Of A 
Pseudosac And Free Fluid For The Prediction Of Tubal 
Pregnancy 
 
One cohort study [265] including 265 women in early pregnancy, evaluated 
the diagnostic accuracy of the combination of free fluid and a pseudosac to 
predict the likelihood of an ectopic pregnancy. Figure 6.4 shows the 
sensitivities and specificities of the combination of free fluid and a pseudosac 
to predict an ectopic pregnancy in the individual studies.  The estimated 
summary sensitivity and specificity for differentiating between an ectopic 
pregnancy and an intrauterine pregnancy are shown in Table 6.2. This study 
found that the presence of the combination of free fluid and pseudosac 
predicts an ectopic pregnancy with a pooled sensitivity of 3.9% (95% CI, 1.7-
7.5%), specificity of 97% (95% CI, 88-100%), positive likelihood ratio of 1.2 (95% 
CI, 0.25-5.3) and negative likelihood ratio of 0.99 (95% CI, 0.94-1.1). In this study 
the median prevalence of an ectopic pregnancy was 78%, but if the 
combination of an adnexal mass and pseudosac were present the probability 
of an ectopic pregnancy was as high as 80% compared with 22% if the 
combination of an adnexal mass and pseudosac were absent. 
 
Diagnostic Accuracy Of The Combination Of A 
Pseudosac, Adnexal Mass And Free Fluid For The 
Prediction Of Tubal Ectopic Pregnancy 
 
One cohort study [265] including 265 women in early pregnancy, evaluated 
the diagnostic accuracy of the combination of a pseudosac, adnexal mass 
and free fluid to predict the likelihood of an ectopic pregnancy.  Figure 6.4 
shows the sensitivities and specificities of this combination of ultrasonographic 
features to predict an ectopic pregnancy.  The estimated summary sensitivity 
and specificity for differentiating between an ectopic pregnancy and an 
intrauterine pregnancy are shown in Table 6.2.  This study found that the 
combination of a pseudosac, adnexal mass and free fluid predicts an ectopic 
pregnancy with a pooled sensitivity of 5.8% (95% CI, 3.1-10%), specificity of 
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100% (95% CI, 94-100%), positive likelihood ratio of infinity and negative 
likelihood ratio of 0.94 (95% CI, 0.91-0.97). In this study the median prevalence 
of an ectopic pregnancy was 78%, but if the combination of a pseudosac, 
adnexal mass and free fluid was present the probability of an ectopic 
pregnancy was as high as 100% compared with 23% if the combination of a 
pseudosac, adnexal mass and free fluid was absent. 
 
Risk Of Bias Within Studies 
 
Figure 6.5: Risk of bias and applicability concerns based on quality assessment 
of diagnostic accuracy studies (QUADAS)-2 across included studies 
Figure 6.5 summarizes the risk of bias and applicability concerns of studies 
based on QUADAS-2 (the assessment of each individual study is presented in 
Table 6.3).  The quality of most of the included studies was considered 
mediocre.  Eight studies [236, 240, 252, 261, 262, 264, 265, 271] were 
retrospective in nature, ten were small (including fewer than 100 participants) 
[235, 240, 251-253, 262, 263, 266, 267, 273] and 22 were undertaken more than 
20 years ago [73, 229, 234, 235, 239, 240, 250, 251, 253, 255-258, 262, 263, 265-
267, 269-271, 274].  Many studies [229, 234, 239, 240, 250, 251, 253, 255, 257, 258, 
263, 266, 269, 270, 273, 274] did not fully describe the methods of patient 
selection hence it is unclear whether the selection of patients could have 
introduced bias.  One study only included women who underwent surgery for 
suspected ectopic pregnancy [265] and three others included women who 
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were at particularly high risk of ectopic pregnancy as they had risk factors for, 
as well as symptoms suggestive of, ectopic pregnancy [262, 266, 273]. 
 
The degree of blinding was also unclear.  The majority of studies did not state 
explicitly whether the ultrasound images were interpreted without knowledge 
of the final diagnosis (reference standard result). Four studies [235, 239, 251, 
264] did not clearly define the ultrasonographic feature under surveillance 
and in those studies that did give a clear definition, there was often 
considerable differences between the studies, for example the study by 
Braffman et al [73] only considered complex adnexal masses, whilst the study 
by Aleem et al [253] included both complex and cystic masses.  Similarly, for 
free fluid, some studies considered merely the presence or absence of free 
fluid [229, 251, 253, 262, 263, 265, 269, 270, 272, 274] whilst others tried to 
quantify its volume [240, 267, 268] and two studies included the appearance 
of the fluid on ultrasound rather than the volume in its definition [234, 258].  
Some of the older studies utilized transabdominal ultrasound only [251, 257, 
270, 274] and the ultrasound approach was not stated in others [235, 239, 240, 
250, 252, 258, 267, 268], hence their results may not be applicable to current 
practice.  Eleven studies did not clearly define the reference standard [73, 
235, 251-253, 262, 269, 270, 272-274] and in the majority of studies it was 
unclear if the results of the reference standard were interpreted without 
knowledge of the index test.  One study clearly stated that the results of the 
ultrasound were known at the time of surgery and were often an important 
factor in the decision making process which could have introduced bias [265].  
Patient flow was considered to be appropriate in all the studies.   
 
Eight studies had a low risk of bias across all seven domains [236, 256, 259-261, 
267, 268, 271] (Table 6.3). Subgroup analysis using only these high quality 
studies was performed and the estimated summary sensitivities and 
specificities and positive and negative likelihood ratios of an empty uterus, 
adnexal mass and free fluid on ultrasound to differentiate between and 
ectopic pregnancy and intrauterine pregnancy are illustrated in Table 6.4.  
Utilizing these studies, an adnexal mass and free fluid were both found to be 
highly specific for an ectopic pregnancy, but not particularly sensitive.  An 
empty uterus on the other hand was less specific but most sensitive. 
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6.5 Discussion 
 
Summary of Evidence 
 
Our systematic review and meta-analysis summarizes the diagnostic accuracy 
of commonly used ultrasonographic signs for predicting a tubal ectopic 
pregnancy and shows that when an obvious extra-uterine pregnancy is not 
present, the ultrasonographic findings of an empty uterus, a pseudosac, an 
adnexal mass and/or free fluid have poor sensitivity for identifying a tubal 
pregnancy. However, the presence of these features on ultrasound has good 
specificity, especially when found in combination.  We can therefore infer 
ultrasound features are more useful for ‘ruling in’ a tubal ectopic pregnancy, 
than for ‘ruling out’ one.   
 
Strengths and Weaknesses of Study 
 
We conducted a prospective and extensive systematic search of electronic 
databases using a predefined protocol that was published.  The high number 
of included studies in our meta-analysis for an empty uterus, the presence of 
adnexal mass and free fluid strengthened the power of these conclusions and 
enabled us to define the diagnostic accuracy of these signs in confirming an 
ectopic pregnancy with relative precision.  Our findings for the presence of a 
pseudosac and various different combinations of ultrasonographic features 
were limited by the small number of included studies.   
 
An additional strength of our review is that we performed an assessment of 
quality of the included studies.  The quality of most of the included studies was 
mediocre.  The risk of bias and concerns regarding the applicability of the 
results to current practice were generally low or unclear with only three studies 
[235, 239, 265] having a high risk of bias or substantial applicability concerns in 
one or two domains only.  We have also conducted a subgroup analysis using 
the results from eight top quality studies (with a low risk of bias in all seven 
QUADAS-2 domains).   
 
The main limitation of our study is that the prevalence of an ectopic 
pregnancy varies considerably between the studies.  This is most likely a 
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reflection of the different inclusion criteria amongst the studies, for example, 
one study only included women who underwent a diagnostic laparoscopy for 
suspicion of an ectopic pregnancy [265].  Clearly the prevalence of an 
ectopic pregnancy in this study will be higher than in those which included 
women with a positive urinary pregnancy test [240, 269, 270] or in those that 
included women with symptoms of abdominal pain and/or vaginal bleeding 
[234, 235, 239, 251, 252, 256, 257, 263, 264, 267, 268, 272, 274].  Studies that 
included women with risk factors for ectopic pregnancy [262, 266, 273] and 
those which included symptomatic pregnant women with indeterminate 
ultrasound scans [73, 236, 250, 253, 255, 259-261, 271] are also likely to have a 
different prevalence of ectopic pregnancy.  In clinical practice it is essential to 
know how a particular test result predicts the risk of abnormality in the 
population being evaluated.  Sensitivities and specificities do not describe 
how a particular test result predicts the risk of abnormality.  The benefit of 
likelihood ratios over sensitivity and specificity measures is that they can be 
used to calculate the probability of abnormality, while adapting for varying a-
priori probabilities of the chance of abnormality from different contexts.  It is 
essential therefore that the prevalence of ectopic pregnancy in individual 
early pregnancy assessment/emergency gynaecology units is known before 
likelihood ratios are applied.  Whilst a subgroup analysis based on the level of 
risk would be interesting and clinically very useful, unfortunately it was not 
possible in this meta-analysis as only one study included women at high risk of 
an ectopic pregnancy [265] and only three studies included women at low risk 
of an ectopic pregnancy [240, 269, 270].  All other studies included women at 
intermediate risk of an ectopic pregnancy and it was not possible to stratify 
them further.   
 
A further limitation of our study is that there is wide variation in sensitivity and 
specificity between studies looking at the same ultrasonographic sign.  For 
example, the sensitivity of an adnexal mass for predicting an ectopic 
pregnancy ranged from 3.6% in the study by Achiron et al [251] to 98% in the 
study by Gabrielli et al [263] and specificity ranged from 33% in the study by 
Kivikoski et al [266] to 100% in the studies by Nyberg et al [240], Sadek and 
Schiotz [272] and Weckstein et al [235].  Similarly for free fluid, the sensitivity 
ranged from 7.7% in the study by Tongsong et al [274] to 96% in the study by 
Sadek and Schiotz [272] and the specificity ranged from 67% in the study by 
Dashefsky et al [262] to 100% in the studies by Achiron et al [251], Mehta et al 
[268] and Weckstein et al [235].  This is again likely to be due to the 
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considerable heterogeneity between the studies involving different 
populations of women, different ultrasound approaches and different 
definitions of the signs under evaluation.   
 
Finally, this systematic review demonstrates that a pseudosac is a rare 
ultrasonographic finding in early pregnancy and is usually absent in women 
with an ectopic pregnancy.  However, when present, it is highly suggestive of 
an ectopic pregnancy.   
 
Although some experts may disagree [114], many find it difficult to 
differentiate a gestation sac from a pseudosac prior to the development of a 
yolk sac or fetal pole.  As already discussed in the previous chapter, several 
different ultrasonographic signs have been proposed to aid in the 
differentiation, including the intradecidual, double decidual sac and chorionic 
rim signs, but as the systematic review concluded, whilst the presence of these 
signs substantially increases the probability that a pregnancy is intrauterine, 
their absence does not exclude an intrauterine pregnancy and a negative 
test result cannot be relied upon to guide clinical practice.  Furthermore, none 
of the signs were as accurate in confirming intrauterine pregnancy location as 
the presence of a yolk sac and hence, in the absence of further research, it is 
still advisable to wait until a yolk sac is visualized before confirming that a 
pregnancy is definitely intrauterine.  So, whilst a true pseudosac, highly 
suggestive of an ectopic pregnancy, is a relatively rare ultrasonographic 
finding in early pregnancy, an empty gestation sac, indicative of an early or 
failing intrauterine pregnancy, is much more common.  It would be preferable 
to differentiate between these potential diagnoses as soon as possible.  Doing 
so would, not only reduce anxiety for women but also prevent unnecessary 
investigations for those with an intrauterine pregnancy and minimise morbidity 
and mortality, permit earlier, potentially less invasive intervention and possibly 
preserve future fertility for women with an ectopic pregnancy.  Therefore this 
systematic review strengthens the need for a definitive test accuracy study 
following recommended guidelines [242] to establish standards for the 
accurate confirmation of an intrauterine pregnancy prior to the development 
of a yolk sac, or more specifically, the differentiation between an early 
gestation sac and a pseudosac.   
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6.6 Conclusion 
 
This review is the first to comprehensively collate evidence of the accuracy of 
various ultrasonographic features to accurately confirm the presence of an 
ectopic pregnancy in the absence of a live extra-uterine embryo.  When an 
obvious extra-uterine pregnancy is not present, the commonly used ultrasound 
features have poor sensitivity for identifying a tubal pregnancy, but they have 
good specificity. We can therefore infer ultrasound features are more useful for 
‘ruling in’ a tubal ectopic pregnancy, than for ‘ruling out’ one.  The findings 
are limited by the small number and poor quality of the included studies and 
by the considerable variation in index test and reference standard amongst 
the different studies. 
  
 
 
 
  
 
Table 6.1 Characteristics of studies included in the systematic review and meta-analysis 
Study Type of Study Inclusion Criteria Exclusion Criteria US Details Sign Definition Outcomes Measured 
Achiron, 1987 
(n=61)[251] 
Prospective  Pain ± PVB Haemodynamically 
unstable 
TAS EU 
PS 
AM 
FF 
Not stated 
Not stated 
Not stated 
Fluid in the cul-de-sac 
EP: histology following laparotomy 
IUP: not stated 
Ahmed, 2004 
(n=77)[252] 
Retrospective  Pain ± PVB Haemodynamically 
unstable 
Not stated PS 
 
 
Any reported sac within uterine 
cavity without a double 
decidual sac or yolk sac 
EP: not stated 
IUP: not stated 
Aleem, 1990 
(n=58)[253] 
Prospective  Positive UPT, pain 
± PVB, 
indeterminate US 
 TVS 5MHz AM 
FF 
Complex or cystic AM 
Fluid in the cul-de-sac 
EP: not stated 
IUP: not stated 
Bateman, 1990 
(n=108)[229] 
Prospective  Volunteers 
recruited from 
infertility unit or 
referred due to 
suspected EP 
 TVS 5MHz FF Fluid in the cul-de-sac EP: documented surgically  
IUP: normal progression in to the second 
trimester or (normal) or histology 
obtained following curettage 
(abnormal) 
Braffman, 1994 
(n=269)[73] 
Prospective Positive UPT, pain 
± PVB, 
indeterminate US 
Haemodynamically 
unstable 
TAS 3.5-5MHz 
and TV 5-
7.5MHz 
AM Complex AM EP: not stated 
IUP: not stated 
 
Cacciatore, 
1988 
(n=100)[257] 
Prospective  Positive UPT, pain  TAS 3-3.5MHz EU Neither sac nor adnexal mass EP: histology following surgery 
IUP: US revealing a live intrauterine fetus 
(normal) or histology obtained following 
curettage (abnormal) 
Cacciatore, 
1989 
(n=100)[255] 
Prospective  Positive UPT, 
indeterminate US 
 TVS 5MHz EU 
 
 
AM 
Neither sac nor adnexal mass 
 
 
Not stated 
EP: histology following surgery 
IUP: US revealing a live intrauterine fetus 
(normal) or histology obtained following 
curettage (abnormal) 
Cacciatore, 
1990 (n=200)[30]  
Prospective  Positive UPT, pain 
± PVB 
Haemodynamically 
unstable 
TVS 5-6MHz EU 
AM 
Neither sac nor adnexal mass 
A complex AM or a gestation 
sac-like adnexal ring ± yolk sac 
or fetal pole 
EP: histology following surgery 
IUP: US revealing a live intrauterine fetus 
(normal) or histology obtained following 
curettage (abnormal) 
 
  
  
  
  
 
Study Type of Study Inclusion Criteria Exclusion Criteria US Details Sign Definition Outcomes Measured 
Chambers, 
1990 
(n=132)[258] 
Prospective  Suspected EP  Not stated AM 
FF 
Solid, complex or cystic 
Transonic fluid or material with low 
level echoes or of mixed echoity in 
the pelvic cavity 
EP: surgically diagnosed 
IUP: viable fetus on subsequent US (normal) 
or no fetus on US and the pregnancy ending 
in miscarriage (abnormal) 
Dart, 1998 
(n=228)[236] 
Retrospective  Positive UPT, pain 
± PVB, 
indeterminate US 
Recent 
delivery/ERPC, 
lost to follow-up 
TVS 5MHz EU 
 
FF 
Empty endometrial cavity without 
a thickened endometrium 
Moderate to large volume of 
anechoic fluid or any echogenic 
fluid 
EP: determined from hospital records and 
results from radiology, laboratory and 
pathology department databases 
IUP: as above 
Dart, 2002 
(n=155)[261] 
Prospective  Positive UPT, pain 
± PVB, 
indeterminate US 
Lost to follow-up TVS 5-
10MHz 
EU 
 
FF 
Empty endometrial cavity without 
a thickened endometrium 
Moderate to large volume of 
anechoic fluid or any echogenic 
fluid 
EP: visualization of an EP at laparoscopy, in 
patients managed with methotrexate, 
identification of an EP on subsequent US or 
rising hCG levels with no chorionic villi at 
pathology after ERPC 
IUP: identification of a fetal heart on 
subsequent US or delivery of a viable fetus 
(normal) or falling hCG values with 
identification of chorionic villi at ERPC, 
absence of chorionic villi after ERPC with 
hCG values that fall to zero without further 
intervention, the patient was observed 
without intervention and had hCG values 
that fell to zero or falling hCG values with no 
EP by laparoscopy (abnormal) 
Dart, 2002 
(n=635)[259] 
Prospective  Positive UPT, pain 
± PVB, 
indeterminate US 
Recent 
delivery/ERPC, 
repeat US, lost to 
follow-up 
TVS 5-
10MHz 
EU 
 
FF 
Empty endometrial cavity without 
a thickened endometrium 
Moderate to large volume of 
anechoic fluid or any echogenic 
fluid 
EP: visualization of an EP at laparoscopy, in 
patients managed with methotrexate, 
identification of an EP on subsequent US or 
rising hCG levels with no chorionic villi at 
pathology after ERPC  
Normal IUP: identification of an IUP with fetal 
heart on subsequent US or delivery  
 
  
  
  
  
 
Study Type of Study Inclusion Criteria Exclusion Criteria US Details Sign Definition Outcomes Measured 
Dart, 2002 
(n=561)[260] 
Retrospective  Positive UPT, pain 
± PVB, 
indeterminate US 
Lost to follow-up TVS 5MHz FF Moderate to large volume of 
anechoic fluid or any echogenic 
fluid 
EP: confirmed by laparoscopy or in patients 
managed with methotrexate, on the basis 
of identifying persistently rising hCG levels 
after a ERPC procedure 
No EP: an IUP was identified on subsequent 
US, hCG levels fell to zero without further 
intervention, a ERPC was performed with 
identification of chorionic villi at pathology 
or no EP was visualized during surgery 
Dashefsky, 
1988 (n=53 
(EU); 27 
(AM/FF))[262] 
Retrospective 
and 
prospective  
Positive UPT, pain 
± PVB or risk 
factors for EP 
 TVS 5MHz EU 
 
AM 
FF 
No ultrasonographic evidence of 
an IUP 
Non-cystic AM 
No IUP and free adnexal fluid 
EP: confirmed by review of the medical and 
surgical records 
IUP: as above 
 
Gabrielli, 1992 
(n=67)[263] 
Prospective  Positive UPT, pain 
± PVB 
 TVS 6.5MHz AM 
 
FF 
Cystic, complex, tubal ring or 
ectopic embryo 
Fluid in the cul-de-sac 
EP: confirmed by histological analysis of 
material obtained at surgery 
IUP: not stated (normal) or histological 
demonstration of CV obtained following 
ERPC (abnormal) 
Hammoud, 
2005 
(n=400)[264] 
Retrospective  Positive UPT, pain 
± PVB 
Haemodynamically 
unstable, definite 
IUP on US, lost to 
follow-up 
TAS and 
TVS 
PS 
 
Not stated 
 
EP: histopathology following surgery. If no 
surgery, diagnosis based on clinical 
evaluation, hormone studies and 
established ultrasonographic criteria  
IUP: not stated 
Huter, 1990 
(n=265)[265] 
Retrospective  Positive UPT, 
underwent 
laparoscopy for 
suspected EP 
 TVS 5-7MHz EU 
AM 
FF 
Not stated 
AM and EU 
EU and fluid in the cul-de-sac 
EP: confirmed surgically 
IUP: not stated 
 
Kivikoski, 1990 
(n=34)[266] 
Prospective  Positive UPT, pain 
± PVB, risk factors 
for EP 
 
 TVS 5-
6.5MHz 
AM Solid or complex , not cystic EP: confirmed surgically 
Non-EP: lack of adnexal findings on US and 
at laparoscopy and/or pathological 
demonstration of chorionic villi at 
endometrial curettage 
 
  
  
  
  
 
Study Type of Study Inclusion Criteria Exclusion Criteria US Details Sign Definition Outcomes Measured 
Mahony, 1985 
(n=81)[267] 
Prospective  Positive UPT, pain 
± PVB 
Repeat US, lost 
to follow-up 
Not stated PS 
 
 
AM 
FF 
A single sac like structure with a 
dense echogenic rind simulating a 
gestation sac 
Cystic or non-cystic or adnexal ring 
Small (only a crescent of fluid seen), 
moderate (extending into the 
adjacent adnexa) or large 
(extending into the lateral 
paracolic gutters) volume of pelvic 
intraperitoneal fluid 
EP: confirmed by review of the 
medical/surgical notes 
IUP: as above 
Mehta, 1999 
(n=128)[268] 
Prospective  Positive UPT, pain 
± PVB 
Definite 
intrauterine 
pregnancy on 
US, lost to follow-
up 
Not stated AM 
FF 
Not stated 
Moderate or large volume of FF 
EP: confirmed surgically, by negative 
findings on ERPC with abnormally rising hCG 
levels, by ultrasonographic demonstration of 
an AM separate from the ovary without an 
IUP or by a combination of these methods 
IUP: subsequent US demonstrating at least a 
gestation sac with yolk sac (normal) or 
documented decreasing serial hCG levels, 
abnormal US showing an irregular 
intrauterine sac and/or clinical passage of 
fetal tissue 
Nyberg, 1988 
(n=211)[243] 
Prospective  Positive UPT Repeat US, lost 
to follow-up 
Not stated EU Not stated EP: all surgically proven  
IUP: normal gestational growth on clinical 
examination or demonstration of a living 
fetus at beyond 10/40 (normal) or lack of 
normal growth demonstrated clinically or by 
later ultrasonographic examination usually 
accompanied by declining serial hCG levels 
(abnormal) 
Nyberg, 1988 
(n=84)[240] 
Retrospective  Positive UPT, pain 
± PVB 
Fetal heart on 
US, repeat US 
Not stated AM 
 
FF 
Solid or complex AM not including 
ovarian cysts 
Small to moderate volume of fluid in 
the cul-de-sac 
EP: all surgically proven  
IUP: normal gestational growth on clinical 
examination or demonstration of a living 
fetus at beyond 10/40 (normal) or lack of 
normal growth demonstrated clinically or by 
later ultrasonographic examination usually 
accompanied by declining serial hCG levels 
(abnormal) 
  
  
  
 
Study Type of Study Inclusion Criteria Exclusion Criteria US Details Sign Definition Outcomes Measured 
Nyberg, 1991 
(n=149)[250] 
Prospective  Positive UPT, 
indeterminate US 
 Not stated AM 
 
 
 
 
 
 
FF 
A living extra-uterine embryo or a 
sac-like structure +/- a mass OR a 
solid complex mass lacking an 
embryo or a sac.  Obvious cysts or 
corpus luteum were not considered 
to be masses and were not 
included. 
Absent, small, moderate or large 
volume of echogenic, anechoic or 
indeterminate fluid 
EP: confirmed by review of surgical and 
clinical records 
IUP: as above 
Rempen, 1988 
(n=404)[269] 
Prospective  Positive UPT or 
clinical findings 
consistent with a 
pregnancy of 4-13 
weeks’ gestation 
 TVS 5MHz FF 
 
Fluid in the cul-de-sac 
 
EP: not stated 
IUP: not stated 
Romero, 1988 
(n=220)[270] 
Prospective  hCG<6000iu/l  TAS 3.5MHz AM 
FF 
Cystic or non-cystic 
Fluid in the cul-de-sac 
EP: not stated 
IUP: resulting in a viable infant 
Russell, 1993 
(n=123 (EU);35 
(AM/FF))[271] 
Retrospective  Positive UPT, pain 
± PVB, 
indeterminate US 
Lost to follow-up TAS 3.5MHz 
and TVS 
5MHz 
EU 
 
AM 
FF 
No IUP (IUP=gestation sac+double 
decidual sac/yolk sac/fetal pole) 
Cystic, solid, mixed or ring 
Pelvic or abdominal fluid; trace, 
small, moderate or large volume; 
anechoic or echogenic 
EP: confirmed by review of the 
medical/surgical records 
IUP: as above 
 
Sadek, 1995 
(n=525)[272] 
Prospective  Positive UPT, pain 
± PVB 
Haemodynamically 
unstable 
TVS 5MHz AM 
FF 
Tubal mass 
Free pelvic fluid 
EP: confirmed by surgery and histology  
IUP: not stated 
Shapiro, 1988 
(n=25)[273] 
Prospective  High risk of EP, 
pain ± PVB, 
abnormally rising 
hCG 
 TVS 5MHz AM Extra-uterine gestation sac ± fetal 
pole ±fetal heart OR a thick 
echogenic band surrounding a 
small hypoechoic core giving the 
appearance of a donut OR a 
diffuse echogenic mass within the 
tube 
EP: surgically proven 
IUP: not stated 
  
  
  
  
 
Study Type of Study Inclusion Criteria Exclusion Criteria US Details Sign Definition Outcomes Measured 
Tongsong, 
1992 (n=167 
(EU); 89 
(AM/FF))[274] 
Prospective  Positive UPT, 
suspected EP 
 
Haemodynamically 
unstable, lost to 
follow-up  
TAS 3.5MHz EU 
 
AM 
FF 
No gestation sac, no PS, no 
intrauterine fluid or blood collection 
Complex mass 
Fluid in the cul-de-sac 
EP: not stated 
IUP: resulting in a viable infant 
 
Tongsong, 
1993 
(n=201)[234] 
Prospective  Positive UPT, 
suspected EP 
 
 
Haemodynamically 
unstable, repeat 
US, lost to follow-
up 
TVS 5MHz EU 
 
PS 
AM 
 
FF 
No gestation sac, no PS, no 
intrauterine fluid or blood collection 
Not stated 
Complex mass without a sac or 
embryo 
Anechoic or echogenic fluid 
EP: determined following review of surgical 
and clinical records 
IUP: as above 
Weckstein, 
1985 
(n=37)[235] 
Prospective  Positive UPT, pain Haemodynamically 
unstable, febrile 
Not stated AM Not given EP: confirmed surgically 
IUP: not stated 
 
  
  
 
  
  
 
Table 6.2 Summary estimates for each ultrasonographic sign for predicting tubal ectopic pregnancy 
Ultrasonographic  
Sign 
Studies 
n [N] 
Sensitivity 
(95% CI)(%) 
Specificity 
(95% CI)(%) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
Pre- and post-test probability (range)(%) 
Pre-test Post-test if 
test positive 
Post-test if 
test negative 
Empty uterus 13 (2499) 81 
(42-96) 
80 
(69-87) 
4.0 
(2.7-5.8) 
0.24 
(0.06-0.94) 
30 
(7.2-78) 
62 
(60-65) 
9 
(8-11) 
Pseudosac 8 (1838) 5.5 
(3.3-9.0) 
94 
(76-99) 
0.96 
(0.26-3.5) 
1.0 
(0.93-1.1) 
32 
(7.2-69) 
12 
(8-16) 
35 
(34-35) 
Adnexal mass 21 (2787) 64 
(49-76) 
91 
(84-96) 
7.4 
(3.6-15) 
0.40 
(0.27-0.59) 
40 
(24-88) 
83 
(80-85) 
21 
(19-22) 
Free fluid 19 (3232) 47 
(33-62) 
92 
(86-96) 
6.1 
(3.08-12) 
0.57 
(0.43-0.76) 
31 
(5.2-78) 
73 
(70-76) 
20 
(19-21) 
Adnexal mass and 
free fluid 
7 (1023) 45 
(34-57) 
97 
(94-98) 
12 
(5.9-24) 
0.57 
(0.46-0.71) 
54 
(33-78) 
93 
(90-96) 
40 
(38-42) 
Adnexal mass and 
pseudosac 
1 (265) 2.9 
(1.1-6.2) 
100 
(93.4-100) 
∞ 0.97 
(0.95-0.99) 
78 100 23 
Free fluid and 
pseudosac 
1 (265) 3.9 
(1.7-7.5) 
97 
(88-100) 
1.2 
(0.25-5.3) 
0.99 
(0.94-1.1) 
78 80 22 
Adnexal mass, free 
fluid and pseudosac 
1 (265) 5.8 
(3.1-10) 
100 
(94-100) 
∞ 0.94 
(0.91-0.97) 
78 100 23 
n[N], number of studies [number of women]  
  
 
  
  
 
Table 6.3: Quality of included studies in the systematic review using quality assessment of diagnostic accuracy studies (QUADAS)-2 
 Risk of Bias Applicability Concerns 
Patient 
Selection 
Index 
Test 
Reference 
Standard 
Flow and 
Timing 
Patient 
Selection 
Index 
Test 
Reference 
Standard 
Achiron, 1987 [251] Unclear Unclear Unclear Low Unclear Low Low 
Ahmed, 2004 [252] Low Low Unclear Low Low Low Low 
Aleem, 1990 [253] Unclear Low Unclear Low Low Low Low 
Bateman, 1990 [229] Unclear Low Low Low Unclear Low Low 
Braffman, 1994 [73] Low Low Unclear Low Low Low Low 
Cacciatore, 1988 [257] Unclear Low Low Low Low Low Low 
Cacciatore, 1989 [255] Unclear Low Low Low Low Low Low 
Cacciatore, 1990 [256] Low Low Low Low Low Low Low 
Chambers, 1990 [258] Unclear Low Low Low Unclear Low Low 
Dart, 1998 [236] Low Low Low Low Low Low Low 
Dart, 2002 [261] Low Low Low Low Low Low Low 
Dart, 2002 [259] Low Low Low Low Low Low Low 
Dart, 2002 [260] Low Low Low Low Low Low Low 
Dashefsky, 1988 [262] Low Low Unclear Low Low Low Low 
Gabrielli, 1992 [263] Unclear Low Low Low Low Low Low 
Hammoud, 2005 [264] Low Unclear Low Low Low Low Low 
  
  
  
 
 
Study Risk of Bias Applicability Concerns 
Patient 
Selection 
Index 
Test 
Reference 
Standard 
Flow and 
Timing 
Patient 
Selection 
Index 
Test 
Reference 
Standard 
Huter, 1990 [265] Low Unclear High Low High Low Low 
Kivikoski, 1990 [266] Unclear Low Low Low Low Low Low 
Mahony, 1985 [267] Low Low Low Low Low Low Low 
Mehta, 1999 [268] Low Low Low Low Low Low Low 
Nyberg, 1988 [239] Unclear Low Low Low Low High Low 
Nyberg, 1988 [240] Unclear Low Low Low Low Low Low 
Nyberg, 1991 [250] Unclear Low Low Low Low Low Low 
Rempen, 1988 [269] Unclear Low Unclear Low Unclear Low Low 
Romero, 1988 [270] Unclear Low Unclear Low Low Low Low 
Russell, 1993 [271] Low Low Low Low Low Low Low 
Sadek, 1995 [272] Low Low Unclear Low Low Low Low 
Shapiro, 1988 [273] Unclear Low Unclear Low Low Low Low 
Tongsong, 1992 [274] Unclear Low Unclear Low Low Low Low 
Tongsong, 1993[234] Unclear Low Low Low Low Low Low 
Weckstein, 1985 [235] Low Unclear Unclear Low Low High Low 
  
  
 
 
  
  
 
Table 6.4 Summary estimates for each ultrasonographic sign for predicting tubal ectopic pregnancy using only high quality studies 
Ultrasonographic  
Sign 
Studies 
n [N] 
Sensitivity 
(95% CI)(%) 
Specificity 
(95% CI)(%) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
Empty uterus 5 (1341) 76 
(31-96) 
71 
(53-84) 
2.6 
(1.5-4.6) 
0.34 
(0.093-1.4) 
Adnexal mass 4 (444) 67 
(43-85) 
95 
(74-99) 
13 
(1.7-102) 
0.34 
(0.16-0.74) 
Free fluid 4 (805) 52 
(36-68) 
94 
(74-99) 
8.1 
(1.9-35) 
0.51 
(0.36-0.72) 
n[N], number of studies [number of women] 
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7. Use Of The Double 
Decidual Sac Sign To Confirm 
An Intrauterine Pregnancy 
Prior To Ultrasonographic 
Visualization Of Embryonic 
Contents 
 
NB; An abridged version of this chapter has been published in the journal 
Ultrasound in Obstetrics and Gynaecology [275] 
 
7.1 Introduction 
 
As discussed in chapter one, a gestation sac is the first ultrasonographic sign of 
an intrauterine pregnancy.   It appears as a uniformly round, hypoechoic 
structure with an echogenic rim.  Initially it does not contain any internal 
echoes and can therefore be difficult to differentiate from a ‘pseudosac’, that 
is, an endometrial fluid collection that occurs in up to 15% of ectopic 
pregnancies [18].  As demonstrated in chapter six, a pseudosac predicts an 
ectopic pregnancy with 94% specificity but only 5.5% sensitivity.  It is clinically 
important not to confuse these two structures and hence several different 
ultrasonographic signs have been proposed to help differentiate between 
them prior to visualization of any embryonic contents.   
 
The double decidual sac sign is one such sign.  It was first described in the 
1980s, as two concentric echogenic rings of tissue surrounding an intra-
endometrial fluid collection that impress upon the endometrial stripe in an 
early intrauterine pregnancy [219].  The inner ring represents the decidua 
capsularis whilst the outer ring represents the decidua basalis. Conversely, in 
an ectopic pregnancy, the decidual reaction presents as only a single 
echogenic ring around the endometrial fluid collection [19].   
 
The systematic review and meta-analysis described in chapter five reported 
that the double decidual sac sign predicted an intrauterine pregnancy with a 
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sensitivity of 82% and specificity of 97% [214].  Unfortunately, the quality of the 
studies included was generally poor: five of the six studies were undertaken in 
the 1980s [218, 219, 238, 241, 243]; two were retrospective [219, 241]; and only 
one utilized transvaginal ultrasound [220].  Hence the diagnostic accuracy of 
the double decidual sac sign for predicting an intrauterine pregnancy may 
have been under, or indeed over, estimated. 
 
Ultrasound technology has advanced considerably over the last thirty years.  
Transvaginal ultrasound utilizes higher frequencies with better axial resolution 
that its transabdominal counterpart and this has revolutionized the 
ultrasonographic study of very early pregnancy.  Not only does transvaginal 
ultrasound reliably identify normal and abnormal pregnancies at an earlier 
gestation than transabdominal ultrasound [14] but also threshold values and 
discriminatory sizes used to distinguish normal and abnormal pregnancies are 
smaller using higher frequency transvaginal ultrasound compared to lower 
frequency transvaginal ultrasound [16].  
 
7.2 Aims 
 
The aim of this study therefore was to determine the diagnostic accuracy of 
the double decidual sac sign for predicting an intrauterine pregnancy prior to 
visualization of embryonic contents using modern, high-resolution transvaginal 
ultrasound. 
 
7.3 Hypotheses 
 
x Intrauterine fluid collections that demonstrate the double decidual sac 
sign represent a true gestation sac 
x Intrauterine fluid collections that do not demonstrate the double decidual 
sac sign represent a pseudosac 
 
7.4 Methods 
 
Ethical Approval 
 
Ethical approval was obtained from Nottingham 1 Research Ethics Committee 
(13-EM-0081) (Appendix 1) and informed written consent was obtained from 
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all participants (Appendix 4).  The study was registered with 
www.clinicaltrials.gov (NCT02700789) and conducted following STARD 
guidelines (Standards for Reporting of Diagnostic Accuracy Studies) [276] 
(Appendix 5).   
 
Diagnostic Accuracy Studies 
 
A diagnostic accuracy study evaluates the ability of one or more medical 
tests to correctly classify study participants as having a target condition.  This 
can be a disease, a disease stage, response or benefit from therapy, or an 
event or condition in the future.  A medical test can be an imaging 
procedure, a laboratory test, elements from history and physical examination, 
a combination of these, or any other method for collecting information about 
the current health status of a patient.   
 
Diagnostic accuracy studies are, like other clinical studies, at risk of bias due to 
shortcomings in design and conduct, and the results of a diagnostic accuracy 
study may not apply to other patient groups and settings.  Readers of study 
reports need to be informed about study design and conduct in sufficient 
detail to judge the trustworthiness and applicability of study findings.  The 
standards for reporting of diagnostic accuracy studies (STARD) statement was 
developed to improve the completely and transparency of reports of 
diagnostic accuracy studies.  STARD contains a list of thirty essential items that 
can be used as a checklist by authors, reviewers and other readers, to ensure 
that a report of diagnostic accuracy study contains the necessary information 
(Appendix 5).  The thirty items were identified by an international expert group 
of methodologists, researchers and editors.  The guiding principle in the 
development of STARD was to select items that, when reported, would help 
readers to judge the potential for bias in the study, to appraise the 
applicability of the study findings and the validity of the conclusions and 
recommendations.  The items include information regarding the population, 
index test, reference standard and outcome of interest.   
 
Population 
 
Diagnostic tests perform differently in different populations [277, 278] and it 
would generally be inappropriate, for example, to evaluate the performance 
of a test in a secondary care population when it is mainly used in primary care.  
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Both the frequency and severity of the target condition would be expected to 
be different in secondary care.  It is therefore important to clearly define the 
population of interest.  The ideal study sample for a diagnostic accuracy study 
is a consecutive or randomly selected series of patients in whom the target 
condition is suspected, or for screening studies, the target population.   Since 
participant sampling methods are often poorly reported in test accuracy 
studies [279], using the sampling method as an inclusion/exclusion criteria is 
likely to result in a substantial reduction in available data.  It is therefore more 
useful to consider the sampling method and/or its reporting as an aspect of 
study quality and to base the inclusion criteria relating to the population upon 
participant characteristics.   
 
Index Test  
 
The test whose accuracy is being evaluated is called the index test. This can 
be an imaging procedure, a laboratory test, elements from history and 
physical examination, a combination of these, or any other method for 
collecting information about the current health status of a patient.  
Furthermore a study can include a number of different technologies 
addressing multiple target conditions or compare the performance of an 
alternative (replacement), less invasive or less costly diagnostic technology 
with that of the reference standard for the detection of a specified target 
condition. Evaluating the performance of a test to correctly classify patients is 
typically done by comparing the distribution of the index test results with those 
of the reference standard.  The traditional concept of diagnostic accuracy 
often implies the dichotomization of data into test results which are classified 
as positive (target condition present) or negative (target condition absent).  
Diagnostic accuracy studies therefore need to consider diagnostic thresholds 
(points at which results are classified as positive or negative) for each included 
index test. 
 
Reference Standard  
 
The reference standard is usually the best available method for establishing 
the presence or absence of the target condition. It need not necessarily be 
the test used routinely in practice, and may include information which is not 
known for some time after the tests have been done. A diagnostic accuracy 
study is based upon a one-sided comparison between the results of the index 
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test and those of the reference standard. Any discrepancy is assumed to arise 
from error in the index test.  Selection of the reference standard is therefore 
critical to the validity of a test accuracy study and the definition of the 
diagnostic threshold forms part of that reference standard.  It is important to 
note that the assumption of 100% accuracy for the reference standard rarely 
holds true in practice.  This represents a fundamental flaw in the diagnostic 
accuracy study design, since the index test can never perform better than the 
reference standard    
 
Where several tests are available to diagnose a target condition, there is often 
no consensus about which test constitutes the reference standard.  In such 
cases, a composite reference standard, which combines the results of several 
available tests to produce a better indicator of true disease status may be 
used [280]. A number of statistical methods have been proposed to estimate 
the performance of tests in the absence of a single accepted reference 
standard [281, 282].   
 
There may be instances when it is deemed unethical to use an invasive 
procedure as a reference standard in a study [283]. In such cases, clinical 
follow-up and final diagnosis may sometimes be used as a reference 
standard. The length of follow-up should ideally be defined in advance. 
Studies using follow-up and clinical outcome in this way may be viewed as 
prognostic studies in that they are measuring the accuracy with which the test 
is able to predict a future event, rather than the accuracy with which it is able 
to determine current status.   When using follow-up as the reference standard 
it may not always be obviously apparent what the clinical outcome/final 
diagnosis is.  In such situations, the use of an adjudication committee may be 
employed.  This is an independent group of experts that reviews all the 
available data in order to give a consensus opinion on what the most likely 
clinical outcome/final diagnosis is.   
 
Outcome of Interest 
 
The outcome of interest may be a disease, a disease stage, response or 
benefit from therapy, or an event or condition in the future.  
 
If test results are categorized as either positive or negative, the cross tabulation 
of the index test results against those of the reference standard can be used 
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to estimate the sensitivity of the index test (the proportion of participants with 
the target condition who have a positive index test), and its specificity (the 
proportion without the target condition who have a negative index test). From 
this cross tabulation (sometimes referred to as the contingency or “2x2” table), 
several other accuracy statistics can be estimated, such as the positive and 
negative predictive values of the test. Confidence intervals around estimates 
of accuracy can then be calculated to quantify the statistical precision of the 
measurements.  
 
If the index test results can take more than two values, categorization of test 
results as positive or negative requires a test positivity cut-off. When multiple 
such cut-offs can be defined, authors can report a receiver-operating 
characteristic (ROC) curve, which graphically represents the combination of 
sensitivity and specificity for each possible test positivity cut-off. The area under 
the ROC curve informs in a single numerical value about the overall diagnostic 
accuracy of the index test. 
 
Ultrasound Scanning Techniques 
 
Sound is a mechanical vibration distinguished by pitch (or frequency) and 
loudness.  The velocity (v) of sound waves is constant (at 1540m/s) and is 
determined by the wavelength (λ) multiplied by the frequency (f).  Higher 
frequencies therefore mean that the wavelengths are shorter because the 
velocity is constant.  The frequency is defined as the number of vibrations (or 
cycles) per second and the unit of frequency is termed Hertz (Hz) (cycles per 
second).  Ultrasound has a frequency above 20,000Hz (20kHz). 
 
The transducers on ultrasound machines have different frequencies and are 
generally in the range of 2-10MHz.  Higher frequency probes have narrower 
beam widths and give better resolution, which means they are more able to 
distinguish two targets close together.  However, they have decreased 
penetration.  Higher frequency probes should therefore be used to visualize 
near structures and lower frequency probes for deeper structures.  For 
obstetric scanning, the abdominal probes generally vary from 3-5MHz and the 
transvaginal probes from 5-7.5MHz, the higher frequency giving better 
resolution for structures closer to the probe.   
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Materials exist which produce an electric current when pressure is applied to 
their surface.  This is known as the piezoelectric effect and the inverse effect 
occurs when a current is applied to the material causing it to expand and 
contract.  An ultrasound transducer for pulse-echo imaging houses one or 
more slabs of piezoelectric material.  An ultrasound image is produced by the 
reflection of ultrasound.  The ultrasound probe acts as both a transmitter and a 
receiver: ultrasound waves are transmitted by the electrical stimulation of 
crystals within the probe. These waves are then reflected from the surfaces of 
the tissue and organs being studied and the returning waves detected by 
receiving crystals within the probe.  This process is repeated in many directions.  
The ultrasound machine then translates the reflected sound waves into a 
greyscale visual representation of the organs being studied.  Selection of the 
appropriate probe frequency and style together with manipulation of 
machine settings including depth, gain, dynamic range, focal zone power 
level, frequency and harmonic imaging can be used to optimize image 
quality.  
 
Present-day equipment employs real time imaging, as opposed to static, and 
this provides an immediate image and reveals movement of the structures 
being examined.  Most of the probes are now electronically rather than 
mechanically driven and utilize an array system, which comprises scanned 
transducer elements mounted in line.  Sets of elements are pulsed in sequence 
to produce a rectangular field of view.  For obstetric use, curved array 
transducers are utilized which give a slightly wider field of view and are easier 
to manipulate on the lower abdomen in early pregnancy.  Transvaginal 
probes work on the same principal.   
 
3-Dimensional Ultrasound 
 
Three-dimensional ultrasound allows a tissue volume to be examined and 
saved for subsequent offline analysis. The volume can be displayed in a series 
of sections simultaneously acquired in three orthogonal planes providing 
access to sections previously unachievable by the traditional two-dimensional 
method - the coronal plane that lies perpendicular to the transducer face.  
 
The most commonly used technique utilizes phased array ultrasound 
transducers, which fan the ultrasound beam and acquire two-dimensional 
images at predefined intervals, described as the ‘swept-volume’ technique. 
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The initial image is the central scan of the volume of interest and the 
transducer scans from one margin to the other of the total volume to be 
acquired. The sweep time varies upon the depth, range, angle and image 
quality.  Following acquisition, the three-dimensional ultrasound data can be 
saved, exported and manipulated or ‘post processed’. This technique enables 
a much more accurate estimation of volume than two-dimensional 
ultrasound, which uses formulae based on geometric assumptions to derive 
measurements. Volume calculation methods include planar methods and the 
more accurate rotational method using Virtual Organ Computer-aided 
AnaLysis (VOCAL), which involves repeated manual delineation of the object 
of interest in the multi-planar display.  The main disadvantage of three-
dimensional ultrasound is its dependence on the image clarity of the two-
dimensional images from which it is derived. 
 
Safety  
 
Within the human species, no harmful bio-effects of ultrasound have been 
noticed since its introduction into the medical world in the 1940s. The prudent 
use of ultrasound is always advised, which means maintaining power levels 
and exposure time as low as reasonably achievable (the ALARA principle).   
 
Bio-effects include the thermal effect of ultrasound and cavitation.  The 
thermal effect refers to the rise in tissue temperature caused by ultrasound. 
Temperature elevations of 1.5ºC above physiological levels can be made 
safely without limiting the examination.  A temperature above 41ºC with fetal 
use is considered harmful.  Cavitation refers to the way that gas bubbles react 
within tissues under the influence of ultrasound.  The thermal index (TI) is an 
indicator of the temperature elevation possible at a particular equipment 
setting and is defined as the ratio of the acoustic power emitted by the 
transducer to the acoustic power required to produce a 1ºC rise at a 
particular equipment setting. With a TI of more than 0.7, the exposure to the 
embryo should be restricted to less than 60minutes.  The mechanical index (MI) 
is an indicator of the likelihood of cavitational events and is defined as the 
maximal rarefaction pressure or the maximal negative pressure divided by the 
square root of the frequency. In general the MI should be below 1.9. 
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Early Pregnancy Measurements  
 
The following measurements/observations were recorded during each 
transvaginal ultrasound scan (Appendix 6).   
 
Endometrium 
 
The uterus was scanned in the sagittal plane from one lateral aspect to the 
other.  The endometrial stripe was measured at its maximum antero-posterior 
thickness along the longitudinal axis of the uterine body. This measurement 
included both the anterior and posterior endometrial layers.  It was obtained 
by placing the calipers at the anterior and posterior uterine walls at the 
margins of the basal layers of the endometrium delineated by the echogenic 
interface between endometrium and inner myometrium.  If the endometrium 
was focally thickened, the calipers were placed at the site of the maximal 
antero-posterior diameter. In the presence of intrauterine fluid, the thicknesses 
of the anterior and posterior endometrial layers was measured separately and 
summed [284].  
  
Gestation Sac 
 
Measurements of the gestation sac  (Figure 1.3a) were taken in three 
orthogonal planes (two in a sagittal plane and one in transverse) using the 
inner borders of the sac from which the mean diameter was calculated [216].   
 
Double Decidual Sac Sign 
 
The double decidual sac sign (Figure 7.1) was defined as two concentric 
echogenic rings surrounding an intra-endometrial fluid collection [285].   
 
Yolk Sac 
 
The yolk sac (Figure 1.3b), if present, was also measured, in three orthogonal 
planes.  Unlike the gestation sac however, it was measured from the outer 
borders of the sac [216].   
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Figure 7.1: An ultrasonogram depicting the double decidual sac sign  
 
Image taken from: www.fetalultrasound.com 
Embryo or Fetus 
 
If present, the embryo was also measured (Figure 1.3c).  Initially, flexures have 
not developed and the cephalic and caudal ends of the embryo cannot be 
differentiated and hence it was the straight-line length (and not the crown-
rump length) that was recorded [216]. 
 
Adnexal Masses 
 
The presence or absence of any adnexal masses as well as their location, size, 
appearance and mobility was also recorded.   
 
Free Fluid 
 
The presence of any free fluid in the pouch of Douglas was determined by 
angling the transvaginal transducer towards the posterior part of the pelvis.  If 
present, an estimate of the volume was made.  The volume was considered 
small if it tracked less than one third up the posterior wall of the uterus on the 
long axis view.  Fluid volume was classed as moderate if it tracked one third to 
two thirds of the way up the posterior wall of the uterus but was not free 
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flowing in the pelvis or abdomen.  Fluid volume was considered large if it 
tracked greater than two thirds of the way up the posterior wall of the uterus 
or if it was free flowing in the pelvis or abdomen [286].  The appearance of any 
fluid (anechoic, echogenic or indeterminate) was also be noted. 
 
Study Design 
 
Population 
 
Participants for the study were recruited prospectively from Nurture Fertility, 
Nottingham, United Kingdom between 1st January and 31st October 2015.  
Women were aged between 18 and 45 years of age and had undergone 
IVF/ICSI treatment using a standard long agonist or antagonist protocol 
depending on ovarian reserve tests [287].  The study was well advertised within 
the IVF unit using posters and patient information leaflets.  Whenever possible, 
a clinician involved in recruitment was also present to discuss the study with 
women following their embryo transfer procedure. All women were invited to 
participate in the study. Women were excluded from the study if they had a 
negative urinary pregnancy test (performed 18 days after oocyte retrieval in a 
fresh cycle or 13-16 days after embryo transfer in a frozen embryo 
replacement cycle depending on the stage of embryo development at the 
time of transfer) or if, at the time of the index test, there was either no 
ultrasonographic evidence of an intrauterine fluid collection, or a yolk sac 
and/or fetal pole was clearly visible within the intrauterine fluid collection. 
Women were also excluded if no outcome data were available or if, following 
the reference standard, the final diagnosis was not known (for example 
resolving or persistent pregnancies of unknown location).   
 
Index Test 
 
If the urinary pregnancy test was positive, an early ultrasound scan was 
scheduled for either 19 or 20 days after oocyte retrieval corresponding to a 
gestational age of 33 or 34 days.  This range was specifically chosen to 
optimize the chances of a gestation sac being present but a yolk sac or fetal 
pole being absent [12, 20].  This early ultrasound scan was considered to be 
the index test. A single investigator with experience in early pregnancy 
ultrasound performed all of these early scans following standard operating 
procedures using a Voluson E8 machine with a high frequency (5-9MHz and 9-
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12MHz) transvaginal probe. During the early scan the presence or absence of 
the following structures were recorded: an intrauterine fluid collection (defined 
as a uniformly round, hypoechoic structure with an echogenic rim); the 
double decidual sac sign (Figure 7.1); yolk sac (defined as a spherical, 
hyperechoic ring situated eccentrically within the gestation sac) (Figure 1.3b); 
and fetal pole (defined as a small linear echogenic structure adjacent to the 
yolk sac, on the side closest to the gestational sac)(Figure 1.3c). If more than 
one intrauterine fluid collection was visualized then each was considered as a 
separate entity.  The findings from the index test were interpreted immediately 
and recorded separate to the main clinical notes.   Images were stored for 
later assessment of inter- and intra-observer reliability (see chapter eight).  
Referral pathways to local Early Pregnancy Assessment Units were in place for 
any woman in whom this index test was strongly suggestive of an ectopic 
pregnancy, for example if there was an empty endometrial cavity and either 
an inhomogenous adnexal mass or an empty extra-uterine sac or a yolk sac or 
fetal pole with or without cardiac activity in an extra-uterine sac.   
 
Reference Standard 
 
All women were scheduled to have a routine viability ultrasound scan at 
between six and seven weeks gestation (between eight and sixteen days after 
the index test) as per the fertility unit’s standard practice.  This viability scan 
was performed by an appropriately trained doctor or nurse following standard 
operating procedures using the same ultrasound equipment as the index test.  
This viability scan plus any subsequent clinical follow-up required i.e. if the 
diagnosis was not certain following the viability scan alone, constituted the 
reference standard.  Clinical follow-up consisted of a repeat transvaginal 
ultrasound 7-10 days after the initial viability scan in cases of pregnancies of 
uncertain viability (defined as the presence of an intrauterine gestation sac of 
less than 25mm mean diameter with no obvious yolk sac or fetal pole or an 
intrauterine gestation sac containing a fetal pole of less than 7mm with no 
obvious fetal heart pulsations) and in cases of pregnancies of uncertain 
location (defined as no evidence of an intra- or extra-uterine pregnancy or 
retained products of conception on transvaginal ultrasound scan in the 
presence of a positive urinary pregnancy test), referral to a local Early 
Pregnancy Assessment Unit for monitoring of serial serum E-hCG levels and 
subsequent ultrasonography and possibly surgery where indicated according 
to departmental protocols until a definitive diagnosis could be made.  
Chapter 7 
 
- 166 - 
Interpretation of the reference standard was performed by an experienced 
gynaecologist without knowledge of the findings from the index test.  Any 
uncertainty regarding the final diagnosis was dealt with by seeking the opinion 
of two other senior gynaecologists and gaining a consensus opinion. 
 
Outcome of Interest 
 
Following the reference standard the possible diagnoses were either an 
intrauterine or ectopic pregnancy.  Intrauterine pregnancies were further 
classified as either viable or non-viable.  A viable intrauterine pregnancy was 
defined by ultrasonographic identification of an intrauterine gestation sac with 
a fetal pole of any length with demonstrable fetal heart pulsations.  A non-
viable intrauterine pregnancy was defined as either an empty intrauterine 
gestation sac with mean sac diameter greater than 25mm or an intrauterine 
gestation sac containing a fetal pole with crown rump length greater than 
7mm with no demonstrable fetal heart pulsations or in the absence of a viable 
embryo, no significant increase in the growth of the gestation sac or length of 
the fetal pole on two ultrasound scans performed more than 7 days apart.  
Where women underwent surgical or medical management of miscarriage, 
histological confirmation of the products of conception was also obtained 
when possible.  Ectopic pregnancies were confirmed either by direct 
visualization of an ectopic pregnancy during surgery with histological 
confirmation, or, in those managed medically with methotrexate or 
conservatively, unequivocal identification of an ectopic pregnancy on 
ultrasound scan.  Ultrasonographic appearances indicative of an ectopic 
pregnancy included: an empty endometrial cavity with either an 
inhomogenous adnexal mass or an empty extra-uterine sac or a yolk sac or 
fetal pole with or without cardiac activity in an extra-uterine sac.  Following 
the reference standard, any pregnancy which did not fall into one of these 
categories was subsequently excluded from the study.  These included 
resolving or persisting pregnancies of unknown location.  
 
Statistical Analysis 
 
The sensitivity and specificity of the double decidual sac sign for predicting an 
intrauterine pregnancy were estimated following cross tabulation of the index 
test results against those of the reference standard.  The overall diagnostic 
accuracy, as well as positive and negative likelihood ratios and predictive 
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values, were also calculated (Table 7.1 and 7.2).  The pre-test probability was 
estimated to be the prevalence of the disease in our sample.  The post-test 
probabilities were calculated using a likelihood ratio nomogram and 
confirmed via an online diagnostic test calculator that determines the post-
test probability of disease given the pre-test probability and the test 
characteristics (http://araw.mede.uic.edu/cgi-bin/testcalc.pl).  Results are 
expressed as percentages and 95% confidence intervals are also given.   
 
Table 7.1: The 2x2 contingency table 
 
Reference Standard 
Positive Negative 
Index 
Test 
Positive True Positive (TP) False Positive (FP) 
Negative False Negative (FN) True Negative (TN) 
 
Table 7.2: Commonly used measures of test performance and how they are 
calculated using a 2x2 contingency table 
Measure Definition Calculation 
Sensitivity 
The proportion of people with the 
target condition who have a 
positive test result 
     TP     . 
TP+FN 
Specificity 
The proportion of people without 
the target condition who have a 
negative test result 
     TN     . 
TN+FP 
Overall 
Accuracy 
The proportion of people correctly 
classified by the test 
        TP+TN       . 
TP+FN+FP+TN 
Positive 
Predictive Value 
The probability of disease amongst 
those with a positive result 
     TP     . 
TP+FP 
Negative 
Predictive Value 
The probability of non-disease 
among persons with a negative 
test result 
     TN     . 
TN+FN 
Positive 
Likelihood Ratio 
The probability of a person who has 
the disease testing positive divided 
by the probability of a person who 
does not have the disease testing 
positive 
   Sensitivity   . 
1-Specificity 
Negative 
Likelihood Ratio 
The probability of a person who has 
the disease testing negative 
divided by the probability of a 
person who does not have the 
disease testing negative 
1-Sensitivity 
Specificity 
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Sample Size Calculation 
 
Based on the results of the systematic review and meta-analysis in chapter 
five, the estimated sensitivity and specificity of the double decidual sac sign to 
predict an intrauterine pregnancy is 82% and 97% respectively.  If we wish to 
estimate the sensitivity and specificity to within 10% with 95% certainty, then 
our sample size is at least 69, to include 57 true positive cases and twelve true 
negative cases [288].   
 
7.5 Results 
 
Figure 7.2: Flow of participants through the study 
 
 
Between 1st January and 31st October 2015, 620 IVF/ICSI cycles were 
undertaken within the unit.  Of these, 124 (20%) women agreed to participate 
in the study.  In addition to these, a further six women were approached at the 
time of embryo transfer and declined to participate in the study due to various 
reasons, namely work commitments (n=3), reluctance to have a transvaginal 
ultrasound (n=2) and distance to travel to the clinic (n=1).  45 (36%) of the 124 
women were subsequently excluded as they had a negative urinary 
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pregnancy test.  Of the 79 women who had a positive pregnancy test, two 
(2.5%) did not attend for the index test and nine (11%) of those that did attend 
did not have an intrauterine fluid collection present on transvaginal ultrasound 
and were therefore excluded.  77 intrauterine fluid collections were observed 
in the remaining 68 women (nine of the women had two intrauterine fluid 
collections detected).  Ten (7.7%) of the 77 intrauterine fluid collections had a 
definite yolk sac visible and were therefore excluded further from the study 
leaving 67 intrauterine fluid collections in the study (Figure 7.2).  The baseline 
characteristics of the study participants are illustrated in Table 7.3.  These were 
not significantly different from the baseline characteristics of the general 
population attending the IVF unit during the same time period. 
 
Table 7.3: Baseline characteristics of study participants (values refer to mean ± 
standard deviation unless otherwise indicated) 
Age (years)  34±6.3 
Gravidity 1.0±1.1 
Parity 0.3±0.5 
BMI (kg/m2) 24±4.5 
Ethnicity (%) 
   White British 
   Asian 
   Other White 
   African/Black British/Mixed 
 
84 
10 
3.9 
1.3 
 
Of the 67 intrauterine fluid collections detected during the index test, 61 
displayed the double decidual sac sign.  Of these, all 61 were subsequently 
demonstrated to have an intrauterine pregnancy on follow-up.  Of the six 
intrauterine fluid collections that did not display the double decidual sac sign, 
four were subsequently proven to have an intrauterine pregnancy and two 
were found to have an ectopic pregnancy (Table 7.4).   
 
Table 7.4: A 2x2 contingency table to show the diagnostic accuracy of the 
double decidual sac sign for predicting an intrauterine pregnancy using high-
resolution transvaginal ultrasound 
 
Reference Standard 
Totals 
IUP present IUP absent 
Index 
Test 
DDSS present 61 0 61 
DDSS absent 4 2 6 
Totals 65 2 67 
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The double decidual sac sign was therefore found to have a sensitivity of 94% 
(95% CI, 85-98%), specificity of 100% (95% CI, 16-100%) and overall diagnostic 
accuracy of 94% (95% CI, 88-100%) for predicting an intrauterine pregnancy.  
The positive and negative predictive values are 100% (95% CI, 94-100%) and 
33% (95% CI, 4.3-78%) respectively whilst the positive likelihood ratio was infinite 
and the negative likelihood ratio was 0.06 (95% CI, 0.02-0.16) (Figure 7.3).  In 
our study, the prevalence of an intrauterine pregnancy was 97% but if the 
double decidual sac sign was present the probability of an intrauterine 
pregnancy was 100% compared with 66% if the double decidual sac sign was 
absent (Table 7.5). 
 
Of the 61 intrauterine pregnancies that demonstrated the double decidual 
sac sign during the index scan, 58 (95%) were viable.  Of the four intrauterine 
pregnancies that did not display the double decidual sac sign during the 
index scan, only two (50%) were viable. 
 
Figure 7.3: Likelihood ratio nomogram for determining post-test probabilities 
 
 
Two ectopic pregnancies were identified at the time of the reference 
standard.  Both women were asymptomatic but had ultrasonographic 
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evidence of an empty endometrial cavity and an inhomogenous adnexal 
mass.  They were referred to the local Early Pregnancy Assessment Unit where 
the diagnosis was confirmed and one chose to have medical management 
with Methotrexate, which was successful and the other underwent 
laparoscopic salpingectomy, which was uncomplicated, and histological 
examination of the specimen confirmed the diagnosis.   
 
Of the nine women that attended for the index scan but did not have an 
intrauterine fluid collection present, seven (78%) were subsequently proven to 
have a viable intrauterine pregnancy, one (11%) had a non-viable intrauterine 
pregnancy and one (11%) was diagnosed with an ectopic pregnancy at 
approximately 7 weeks’ gestation. 
 
All ten intrauterine fluid collections that contained yolk sacs at the time of the 
index test were subsequently proven to be viable intrauterine pregnancies.   
 
No adverse events from performing the index test or reference standard were 
reported.   
 
7.6 Discussion 
 
Our results demonstrate that the probability of an intrauterine pregnancy 
when the double decidual sac sign was present was 100%.  The probability of 
having an ectopic pregnancy when the double decidual sac sign was absent 
was 33%.  Accordingly, only our first hypothesis is accepted.  Using modern 
high-resolution transvaginal ultrasound, the presence or absence of the 
double decidual sac sign correctly located 94% of pregnancies.  The double 
decidual sac sign was present in 94% of intrauterine pregnancies and absent 
in both the ectopic pregnancies. In this study, the prevalence of an 
intrauterine pregnancy was 97%, but if the double decidual sac sign was 
present the probability of an intrauterine pregnancy was 100% compared with 
66% (range, 49-88%) if the double decidual sac sign was absent.  These 
findings suggest that the diagnostic accuracy of the double decidual sac sign 
for predicting an intrauterine pregnancy reported in the systematic review 
and meta-analysis described in chapter four was underestimated. 
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One of the studies included in the systematic review suggested that whilst the 
overall sensitivity and specificity of the double decidual sac sign for 
distinguishing between an intrauterine pregnancy and an ectopic pregnancy 
was 64% and 100% respectively, in cases where embryonic contents were not 
yet visible the specificity dropped to 53%, rendering it a useless test in clinical 
practice [220].  Inherent with a diagnostic test to confirm an intrauterine 
pregnancy, is the absolute requirement for false positive and false negative 
rates of zero.  This is because of the clinical implications of labeling a 
pregnancy as intrauterine with subsequently little or no follow-up, when 
actually it is ectopic and any delay in diagnosis could be detrimental or 
labeling a pregnancy as an ectopic and initiating treatment when actually it is 
intrauterine.  
 
In our study however, women were excluded if embryonic contents were 
visible, hence our results suggest that the double decidual sac sign is actually 
very valuable in clinical practice: women who present with abdominal pain 
and/or vaginal bleeding in early pregnancy who have ultrasonographic 
evidence of an empty sac which demonstrates the double decidual sac sign 
can, according to our results, be managed following pregnancy of uncertain 
viability protocols rather than, what has become standard practice in many 
units, pregnancy of unknown location protocols and consequently not use 
valuable resources inappropriately nor generate undue anxiety for women.   
 
It is important to note that despite our specificity of 100%, a thorough 
assessment of the adnexa is still required even when an intrauterine fluid 
collection does demonstrate the double decidual sac sign because of the 
possibility, albeit remote, of a heterotopic pregnancy.   
 
Furthermore, even though the sensitivity of the double decidual sac sign to 
predict an intrauterine pregnancy in this study was extremely high, it was not 
100% and therefore intrauterine fluid collections that do not demonstrate the 
double decidual sac sign cannot be labeled as pseudosacs associated with 
ectopic pregnancies.  Such ultrasonographic findings require follow-up until 
pregnancy location can be conclusively determined.   
 
The main limitation of our study is that it only included two true negative cases.  
Whilst neither of these demonstrated the double decidual sac sign resulting in 
a specificity of 100%, as there were only two, the confidence intervals are 
Chapter 7 
 
- 173 - 
wide.  If more women were recruited, more pseudosacs might have been 
identified but accepting that (1) the incidence of an ectopic pregnancy is 
relatively low, even following IVF/ICSI treatment [289], and (2) pseudosacs 
occur in less than 15% of ectopic pregnancies [18], approximately 1700 
women would need to participate in the study to identify the required number 
of pseudosacs from our sample size calculation.  Taking into consideration the 
throughput and success rates of our IVF unit and the recruitment rate 
observed during our study, this would take over a decade to achieve. A multi-
center approach would generate greater numbers more quickly but this 
would incorporate variations in practice that could affect the validity of our 
results in other ways. 
 
Another limitation of our study is that all scans were performed and interpreted 
by a single investigator.  Although it would have been ideal if more than one 
operator performed each ultrasound, this was not incorporated into the study 
protocol for two reasons.  Firstly, many of the scans were performed out-of-
hours for the convenience of the participants and logistically it would have 
been difficult to coordinate these appointments if multiple investigators were 
simultaneously required. Secondly, following a focus group discussion with 
potential participants during the planning phase of the study, it was 
discovered that many women felt apprehensive about having a transvaginal 
ultrasound when there was no clinical indication.  Whilst other women said 
that they would be willing to undergo one additional transvaginal ultrasound 
as part of a research study, most women were reluctant to have more than 
one.  However, the inter-observer variability associated with ultrasonographic 
detection of the double decidual sac sign is an important consideration if it is 
to be used in clinical practice and this is the focus a subsequent study 
described in the following chapter.   
 
Finally, all participants in the study were pregnant as a consequence of 
IVF/ICSI treatment.  This was so that we could be certain of the exact 
gestational age of the pregnancy and schedule the index test to be 
performed at an appropriate time. From the literature, a gestation sac first 
appears at approximately 28 days gestation [12] but since the women in our 
study had been instructed to perform their urinary pregnancy test 18 days 
after egg collection (corresponding to a gestational age of 32) as part of the 
fertility units standard practice, we could not perform the index test any earlier 
than this.  We also wanted to perform the index test at a time when there was 
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a low probability of identifying embryonic contents, which is thought to be 
around day 35 [20].  It is possible that the accuracy of the double decidual 
sac sign to predict an intrauterine pregnancy may be related to gestational 
age and perhaps intrauterine fluid collections identified ultrasonographically 
prior to day 33 or after day 34 may be more or less likely to demonstrate the 
double decidual sac sign than those identified in our study. Scheduling the 
index test for this specific time would have been difficult if using spontaneous 
conceptions.  However, there is no theoretical reason to suggest that the 
diagnostic accuracy of the double decidual sac sign to predict an 
intrauterine pregnancy would be any different in spontaneous pregnancies 
compared to assisted conceptions.    
 
7.7 Conclusion 
 
Using modern high-resolution transvaginal ultrasound, the presence of the 
double decidual sac sign can be used to accurately confirm an intrauterine 
pregnancy prior to visualization of embryonic contents. The absence of it 
however does not preclude an intrauterine pregnancy. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
Table 7.5: Summary estimates of the double decidual sac sign to predict an intrauterine pregnancy  
 
 
Sensitivity 
(95% CI)(%) 
Specificity 
(95% CI)(%) 
PPV 
(95% CI)(%) 
NPV 
(95% CI)(%) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
Pre- and post-test probability 
Pre-test Post-test if test 
positive 
Post-test if test 
negative 
DDSS 94 
(85-98) 
100 
(16-100) 
100 
(94-100) 
33 
(4.3-78) 
∞ 0.06 
(0.02-0.16) 
97 100 
(93-100) 
66 
(49-88) 
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8. Inter- and Intra-Observer 
Reliability Associated with 
Ultrasonographic 
Visualization of the Double 
Decidual Sac Sign 
 
8.1 Introduction  
 
The ability to accurately differentiate a true gestation sac from a pseudosac 
prior to ultrasonographic visualization of embryonic contents would be very 
useful clinically.  As described in the preceding chapters, several different 
ultrasonographic signs have been proposed to help discriminate between the 
two structures [218-220].  The double decidual sac sign is one such sign.  It was 
first described in the early 1980s as two concentric echogenic rings of tissue 
surrounding an intra-endometrial fluid collection that impress upon the 
endometrial stripe in an early intrauterine pregnancy [219].  Conversely, in an 
ectopic pregnancy, the decidual reaction presents as only a single echogenic 
ring around the endometrial fluid collection [19].   
 
Following the conclusions made in chapter five, we undertook a study to 
determine the diagnostic accuracy of the double decidual sac sign for 
predicting an intrauterine pregnancy prior to visualization of embryonic 
contents using modern, high-resolution transvaginal ultrasound.  This study, 
reported in chapter seven, demonstrated that the double decidual sac sign 
had a sensitivity of 94%, specificity of 100% and overall diagnostic accuracy of 
94% for predicting an intrauterine pregnancy [275] and concluded that, using 
high resolution transvaginal ultrasound, the presence of the double decidual 
sac sign could be used to accurately confirm an intrauterine pregnancy prior 
to visualization of embryonic contents.  These results could potentially 
revolutionize the management of diagnostic uncertainties in early pregnancy 
by rationalising the follow-up of women with ultrasonographic evidence of an 
‘empty sac’.   
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For various reasons, described in the previous chapter, all of the scans 
undertaken in the diagnostic accuracy study were performed and interpreted 
by a single investigator.  For the double decidual sac sign to be rendered 
clinically useful, multiple different observers assessing the same ultrasonogram 
independently should agree about whether the sign is present or not.  As the 
presence or absence of the double decidual sac sign informs further 
management decisions, and the consequences of a false positive diagnosis 
are to overlook an ectopic pregnancy (which could have catastrophic 
clinical consequences), a high degree of reliability is essential.   The more 
objective and unambiguous the criteria are for a sign, the more likely it is that it 
will have high inter- and intra-observer agreement and vice versa.     
 
8.2 Aims 
 
The aim of this study therefore was to determine the inter- and intra-observer 
reliability associated with ultrasonographic identification of the double 
decidual sac sign as well as the diagnostic interpretation and management of 
‘empty sacs’.  
 
8.3 Methods 
 
Study Design 
 
All ultrasonographic images were collected prospectively as part of the study 
attempting to determine the diagnostic accuracy of the double decidual sac 
sign for predicting an intrauterine pregnancy prior to ultrasonographic 
visualization of embryonic contents as described in chapter seven.   
 
For the assessment of inter-observer reliability, two-dimensional images from a 
selection of 25 of the study participants were distributed to eighteen 
individuals with experience in early pregnancy ultrasound to assess.  In an 
attempt to reflect normal clinical practice as far as possible we surveyed 
observers from different hospitals with different levels of experience.  The 
observers were colleagues of the author who had expressed an interest in 
participating in the study.  Both clinicians and ultrasonographers were 
included in the study because in the United Kingdom a large proportion of
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early pregnancy ultrasound scans are performed by ultrasonographers.  The 
experience of each observer was assessed both subjectively, by asking what 
level of experience they had i.e. beginner, intermediate or advanced, and 
objectively, by asking how many years’ experience they had.   
 
Each observer was provided with an electronic link to a secure website 
(Dropbox Inc, San Francisco, USA) where they could view the ultrasound 
images (Appendix 7).  The author selected several images from 25 of the 
original study participants which they believed depicted intrauterine fluid 
collections that both did and did not exhibit the double decidual sac sign.  
Determining the exact sample size and method of selection was difficult. We 
wanted to ensure a range of cases, including borderline ones, were 
incorporated into the study, and this would not have been possible by using 
consecutive cases.  Neither were they chosen at random as we needed to 
ensure that image quality was for the most part reasonable and that we 
included intrauterine fluid collections that both did, and did not, demonstrate 
the double decidual sac sign.  For practical purposes it was thought that 
twenty-five cases was an acceptable number for observers to assess.  For 
each of the 25 cases selected, between three and four two-dimensional 
images were provided for assessment.  The images given for review included 
standard transverse and sagittal planes.  The final diagnoses were not known 
at the time of selection of cases/images for inclusion in the study. All datasets 
were anonymized to comply with research ethics approval.  Observers were 
informed that all images were taken from asymptomatic women who were 
between four and five weeks pregnant following IVF treatment.  No other 
clinical history was provided.   
 
Each observer independently performed off-line analysis of the 
ultrasonographic images and was asked to complete a standardized 
assessment form.  For each of the 25 cases, the observers were asked three 
questions: (1) is the double decidual sac sign present; (2) what does the 
structure represent; and (3) what initial follow-up would you recommend?  
Available options from a drop down menu included: ‘yes’ and ‘no/uncertain’ 
for question one; ‘gestation sac’ and ‘pseudosac/uncertain’ for question two; 
and ‘re-scan in 7-10 days’ and ‘serial hCGs’ for question three.  Although a 
repeat ultrasound is advocated in addition to serial hCGs in the management 
of pregnancies of unknown location, the initial management consists of serial 
hCGs and then, depending on both the trend and the absolute levels, a 
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repeat ultrasound may be undertaken at some point in the future. Question 3 
was primarily concerned with the initial management plan, hence the two 
options available.   
 
Following the initial assessment of inter-observer reliability, six of the observers 
who were locally available were provided with training.  This training included 
both theoretical and practical components, static image review and live 
scanning.  Observers had a group tutorial of approximately two hours duration 
and an individual supervised scanning session in a dedicated early pregnancy 
setting.  To determine the effect of training on the inter-observer reliability, 
these six observers were asked to assess the same set of images two weeks 
after completion of training.  A further four weeks later, in an attempt to assess 
the intra-observer reliability, the six local observers were asked to assess the 
same set of images one third and final time.  The order of the cases was 
randomly manipulated prior to the second and third assessments in an 
attempt to eliminate recall bias. 
 
Statistical Analysis 
 
Table 8.1: Recommended descriptions of numerical kappa (κ) values [290]   
κ Statistic Level of Agreement 
<0 Less than chance 
0.01-0.20 Slight 
0.21-0.40 Fair 
0.41-0.60 Moderate 
0.61-0.80 Substantial 
0.81-0.99 Almost perfect 
 
For the determination of inter- and intra-observer reliability, statistical analysis 
was performed using Mini Tab 17 (Coventry, UK).  To describe inter-observer 
reliability, the Fleiss-Kappa statistic was used.  Fleiss-Kappa is a generic term for 
several similar measures of agreement used with categorical data, which 
reflect the classification of objects into different groups or categories. Typically 
it is used in assessing the degree to which two or more raters, examining the 
same data, agree when it comes to assigning the data into categories.  In this 
study, the Fleiss-Kappa statistic was used to assess the extent by which the 
observers vary in their interpretation of the ultrasonographic images provided 
to them.  Complete agreement corresponds to K=1, and lack of agreement 
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corresponds to K=0. A negative value of kappa would mean negative 
agreement, usually caused by the rater’s tendency toward avoiding a grade 
assigned to an object by others. Recommended descriptions of numerical K 
values are illustrated in Table 8.1[290].   
 
8.4 Results  
 
Fifteen (83%) of the eighteen observers asked completed the survey.  Within 
the UK, observers were located in London, Nottingham, Cambridge, 
Winchester, Milton Keynes, Plymouth, Salisbury and High Wycombe.  Observers 
from Denmark and Australia also completed the survey.  Twelve (80%) 
observers were clinicians with a special interest in ultrasonography, two (13%) 
were ultrasonographers and one (6.7%) was a nurse ultrasonographer.  The 
number of years’ experience with early pregnancy ultrasound ranged from 
between one and fifteen.  Three (20%) observers subjectively rated themselves 
as having a ‘beginner’ level of experience with early pregnancy ultrasound, 
five (33%) as ‘intermediate’ and seven (47%) as ‘advanced’.  Fourteen (93%) 
observers had heard of the double decidual sac sign prior to completing the 
survey but only eight (53%) utilized it in clinical practice.   
 
Overall, there was significant agreement amongst the fifteen observers for 
question one (is the double decidual sac sign present?) but the level of 
agreement was only ‘fair’ (K=0.25, p<0.01).  Although the level of agreement 
amongst the two ultrasonographer was only ‘slight’ (K=0.17, p>0.05) and 
amongst the twelve clinicians it was ‘fair’ (K=0.28, p<0.01), the difference 
between the two groups was not statistically significant, as reflected by the 
overlapping confidence intervals.  The eight observers who utilized the double 
decidual sac sign in their clinical practice had ‘fair’ levels of agreement 
(K=0.34, p<0.01), which was significantly higher than the seven observers who 
did not (K=0.13, p<0.01).  Despite the fact that there was a ‘moderate’ level of 
agreement amongst the five observers who subjectively rated their ultrasound 
skills as ‘intermediate’ (K=0.41, p<0.01) and only ‘fair’ agreement amongst the 
seven observers who rated their skills as ‘advanced’ (K=0.23, p<0.01), the 
difference between the two groups was not statistically significant.  Both 
groups however had significantly higher levels of agreement than the three 
observers who rated themselves as a ‘beginner’.  The levels of agreement 
were significantly higher in observers with five or more years’ experience 
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(K=0.24, p<0.01) compared to those with less than five years’ experience 
(K=0.16, p<0.01).  The highest levels of agreement were witnessed in the three 
observers who rated themselves as ‘advanced’ and had five or more years’ 
experience (K=0.41, p<0.01) (Table 8.2).  
 
Overall, there was significant agreement amongst the fifteen observers for 
question two (what does the structure represent?) but again the level of 
agreement was only ‘fair’ (K=0.33, p<0.01).  Levels of agreement were ‘fair’ 
regardless of job description, use in clinical practice, subjective level of 
experience and number of years’ experience.  The highest levels of 
agreement were witnessed in the eight observers who utilized the double 
decidual sac sign in their clinical practice (K=0.36, p<0.01) (Table 8.3).   
 
Interpretation of the ultrasonographic findings was in-keeping with the 
observers impression of whether or not the double decidual sac sign was 
present in 82% of cases but in 15 of the 187 (8.0%) instances when the double 
decidual sac sign was considered to be present, the structure was thought to 
represent a pseudosac and in 52 of the 188 (28%) instances when the double 
decidual sac sign was considered to be absent, it was thought that the 
structure represented a gestation sac. 
 
Overall, there was significant agreement amongst the fifteen observers for 
question three (what follow-up would you recommend?) but again the level 
of agreement was only ‘fair’ (K=0.21, p<0.01).  There was no significant 
difference between the levels of agreement amongst the twelve clinicians 
(K=0.24, p<0.01) and the two ultrasonographers (K=0.40, p<0.05), which were 
all ‘fair’.  The eight observers who utilized the double decidual sac sign in their 
clinical practice also had ‘fair’ levels of agreement (K=0.32, p<0.01), which 
was significantly higher than the seven observers who did not (K=0.085, 
p<0.05).  Although there was a trend towards increasing levels of agreement 
with increasing skill level, the difference between those with beginner, 
intermediate and advanced ultrasound skills was not statistically significant.  
There was ‘slight’ agreement amongst observers with less than five years’ 
experience (K=0.17, p<0.01) and ‘fair’ agreement amongst those with five or 
more years’ experience (K=0.26, p<0.01) but again there was no statistically 
significant difference between the two groups (Table 8.4).   
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The recommended follow-up was considered appropriate in 91% of cases 
based on the observers interpretation of what they thought the structure 
represented (irrespective of whether they thought the double decidual sac 
sign was present or not) but in 28 of the 224 (13%) presumed gestation sacs, 
serial hCGs were recommended and in six of the 151 (4.0%) presumed 
pseudosacs, a re-scan in 7-10 days was advised.   
 
Amongst the six local observers, there were three clinicians with a special 
interest in ultrasonography, two ultrasonographers and one nurse 
ultrasonographer.  The number of years’ experience with early pregnancy 
ultrasound ranged from between one and eight.  Three observers subjectively 
rated themselves as having a ‘beginner’ level of experience with early 
pregnancy ultrasound, two as ‘intermediate’ and one as ‘advanced’.  All six 
had heard of the double decidual sac sign prior to being asked to participate 
in the study but only two utilized it in clinical practice.  Prior to training, there 
was significant (p<0.01) agreement amongst the six observers for questions 1, 2 
and 3 but the level of agreement was only ‘fair’ for questions 1 and 2 and 
‘slight’ for question 3 reflected by kappa scores of 0.23, 0.37 and 0.12 
respectively (Table 8.5).  After training, there was ‘substantial’ agreement for 
questions 1 and 3 and ‘moderate’ for question 2 reflected by kappa scores of 
0.70, 0.63 and 0.53.  This improvement was statistically significant for questions 1 
and 3 (Table 8.5).   
 
After training, the level of agreement within the six local observers when 
reassessing the same set of still images ranged from ‘substantial’ (observer 4, 
question 3, K=0.65) to ‘almost perfect’ (observer 1, question 1, K=0.92) (Table 
8.6).  Consistency was greatest for question two as five of the six observers had 
‘almost perfect’ levels of agreement.  Least consistency occurred for question 
3 but at worst there was still a ‘substantial’ level of agreement (observer 4, 
K=0.65) and at best an ‘almost perfect’ level of agreement (observer 1, 
K=0.84).   
 
8.5 Discussion 
 
This aim of this study was to determine the inter- and intra-observer reliability 
associated with ultrasonographic identification of the double decidual sac 
sign as well as the diagnostic interpretation and management of ‘empty 
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sacs’.  Although similar studies exist [246], this is the first study to utilize multiple 
observers from different institutions with varying levels of experience.  Previous 
studies did not consider intra-observer reliability or the effect of training.  Our 
study is also the first to utilize images that were obtained prospectively, using 
high-resolution transvaginal ultrasound, with the specific intention of 
demonstrating the double decidual sac sign.   
 
Although our results suggest that agreement between observers when 
determining the presence or absence of the double decidual sac sign were 
generally only ‘fair’, the fact that it was significantly higher amongst observers 
who utilized the sign in clinical practice and were more experienced implies 
that the double decidual sac sign could be useful after training.  Indeed, our 
secondary analysis, incorporating six of the original observers, proves that 
training significantly improves the levels of agreement.   
 
As described in chapter five, due to previous studies reporting variable 
degrees of accuracy, with sensitivities between 64-95% [220, 238] and 
specificities between 60-100% [219, 220, 238], the clinical utility of the double 
decidual sac sign has been questioned [220], perhaps negating the need for it 
to be included in ultrasound training.  Current clinical practice advocates 
waiting until a yolk sac and/or fetal pole is visualized ultrasonographically 
before stating that a pregnancy is definitely intrauterine.  This is because the 
yolk sac is a reliable indicator of an intrauterine pregnancy with a positive 
predictive value of 100% [243].  However, since we have demonstrated in 
chapter seven that the double decidual sac sign also has a specificity and 
positive predictive value of 100% [275], an intrauterine pregnancy can be 
accurately diagnosed prior to ultrasonographic visualization of embryonic 
contents, and hence the double decidual sac sign should now be 
incorporated into standard ultrasound training in early pregnancy because of 
the potential clinical benefit that could be gained from it. 
 
Whilst variation between observers can introduce bias and make it difficult to 
interpret results, variation within an observer is random and, as such, does not 
cause bias in itself but affects precision, which is also an important 
consideration if the double decidual sac sign is to be used clinically.  The high 
levels of intra-observer reliability found in our study adds further value to its use 
in clinical practice.   
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The main limitation of our study is that static ultrasound images were used.  
Although multiple images were provided, still images don’t adequately reflect 
the full assessment made when performing the scan.  Although it would have 
been preferable to have had each observer perform each scan 
independently, this was not feasible for reasons described in the previous 
chapter.  A cineloop recording in addition to the still images would have 
enhanced the observers assessment in lieu of performing the scan themselves 
which may have improved the levels of agreement reported.   
 
Additionally, the observers were not blinded to the clinical information and this 
may have altered their responses, particularly to questions two and three.  
However, the clinical history was the same for each case and suitably vague.   
 
Finally, the Fleiss Kappa statistic was used to determine reliability and although 
the appropriate test to measure agreement between more than two 
observers when responses fall into categories, there are several problems 
inherent with both its use and the use of the recommended descriptions of 
numerical K values leading to an under, or indeed over, estimation of 
reliability. Firstly, it depends on the true proportions of subjects in each 
category, secondly it assumes the sample is representative of the underlying 
population and thirdly, it ignores the influence experimental conditions have 
on the magnitude of estimated agreement coefficients [291-293].  Another 
problem with the Fleiss Kappa statistic is the interpretation of what a 
statistically significant test means in clinical practice.  In a practical situation in 
which ratings are compared across clinicians, agreement will usually be better 
than that expected by chance and specifying a zero value for kappa in the 
null hypothesis i.e. no agreement, is therefore not very meaningful [294, 295].  
Thus, the value in the null hypothesis should usually be set at a level below 
which would be considered clinically unacceptable.  This will of course, 
depend on the clinical context. In the context of the double decidual sac 
sign, the minimal acceptable level of agreement on this categorization should 
be set fairly high, for example, greater than 0.60, so that decisions on patient 
management are made with a high degree of consistency.   
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8.6 Conclusion 
 
In conclusion, using modern high resolution transvaginal ultrasound, the 
double decidual sac sign is not only accurate in its ability to confirm an 
intrauterine pregnancy prior to visualization of embryonic contents, but also, 
as demonstrated by this study, has the potential (after training) to be both 
reliable and precise, making it a very useful ultrasonographic sign in clinical 
practice.   
  
 
Table 8.2: Inter-observer reliability for question 1 ‘Is the double decidual sac sign present?’ 
  n κ Level of Agreement SE 95%CI p-value 
ALL 15 0.25 Fair 0.20 -0.13-0.63 <0.01 
JOB 
DESCRIPTION 
Clinician 12 0.28 Fair 0.025 0.23-0.33 <0.01 
Ultrasonographer 2 0.17 Slight 0.20 -0.23-0.56 ns 
KNOWLEDGE 14 0.26 Fair 0.021 0.22-0.30 <0.01 
PRACTICE 
Yes 8 0.34 Fair 0.038 0.27-0.4182 <0.01 
No 7 0.13 Slight 0.044 0.043-0.2135 <0.01 
LEVEL OF 
EXPERIENCE 
Beginner 3 -0.036 Less than Chance 0.12 -0.26-0.1907 ns 
Intermediate 5 0.41 Moderate 0.063 0.28-0.5301 <0.01 
Advanced 7 0.23 Fair 0.044 0.15-0.3164 <0.01 
YEARS 
EXPERIENCE 
< 5 5 0.16 Slight 0.63 -1.1-1.4 <0.01 
≥ 5 10 0.24 Fair 0.030 0.18-0.30 <0.01 
ADVANCED AND ≥5 YRS EXPERIENCE 3 0.41 Moderate 0.12 0.18-0.63 <0.01 
 
 
 
 
  
  
 
  
  
  
 
Table 8.3: Inter-observer reliability for question 2 ‘What does the structure represent?’ 
  n κ Level of Agreement SE 95%CI p-value 
ALL 15 0.33 Fair 0.20 -0.049-0.72 <0.01 
JOB 
DESCRIPTION 
Clinician 12 0.31 Fair 0.025 0.26-0.36 <0.01 
Ultrasonographer 2 0.35 Fair 0.20 -0.041-0.74 <0.05 
KNOWLEDGE 14 0.34 Fair 0.021 0.30-0.38 <0.01 
PRACTICE 
Yes 8 0.36 Fair 0.038 0.29-0.44 <0.01 
No 7 0.33 Fair 0.044 0.24-0.41 <0.01 
LEVEL OF 
EXPERIENCE 
Beginner 3 0.30 Fair 0.12 0.077-0.53 <0.01 
Intermediate 5 0.33 Fair 0.063 0.21-0.46 <0.01 
Advanced 7 0.34 Fair 0.044 0.26-0.43 <0.01 
YEARS 
EXPERIENCE 
< 5 5 0.26 Fair 0.63 -0.98-1.5 <0.01 
≥ 5 10 0.34 Fair 0.030 0.28-0.40 <0.01 
ADVANCED AND ≥5 YRS EXPERIENCE 3 0.22 Fair 0.12 -0.0041-0.45 <0.05 
 
  
  
 
 
  
  
 
Table 8.4: Inter-observer reliability for question 3 ‘What follow-up would you recommend?’ 
  n κ Level of Agreement SE 95%CI p-value 
ALL 15 0.21 Fair 0.20 -0.17-0.60 <0.01 
JOB 
DESCRIPTION 
Clinician 12 0.24 Fair 0.025 0.19-0.28  <0.01 
Ultrasonographer 2 0.40 Fair 0.20 0.013-0.80  <0.05 
KNOWLEDGE 14 0.24 Fair 0.021 0.20-0.28 <0.01 
PRACTICE 
Yes 8 0.32 Fair 0.038  0.24-0.39  <0.01 
No 7 0.085 Slight 0.044  -0.0005-0.17  <0.05 
LEVEL OF 
EXPERIENCE 
Beginner 3 -0.023 Less than chance 0.12 -0.25-0.20  ns 
Intermediate 5 0.16 Slight 0.063 0.035-0.28  <0.01 
Advanced 7 0.31 Fair 0.044  0.22-0.40  <0.01 
YEARS 
EXPERIENCE 
< 5 5 0.17 Slight 0.63  -1.1-1.41  <0.01 
≥ 5 10 0.26 Fair 0.030  0.20-0.32  <0.01 
ADVANCED AND ≥5 YRS EXPERIENCE 3 0.22 Fair 0.12  -0.0041-0.45  <0.05 
 
  
  
 
 
  
  
 
Table 8.5: Inter-observer reliability for questions 1, 2 and 3 for six observers before (assessment 1) and after (assessment 2) training   
 Q1: Is the DDSS present?  Q2: What does the structure represent?  Q3: What follow-up would you recommend?  
κ  
Level of   
Agreement  95%CI  p-value  κ  
Level of  
Agreement  95%CI  p-value  κ  
Level of  
Agreement  95%CI  p-value  
1  0.23  Fair  0.13-0.33  <0.01  0.37  Fair  0.27-0.47  <0.01  0.12  Slight  0.023-0.23  <0.01  
2  0.70  Substantial  0.60-0.80  <0.01  0.53  Moderate  0.43-0.63  <0.01  0.63  Substantial  0.53-0.73  <0.01  
  
Table 8.6: Intra-observer reliability for questions 1, 2 and 3 for six observers  
Question κ statistic (95% CI) 
Observer 1 Observer 2 Observer 3 Observer 4 Observer 5 Observer 6 
1. Is the DDSS present? 0.92 
(0.53-1.3) 
0.84 
(0.45-1.2) 
0.75 
(0.36-1.1) 
0.73 
(0.34-1.1) 
0.84 
(0.45-1.2) 
0.92 
(0.53-1.3) 
2. What does the structure 
represent? 
0.82 
(0.42-1.2) 
0.86 
(0.47-1.3) 
0.83 
(0.43-1.2) 
0.76 
(0.37-1.1) 
0.90 
(0.50-1.3) 
0.92 
(0.53-1.3) 
3. What follow-up would you 
recommend? 
0.84 
(0.45-1.2) 
0.76 
(0.37-1.2) 
0.68 
(0.28-1.1) 
0.65 
(0.26-1.0) 
0.76 
(0.37-1.2) 
0.84 
(0.45-1.2) 
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9. Predicting Outcome in 
Pregnancies of Uncertain 
Viability Using Novel Serum 
Biomarkers 
 
NB; An abridged version of this chapter has been accepted for publication in 
the Journal of Obstetrics and Gynaecology 
 
9.1 Introduction 
 
As discussed in chapter three, in cases of known intrauterine pregnancy, 
viability will be uncertain in approximately 10% of women attending an Early 
Pregnancy Assessment Unit [138].  The diagnosis of a pregnancy of uncertain 
viability is made following ultrasonographic visualization of either a small 
gestation sac (mean diameter ≤25mm) with no obvious yolk sac or fetal pole, 
or a small fetal pole (crown rump length ≤7mm) with no obvious fetal heart 
activity.  These findings may represent a normal early pregnancy of between 
four and six weeks’ gestation or they may be failed or failing pregnancies with 
arrested development which are destined to miscarry.  
 
The diagnosis of a pregnancy of uncertain viability generates significant 
anxiety for women, as discussed in chapter four, and a considerable workload 
for Early Pregnancy Assessment Units as they all need to be followed up until a 
definitive diagnosis of either a viable or non-viable intrauterine pregnancy can 
be made, which takes at least seven days to achieve [138].     
 
Unfortunately, as mentioned in chapter three, the prediction of outcome in 
pregnancies of uncertain viability is challenging [296, 297].  Many studies have 
attempted to establish methods of differentiating viable from non-viable 
pregnancies in cases of uncertainty, some using hCG levels [34, 38, 106, 150, 
298], others progesterone concentrations [39-42], and others still various 
different ultrasonographic features [23, 25, 299-304].  No studies however, not 
even those that incorporate multiple demographic, clinical, ultrasonographic 
and serological parameters [305, 306] have been shown to predict pregnancy 
viability with absolute certainty.  It is necessary for a test to have a sensitivity of 
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100% to avoid the unintentional termination of a viable pregnancy resulting 
from a false negative diagnosis. 
 
This predicament has led to the search for alternative prognostic markers and 
substances involved in either vascular development or immune responses 
have been prime candidates of late.  Recent studies have shown that, in 
women with certain diagnoses (i.e. viable, non-viable or ectopic 
pregnancies), serum angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2) and 
soluble fms-like tyrosine kinase-1 (Flt-1) concentrations are significantly higher 
[307-310] and levels of interleukin-15 (IL-15) and TNF-related apoptosis inducing 
ligand (TRAIL) significantly lower [311, 312] in women with viable intrauterine 
pregnancies compared to those with non-viable intrauterine or ectopic 
pregnancies.   
 
9.2 Aims 
 
The aim of our study was to determine whether serum concentrations of Ang-
1, Ang-2, Flt-1, IL-15 or TRAIL can be used to predict pregnancy viability in 
cases of uncertainty. 
 
9.3 Hypotheses 
 
x Women with a pregnancy of uncertain viability and a high serum 
concentration of Ang-1, Ang-2 and/or Flt-1 are more likely to subsequently 
be diagnosed with a viable intrauterine pregnancy than women with a 
low serum concentration of Ang-1, Ang-2 and/or Flt-1. 
x Women with a pregnancy of uncertain viability and a low serum 
concentration of IL-15 and/or TRAIL are more likely to subsequently be 
diagnosed with a viable intrauterine pregnancy than women with a high 
serum concentration of IL-15 and/or TRAIL. 
 
9.4 Methods 
 
Ethical Approval 
 
Ethical approval was obtained from Nottingham 1 Research Ethics Committee 
(13-EM-0081) (Appendix 1) and informed written consent was obtained from 
all participants (Appendix 8). 
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Study Design 
 
Participants were prospectively recruited from the Early Pregnancy Assessment 
Unit at the Queen’s Medical Centre in Nottingham between 17th June 2014 
and the 1st September 2015.   
 
Women given a diagnosis of a pregnancy of uncertain viability following a 
transvaginal ultrasound were eligible to take part in the study.  A pregnancy of 
uncertain viability was defined as the presence of an intrauterine gestation 
sac of less than 25mm mean diameter with no obvious yolk sac or fetal pole or 
an intrauterine gestation sac containing a fetal pole of less than 7mm with no 
obvious fetal heart pulsations [313, 314].  Women were excluded from the 
study if they were haemodynamically unstable, had attended the unit 
previously in the same pregnancy and had already had an ultrasound scan, if 
it was subsequently proven to be a multiple pregnancy or if the final diagnosis 
was not known. 
 
Following the diagnosis of a pregnancy of uncertain viability, women were 
managed according to departmental protocols that involved a repeat 
ultrasound seven to ten days after the initial ultrasound.  After follow-up, the 
final diagnosis of either a viable or non-viable intrauterine pregnancy was 
recorded. A viable intrauterine pregnancy was defined by subsequent 
ultrasonographic identification of an intrauterine gestation sac with a fetal 
pole of any length with demonstrable fetal heart pulsations.   A non-viable 
intrauterine pregnancy was defined as either an empty intrauterine gestation 
sac with mean sac diameter greater than 25mm or an intrauterine gestation 
sac containing a fetal pole with crown rump length greater than 7mm with no 
demonstrable fetal heart pulsations or, in the absence of a viable embryo, no 
significant increase in the growth of the gestation sac or length of the fetal 
pole on two ultrasound scans performed more than 7 days apart.  If the 
gestation sac and/or fetal pole had increased in size since the initial 
ultrasound, but obvious fetal heart pulsations were still not visible, a further 
ultrasound was scheduled ten to fourteen days later.  Histological confirmation 
of all products of conception was also sought when available. 
 
Demographic details, current and past obstetric history and ultrasonographic 
findings were recorded at the time of entry into the study (Appendix 9) and 
10mls of blood in a serum separating tube was taken from the antecubital 
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fossa by a trained practitioner using aseptic technique. Blood was processed 
by centrifuge (4000rpm for 20 minutes) within two hours of collection and the 
supernatants were stored at -80oC until analyzed.  Serum samples were 
assayed for Ang-1, Ang-2, TRAIL, Flt-1, IL-15 and hCG by trained technicians 
utilizing the methods described below.  The final diagnosis, determined by 
clinical follow-up as described above, was not known at the time of 
interpreting the biomarker assays, nor were the assay results known by those 
interpreting the final diagnosis.   
 
As this was a phase I exploratory prognostic factor study, where possible, we 
have followed the recommendations for the REporting of tumour MARKer 
prognostic studies (REMARK) [315].  These guidelines, similar to the successful 
CONSORT initiative for randomized controlled trials [316] and the STARD 
statement for diagnostic studies [276], aim to encourage transparent and 
complete reporting so that the relevant information will be available to others 
to help them judge the usefulness of the data and understand the context in 
which the conclusions apply by ensuring relevant information about the study 
design, preplanned hypotheses, patient and specimen characteristics, assay 
methods, and statistical analysis methods is provided.  Although initially 
developed for tumour marker prognostic studies, the guidelines have been 
labeled as applying to clinical prognostic studies in general (Appendix 10).   
 
Candidate Biomarkers 
 
Angiopoietin-1 and 2 
 
The angiopoietin family of angiogenic proteins are involved in vasculature 
development and angiogenesis [317]. They are also important in the process 
of placental maturation and growth from early pregnancy onwards.  A major 
developmental step during placentation is the remodeling of maternal 
vasculature to gain a uteroplacental circulation and development of a 
competent fetoplacental vasculature within the trophoblast.  Angiopoietins 
have been shown to be critically involved in vasculature development and 
angiogenesis, especially in the female reproductive tract [317-319].  
Angiopoietin 1 (Ang-1) and 2 (Ang-2) are specific ligands of the Tie2 receptor 
and both bind to it with similar affinity to promote vessel assembly and 
maturation by mediating survival signals for endothelial cells and regulating 
the recruitment of mural cells.  Ang-1 acts in a paracrine agonistic manner 
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inducing Tie2 phosphorylation and subsequent vessel stabilization.  In contrast, 
Ang-2 is produced by endothelial cells and acts as an autocrine antagonist of 
Ang-1-mediated Tie2 activation.  Ang-2 thereby primes the vascular 
endothelium to exogenous cytokines and induces vascular destabilization at 
higher concentrations [320]. 
 
Ang-1 and Ang-2 are both produced by the developing syncytiotrophoblast 
and cytotrophoblast and Ang-2 is also produced by placental macrophages 
and endothelial cells.  Ang-1 and Ang-2 help in the formation of new blood 
vessels from pre-existing ones during vascular development of the placenta.  
As syncytiotrophoblasts are in direct contact with maternal blood in the 
intervillous space (Figures 1.1b-e), Ang-1 and Ang-2 concentrations in the feto-
placental unit may be reflected in maternal serum.  Decidual tissues of healthy 
pregnancies and miscarriages have shown an altered Ang-2/Ang-1 ratio 
based on different oxygen levels in both groups (since hypoxia upregulates 
Ang-2 transcription and destabilizes Ang-1 in healthy pregnancies).  Any 
change in the hypoxic conditions of an early pregnancy therefore, such as 
that which occurs during pregnancy failure, could alter angiopoietins 
expression and ratio in the feto-placental unit, which may then be reflected in 
the maternal serum concentration.   
 
In a recent study, maternal serum Ang-1 and Ang-2 concentrations were 
measured at between 6 and 8 weeks gestation in 33 women with a viable 
intrauterine pregnancy and 60 women with a failed pregnancy (either a 
missed miscarriage (n=30) or a ruptured ectopic (n=30)) [307].  Both Ang-1 and 
Ang-2 concentrations were lower in the ectopic pregnancy (median 689 and 
302pg/ml respectively) and missed miscarriage (median 810 and 402pg/ml 
respectively) groups compared to the viable intrauterine pregnancy group 
(median 963 and 1477pg/ml).  All the differences were found to be statistically 
significant. In addition, Ang-1 was also able to differentiate between an 
ectopic pregnancy and a missed miscarriage (p=0.011).  
 
Serum TNF-Related Apoptosis-Inducing Ligand  
 
Successful implantation, trophoblast invasion and placental insufficiency are 
key processes in early pregnancy and placental insufficiency increases the risk 
of miscarriage and other pregnancy complications.  Due to the difficulties in 
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obtaining first trimester placental tissue material, only a limited number of 
investigations on targeted gene expression in placentas from miscarriage 
cases have been conducted.   
 
Increased expression of TNF-related apoptosis-inducing ligand (TRAIL) has 
been detected in placentas of women suffering from recurrent miscarriage 
[311].  TRAIL is the protein product of this gene found in the serum.  It has been 
indicated as a potential predictive biomarker in maternal serum for early 
pregnancy complications.   
 
Maternal TRAIL concentrations were found to be significantly elevated both at 
the recurrent miscarriage event (33.6 ± 4.3pg/ml) and in pregnancies which 
were uncomplicated at the time of sampling but later resulted in an 
unexpected first trimester miscarriage (28.5 ± 4.4pg/ml) compared to normal 
first trimester pregnancies (16.1 ± 1.6pg/ml).  The differences were found to be 
statistically significant (p=0.00027 and 0.039 respectively) [311].  
 
Interleukin-15  
 
During implantation and early pregnancy, the immunological processes that 
take place within the uterus are modulated by pro- and anti-inflammatory 
cytokines and their altered expression in the maternal serum may play a role in 
early pregnancy failure [2].  Successful pregnancy is considered a T helper (Th) 
1 – Th2 cooperation phenomenon, with a predominantly Th2-type lymphocyte 
response and specific cytokine production [321].  Th2 responses favour a 
cytokine environment that promotes the induction of autoantibodies and 
several studies have attempted to link pregnancy failures with the presence of 
specific cytokines and autoantibodies, for example, interleukin-15 (IL-15) [322].   
 
In women with recurrent miscarriage, there is an up-regulation of IL-15 
expression in trophoblasts [323], suggesting that it may be a marker of a failing 
pregnancy.  IL-15 is a cytokine that is expressed by human placental tissue 
culture and its serum levels correlate with the duration of the pregnancy [321, 
324].   
 
A recent study measured IL-15 levels in 33 women with a viable intrauterine 
pregnancy and 60 women with a failed pregnancy (either a missed 
miscarriage (n=30) or a ruptured ectopic (n=30)) [312] and found that IL-15 
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concentrations were higher in the women with a failed pregnancy (median 
19.86pg/ml) compared to women with a viable intrauterine pregnancy 
(median 15.06pg/ml) and this difference was found to be highly significant 
(p<0.001).   This is mainly due to the fact that the concentration of IL-15 in 
women with an ectopic is significantly higher than the concentration of IL-15 in 
women with a viable intrauterine pregnancy (median 24.9pg/ml and 
15.06pg/ml respectively; p<0.001).  IL-15 is able to discriminate a viable 
intrauterine pregnancy from an ectopic pregnancy with high diagnostic 
accuracy (AUC 0.818), and, at the threshold of 16.1pg/ml, has a sensitivity, 
specificity and clinically important negative predictive value of 92%, 68% and 
0.999 respectively.  Furthermore, IL-15 was also able to distinguish an ectopic 
pregnancy from a missed miscarriage (p=0.015).   
 
Soluble FMS-like Tyrosine Kinase-1  
 
Angiogenic factors are involved in the formation of new blood vessels required 
for placental development and function.  They are therefore critical for fetal 
growth and development.  Soluble FMS-like Tyrosine Kinase (Flt-1), the soluble 
form of vascular endothelial growth factor, is an anti-angiogenic protein that 
inhibits the formation of new blood vessels resulting in potential pregnancy 
complications.  It is expressed at very high levels in the trophoblast [325] and its 
production is highly increased in hypoxic conditions [326].  
 
In a systematic review looking at the Flt-1 concentrations in the first trimester 
and subsequent development of pregnancy complications [327], twelve 
relevant studies were identified. The review found no clear evidence of an 
association between Flt-1 levels in the first trimester and adverse pregnancy 
outcomes.  However, as the findings were affected by methodological, 
biological and testing variations between studies, no meta-analysis was 
performed.  Furthermore, the search strategy included the terms ‘adverse 
pregnancy outcomes’, ‘pregnancy complications’ ‘still birth’, ‘preterm birth’, 
‘prematurity’, ‘small for gestational age’, ‘SGA’, ‘IUGR’ and ‘pre-eclampsia’.  
They did not specifically include early pregnancy complications such as 
miscarriage and ectopic pregnancy.   
 
Two recent studies [308, 309] have however looked at the relationship 
between serum Flt-1 concentrations and the development of early pregnancy 
complications.  In the first of these [309], Flt-1 levels were measured in 21 
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women with threatened miscarriage who subsequently went on to have a live 
birth, 19 women with threatened miscarriage who did later miscarry, 32 
asymptomatic pregnant women in the first trimester and 14 non-pregnant 
women. Flt-1 levels were significantly (p<0.001) higher in pregnant women 
compared to the non-pregnant women.  Similarly Flt-1 levels were significantly 
higher in women with threatened miscarriage who subsequently had a live 
birth compared to women with threatened miscarriage who did in fact 
miscarry (p≤0.001).   
 
In the second study [308], Flt-1 concentrations were measured at between 6 
and 8 weeks gestation in 50 women with a viable intrauterine pregnancy, 40 
women with a missed miscarriage and 38 women with a ruptured ectopic.  
The concentration of Flt-1 was lower in women with ectopic pregnancies 
(178.16r76.03pg/ml) and missed miscarriages (399.42r337.54pg/ml) compared 
to women with viable intrauterine pregnancies (1390.32r655.37pg/ml).  
Similarly, Flt-1 concentrations were higher in viable intrauterine pregnancies 
(1390pg/ml) compared to all pregnancy failures (375.76pg/ml) and the 
difference was found to be statistically significant (p<0.001). Flt-1 also had the 
ability to discriminate an ectopic pregnancy from a missed miscarriage 
(p=0.033).  Flt-1 was also able to accurately discriminate between a normal 
pregnancy and a missed miscarriage (AUC of 0.771) and a normal pregnancy 
and an ectopic (AUC 0.758).  For the clinically important discrimination 
between a missed miscarriage and an ectopic pregnancy, Flt-1 had a 
sensitivity and specificity of 62.5% and 92.1% respectively at the threshold 
value of 228.08pg/ml.  The optimal threshold value for differentiating between 
a normal intrauterine pregnancy and an abnormal pregnancy (missed 
miscarriage or ectopic pregnancy) were 741.5pg/ml for Flt-1.  At these 
thresholds, the sensitivity, specificity, positive and negative predictive values 
were 88%, 96.2%, 0.815 and 0.977 respectively. 
 
The results from these studies suggest that Ang-1, Ang-2, TRAIL, IL-15 and Flt-1 
may be potential prognostic factors in women with pregnancies of uncertain 
viability (Table 9.1). 
 
Enzyme-Linked Immunosorbent Assays  
 
Enzyme-linked immunosorbent assay (ELISA) is a biochemical technique used 
mainly in immunology to detect the presence of an antibody or antigen in a 
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sample.  It is a popular format of wet-lab type analytic biochemistry assay that 
involves detection of an analyte in a liquid sample by a method that 
continues to use liquid reagents during the analysis that stays liquid and 
remains inside a reaction chamber or well needed to keep the reactants 
contained.  ELISAs have been used as diagnostic tools in medicine and plant 
pathology as well as a quality-control check in various industries, including the 
food industry.   
 
Table 9.1: Summary of relative Ang-1 [307], Ang-2 [307], TRAIL [311], IL-15 [312] 
and Flt-1 [308, 309] concentrations in women with viable and non-viable 
intrauterine pregnancies 
Biomarker Viable 
Pregnancy 
Failing 
Pregnancy 
Ability to discriminate between 
non-viable and ectopic  
Ang-1  High Low Yes 
Ang-2  High Low No 
TRAIL  Low High Not assessed 
IL-15  Low High Yes 
Flt-1 [308, 309] High Low Yes 
 
Performing an ELISA involves at least one antibody with specificity for a 
particular antigen.  The sample, with an unknown concentration of antigen, is 
immobilized on a solid support, usually a polystyrene microtiter plate, either 
non-specifically, via adsorption to the surface, or specifically, via capture by 
another antibody specific to the same antigen.  After the antigen is 
immobilized, the detection antibody is added, forming a complex with the 
antigen.  The detection antibody can be covalently linked to an enzyme, or 
can itself be detected by secondary antibody that is linked to an enzyme 
through bioconjugation.  Between each step, the plate is typically incubated 
and then washed with a mild detergent solution to remove any proteins or 
antibodies that are non-specifically bound.  After the final wash step, the plate 
is developed by adding an enzymatic substrate to produce a visible signal, 
which is proportional to the quantity of antigen in the sample.  The qualitative 
reading is usually based on the intensity of transmitted light detected by 
spectrophotometry, which involves quantitation of transmission of some 
specific wavelength of light through the liquid.  
 
There are various different types of ELISAs including indirect, direct, sandwich 
and competitive.  Sandwich ELISAs are used in our study.  These are a less 
common variant of ELISA but are highly efficient in sample antigen detection.  
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The sandwich ELISA quantifies antigens between two layers of antibody i.e. 
capture and detection antibody.  The antigen to be measured must therefore 
contain at least two antigenic epitopes capable of binding to antibody since 
at least two antibodies act in the sandwich.  Either monoclonal or polyclonal 
antibodies can be used as the capture and detection antibodies in Sandwich 
ELISA systems. Monoclonal antibodies recognize a single epitope that allows 
fine detection and quantification of small differences in antigen. A polyclonal 
is often used as the capture antibody to pull down as much of the antigen as 
possible. The advantage of Sandwich ELISA is that the sample does not have 
to be purified before analysis, and the assay can be very sensitive. 
 
The steps in a sandwich ELISA are as follows: (1) prepare a surface to which a 
known quantity of capture antibody is bound (Figure 9.1(1)); (2) block any 
non-specific binding sites on the surface; (3) apply the antigen-containing 
sample to the plate (Figure 9.1(2)); (4) wash the plate, so that unbound 
antigen is removed; (5) add a specific antibody which binds to the antigen 
(Figure 9.1(3)); (6) apply enzyme-linked secondary antibodies as detection 
antibodies that also bind specifically to the antibody's Fc region (Figure 9.1(4)); 
(7) wash the plate, so that the unbound antibody-enzyme conjugates are 
removed; (8) apply a chemical that is converted by the enzyme into a color or 
fluorescent or electrochemical signal (Figure 9.1(5)); and (9) measure the 
absorbency or fluorescence or electrochemical signal of the plate wells to 
determine the presence and quantity of antigen. 
 
Figure 9.1: Schematic procedure of a sandwich ELISA  
 
 
Image taken from: https://www.genwaybio.com/services/sandwich-elisa 
 
Figure 9.1 includes the use of a secondary antibody conjugated to an 
enzyme, though, in the technical sense, this is not necessary if the primary 
antibody is conjugated to an enzyme. However, use of a secondary-antibody 
conjugate avoids the expensive process of creating enzyme-linked antibodies 
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for every antigen one might want to detect. By using an enzyme-linked 
antibody that binds the Fc region of other antibodies, this same enzyme-linked 
antibody can be used in a variety of situations. Without the first layer of 
capture antibody, any proteins in the sample (including serum proteins) may 
competitively adsorb to the plate surface, lowering the quantity of antigen 
immobilized. Use of the purified specific antibody to attach the antigen to the 
plastic eliminates a need to purify the antigen from complicated mixtures 
before the measurement, simplifying the assay, and increasing the specificity 
and the sensitivity of the assay. 
 
Biomarker Assay Technique 
 
Serum concentrations of hCG were determined in the hospital biochemistry 
laboratory by appropriately trained technicians using a chemiluminometric 
two-site sandwich immunoassay (ADIVA Centaur® XP System).    
 
Quantitative enzyme-linked immunosorbent assays were performed to 
measure the serum levels of Ang-1, Ang-2, IL-15, TRAIL and Flt-1 in accordance 
with the manufacturer’s instructions (Quantikine, R&D Systems, Minneapolis, 
MN).  Briefly, monoclonal antibodies specific for Ang-1, Ang-2, TRAIL, Flt-1 or IL-
15 were pre-coated onto separate 96-well polystyrene microplates.  Eight 
standards were prepared for each biomarker from a pre-made, readily 
available stock solution as instructed by the manufacturer (Table 9.2). For Ang-
1, Ang-2, IL-15 and TRAIL, 50μl of the individual standards, samples and controls 
were pipetted into the wells containing 100μl of assay diluent specific for the 
biomarker.  Serum samples were diluted 50-fold for Ang-1 and 5-fold for Ang-2.  
For Flt-1, 100μl of the individual standards, samples and controls was used.  For 
Ang-1, Ang-2, TRAIL and Flt-1, the plates were then incubated for two hours at 
room temperature on a horizontal orbital microplate shaker set at 500±50rpm.  
For IL-15, the plates were incubated for three hours at room temperature.  
After four washes to remove any unbound substances, 200μl of an enzyme-
linked monoclonal antibody specific for the corresponding biomarker was 
added to each well.  For Ang-1, Ang-2, TRAIL and Flt-1, the plates were again 
incubated for two hours at room temperature on a horizontal orbital 
microplate shaker set at 500±50 rpm.  For IL-15, the plates were incubated for 
one hour at room temperature.  Following four washes to remove any 
unbound antibody-enzyme reagent, 200μl of substrate solution (hydrogen 
peroxide/tetramethyl benzidine) was added to the wells, which were then 
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incubated for 30 minutes at room temperature in the dark.  The colour 
development reaction was stopped using 50μl of 2 N sulphuric acid and the 
absorbance values (optical densities) were determined in a microplate reader 
(Biorad Benchmark) at 450nm with the correction wavelength set at 540nm.  
The concentrations of the serum levels of each specific biomarker were 
calculated with the data analysis software (Microplate Manager; Bio-Rad).  All 
tests were done in duplicate and the average of the duplicate readings was 
used for the analysis.   
 
Table 9.2: Concentration of standards used for the different ELISAs  
Standard Concentration (pg/ml) 
Ang-1 Ang-2 Flt-1 TRAIL IL-15 
1 4000 3000 2000 1000 250 
2 2000 1500 1000 500 125 
3 1000 750 500 250 62.5 
4 500 375 250 125 31.3 
5 250 187.5 125 62.5 15.6 
6 125 93.7 62.5 31.3 7.8 
7 62.5 46.9 31.3 15.6 3.9 
8 0 0 0 0 0 
 
Statistical Analysis 
 
Statistical analysis was performed using SPSS 21 (Statistical Package for Social 
Sciences; IBM, Chicago, IL, USA).  The continuous exposure variables (Ang-1, 
Ang-2, Flt-1, TRAIL and IL-15 concentrations) were first categorized and the 
nature of the association between each and the binary outcome measure 
(viable or non-viable intrauterine pregnancy) explored by computing odds 
ratios and risk ratios (with corresponding 95% confidence intervals) for each 
exposure category relative to the lowest category.  Chi-squared test and chi-
squared test for trend were undertaken to determine the statistical 
significance of the associations. Multivariate logistic regression was then 
performed to explore whether hCG acted as a confounder in each of the 
associations, and adjusted risk ratios presented if controlling for hCG materially 
altered the magnitude of the risk ratios (difference of greater than ±10%).   
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9.5 Results  
 
Figure 9.2: Flow of participants through the study 
 
Between 17th June 2014 and the 1st September 2015, 7350 women were 
assessed in the Early Pregnancy Assessment Unit at the Queen’s Medical 
Centre in Nottingham.  Of these, 512 (6.9%) were given the diagnosis of a 
pregnancy of uncertain viability following a transvaginal ultrasound.  106 (21%) 
women with a pregnancy of uncertain viability agreed to participate in the 
study.  Five women were excluded as they were subsequently proven to have 
a multiple pregnancy and a further seven women were excluded because 
the final diagnosis was not known. Of the remaining 94 women, 61 (65%) had a 
viable intrauterine pregnancy and the remaining 33 (35%) had a non-viable 
intrauterine pregnancy confirmed on subsequent ultrasound (Figure 9.2).   
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The baseline characteristics of the 94 women that formed our study sample 
are given in Table 9.3.  Most participants were non-smoking, nulliparous 
women, in their early thirties with a slightly raised body mass index, presenting 
at between 6 and 7 weeks gestation with abdominal pain and vaginal 
bleeding.  An empty sac measuring approximately 7mm was the most 
common ultrasound finding.   
 
Table 9.3: Baseline characteristics of study participants 
 n (%) 
 Overall 
(n=94) 
Viable 
(n=61) 
Non-viable 
(n=33) 
Age (mean±SD) 32±11 33±12 32±6.8 
Gravidity (mean±SD) 2.5±1.6 2.4±1.7 2.9±1.5 
Parity  (mean±SD) 0.8±1.0 0.6±1.0 1.0±1.0 
Uncertain LMP  9 (10) 5 (8.2) 4 (12) 
EGA (mean±SD) 45±13 38±8.5 57±12 
Presenting complaint  
   Pain 
   Bleeding 
   Pain and bleeding 
 
21 (22) 
26 (28) 
47 (50) 
 
13 (21.3) 
19 (31.2) 
29 (47.5) 
 
8 (24) 
7 (21) 
18 (55) 
Previous miscarriage  28 (30) 15 (24.6) 13 (39) 
Previous ectopic  7 (7.4) 7 (11.5) 0 (0.0) 
Body mass index (mean±SD) 26±5.6 25±4.9 27.4±7.1 
Smoking status  
   Never 
   Ex 
   Current 
 
64 (68) 
17 (18) 
13 (14) 
 
45 (74) 
8 (13) 
8 (13) 
 
19 (58) 
9 (27) 
5 (15) 
US findings  
   MSD (mean±SD) 
   Empty GS  
   GS with YS only 
   GS with YS and FP 
   CRL (mean±SD) 
 
7.3±5.0 
64 (68) 
16 (17) 
14 (15) 
3.3±1.2 
 
5.6±3.2 
 44 (72) 
12 (20) 
5 (8.2) 
2.9±1.3 
 
11±6.2 
20 (61) 
4 (12) 
9 (27) 
3.6±1.1 
 
Eighty-one of the 94 (86%) samples had TRAIL concentrations less than 
15.6pg/ml i.e. the lowest standard (Table 9.2) and therefore could not be 
accurately interpreted. There were too few samples remaining to perform any 
meaningful statistical analyses.  Similarly, all 94 samples had IL-15 
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concentrations less than 3.9pg/ml and therefore could not be accurately 
interpreted.  
 
Figure 9.3 Serum biomarker concentrations according to subsequent 
pregnancy viability (median/IQR) 
 
 
Table 9.4: Serum biomarker concentration according to subsequent 
pregnancy viability (median/IQR) 
Biomarker Serum concentration (pg/ml) p-value* 
Viable (n=61) Non-viable (n=33) 
Ang-1 36660 
(27684-49070) 
32100 
(30099-36702) 
>0.05 
Ang-2 1510 
(1250-2093) 
2365 
(1754-3200) 
<0.01 
Flt-1 103 
(77-134) 
202 
(129-317) 
<0.01 
*Mann-Witney U Test 
 
The median concentrations of Ang-1, Ang-2 and Flt-1 according to 
subsequent pregnancy viability are illustrated in Figure 9.3 and Table 9.4.  The 
median concentrations of Ang-2 and Flt-1 were significantly lower in 
pregnancies of uncertain viability that were subsequently proven to be viable 
than those that were subsequently proven to be non-viable.  There was no 
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significant difference in the median concentration of Ang-1 in pregnancies of 
uncertain viability that were subsequently proven to be viable compared to 
those that were subsequently proven to be non-viable.   
 
There was a statistically significant (p=0.026), non-linear (p-value for 
trend=0.20) association between Ang-1 concentration and pregnancy viability 
such that women with Ang-1 concentrations between 30337pg/ml and 
38391pg/ml were 30% less likely to have a viable intrauterine pregnancy than 
women with Ang-1 concentrations less than or equal to 30337pg/ml and 
women with Ang-1 concentrations greater than or equal to 38391pg/ml were 
31% more likely to have a viable intrauterine pregnancy than women with 
Ang-1 concentrations less than or equal to 30337pg/ml (Table 9.5 and Figure 
9.4).  
 
Table 9.5: Likelihood of subsequent pregnancy viability according to serum 
Ang-1, Ang-2 and Flt-1 concentrations 
Biomarker Group Cut-off (pg/ml) n Viable n (%) RR (95% CI) 
Ang-1 1 ≤30337 32 22 (69) 1.0 
2 30338-38391 31 15 (48)  0.70 (0.46-1.1) 
3 ≥38391 31 28 (90) 1.3 (1.0-1.7) 
Ang-2 1 ≤1382 24 23 (96) 1.00 
2 1383-1772 24 16 (67) 0.70 (0.52-0.93) 
3 1773-2666 23 14 (61) 0.64 (0.45-0.89) 
4 ≥2666 23 8 (35) 0.36 (0.21-0.64) 
Flt-1 1 ≤87 32 25 (78) 1.00 
2 88-142 31 26 (84) 1.1 (0.84-1.4) 
3 ≥142 31 12 (39) 0.50 (0.31-0.80) 
 
There was a statistically significant (p<0.01), linear (p-value for trend <0.01) 
association between Ang-2 concentration and pregnancy viability such that 
women with Ang-2 concentrations greater than or equal to 2666pg/ml were 
64% less likely to have a viable intrauterine pregnancy than women with Ang-2 
concentrations less than or equal to 1382pg/ml (Table 9.5 and Figure 9.4).   
 
Similarly, there was a statistically significant (p<0.01), linear (p-value for 
trend=0.01) association between Flt-1 concentration and pregnancy viability 
such that women with Flt-1 concentrations greater than or equal to 142pg/ml 
were 50% less likely to have a viable intrauterine pregnancy than women with 
Flt-1 concentrations less than or equal to 87pg/ml (Table 9.5 and Figure 9.4).   
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Controlling for serum hCG concentration had no material effect on any of the 
associations. 
 
Figure 9.4: Percentage chance of subsequent pregnancy viability according 
to serum Ang-1, Ang-2 and Flt-1 group 
 
 
 
 
9.6 Discussion 
 
The aim of our study was to determine whether serum concentrations of Ang-
1, Ang-2, Flt-1, IL-15 or TRAIL could potentially be used to predict pregnancy 
viability in cases of uncertainty.  Although previous studies have demonstrated 
statistically significant differences in the concentrations of these biomarkers 
between women diagnosed with viable and non-viable intrauterine 
pregnancies [307-312], this is the first study to investigate the prognostic 
potential of these serum biomarkers to predict pregnancy outcome in cases of 
uncertainty.   
 
The findings of our prospective study incorporating 94 women presenting with 
abdominal pain and/or vaginal bleeding in early pregnancy and diagnosed, 
following transvaginal ultrasound, with pregnancies of uncertain viability 
suggest that Ang-2 and Flt-1, and to a lesser extent Ang-1, may be useful in the 
prediction of pregnancy viability in cases of uncertainty.  Our results 
demonstrate that women with low serum concentrations of Ang-2 and Flt-1 
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are significantly more likely to have viable intrauterine pregnancies than 
women with high serum concentrations.   
 
These findings are not altogether consistent with previous studies [307-310, 312] 
which reported significantly higher concentrations of Flt-1 and Ang-2 in viable 
pregnancies.  This phenomenon is not uncommon in prognostic marker studies: 
often initially reported studies of a marker show great promise but subsequent 
studies on the same or related markers yield inconsistent conclusions or stand 
in direct contradiction to the promising results [315]. In these earlier studies, in 
women with viable intrauterine pregnancies at the time of sampling, serum 
Ang-1, Ang-2 and Flt-1 concentrations were significantly higher than women 
with non-viable intrauterine pregnancies [307-310].  This led us to hypothesize 
that women with pregnancies of uncertain viability and a high serum 
concentration of Ang-1, Ang-2 and/or Flt-1 would be more likely to be 
subsequently diagnosed with viable intrauterine pregnancies than women 
with pregnancies of uncertain viability and low serum concentrations of Ang-1, 
Ang-2 and/or Flt-1.  In fact, our results have suggested that the opposite may 
be true. 
 
The reasons for these discrepancies are not fully understood but are likely to be 
due to fundamental differences in study design as well as the complex 
processes involved in implantation and placentation in normal, and abnormal, 
early pregnancy development. 
 
The aim of the studies by Daponte et al [307, 308], was to assess whether a 
single serum measurement of Ang-1, Ang-2 and Flt-1 at 6-8 weeks gestation, 
could contribute to the differential diagnosis between failed pregnancies, 
whether ectopic or non-viable intrauterine, and viable intrauterine 
pregnancies whilst the aim of our study was to determine whether serum 
concentrations of Ang-1, Ang-2 and Flt-1 could be used to predict pregnancy 
viability in cases of uncertainty.  This subtle but important difference relies upon 
a different study design (case-control versus cohort) and statistical analysis, 
which may, at least partially, be responsible for the differences in the results 
observed. 
 
The methodology described in the Daponte studies [307, 308] is not altogether 
clear. Although it states that Ang-1, Ang-2 and Flt-1 concentrations were 
measured in a group of controls with healthy intrauterine pregnancies of 
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between six and eight weeks of gestation, it does not state whether they 
underwent an ultrasound scan to confirm either the gestation or the viability of 
the pregnancy.  In the study regarding the angiopoietins [307], the cases 
appear to consist of women who presented with abdominal pain and/or 
vaginal bleeding at between six and eight weeks gestation, in whom the 
precise diagnosis could not be made following the initial transvaginal 
ultrasound and hence were admitted to hospital for further investigation.  
Serum samples were apparently collected ‘at the initial visit before treatment’.  
It is not clear from the methodology described whether the serum samples 
were taken at the time of uncertainty i.e. at the initial visit when they were 
admitted to hospital, or after the miscarriage or ectopic pregnancy had been 
diagnosed but before treatment was initiated.  In the Flt-1 study [308], serum 
samples were collected from women presenting with mild abdominal pain or 
vaginal bleeding between six and eight weeks’ gestation who were 
subsequently diagnosed with a missed miscarriage.  How the gestation was 
calculated (i.e. from last menstrual period or by measurement of gestation sac 
diameter) or how the diagnosis of a missed miscarriage was made (i.e. 
clinically or ultrasonographically) is not fully described.   These ambiguities may 
explain some of the differences in biomarker concentrations observed. 
 
Our study sample consisted of women who had been given the 
ultrasonographic diagnosis of a pregnancy of uncertain viability following 
presentation with abdominal pain and/or vaginal bleeding in early 
pregnancy.  Serum samples were taken immediately after the ultrasound, at 
the time of diagnostic uncertainty, and women were followed up until a 
definitive diagnosis of either a viable or non-viable intrauterine pregnancy was 
made.   Although in our study we did not control for gestation in the sense that 
we recruited any woman with a pregnancy of uncertain viability, irrespective 
of the date of her last menstrual period, we did measure serum hCG 
concentrations in all women and control for hCG concentration in our 
statistical analysis.  Whilst, as already mentioned in chapter one, hCG is not a 
precise indicator of gestation [27, 28], neither is dating a pregnancy by last 
menstrual period alone [142-144].   
 
The situation is complicated by the fact that the physiological processes 
involved in implantation and placentation are complex.  As described in 
chapter one, the process of placentation is initiated once the blastocyst 
makes contact with the epithelium of the uterus.  An initial trophoblastic shell is 
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penetrated by columns of proliferating extra-villous cytotrophoblast that form 
the anchoring villi and provide specialized invasive cells that transform the 
decidual and proximal portions of the decidual spiral arteries [328].  During the 
initial phase of implantation and uterine wall invasion, the main role of extra-
villous trophoblast is to form plugs that occlude capillaries in the endometrial 
gland stroma; this prevents maternal haemorrhage from disrupting the 
conceptus and maternal blood from entering the lacunar spaces of the 
trophoblastic shell. Embryogenesis thus takes place in a hypoxic environment 
for the first ten weeks of pregnancy because oxygen tension within the 
placenta is much lower than in the surrounding endometrial glands [329-332]. 
The plugging mechanism protects the growing embryo and the primitive 
placental villi against oxidative damage.  After approximately ten weeks, the 
trophoblastic plugs are breached by maternal blood that then enters the 
inter-villous space. This sudden perfusion is thought to render the placenta less 
hypoxic than in earlier pregnancies.  Utero-placental blood flow increases 
exponentially from less than 50 mL/min in the non-pregnant state to 
approximately 350 mL/min by full-term. The demands of this large rise in 
uteroplacental blood flow (up to 20% of the total maternal cardiac output), 
require large adaptations in maternal physiology [333].  Approximately two-
thirds of miscarriages are attributed to defective placentation associated with 
an absence of physiological change in maternal spiral arteries and premature 
onset of maternal circulation through the placenta [334].  
 
Concentrations of hCG, Ang-1, Ang-2 and Flt-1 are dependent on both 
pregnancy gestation and pregnancy viability.  The concentration of hCG in 
the maternal blood increases with advancing gestation reaching a peak at 
between ten and twelve weeks of gestation. The concentration then declines 
to a stable plateau for the remainder of the pregnancy (Figure 1.4)[26].  In a 
non-viable pregnancy, the rate of hCG decrease is described by a quadratic 
profile, with a faster decline in hCG value with higher presentation levels [32]. 
Unfortunately such nomograms for serum concentrations of Ang-1, Ang-2 and 
Flt-1 do not exist to the same extent as they do for serum hCG concentrations.  
We do know however, that the local balance between Ang-1 and its 
antagonist Ang-2 determines whether blood vessels grow, are maintained or 
regress.  We also know that the relative levels of Ang-1 and Ang-2 are 
regulated by local oxygen tension by different mechanisms and this may be 
important during normal human placentation [335].  Furthermore, high levels 
of Flt-1 occur in normal first trimester pregnancies as a consequence of 
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excessive placental production under hypoxic conditions [326] but following 
the onset of maternal circulation through the placenta, the placenta 
becomes less hypoxic and Flt-1 concentrations may alter to reflect this 
change.  Hence it is difficult to ascertain whether certain concentrations of 
hCG, Ang-1, Ang-2 and Flt-1 are observed because the gestation is early but 
progressing or more advanced and failing.  
 
The median concentrations of all biomarkers were substantially different 
between our study and the studies by Daponte et al (Table 9.8).  In the 
Daponte studies [307, 308], although all women were recruited at between six 
and eight weeks gestation, the median concentration of hCG in those with a 
viable pregnancy was vastly different from those with a non-viable pregnancy 
(59668mIU/ml and 56130mIU/ml versus 3000mIU/ml and 4710mIU/ml).  Whilst a 
serum hCG concentration of 59668mIU/ml correlates to a gestation of 
approximately seven weeks and one or two days, a serum hCG concentration 
of 3000mIU/ml is more suggestive of a pregnancy of less than five weeks’ 
gestation.  Granted the latter were failing pregnancies, which may account 
for the lower hCG concentrations observed, but a difference of approximately 
15-fold is quite pronounced particularly since hCG concentrations remain 
elevated in the maternal serum for some time following a miscarriage, 
especially when the trophoblastic tissue is still in situ [32] as it was in these 
women.  Furthermore, in our study, the median hCG concentrations of women 
with a pregnancy of uncertain viability that was subsequently proven to be 
viable was 2313.3iu/l (correlating to a gestational age of approximately four 
weeks and five days) and the median hCG concentrations of women with a 
pregnancy of uncertain viability that was subsequently proven to be non-
viable was 6754.0iu/l (correlating to a gestational age of five weeks and three 
days).  Using hCG as a crude marker of gestation, it therefore appears that we 
have sampled our viable intrauterine pregnancies at an earlier gestation and 
our non-viable intrauterine pregnancies at a later gestation than the Daponte 
studies.  This may account for the differences in the absolute levels of Ang-1, 
Ang-2 and Flt-1 concentrations observed as well as the differences in the 
trends between the viable and non-viable pregnancies (Table 9.6).   
 
As part of the analyses in the Daponte studies [307, 308], the median 
concentration of Ang-1, Ang-2 and Flt-1 in women with a viable intrauterine 
pregnancy was compared to the median concentration of Ang-1, Ang-2 and 
Flt-1 in women with a non-viable intrauterine pregnancy.  Using the Kruskal-
Chapter 9 
 
- 217 - 
Wallis test, concentrations of Ang-1, Ang-2 and Flt-1 were found to be 
significantly higher in women with viable intrauterine pregnancies compared 
to those with non-viable intrauterine pregnancies.  In our study, a similar 
analysis demonstrated (1) no significant difference in the median 
concentrations of Ang-1 between women with pregnancies of uncertain 
viability that were subsequently proven to be viable compared to those with 
pregnancies of uncertain viability that were subsequently proven to be non-
viable and (2) significantly lower concentrations of Ang-2 and Flt-1 in women 
with pregnancies of uncertain viability that were subsequently proven to be 
viable compared to those with pregnancies of uncertain viability that were 
subsequently proven to be non-viable (Figure 9.3 and Table 9.4).  However, the 
median concentrations of Ang-1, Ang-2 and Flt-1 in our study were very 
different to those reported in the Daponte studies (Table 9.6) despite exactly 
the same assays being performed in both.  These discrepancies may be 
related to differences in the timing of serum sampling, either in terms of 
gestational age or in relation to the miscarriage event.   
 
Strengths and Limitations 
 
This is the first study of its kind to investigate the prognostic potential of Ang-1, 
Ang-2 and Flt-1 to predict pregnancy outcome in cases of uncertainty. We 
included 94 participants and whilst only 33 of these were subsequently found 
to have non-viable intrauterine pregnancies, this is reflective of the clinical 
course of pregnancies of uncertain viability [306].  Our study was prospective 
in nature, had clearly defined hypotheses based upon the best available 
evidence at conception of the study, had explicit inclusion and exclusion 
criteria and the selection of patients was not related to outcome.  
Furthermore, our statistical analysis controlled for hCG concentration as a 
marker of gestation.  Whilst hCG is not a precise indicator of gestation [27, 28], 
neither is dating a pregnancy by last menstrual period alone [142-144]. 
 
The multi-variable character of prognostic research makes it notoriously 
difficult to estimate the required sample size [315].  One weakness of our study 
is that we were unable to do an a priori sample size calculation due to 
absence of the relevant data in the scientific literature.  In the lieu of this, we 
undertook a post-hoc power calculation which revealed that on the basis of 
the means, the between-groups comparison effect sizes observed, and the 
size of each of our two groups, a statistical power of >0.90 was observed for 
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Ang-2 and Flt-1. Unfortunately a statistical power of only 0.26 was observed for 
Ang-1.  This limited statistical power generated by our modest sample size only 
limits the statistical comparisons conducted for Ang-1 and fortunately our main 
conclusions relate to Ang-2 and Flt-1.      
 
Another weakness of our study is that viability was defined as visible fetal heart 
pulsations on a subsequent ultrasound scan rather than viability at twelve 
weeks gestation.  Approximately 25% of pregnancies of uncertain viability that 
are initially found to be viable subsequently fail [306].  However, it was felt that 
because the mechanisms surrounding miscarriage are multifold and complex, 
a marker of initial pregnancy viability would still be useful clinically.   
 
Only symptomatic women with pregnancies of uncertain viability were 
included in our study.  It is not clear whether our results could be extrapolated 
to all women in early pregnancy in an attempt reassure women that their 
pregnancy is progressing normally or identify failing pregnancies at a very 
early gestation.   
 
As with all prognostic factor studies, discoveries made in small studies such as 
this are prone to overestimating or underestimating the actual association.  
Evidence from multiple studies, in particular large studies, is necessary to 
appreciate the discriminating ability of these emerging prognostic factors.  
Rapid clinical adoption in the absence of such evidence may lead to wasted 
resources.  It is therefore imperative that we replicate and confirm our findings 
before implementing them in clinical practice.   
 
Furthermore, if validated, it is necessary to determine appropriate threshold 
levels, above or below which we can confidently diagnose a viable or non-
viable intrauterine pregnancy.  The sensitivity needs to be 100% because the 
clinical consequences of a false negative diagnosis could be to induce, either 
medically or surgically, termination of a wanted, viable intrauterine 
pregnancy. It may be that on their own our biomarkers are not capable of 
generating this high degree of accuracy, but in combination with other 
demographic, clinical, serological and radiological parameters they may be 
used to generate a prognostic research model capable of predicting 
individual risk of a future outcome.  This would, if proven to be cost effective, 
reduce the strain on limited resources and alleviate anxiety for women. 
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9.7 Conclusion 
 
Serum concentrations of Ang-2 and Flt-1, and to a lesser extent Ang-1, may be 
able to predict outcome in women with pregnancies of uncertain viability.  
Although further work is required to confirm these findings before 
implementation into clinical practice, they appear to be promising prognostic 
factors.   
  
 
Table 9.6: Differences in serum concentrations of hCG, Ang-1, Ang-2 and Flt-1 between our study and the studies by Daponte et al. [307, 308]   
 hCG Ang-1 Ang-2 Flt-1 
Richardson Daponte [307] Daponte [308] Richardson Daponte [307] Richardson Daponte [307] Richardson Daponte [308] 
Viable 2313 59688 56130 36660 964 1510 1477 103 1390 
Non-viable 6754 3000 4710 32100 811 2365 402 202 399 
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10. Clinical Impact & Future 
Research Recommendations 
 
10.1 Clinical Impact 
 
The aim of this research was to try to minimise the number of women given 
uncertain diagnoses in early pregnancy, and if that was not possible, to at 
least minimise the duration of uncertainty for them.  The premise for this work 
was that the current clinical management of women with diagnostic 
uncertainties in early pregnancy was often haphazard and protracted and 
utilized valuable, limited resources.  Furthermore, in the time taken to make a 
definitive diagnosis, a stable woman with an unknown ectopic pregnancy or 
miscarriage might become unstable, and require immediate resuscitation, life-
saving blood transfusion and/or emergency surgery. 
 
In the first of our studies, described in chapter four, we describe another 
reason why it is important to minimise the number of women given uncertain 
diagnoses in early pregnancy and that is because of the considerable levels 
of anxiety that diagnoses such as pregnancies of uncertain viability and 
unknown location generate.  We demonstrate that women who present to 
Early Pregnancy Assessment Units with abdominal pain and/or vaginal 
bleeding in early pregnancy and who are subsequently given an uncertain 
diagnosis have significantly higher levels of anxiety than their counterparts who 
are given certain diagnoses, even if those certain diagnoses are not 
associated with ongoing pregnancies.  Although perhaps intuitive to some, this 
has never before been described in the scientific literature. 
 
A number of studies have noted anxiety, distress [336], depression [337] and 
hostility [338] in response to non-definitive ultrasound findings.  Some of these 
emotions have been reported to be stronger following an uncertain diagnosis 
than a negative, but less ambiguous one [338].  The levels of anxiety reported 
by the women in our study prior to the ultrasound scan suggest that they are 
aware that the experience of symptoms such as abdominal bleeding and/or 
vaginal bleeding in early pregnancy may be indicative of a problem.  Whilst 
they may anticipate being given bad news, it is likely that they do not expect 
to hear uncertain news, or that there may be threats to their own health, or 
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that they require a plethora of further investigations, or that they may not get 
a definitive answer for several weeks.  It is of no surprise therefore that 
uncertain diagnoses in early pregnancy generate considerable anxiety.   
 
It is crucial that having demonstrated that uncertain diagnoses in early 
pregnancy generate considerable anxiety, we address this potential for 
anxiety in clinical practice.  We can do this is several ways.  Firstly, in an 
attempt to minimise the number of women given an uncertain diagnosis in 
early pregnancy, it is imperative that asymptomatic women are not offered 
an ultrasound scan when the likelihood of an uncertain diagnosis is high.     
Based on a study of 1442 women [172], the commonest transvaginal 
ultrasound finding prior to 35 days gestation was a pregnancy of unknown 
location and from 42 days gestation it was a viable intrauterine pregnancy 
although the chance of confirming viability increased rapidly per day of 
gestation until 49 days and thereafter plateaued.  A miscarriage could not be 
diagnosed on initial transvaginal ultrasound prior to 35 days gestation.  
Between 35 and 41 days gestation the commonest transvaginal ultrasound 
finding was a pregnancy of uncertain viability.  It is sensible therefore that in 
asymptomatic women, with no previous ectopic pregnancy, transvaginal 
ultrasound should be delayed until 49 days gestation which will decrease the 
number of inconclusive ultrasound scans performed without an associated 
increase in morbidity from missed ectopic pregnancy.  Symptomatic women 
however should not have an ultrasound scan deferred, regardless of 
gestation, due to the risk of serious morbidity associated with a missed 
diagnosis of an ectopic pregnancy.  Whilst performing an ultrasound scan too 
early in pregnancy may lead to an uncertain diagnosis, deferring an 
ultrasound scan based on arbitrary limits for gestation may be associated with 
physical and psychological morbidity or mortality due to a delay in the 
diagnosis of a miscarriage [170] or ectopic pregnancy [171] and this is 
unacceptable. 
 
Secondly, others have previously suggested that patient education about 
potential findings on routine ultrasound examinations should be made explicit 
to patients before they undergo the procedure [336, 339, 340].  This approach 
would also be useful for non-routine ultrasound examinations in early 
pregnancy such as those which occur when women present with symptoms of 
abdominal pain and/or vaginal bleeding.  If women are given information 
regarding all the possible diagnoses, including the uncertain ones, prior to 
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having the ultrasound scan, then the initial shock of an uncertain diagnosis 
may be slightly abated.  They are less likely to feel that they are being ‘fobbed 
off’ if they have been previously informed that an uncertain diagnosis in early 
pregnancy is not only a recognized phenomenon but also a fairly common 
one at that.  This information need not be extensive, it merely serves to set the 
scene and focus the mind prior to the scan. It could be as simple as an 
information leaflet given to all patients when they report to the front desk for 
their scheduled appointment.   
 
Finally, once an uncertain diagnosis has been given, women need to be 
supported.  Those with non-viable intrauterine pregnancies, and to a lesser 
extent those with ectopic pregnancies, have access to different support 
groups and forums, either locally, nationally or via the internet.  Women with 
uncertain diagnoses have no such psychological support and this must be 
addressed if we are to improve the holistic nature of care provided to women 
with complications of early pregnancy.  Initially this should be face-to-face, 
but given that it is likely that women will be acutely distressed immediately 
following the ultrasound scan, this should be accompanied by detailed written 
information.  Most women will seek additional information beyond that which is 
given by the provider.  The value of these outside sources is generally to 
reinforce information that is provided at the time of the diagnosis, at a time 
when the woman is more receptive, in an environment that is less emotionally 
charged. In today’s world the use of the internet as a primary tool for seeking 
this information is a reality, hence providers should consider developing a brief 
list of sites that contain accurate information and distributing it at the time of 
diagnosis e.g. www.miscarriageassociation.org.uk, www.ectopic.org.uk and 
www.nhs.uk.  Women with a pregnancy of unknown location will likely be 
returning to the Early Pregnancy Assessment Unit 48 hours later for a repeat 
hCG blood test and it is important that time is taken during this visit to see how 
they are, both physically and psychologically.  Women with a pregnancy of 
uncertain viability will not be returning to the Unit for at least seven days and it 
is important that they are not left to fester at home.  The results from our study 
show that their anxiety levels continue to increase 48-72 hours after the 
ultrasound scan, so this would be the opportune time for a courtesy telephone 
call to see how they are.  Women need to be reassured that they are not on 
their own in this limbo period.    
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Having demonstrated that diagnostic uncertainties in early pregnancy 
generate considerable anxiety for women, it is now imperative that further 
research focuses on reducing the number of women to whom uncertain 
diagnoses are given and this is what the studies described in chapters five to 
eight have tried to accomplish.  Equally, if an uncertain diagnosis is absolutely 
unavoidable, future research efforts should try to at least minimise the duration 
of uncertainty, so that women have to wait the shortest amount of time 
possible for an accurate and definitive diagnosis.  This was the aim of the study 
reported in chapter nine. 
 
In an attempt to minimise the number of women given the diagnosis of a 
pregnancy of unknown location, we chose to focus on the ‘pseudosac’.  One 
of the biggest challenges in early pregnancy ultrasonography is trying to 
differentiate between an empty early gestation sac and a pseudosac.  
Pseudosacs occur in up to 15% of ectopic pregnancies and although rare, if 
present they are highly suggestive of an ectopic pregnancy, hence it is an 
important distinction to make, ideally as soon as possible.  Although experts 
may claim that it is an easy distinction to make, in clinical practice, many of 
those undertaking the early pregnancy ultrasound scans do not claim to be 
experts.  Traditional teaching has always been that one should wait until a yolk 
sac or fetal pole has been visualized before confirming that an intrauterine 
fluid collection is indeed an intrauterine gestation sac.  Although safe, the 
problem with this approach is that using modern transvaginal ultrasound, an 
intrauterine fluid collection may be visible at 28 days gestation whilst a yolk sac 
may not appear for another seven days at least and if an ultrasound is 
undertaken during this time uncertainty will ensue.   
 
We undertook a systematic review of the literature in an attempt to see if there 
were any ultrasonographic signs that could be used to reliably differentiate a 
true gestation sac from a pseudosac prior to visualization of a yolk sac.  This 
systematic review, described in chapters five and six, identified three potential 
signs: the double decidual sac sign; the intradecidual sign; and the chorionic 
rim sign.  Meta-analysis revealed that the double decidual sac sign was the 
most promising candidate with a sensitivity of approximately 82% and a 
specificity of 97%.  Unfortunately however only six small studies were included 
in the meta-analysis, the majority of which were considered to be of mediocre 
quality at best, mainly because they were performed 20 to 30 years ago using 
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ultrasound technology vastly inferior to what we have available today 
resulting in high applicability concerns with regards to the index test.   
 
Our systematic review and meta-analysis also demonstrated that a pseudosac 
has a sensitivity of 5.5% and a specificity of 94% for predicting an ectopic 
pregnancy in the absence of an obvious extra-uterine embryo.  So, whilst a 
true pseudosac, highly suggestive of an ectopic pregnancy is a relatively rare 
finding in early pregnancy and usually absent in women with an ectopic 
pregnancy, an empty gestational sac, indicative of an early or failing 
intrauterine pregnancy, is much more common.   
 
This prompted us to undertake our own study, reported in chapter seven, to 
determine the diagnostic accuracy of the double decidual sac sign to predict 
an intrauterine pregnancy prior to ultrasonographic visualization of embryonic 
contents using modern, high-resolution transvaginal ultrasound.  This study 
found that the overall diagnostic accuracy of the double decidual sac sign to 
predict an intrauterine pregnancy prior to visualization of embryonic contents 
was 94% suggesting that the results from the meta-analysis in chapter five were 
underestimated.   
 
One of the main limitations of this study is that, for a variety of reasons, all of 
the ultrasound scans were performed and interpreted by a single investigator.  
However, if we want to start using the double decidual sac sign in clinical 
practice, to inform management decisions, it is important that we not only 
demonstrate that it is accurate, but also reliable.  In our penultimate study, 
described in chapter eight, we assessed the inter- and intra-observer reliability 
associated with ultrasonographic visualization of the double decidual sac sign.  
Although the inter-observer reliability was only fair, it did improve significantly 
after a period of training and as such, may still be rendered clinically useful 
after incorporation into ultrasound training and widespread dissemination into 
the relevant communities.  This is in progress following presentation of our 
findings at national and international conferences and publication in relevant 
peer-reviewed journals.  
 
Our study looking at the inter- and intra-observer reliability associated with 
ultrasonographic visualization of the double decidual sac sign also highlights 
that the management of women with ultrasonographic evidence of an 
‘empty sac’ is inconsistent.  Irrespective of whether or not the double decidual 
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sac sign was thought to be present or not, when the intrauterine fluid 
collection was considered to be a gestation sac, the vast majority of observers 
advised a rescan in at least seven days, in line with UK guidelines for 
pregnancies of uncertain viability [341].  However, observers recommended 
serial hCG blood tests in 13% of cases.  Since serial hCGs cannot reliably 
discriminate between viable and non-viable pregnancies [34, 38, 106, 150, 
298], the main indication for them is to help rule in, or indeed out, an ectopic 
pregnancy in which case these ‘empty sacs’ are being managed according 
to pregnancy of unknown location guidelines [341] despite the fact that the 
ultrasonographic finding of an ‘empty sac’ does not fulfill the criteria for a 
pregnancy of unknown location according to the current definition [108].  
Similarly, when the intrauterine fluid collection was considered to be a 
pseudosac, the vast majority of observers advised serial serum hCG 
measurements be taken, consistent with pregnancy of unknown location 
guidelines.  However, observers recommended a rescan in 4% of cases.    
 
Therefore the management of an ‘empty sac’ appears to fall into a grey area 
– are they pregnancies of uncertain viability even though they lack a yolk sac 
or fetal pole and as such are not, by traditional teaching, definitely intrauterine 
pregnancies – or are they pregnancies of unknown location, despite the fact 
that there is some evidence of a potential, albeit not definite, intrauterine 
pregnancy?  Should a rescan to confirm viability or serial hCGs to confirm 
location be advised?  This ambiguity needs clarification.  Some women seem 
to be being over-investigated which takes time, costs money and generates 
undue anxiety but, of greater concern, we are under-investigating other 
women, which jeopardizes patient safety. 
 
Based on the results of the reliability study reported in chapter eight, and of 
the diagnostic accuracy study reported in chapter seven, we propose that 
the current definitions for pregnancies of unknown location and uncertain 
viability be refined to include the ultrasonographic finding of a small ‘empty 
sac’ and we suggest that the definitions take into consideration the double 
decidual sac sign.  For example, if there is ultrasonographic evidence of an 
‘empty sac’ which demonstrates the double decidual sac sign, according to 
the results of our diagnostic accuracy study, it is definitely an intrauterine 
pregnancy, and it should therefore be regarded as a pregnancy of uncertain 
viability and follow-up should consist of a repeat ultrasound scan at an interval 
of at least seven days.  If there is ultrasonographic evidence of an ‘empty sac’ 
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which does not demonstrate the double decidual sac sign, then 
notwithstanding the fact that pseudosacs are extremely rare [244], it should 
prudently be regarded as a potential ectopic pregnancy and managed 
according to pregnancy of unknown location protocols with serial serum hCGs 
measurements.  Adopting this strategy will enhance the clinical care of 
women with the ultrasonographic finding of an empty sac in early pregnancy 
by improving consistency, appropriately rationalising follow-up and minimising 
error. 
 
Arguably, this doesn’t actually reduce uncertainty; merely convert what might 
previously have been regarded as a pregnancy of unknown location to one 
of uncertain viability.  However, in clinical practice it is the pregnancies of 
unknown location that are more concerning given the immediate threats to 
health and potential threats to future fertility.  It is also the pregnancies of 
unknown location that have a more haphazard follow-up, with different 
institutions, and even different individuals within the same institution, using 
different algorithms [34, 37, 38].  This follow-up also utilizes more resources and 
is therefore also more costly.  
 
The aim of our final study, reported in chapter nine, was to minimise the 
duration of uncertainty for women with pregnancies of uncertain viability using 
novel serum biomarkers.  Although subject to confirmatory studies, our 
preliminary findings suggest that serum concentrations of Ang-2 and Flt-1, and 
to a lesser extent Ang-1, may be able to predict outcome in women with 
pregnancies of uncertain viability.  The findings of our prospective study 
incorporating 94 women presenting with abdominal pain and/or vaginal 
bleeding in early pregnancy and diagnosed, following transvaginal 
ultrasound, with pregnancies of uncertain viability, suggest that women with 
low serum concentrations of Ang-2 and Flt-1 are significantly more likely to 
have viable intrauterine pregnancies than women with high serum 
concentrations.   
 
If these findings are validated and appropriate threshold levels for our 
biomarkers determined, it may be possible to minimise the duration of 
uncertainty for women with pregnancies of uncertain viability to hours (i.e. the 
turn-around time for the blood work) rather than weeks.  It may be that on 
their own our biomarkers are not capable of generating the high degree of 
accuracy required, but in combination with other demographic, clinical, 
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serological and radiological parameters they may be used to generate a 
prognostic research model capable of predicting individual risk of a future 
outcome which would be clinically welcome, and if found to be cost-
effective, extremely useful.   
 
Hence, if, using ultrasound and the double decidual sac sign, we can 
successfully convert the vast majority of uncertainties regarding location to 
those regarding viability, we can then potentially use our biomarkers to 
minimise the duration of uncertainty to hours rather than weeks and we will 
therefore, using a combination of approaches, have achieved the overall aim 
of this thesis in minimising diagnostic uncertainties in early pregnancy.   
 
10.2 Future Research Recommendations 
 
This thesis has made steps towards improving the care of women with 
diagnostic uncertainties in early pregnancy.  However, all research, and this 
work is no exception, invariably produces further questions that need to be 
answered. The cycle of identifying and prioritizing research agendas, carrying 
out research to answer a question and subsequently identifying further areas 
for exploration is paramount to moving practice forward.  For women who 
experience diagnostic uncertainties in early pregnancy, this work is a stepping-
stone, and it is with great hope that this project will stimulate others to take an 
interest in this area and help to make a difference to the clinical care of 
women through continuing the research cycle. 
 
Themes identified from each of our individual studies should be further 
explored on a larger scale.  Our understanding of diagnostic uncertainties in 
early pregnancy, the distress they cause and how to minimise them, could be 
improved by future research to address the following questions: 
 
x Do women given a certain negative diagnosis following an initial uncertain 
diagnosis fare better psychologically than their counterparts who are given 
an immediate diagnosis of either a non-viable or ectopic pregnancy.  
Does the period of uncertainty prepare them better for a negative 
diagnosis or does a diagnosis of a non-viable or ectopic pregnancy still 
come as a shock?   
Chapter 10 
- 230 - 
x What happens to those women given a certain positive diagnosis after an 
initial uncertain diagnosis – do anxiety levels quickly abate or do they 
remain elevated for the remainder of the pregnancy?   
x Do simple measures to reduce anxiety, such as those described in the 
previous section, make a significant difference to women given an 
uncertain diagnosis following the ultrasound? Are any additional resources 
required to do this justified? 
x In a larger sample, containing more ectopic pregnancies, how accurate is 
the double decidual sac sign for predicting an intrauterine pregnancy 
prior to visualization of embryonic contents? 
x If we adopt a strategy for the management of empty sacs based on the 
presence or absence of the double decidual sac sign, what are the 
chances of delaying the diagnosis of an ectopic pregnancy? 
x Are ultrasonographers ready to incorporate the double decidual sac sign 
into their clinical practice?  Does training improve the inter-observer 
reliability associated with the double decidual sac sign? 
x Is it possible to replicate our findings with regards to the prognostic 
capability of Ang-2 and Flt-1?  If so, what threshold levels should we use 
and how accurate are they? 
x Are these new approaches to minimise diagnostic uncertainties in early 
pregnancy cost effective? 
 
10.3 Concluding Remarks 
 
Minimising diagnostic uncertainties in early pregnancy has many advantages, 
the importance of which cannot be over-emphasized.  Not only will it 
decrease anxiety for women and their partners but it also permits Early 
Pregnancy Assessment Units to redistribute their workload so that they can see 
more new patients, more quickly, as they will be seeing fewer women for 
follow-up appointments.  Earlier diagnosis of non-viable and ectopic 
pregnancies will minimise the number of women presenting to hospital in a 
state of haemodynamic compromise and enable women to choose more 
conservative forms of management for their early pregnancy complications if 
they wish.   
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NRES Committee East Midlands - Nottingham 1 
The Old Chapel 
Royal Standard Place 
Nottingham 
NG1 6FS 
 
Telephone: 0115 883 9390  
  
16 April 2013 
 
Mr Nick Raine-Fenning 
NURTURE 
B Floor, East Block, Queens Medical Centre 
Nottingham 
NG7 2UH 
 
 
Dear Mr Raine-Fenning, 
 
Study title: Pregnancies of Uncertain Location or Viability Research (PULoVR) 
REC reference: 13/EM/0081 
Protocol number: 13008 
IRAS project ID: 121905 
 
7KDQN \RX IRU \RXU OHWWHU RI $SULO  UHVSRQGLQJ WR WKH&RPPLWWHH¶V UHTXHVW IRU IXUWKHU
information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair.  
 
We plan to publish your research summary wording for the above study on the NRES website, 
together with your contact details, unless you expressly withhold permission to do so.  
Publication will be no earlier than three months from the date of this favourable opinion letter.  
Should you wish to provide a substitute contact point, require further information, or wish to 
withhold permission to publish, please contact the Co-ordinator Liza Selway, 
NRESCommittee.EastMidlands-Nottingham1@nhs.net. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
as revised, subject to the conditions specified below. 
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Ethical review of research sites 
 
NHS sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 
"Conditions of the favourable opinion" below). 
 
Non-NHS sites 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of the 
study. 
 
Management permission or approval must be obtained from each host organisation prior to the 
start of the study at the site concerned. 
 
Management permission ("R&D approval") should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk.   
 
:KHUH D 1+6 RUJDQLVDWLRQ¶V UROH LQ WKH VWXG\ LV OLPLWHG WR LGHQWLI\LQJ DQG UHIHUULQJ SRWHQWLDO
participants to research sites ("participant identification centre"), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.  
 
Sponsors are not required to notify the Committee of approvals from host organisations 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
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Approved documents 
 
The final list of documents reviewed and approved by the Committee is as follows: 
  
Document    Version    Date    
Advertisement  1.0  25 January 2013  
Covering Letter    30 January 2013  
Evidence of insurance or indemnity    06 August 2012  
Investigator CV  Nicholas 
Raine-Fenning  
04 December 2012  
Investigator CV  Bruce Campbell  28 January 2013  
Investigator CV  Alison Richardson  25 January 2013  
Letter from Sponsor    25 January 2013  
Other: Pregnancies of Uncertain Location or Viability 
Outcome Letter  
1.1  26 March 2013  
Other: Referee Report - Peer Review       
Participant Consent Form: Part One (NURTURE (IVF/ICSI 
and Natural Conceptions))  
1.0  25 January 2013  
Participant Consent Form: Part two (EPU)  1.1  01 April 2013  
Participant Consent Form: Part one 
(Nurture(IVF/ICSI/Natural Conception  
1  25 January 2013  
Participant Information Sheet: NURTURE (Natural 
Conception)  
1.1 01 April 2013  
Participant Information Sheet: NURTURE (IVF/ICSI)  1.1  01 April 2013  
Participant Information Sheet: Early Pregnancy Unit   1.1  01 April 2013  
Protocol  1.0  25 January 2013  
REC application  121905/406634/1/291  28 January 2013  
Response to Request for Further Information    11 April 2013  
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
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After ethical review 
 
Reporting requirements 
 
The attached document ³$IWHU HWKLFDO UHYLHZ ± JXLGDQFH IRU UHVHDUFKHUV´ gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
x Notifying substantial amendments 
x Adding new sites and investigators 
x Notification of serious breaches of the protocol 
x Progress and safety reports 
x Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
 
Feedback 
 
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  If you wish to make your views known 
please use the feedback form available on the website. 
 
Further information is available at National Research Ethics Service website > After Review 
 
13/EM/0081                          Please quote this number on all correspondence 
 
:HDUH SOHDVHG WRZHOFRPH UHVHDUFKHUV DQG5	' VWDII DW RXU15(6FRPPLWWHHPHPEHUV¶
training days ± see details at http://www.hra.nhs.uk/hra-training/  
 
:LWKWKH&RPPLWWHH¶VEHVWZLVKHVIRUWKHVXFFHVVRIWKLVSURMHFW. 
 
Yours sincerely, 
 
Mr Robert Johnson 
Chair 
 
Email:NRESCommittee.EastMidlands-Nottingham1@nhs.net 
 
Enclosures:  ³$IWHUHWKLFDOUHYLHZ± guidance for UHVHDUFKHUV´[SL-AR2] 
 
Copy to:  Mr Paul Cartledge 
   Miss Shabina Sadiq, Nottingham University Hospitals NHS Trust 
 
 
 
 NRES Committee East Midlands - Nottingham 1 
Royal Standard Place 
Nottingham 
NG1 6FS 
 
Tel: 0115 8839697 
17 July 2014 
 
Mr Nick Raine-Fenning 
Associate Professor and Reader in Reproductive Medicine and Surgery 
University of Nottingham 
NURTURE 
B Floor, East Block, Queens Medical Centre 
Nottingham 
NG7 2UH 
 
Dear Mr Raine-Fenning, 
 
Study title: Pregnancies of Uncertain Location or Viability Research 
(PULoVR) 
REC reference: 13/EM/0081  
Protocol number: 13008  
Amendment number: 1.1 
Amendment date: 15 July 2014 
IRAS project ID: 121905 
 
Thank you for submitting the above amendment, which was received on 15 July 2014. I can 
confirm that this is a valid notice of a substantial amendment and will be reviewed by the 
Sub-Committee of the REC at its next meeting. 
 
Documents received 
 
The documents to be reviewed are as follows: 
 
Document   Version   Date   
Notice of Substantial Amendment (non-CTIMP)    15 July 2014  
Participant consent form [(Nurture (IVF/ICSI)]  1.1  10 July 2014  
Participant information sheet (PIS) [Nurture (IVF/ICSI)]  1.2  10 July 2014  
Research protocol or project proposal  1.1  10 July 2014  
 
1RWLILFDWLRQRIWKH&RPPLWWHH¶VGHFLVLRQ 
 
The Committee will issue an ethical opinion on the amendment within a maximum of 35 
days from the date of receipt. 
 
R&D approval 
 
All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D 
approval for the research. 
 
:HDUHSOHDVHGWRZHOFRPHUHVHDUFKHUVDQG5	'VWDIIDWRXU15(6FRPPLWWHHPHPEHUV¶
training days ± see details at http://www.hra.nhs.uk/hra-training/  
 
13/EM/0081:      Please quote this number on all correspondence 
 
Yours sincerely, 
 
 
 
Ms Rachel Nelson 
REC Assistant 
 
E-mail:   NRESCommittee.EastMidlands-Nottingham1@nhs.net 
 
 
Copy to:  Miss Shabina Sadiq 
 
Mr Paul Cartledge 
 
 
 NRES Committee East Midlands - Nottingham 1 
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Nottingham 
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Tel: 0115 8839428 
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Mr Nick Raine-Fenning 
Associate Professor and Reader in Reproductive Medicine and Surgery 
University of Nottingham 
NURTURE 
B Floor, East Block, Queens Medical Centre 
Nottingham 
NG7 2UH 
 
 
Dear Mr Raine-Fenning 
 
Study title: Pregnancies of Uncertain Location or Viability Research 
(PULoVR) 
REC reference: 13/EM/0081 
Protocol number: 13008 
Amendment number:  Substantial Amendment 2  
Amendment date: 14 January 2015 
IRAS project ID: 121905 
 
The above amendment was reviewed on 27 January 2015 by the Sub-Committee in 
correspondence.  
 
Ethical opinion 
 
The members of the Committee taking part in the review gave a favourable ethical opinion 
of the amendment on the basis described in the notice of amendment form and supporting 
documentation. 
 
Approved documents 
 
The documents reviewed and approved at the meeting were: 
 
Document   Version   Date   
Non-validated questionnaire [Pregnancies of Uncertain Location or 
Viability Research Anxiety Questionnaire]  
1.1  4 February 2015  
Notice of Substantial Amendment (non-CTIMP)    14 January 2015  
Participant consent form [Tracked]  1.2  15 January 2015  
Participant information sheet (PIS) [Tracked]  1.3  4 February 2015  
Research protocol or project proposal [Tracked]  1.2  13 January 2015  
 
Membership of the Committee 
 
The members of the Committee who took part in the review are listed on the attached 
sheet. 
 
R&D approval 
 
All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D 
approval of the research. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
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Yours sincerely 
 
 
 
Dr Carl Edwards 
Chair 
 
E-mail: NRESCommittee.EastMidlands-Nottingham1@nhs.net 
 
 
Enclosures: List of names and professions of members who took part in the 
review 
 
Copy to:  Miss Shabina Sadiq, Nottingham University Hospitals NHS Trust 
Mr Paul Cartledge 
NRES Committee East Midlands - Nottingham 1 
 
Attendance at Sub-Committee of the REC meeting on 27 January 2015 
 
  
Committee Members:  
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Dr Carl Edwards  Development Lead, 
Research Delivery and 
Support Unit  
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Dr Ursula Holdsworth  Retired Staff Grade 
Community Paediatrician  
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7LWOHRI*XLGHOLQHPXVWLQFOXGHWKHZRUG³*XLGHOLQH´QRW
protocol, policy, procedure etc) 
 
Guidelines on management of 
pregnancy of unknown location (PUL) 
 
 
Contact Name and Job Title (author) 
 
Dr. Shilpa Deb 
Consultant Obstetrician and Gynaecologist 
 
 
 
Directorate & Speciality 
 
Family Health 
Obstetrics and Gynaecology 
 
 
Date of submission 
 
March 2016 
 
 
Date on which guideline must be reviewed (this should be one to 
three years)  
 
March 2021 
 
 
Explicit definition of patient group to which it applies (e.g. 
inclusion and exclusion criteria, diagnosis) 
 
3DWLHQWVZLWKDQHDUO\SUHJQDQF\RIZHHNV 
 
 
Abstract 
 
This guideline is aimed at management of 
women with an early pregnancy when the 
location of pregnancy is not known.  
 
 
 
Key Words 
 
Ultrasound, early pregnancy, intra-uterine, 
ectopic, hCG 
 
Statement of the evidence base of the guideline ± has the 
guideline been peer reviewed by colleagues? 
 
Evidence base: (1-5) 
1a meta analysis of randomised controlled trials 
1b at least one randomised controlled trial 
2a at least one well-designed controlled study without 
randomisation 
2b at least one other type of well-designed quasi-
experimental study 
3 well ±designed non-experimental descriptive studies 
(ie comparative / correlation and case studies) 
4 expert committee reports or opinions and / or clinical 
experiences of respected authorities 
5 recommended best practise based on the clinical 
experience of the guideline developer    
 
 
Literature review, evidence ranging from 1 to 5. 
 
Peer-reviewed by the risk management group 
 
 
Consultation Process 
 
Risk Management Group 
Consultant Gynaecologists 
Ward Sisters 
Gynaecology Nurse Specialists 
Practice Development Matron 
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Target audience  All the medical, nursing and admin staff involved 
with emergency gynaecology 
 
 
This guideline has been registered with the trust. However, clinical guidelines are guidelines only. The 
interpretation and application of clinical guidelines will remain the responsibility of the individual clinician. If 
in doubt contact a senior colleague or expert. Caution is advised when using guidelines after the review 
date.  
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Introduction 
 
In the absence of either an intra- or extra-uterine pregnancy or retained 
products of conception in a woman with a positive pregnancy test, the 
SUHJQDQF\ VKRXOG EH GHVFULEHG DV ³SUHJQDQF\ RI XQNQRZQ ORFDWLRQ´
Even with expert use of TVS (Transvaginal Scanning) using agreed 
criteria, it may not be possible to confirm if a pregnancy is intrauterine or 
extra-uterine in 8±31% of cases at the first visit. These women should 
be classified as having a pregnancy of unknown location. In specialised 
scanning units, the overall incidence of pregnancy of unknown location 
is as low as 8±10%. In cases of known intrauterine pregnancy, viability 
will be uncertain in approximately 10% of women at their first EPAU 
(Early Pregnancy Assessment Unit) visit. The number of cases falling 
into these two groups can be kept to a minimum by using a thorough 
and critical approach to TVS in conjunction with strict diagnostic criteria. 
7KH VRQRJUDSKHU VKRXOG UHFRUG ZKHWKHU DQ µDSSDUHQWO\ HPSW\¶ VDF LV
HFFHQWULFDOO\ SODFHG LQ WKH IXQGXV ZKHWKHU LW H[KLELWV D µGRXEOH-ULQJ¶
pattern, and so on. These findings will help to delineate whether this is 
likely to be an intra- or extra-uterine pregnancy. 
At levels above 1500 iu/l, an ectopic pregnancy will usually be visualised 
with TVS. However, the importance of levels that plateau below 1000 iu/l 
must be recognised. In these cases, an ectopic pregnancy and 
miscarriage are both possible outcomes. The potential for rarer 
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diagnoses, such as gestational trophoblastic disease or cranial germ 
cell tumour, must be considered although, in these cases, serum hCG 
(Human Chorionic Gonadotropin) levels are likely to be greater than 
1000 IU/l.  With a history and TVS findings suggestive of complete 
miscarriage, a 5.9% incidence of ectopic pregnancy has been reported 
and therefore the importance of performing serial hCG. 
Anti D immunoglobulin should be administered when a surgical recourse 
(ERPC - Evacuation of Retained Products of Conception / laparoscopy) 
is taken to managing pregnancy of unknown location. 
 
Guidelines for management of Inconclusive Scan Result after the Initial Visit to 
EPU using Serum hCG and TVS 
 
hCG IU/L Ultrasound Pattern of change 
Of hCG level after 48 
hours 
Management 
 
чϭϬϬϬ 
 
No intrauterine sac 
No Adnexal mass 
No fluid in POD 
No symptoms 
 
hCG rise > 66% or 
doubled 
 
If hCG>1000 repeat 
ultrasound or If hCG < 
1000 repeat hCG 
 
>1000                No intrauterine sac 
 
 1. No adnexal mass 
No fluid POD 
No symptoms 
 Repeat hCG and 
repeat ultrasound 2 
days later 
  A. Falling hCG 
 
Serial hCG levels until 
hCG <20 
  B. Rising Or     
      plateauing hCG  
      x 3  
      Diagnosis: 
      Ectopic or PUL 
   
Laparoscopy (if 
symptomatic) Or 
Methotrexate (if 
asymptomatic) 
(refer to guidelines on 
ectopic pregnancy) 
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 2. Suspicious adnexal 
mass <3.5cm  
No fluid POD 
Asymptomatic 
 Repeat hCG and 
repeat ultrasound 2 
days later 
  A. Falling hCG Serial hCG levels until 
hCG <20 
  B. Rising/ plateauing 
hCG x 3 
Laparoscopy +/-D&C 
or Methotrexate 
 3. Ad.Mass ш3.5cm 
Or 
      Fluid POD 
      Or 
      Symptomatic 
 Laparoscopy 
>2400 No intrauterine sac 
Adnexal findings +/- 
Asymptomatic 
Fluctuating x3 
Diagnosis: Ectopic 
Or PUL 
Laparoscopy or 
Methotrexate 
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Guidelines on management of pregnancy of unknown location (PUL) 
 
 
Positive Urine Pregnancy Test 
Transvaginal ultrasound scan 
PUL / Inconclusive scan 
Haemodynamically stable 
Pain free 
Haemodynamically stable 
In pain  
Haemodynamically unstable 
In pain 
Expectant management 
Serum hCG at 0 & 48 hrs 
Admit and Serum hCG 
Consider laparoscopy Consider laparotomy 
>66% increase in Serum 
hCG 0-48 hours 
<66% increase or <15% 
decrease in Serum hCG 0-
48 hrs 
>15% decrease in Serum 
hCG 0-48 hrs 
? Failing PUL ? Ectopic pregnancy ? Intra Uterine Pregnancy 
Rescan in 1 week to 
confirm pregnancy 
location 
Serum hCG in 48 hrs. 
Rescan if hCG >1000 IU/L 
Repeat serum hCG in 1 
week to confirm failing preg 
Consider weekly hCG 
monitoring until < 25 
IU/L 
Rescan 2 weeks to 
confirm viability 
Early IUP Ectopic pregnancy PUL 
Repeat hCG now 
and 48 hrs later 
Management as 
clinically indicated 
If no pregnancy seen on repeat scan and suboptimal rise in 
hCG, consider methotrexate (refer to guidelines on medical 
management of ectopic pregnancy) 
Emergency Gynaecology SSU_S.Deb       Guidelines on Management of PUL          7 
 
References 
 
Banerjee S, Aslam N, Woelfer B, Lawrence A. Elson J, Jurkovic D. Expectant management of 
pregnancies of unknown location:a prospective evaluation of methods to predict 
spontaneous resolution of pregnancy. BJOG 2001;108:158ʹ63. 
 
Condous G, Okaro E, Bourne T. The conservative management of early pregnancy 
complications: a review of the literature. Ultrasound Obstet Gynecol 2003;22:420ʹ30. 
 
Condous G, Okaro E, Khalid A, Bourne T. Do we need to follow up complete miscarriages 
with serum human chorionic gonadotrophin levels? BJOG 2005;112:827ʹ9.  
 
Hahlin M, Thorburn J, Bryman I. The expectant management of early pregnancy of uncertain 
site.HumReprod 1995;10:1223ʹ7.  
 
Jauniaux E, Johns J, Burton GJ. The role of ultrasound imaging in diagnosing and 
investigating early pregnancy failure. Ultrasound Obstet Gynecol 2005;25:613ʹ24. 
 
NICE Guideline CG154, Ectopic pregnancy and miscarriage ʹ Diagnosis and initial 
management in early pregnancy of ectopic pregnancy and miscarriage. December 2012. 
 
Royal College of Obstetricians and Gynaecologists. Use of Anti-D Immunoglobulin for Rh 
Prophylaxis. Guideline No. 22. London: RCOG; 2002. 
 
Royal college of Obstetrician and Gynaecologist. The management of early pregnancy loss. 
Guideline No. 25, London: RCOG; 2004. 
 
Royal college of Obstetrician and Gynaecologist. The management of tubal pregnancy. 
Guideline No. 21, London: RCOG; 2004, reviewed 2010. 
 
 
	 	
	 	-272- 
Appendix 3 
		
			
	 
Pregnancies of Uncertain Location or Viability Research Anxiety Questionnaire Final Version 1.1    4 February 2015 
 
RESEARCH INTO STRESS AND ANXIETY IN EARLY PREGNANCY 
 
We are trying to determine how women visiting the Early Pregnancy Unit feel at various 
stages of their visit.  We appreciate that pain and bleeding in early pregnancy can cause a 
lot of stress and anxiety for women and we would like to try to quantify this further.  By 
completing this short questionnaire you will be giving us invaluable information that we can 
use to improve the services we provide for you, and other women like you, in the future.   
  
There are three short questionnaires to fill in: one before your ultrasound scan, one just after 
and one optional one 24-48 hours later.  If you are willing to complete this optional one, 
please leave your contact details when requested on page 3.   
 
We appreciate that some people might not feel able to complete the questionnaires after 
the ultrasound scan if they have been given bad news but please do try if possible because 
your feelings at this time are particularly important to us.     
 
Please be reassured that your answers will be kept strictly confidential.  The only reason we 
ask for your initials and date of birth is so that we can match your questionnaire answers with 
your ultrasound findings when we analyse the data.   
 
Please follow the instructions on the questionnaire and feel free to ask a member of the Early 
Pregnancy Team if you have any questions. 
 
Many thanks 
 
 
 
 
 
Dr Alison Richardson 
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Initials   __________________ 
Date of birth   _____ /_____ /_____ 
Date today  _____ /_____ /_____ 
 
PART I (to be completed in the waiting area before the ultrasound scan) 
 
A number of statements which people have used to describe themselves are given below.  
Read each statement and then write the number in the blank to the right of the statement 
that indicates how you generally feel.  There are no right or wrong answers.  Do not spend 
too much time on any one statement but give the answer which seems to describe how you 
generally feel.  Please make sure you answer all the questions. 
 
1 = Almost never     2 = Sometimes     3 = Often      4 = Almost always 
 
1. I feel pleasant ____ 
2. I feel nervous and restless ____ 
3. I feel satisfied with myself ____ 
4. I wish I could be as happy as others seem to be ____ 
5. I feel like a failure ____ 
6. I feel rested ____ 
7. I am ‘cool, calm and collected’ ____ 
8. I feel that difficulties are piling up so that I cannot overcome them ____ 
9. I worry too much over something that really doesn’t matter ____ 
10. I am happy ____ 
11. I have disturbing thoughts ____ 
12. I lack self-confidence ____ 
13. I feel secure ____ 
14. I make decisions easily ____ 
15. I feel inadequate ____ 
16. I am content ____ 
17. Some unimportant thought runs through my mind and bothers me ____ 
18. I take disappointments so keenly that I can’t put them out of my mind ____ 
19. I am a steady person ____ 
20. I get in a state of tension or turmoil as I think over my recent concerns and interests ____ 
 
PART II (to be completed in the waiting area before the ultrasound scan) 
 
Now read each statement and circle the number that best indicates how you feel right now.   
  
         Not at all     Somewhat       Moderately      Very much 
 
21. I feel calm   1  2  3  4 
22. I am tense   1  2  3  4 
23. I feel upset   1  2  3  4 
24. I am relaxed  1  2  3  4 
25. I feel content  1  2  3  4 
26. I am worried  1  2  3  4 
 
 
PLEASE KEEP HOLD OF THIS FOR THE TIME BEING AND COMPLETE THE NEXT PAGE AFTER YOU 
HAVE HAD YOUR ULTRASOUND SCAN
	For EPAU use only: VIUP o NVIUP o EP o PUL o PUV o 
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PART III (to be completed soon after the ultrasound scan) 
A number of statements which people have used to describe themselves are given below.  
Read each statement and then circle the number that corresponds to the statement that 
best indicates how you feel right now.  There are no right or wrong answers.  Do not spend 
too much time on any one statement but give the answer which seems to describe your 
present feelings best.  Please make sure you answer all the questions. 
  
         Not at all     Somewhat       Moderately      Very much 
 
27. I feel calm   1  2  3  4 
28. I am tense   1  2  3  4 
29. I feel upset   1  2  3  4 
30. I am relaxed  1  2  3  4 
31. I feel content  1  2  3  4 
32. I am worried  1  2  3  4 
 
 
 
 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
  
 
 
 
 
Would you be willing for us to contact you in 24-48 hours to answer the same 6 questions one 
final time?  This would greatly help our research.  If you are happy to consent to this, please 
indicate your preferred contact method below and clearly write your contact details: 
  
o Telephone _______________________________ o Morning o Afternoon o Evening o Any time 
 
o E-mail _________________________________________________________________________________ 
 
Signed ____________________________________________________________Date _____/_____/_____ 
 
If you choose telephone, please be aware that the call may come from a withheld number.  
If you choose e-mail, please look out for an email from alison.richardson@nottingham.ac.uk 
with the subject ‘Early Pregnancy Research Questionnaire’. 
 
 
 
 
 
Many thanks for taking the time to complete this questionnaire. 
It is very much appreciated. 
 
 
 
 
 
PLEASE RETURN THIS COMPLETED QUESTIONNAIRE TO A MEMBER OF THE 
EARLY PREGNANCY TEAM BEFORE YOU LEAVE THE DEPARTMENT 
 
	For EPAU use only: VIUP o NVIUP o EP o PUL o PUV o 
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PART IV (to be completed by a member of the research team 24-48 hours after the ultrasound 
scan (optional)) 
 
A number of statements which people have used to describe themselves are given below.  
Read each statement and then circle the number that corresponds to the statement that 
best indicates how you feel right now.  There are no right or wrong answers.  Do not spend 
too much time on any one statement but give the answer which seems to describe your 
present feelings best.  Please make sure you answer all the questions. 
  
         Not at all     Somewhat       Moderately      Very much 
 
33. I feel calm   1  2  3  4 
34. I am tense   1  2  3  4 
35. I feel upset   1  2  3  4 
36. I am relaxed  1  2  3  4 
37. I feel content  1  2  3  4 
38. I am worried  1  2  3  4 
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CONSENT FORM 
(Final version 1.1: 10th July 2014) 
 
Title of Study: Pregnancies of Uncertain Location or Viability Research (PULoVR) 
 
REC ref: 13/EM/0081   
 
Name of Researcher: Dr Alison Richardson 
        
Name of Participant: 
 
1. I confirm that I have read and understand the information sheet version 
number …………dated...................................... for the above study and have 
had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, and without my medical care or legal 
rights being affected. I understand that should I withdraw then the information 
collected so far cannot be erased and that this information may still be used in 
the project analysis. 
 
3. I understand that relevant sections of my medical notes and data collected in 
the study may be looked at by authorised individuals from the University of 
Nottingham, the research group and regulatory authorities where it is relevant 
to my taking part in this study. I give permission for these individuals to have 
access to these records and to collect, store, analyse and publish information 
obtained from my participation in this study. I understand that my personal 
details will be kept confidential. 
 
4. I understand and agree that a transvaginal ultrasound scan will be performed 
for analysis of very early pregnancy development. 
 
5. I agree to be contacted regarding the outcome of the pregnancy if the 
information required cannot be obtained from my hospital records. 
 
6. I agree to take part in the above study. 
 
 
 
_________________________  _______________ _________________ 
Name of Participant    Date          Signature 
 
 
 
_________________________      _______________ _________________ 
Name of Person taking consent  Date          Signature 
 
Please initial box 
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  Section & Topic No Item 
    
 TITLE OR ABSTRACT   
  1 Identification as a study of diagnostic accuracy using at least one measure of accuracy 
(such as sensitivity, specificity, predictive values, or AUC) 
 ABSTRACT   
  2 Structured summary of study design, methods, results, and conclusions  
(for specific guidance, see STARD for Abstracts) 
 INTRODUCTION   
  3 Scientific and clinical background, including the intended use and clinical role of the index test 
  4 Study objectives and hypotheses 
 METHODS   
 Study design 5 Whether data collection was planned before the index test and reference standard  
were performed (prospective study) or after (retrospective study) 
 Participants 6 Eligibility criteria  
  7 On what basis potentially eligible participants were identified  
(such as symptoms, results from previous tests, inclusion in registry) 
  8 Where and when potentially eligible participants were identified (setting, location and dates) 
  9 Whether participants formed a consecutive, random or convenience series 
 Test methods 10a Index test, in sufficient detail to allow replication 
  10b Reference standard, in sufficient detail to allow replication 
  11 Rationale for choosing the reference standard (if alternatives exist) 
  12a Definition of and rationale for test positivity cut-offs or result categories  
of the index test, distinguishing pre-specified from exploratory 
  12b Definition of and rationale for test positivity cut-offs or result categories  
of the reference standard, distinguishing pre-specified from exploratory 
  13a Whether clinical information and reference standard results were available  
to the performers/readers of the index test 
  13b Whether clinical information and index test results were available  
to the assessors of the reference standard 
 Analysis 14 Methods for estimating or comparing measures of diagnostic accuracy 
  15 How indeterminate index test or reference standard results were handled 
  16 How missing data on the index test and reference standard were handled 
  17 Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from exploratory 
  18 Intended sample size and how it was determined 
 RESULTS   
 Participants 19 Flow of participants, using a diagram 
  20 Baseline demographic and clinical characteristics of participants 
  21a Distribution of severity of disease in those with the target condition 
  21b Distribution of alternative diagnoses in those without the target condition 
  22 Time interval and any clinical interventions between index test and reference standard 
 Test results 23 Cross tabulation of the index test results (or their distribution)  
by the results of the reference standard 
  24 Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals) 
  25 Any adverse events from performing the index test or the reference standard 
 DISCUSSION   
  26 Study limitations, including sources of potential bias, statistical uncertainty, and generalisability 
  27 Implications for practice, including the intended use and clinical role of the index test 
 OTHER INFORMATION   
  28 Registration number and name of registry 
  29 Where the full study protocol can be accessed 
  30 Sources of funding and other support; role of funders 
    
 STARD 2015 
AIM  
^dZƐƚĂŶĚƐĨŽƌ͞^ƚĂŶĚĂƌĚƐĨŽƌ ZĞƉŽƌƚŝŶŐŝĂŐŶŽƐƚŝĐĂĐĐƵƌĂĐǇƐƚƵĚŝĞƐ͘͟dŚŝƐ list of items was developed to contribute to the 
completeness and transparency of reporting of diagnostic accuracy studies. Authors can use the list to write informative 
study reports. Editors and peer-reviewers can use it to evaluate whether the information has been included in manuscripts 
submitted for publication.  
EXPLANATION 
A diagnostic accuracy study evaluates the ability of one or more medical tests to correctly classify study participants as having 
a target condition. This can be a disease, a disease stage, response or benefit from therapy, or an event or condition in the 
future. A medical test can be an imaging procedure, a laboratory test, elements from history and physical examination, a 
combination of these, or any other method for collecting information about the current health status of a patient. 
The test whose accuracy is evaluated is called index test. A study can evaluate the accuracy of one or more index tests. 
Evaluating the ability of a medical test to correctly classify patients is typically done by comparing the distribution of the index 
test results with those of the reference standard. The reference standard is the best available method for establishing the 
presence or absence of the target condition. An accuracy study can rely on one or more reference standards. 
If test results are categorized as either positive or negative, the cross tabulation of the index test results against those of the 
reference standard can be used to estimate the sensitivity of the index test (the proportion of participants with the target 
condition who have a positive index test), and its specificity (the proportion without the target condition who have a negative 
index test). From this cross tabulation (sometimes referred to as the contingency or ͞2x2͟ table), several other accuracy 
statistics can be estimated, such as the positive and negative predictive values of the test. Confidence intervals around 
estimates of accuracy can then be calculated to quantify the statistical precision of the measurements. 
If the index test results can take more than two values, categorization of test results as positive or negative requires a test 
positivity cut-off. When multiple such cut-offs can be defined, authors can report a receiver operating characteristic (ROC) 
curve which graphically represents the combination of sensitivity and specificity for each possible test positivity cut-off. The 
area under the ROC curve informs in a single numerical value about the overall diagnostic accuracy of the index test.  
The intended use of a medical test can be diagnosis, screening, staging, monitoring, surveillance, prediction or prognosis. The 
clinical role of a test explains its position relative to existing tests in the clinical pathway. A replacement test, for example, 
replaces an existing test. A triage test is used before an existing test; an add-on test is used after an existing test.  
Besides diagnostic accuracy, several other outcomes and statistics may be relevant in the evaluation of medical tests. Medical 
tests can also be used to classify patients for purposes other than diagnosis, such as staging or prognosis. The STARD list was 
not explicitly developed for these other outcomes, statistics, and study types, although most STARD items would still apply.  
DEVELOPMENT 
This STARD list was released in 2015. The 30 items were identified by an international expert group of methodologists, 
researchers, and editors. The guiding principle in the development of STARD was to select items that, when reported, would 
help readers to judge the potential for bias in the study, to appraise the applicability of the study findings and the validity of 
conclusions and recommendations. The list represents an update of the first version, which was published in 2003.  
 
More information can be found on http://www.equator-network.org/reporting-guidelines/stard. 
Prototypical STARD diagram to report flow of participants through the study 
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Name   _______________________________________________________ 
Unit Number  ________________________  DOB _______ / _______ / _______  
Email    _______________________________________________________ 
Gravidity   ________________________  Parity ________________________ 
Ethnicity   _______________________________________________________ 
Height    _____________ cm OR ____________ ft ____________  inches 
Weight   ______________ kg OR ______________ st _____________  lbs 
AMH    ________________________  AFC  _________________________  
Date of TVOR  _______ / _______ / _______ No. of eggs collected ________  
Date of ET     _______ / _______ / _______  
Stage of ET     d2 / d3 / d5 
No. of embryos  sET / dET    
Status of embryo(s)   Fresh / Frozen 
Grade of embryo(s)  _________________________ 
Date of official UPT  _______ / _______ / _______  Result   Positive / Negative 
 
Date of US  _______ / _______ / _______ 
Calculated GA _______ /  40  
Uterus  AV / RV ET  _______ mm 
GS   present / absent Number _____ 
GS dimensions _____ x  _____ x  _____ mm   Vol _____ cm3  
DDSS   present / absent 
YS   present / absent    Size _____ x  _____ x  _____ mm   Vol _____ cm3 
FP   present / absent  Length _____ mm  FH  present / absent 
RO   _________________________  LO _________________________ 
AM   present / absent Side  left / right Size _____ x  _____ x  _____ mm 
FF   present / absent   Volume  min / mod / large 
 
Initial Outcome Viable IUP / Non-viable IUP / EP / PUL 
Final Outcome Miscarriage / TOP / Livebirth / Stillbirth 
Study Number:_____ 
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CONSENT FORM 
(Final version 1.1: 10th July 2014) 
 
Title of Study: Pregnancies of Uncertain Location or Viability Research (PULoVR) 
 
REC ref: 13/EM/0081   
 
Name of Researcher: Dr Alison Richardson 
        
Name of Participant: 
 
1. I confirm that I have read and understand the information sheet version 
number …………dated...................................... for the above study and have 
had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, and without my medical care or legal 
rights being affected. I understand that should I withdraw then the information 
collected so far cannot be erased and that this information may still be used in 
the project analysis. 
 
3. I understand that relevant sections of my medical notes and data collected in 
the study may be looked at by authorised individuals from the University of 
Nottingham, the research group and regulatory authorities where it is relevant 
to my taking part in this study. I give permission for these individuals to have 
access to these records and to collect, store, analyse and publish information 
obtained from my participation in this study. I understand that my personal 
details will be kept confidential. 
 
4. I understand and agree that serum samples will be taken for analysis of very 
early pregnancy development. 
 
5. I agree to be contacted regarding the outcome of the pregnancy if the 
information required cannot be obtained from my hospital records. 
 
6. I agree to take part in the above study. 
 
 
 
_________________________  _______________ _________________ 
Name of Participant    Date          Signature 
 
 
 
_________________________      _______________ _________________ 
Name of Person taking consent  Date          Signature 
 
Please initial box 
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PRISMA 2009 Checklist 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.   
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.   
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).   
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.  
 
 
Page 1 of 2  
PRISMA 2009 Checklist 
Section/topic  # Checklist item  Reported on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).   
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.   
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).   
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).   
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.   
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
Page 2 of 2  
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QUADAS-2: Background Document 
 
QUADAS-2 
QUADAS-2 is designed to assess the quality of primary diagnostic accuracy studies; it is not 
designed to replace the data extraction process of the review and should be applied in 
addition to extracting primary data (e.g. study design, results etc) for use in the review.  It 
consists of four key domains covering patient selection, index test, reference standard, and 
flow of patients through the study and timing of the index test(s) and reference standard 
;͞flow and timing͟) (Table 1).  The tool is completed in four phases: 1) state the review 
question; 2) develop review specific guidance; 3) review the published flow diagram for the 
primary study or construct a flow diagram if none is reported; 4) judgement of bias and 
applicability.  Each domain is assessed in terms of the risk of bias and the first three are also 
assessed in terms of concerns regarding applicability.   To help reach a judgement on the 
risk of bias, signalling questions are included.  These flag aspects of study design related to 
the potential for bias and aim to help reviewers make risk of bias judgements.   
 
Phase 1: Review Question 
Review authors are first asked to report their systematic review question in terms of 
patients, index test(s), and reference standard and target condition.  As the accuracy of a 
test may depend on where in the diagnostic pathway it will be used, review authors are 
asked to describe patients in terms of setting, intended use of the index test, patient 
presentation and prior testing.(1;2)  
 
Phase 2: Review Specific Tailoring (Figure 1) 
It is essential to tailor QUADAS-2 to each review by adding or omitting signalling questions 
and developing review-specific guidance on how to assess each signalling question and use 
this information to judge the risk of bias.   The first step is to consider whether any signalling 
question does not apply to the review or whether any specific issues for the review are not 
adequately covered by the core signalling questions. For example, for a review of an 
objective index test it may be appropriate to omit the signalling question relating to blinding 
of the test interpreter to results of the reference standard. Review authors should avoid 
complicating the tool by adding too many signalling questions. Once tool content has been 
agreed, review-specific rating guidance should be developed. The tool should be piloted 
independently by at least two people. If agreement is good, the tool can be used to rate all 
included studies. If agreement is poor, further refinement may be needed. 
 
Figure 1: Process for tailoring QUADAS-2 to your systematic review 
 
 
 
Phase 3: Flow Diagram 
The next stage is to review the published flow diagram for the primary study or to draw one 
if none is reported or the published diagram is not adequate. The flow diagram will facilitate 
judgments of risk of bias, and should provide information about the method of recruitment 
of patients (e.g. based on a consecutive series of patients with specific symptoms suspected 
of having the target condition, or of cases and controls), the order of test execution, and the 
number of patients undergoing the index test and the reference standard. A hand drawn 
diagram is sufficient as this step does not need to be reported as part of the QUADAS-2 
assessment.  Figure 2 shows an example based on a primary study of B type natriuretic 
peptide for the diagnosis of heart failure. 
 
Figure 2: Flowchart based on diagnostic cohort study of BNP for diagnosing heart failure 
 
 
Phase 4: Judgments on bias and applicability  
Risk of bias  
The first part of each domain concerns bias and comprises three sections: 1) information 
used to support the risk of bias judgment, 2) signalling questions, and 3) judgment of risk of 
bias. By recording the information used to reach the judgment ;͞ƐƵƉƉŽƌƚĨŽƌũƵĚŐŵĞŶƚ͟Ϳ͕ǁĞ
aim to make the rating transparent and facilitate discussion between review authors 
completing assessments independently.(3) The additional signalling questions are included 
to assist judgments.  dŚĞǇĂƌĞĂŶƐǁĞƌĞĚĂƐ͞ǇĞƐ͕͟͞ŶŽ͕͟Žƌ͞ƵŶĐůĞĂƌ͕͟ĂŶĚĂƌĞƉŚƌĂƐĞĚƐƵĐŚ
ƚŚĂƚ͞ǇĞƐ͟ŝŶĚŝĐĂƚĞƐlow risk of bias. 
 
Risk of bias is judged ĂƐ͞ůŽǁ͕͟͞ŚŝŐŚ͕͟Žƌ͞ƵŶĐůĞĂƌ͘͟/ĨĂůůƐŝŐŶĂůůŝŶŐƋƵĞƐƚŝŽŶƐĨŽƌĂĚŽŵĂŝŶ
ĂƌĞĂŶƐǁĞƌĞĚ͞ǇĞƐ͟ƚŚĞŶrisk of bias ĐĂŶďĞũƵĚŐĞĚ͞ůŽǁ͘͟/ĨĂŶǇƐŝŐŶĂůůŝŶŐƋƵĞƐƚŝŽŶŝƐ
ĂŶƐǁĞƌĞĚ͞ŶŽ͟ƚŚŝƐĨůĂŐƐƚŚĞƉŽƚĞŶƚŝĂůĨŽƌďŝĂƐ͘ZĞǀŝĞǁĂƵthors then need to use the 
guidelines developed in phase 2 to judge risk of bias. TŚĞ͞ƵŶĐůĞĂƌ͟ĐĂƚĞŐŽƌǇƐŚŽƵůĚďĞƵƐĞĚ
only when insufficient data are reported to permit a judgment. 
 
Applicability 
Applicability sections are structured in a similar way to the bias sections, but do not include 
signalling questions. Review authors are asked to record the information on which the 
judgment of applicability is made and then to rate their concern that the study does not 
match the review question. Concerns regarding applicability are rated as ͞low͟, ͞high͟ or 
͞unclear͟. Applicability judgments should refer to the first phase, where the review question 
was recorded. Again, the ͞unclear͟ category should only be used when insufficient data are 
reported. 
 
The following sections provide brief explanations of the signalling questions and risk of 
bias/concerns regarding applicability questions for each domain. 
 
DOMAIN 1:  PATIENT SELECTION   
Risk of bias: Could the selection of patients have introduced bias? 
Signalling question 1: Was a consecutive or random sample of patients enrolled? 
Signalling question 2: Was a case-control design avoided? 
Signalling question 3: Did the study avoid inappropriate exclusions? 
A study should ideally enrol all consecutive, or a random sample of, eligible patients with 
suspected disease ʹ otherwise there is potential for bias. Studies that make inappropriate 
exclusions, e.g. excluding ͞ĚŝĨĨŝĐƵůƚƚŽĚŝĂŐŶŽƐĞ͟ƉĂƚŝĞŶƚƐ͕ŵĂǇƌĞƐƵůƚŝŶŽǀĞƌŽƉƚŝŵŝƐƚŝĐ
estimates of diagnostic accuracy. In a review of anti-CCP antibodies for the diagnosis of 
rheumatoid arthritis, we found that some studies enrolled consecutive patients who had 
confirmed diagnoses.  These studies showed greater sensitivity of the anti-CCP test than 
studies that included patients with suspected disease but in whom the diagnosis had not 
been confirmed ʹ ͞ĚŝĨĨŝĐƵůƚƚŽĚŝĂŐŶŽƐĞ͟ƉĂƚŝĞŶƚƐ.(4)  Similarly, studies enrolling patients 
with known disease and a control group without the condition may exaggerate diagnostic 
accuracy.(5;6) Exclusion of ƉĂƚŝĞŶƚƐǁŝƚŚ͞ƌĞĚĨůĂŐƐ͟ĨŽƌƚŚĞƚĂƌŐĞƚĐŽŶĚŝƚŝŽŶ, who may be 
easier to diagnose, may lead to underestimation of diagnostic accuracy. 
 
Applicability: Are there concerns that the included patients and setting do not match the 
review question? 
There may be concerns regarding applicability if patients included in the study differ, 
compared to those targeted by the review question, in terms of severity of the target 
condition, demographic features, presence of differential diagnosis or co-morbidity, setting 
of the study and previous testing protocols.  For example, larger tumours are more easily 
seen with imaging tests than smaller ones, and larger myocardial infarctions lead to higher 
levels of cardiac enzymes than small infarctions making them easier to detect and so 
increasing estimates of sensitivity.(7) 
 
DOMAIN 2:  INDEX TEST   
Risk of Bias: Could the conduct or interpretation of the index test have introduced bias? 
Signalling question 1: Were the index test results interpreted without knowledge of the 
results of the reference standard? 
dŚŝƐŝƚĞŵŝƐƐŝŵŝůĂƌƚŽ͞ďůŝŶĚŝŶŐ͟ŝŶŝŶƚĞƌǀĞŶƚŝŽŶƐƚƵĚŝĞƐ͘/ŶƚĞƌƉƌĞƚĂƚŝŽŶŽĨindex test results 
may be influenced by knowledge of the reference standard.(6) The potential for bias is 
related to the subjectivity of index test interpretation and the order of testing. If the index 
test is always conducted and interpreted prior to the reference standard,this item can be 
ƌĂƚĞĚ͞ǇĞƐ͘͟ 
Signalling question 2: If a threshold was used, was it pre-specified? 
Selecting the test threshold to optimise sensitivity and/or specificity may lead to 
overoptimistic estimates of test performance, which is likely to be poorer in an independent 
sample of patients in whom the same threshold is used.(8) 
 
Applicability: Are there concerns that the index test, its conduct, or interpretation differ 
from the review question? 
Variations in test technology, execution, or interpretation may affect estimates of its 
diagnostic accuracy.  If index tests methods vary from those specified in the review question 
there may be concerns regarding applicability.   For example, a higher ultrasound transducer 
frequency has been shown to improve sensitivity for the evaluation of patients with 
abdominal trauma.(9)  
 
DOMAIN 3: REFERENCE STANDARD 
Risk of Bias: Could the reference standard, its conduct, or its interpretation have 
introduced bias? 
Signalling question 1: Is the reference standard likely to correctly classify the target 
condition? 
Estimates of test accuracy are based on the assumption that the reference standard is 100% 
sensitive and specific disagreements between the reference standard and index test are 
assumed to result from incorrect classification by the index test.(10;11)  
 
Signalling question 2: Were the reference standard results interpreted without knowledge of 
the results of the index test? 
This item is similar to the signalling question related to interpretation of the index test. 
Potential for bias is related to the potential influence of prior knowledge on the 
interpretation of the reference standard.(6) 
 
Applicability: Are there concerns that the target condition as defined by the reference 
standard does not match the question? 
The reference standard may be free of bias but the target condition that it defines may 
differ from the target condition specified in the review question.  For example, when 
defining urinary tract infection the reference standard is generally based on specimen 
culture but the threshold above which a result is considered positive may vary.(12) 
 
DOMAIN 4: FLOW AND TIMING 
Risk of Bias: Could the patient flow have introduced bias? 
Signalling question 1: Was there an appropriate interval between index test and reference 
standard? 
Ideally results of the index test and reference standard are collected on the same patients at 
the same time. If there is a delay or if treatment is started between index test and reference 
standard, misclassification may occur due to recovery or deterioration of the condition. The 
length of interval leading to a high risk of bias will vary between conditions. A delay of a few 
days may not be a problem for chronic conditions, while for acute infectious diseases a 
short delay may be important. Conversely, when the reference standard involves follow-up 
a minimum follow-up period may be required to assess the presence or absence of the 
target condition.  For example, for the evaluation of magnetic resonance imaging for the 
early diagnosis of multiple sclerosis, a minimum follow-up period of around 10 years is 
required to be confident that all patients who will go on to fulfil diagnostic criteria for 
multiple sclerosis will have done so.(13) 
 
Signalling question 2: Did all patients receive the same reference standard? 
Verification bias occurs when not all of the study group receive confirmation of the 
diagnosis by the same reference standard. If the results of the index test influence the 
decision on whether to perform the reference standard or which reference standard is used, 
estimated diagnostic accuracy may be biased.(5;14) For example, a study evaluating the 
accuracy of the D-dimer test for the diagnosis of pulmonary embolism carried out 
ventilation perfusion scans (reference standard 1) in those testing positive and used clinical 
follow-up to determine whether or not those testing negative had a pulmonary embolism 
(reference standard 2).  This may result in misclassifying some of the false negatives as true 
negatives as some patients who had a pulmonary embolism but were index test negative 
may be missed by clinical follow-up and so be classified as not having a pulmonary 
embolism.  This misclassification will overestimate sensitivity and specificity. 
 
Signalling question 3: Were all patients included in the analysis? 
All patients who were recruited into the study should be included in the analysis.(15) There 
is a potential for bias if the number of patients enrolled differs from the number of patients 
included in the 2x2 table of results, for example because patients lost to follow-up differ 
systematically from those who remain.  
 
Incorporating QUADAS-2 assessments in diagnostic accuracy reviews 
We emphasise that QUADAS-ϮƐŚŽƵůĚŶŽƚďĞƵƐĞĚƚŽŐĞŶĞƌĂƚĞĂƐƵŵŵĂƌǇ͞ƋƵĂůŝƚǇƐĐŽƌĞ͕͟
because of the well-known problems associated with such scores.(16;17)  If a study is 
ũƵĚŐĞĚĂƐ͞ůŽǁ͟on all domains relating to bias or applicability then it is appropriate to have 
ĂŶŽǀĞƌĂůůũƵĚŐŵĞŶƚŽĨ͞ůŽǁƌŝƐŬŽĨďŝĂƐ͟Žƌ͞ůŽǁĐŽŶĐĞƌŶƌĞŐĂƌĚŝŶŐĂƉƉůŝĐĂďŝůŝƚǇ͟ĨŽƌƚŚĂƚ
study. If a study is judged "high" or "unclear" on one or more domains then it may be judged 
͞ĂƚƌŝƐŬŽĨďŝĂƐ͟ŽƌĂƐŚĂǀŝŶŐ͞ĐŽŶĐĞƌŶƐƌĞŐĂƌĚŝŶŐĂƉƉůŝĐĂďŝůŝƚǇ͘͟ 
 
At minimum, reviews should present a summary of the results of the QUADAS-2 assessment 
for all included studies.  This could include summarising the number of studies that found 
low, high or unclear risk of bias/concerns regarding applicability for each domain. If studies 
are found to consistently rate well or poorly on particular signalling questions then 
reviewers may choose to highlight these.  Tabular (Table) and graphical (Figure 3) displays 
are helpful to summarise QUADAS-2 assessments.    
 
Table: Suggested tabular presentation for QUADAS-2 results 
Study RISK OF BIAS APPLICABILITY CONCERNS 
PATIENT 
SELECTION 
INDEX TEST REFERENCE 
STANDARD 
FLOW AND 
TIMING 
PATIENT 
SELECTION 
 
INDEX TEST REFERENCE 
STANDARD 
Study 1 - - - - / - - 
Study 2 - - - - / - - 
Study 3 / / - - / - - 
Study 4 / / - - / - - 
Study 5 /   ? - - / - - 
Study 6 /   ? - - /   ? - 
Study 7 /   ? - - / - - 
Study 8 /   ? - - /   ? - 
Study 9 /   ? - - / - - 
Study 10 /   ? - / / - - 
Study 11 -   ? - / - - - 
-Low Risk /High Risk   ? Unclear Risk  
Figure 3: Suggested Graphical Display for QUADAS-2 results 
 
 
Review authors may choose to restrict the primary analysis so that only studies at low risk of 
bias and/or low concern regarding applicability for all or specified domains are included.  It 
may be appropriate to restrict inclusion to the review based on similar criteria, but it is often 
preferable to review all relevant evidence and then investigate possible reasons for 
heterogeneity.(13;18) Subgroup and or sensitivity analysis can be conducted by 
investigating how estimates of accuracy of the index test vary between studies rated as 
high, low, or unclear on all or selected domains.   Domains or signalling questions can be 
included as items in meta-regression analyses, to investigate their association with 
estimated accuracy.  
 
Website 
The QUADAS website (www.quadas.org) contains QUADAS-2, information on training, a 
bank of additional signalling questions, more detailed guidance for each domain, examples 
of completed QUADAS-2 assessments, and downloadable resources including a Microsoft 
ĐĐĞƐƐΡĚĂƚĂďĂƐĞĨŽƌĚĂƚĂĞǆƚƌĂĐƚŝŽŶ͕ĂŶǆĐĞůΡƐƉƌĞĂĚƐŚĞĞƚƚŽƉƌŽĚƵĐĞŐƌĂƉŚŝĐĂůĚŝƐƉůĂǇƐ
ŽĨƌĞƐƵůƚƐ͕ĂŶĚƚĞŵƉůĂƚĞƐĨŽƌtŽƌĚΡƚĂďůĞƐƚŽƐƵŵŵĂƌŝƐĞƌĞƐƵůƚƐ͘ 
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